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Abstract   
Pro-inflammatory and pro-fibrotic G protein-coupled receptor 84 (GPR84), a 
member of the rhodopsin-like Class A GPCR family, recently has attracted 
interest as a potential drug target for chronic inflammation-associated diseases 
including ulcerative colitis, neuropathic pain, atherosclerosis and fibrosis-
associated diseases including idiopathic pulmonary fibrosis. However, GPR84 still 
remains poorly characterized in terms of its signal transduction pathways and 
pathophysiological roles and is officially considered as ‘orphan’ receptor as the 
putative endogenous agonists MCFAs are weak activators of the receptor with a 
poorly defined mode of interaction with the receptor. The modes of ligand 
binding and mechanism(s) of action of the currently available pharmacological 
tool compounds are also very limited which have hindered the target validation 
process. Herein, the G protein coupling selectivity of GPR84, ligand-GPR84 
interactions and modes of action of orthosteric and allosteric GPR84 ligands 
along with their orthologue selectivity were investigated in an attempt to 
characterize this enigmatic receptor. Employing a series of BRET-based GPR84 
SPASM biosensors, GPR84 activation was found to couple to the Gαi/o G protein 
family with preferential recruitment of Gαi1/2 and Gαi3 over Gαo and Gαz G 
proteins. Based on homology modelling and site-directed mutagenesis studies, 
integral roles of arginine 172 of extracellular loop 2 in orthosteric ligand 
recognition and functions were identified wherein this residue acted as the 
putative charge partner for the carboxylate of MCFAs or the hydrophilic head 
groups of embelin or embelin-like ligands. Homology modelling, mutational 
analysis and subsequent docking studies also suggested that phenylalanine 
170EL2, phenylalanine 335F6.51 and tryptophan 3607.43 might be associated with 
orthosteric ligand detection. 3,3´-diindolylmethane (DIM) and DIM analogue 
di(5,7-difluoro-1H-indole-3-yl)methane (PSB-16671) were found to bind to a site 
which is topographically distinct from the orthosteric site as both ligands 
retained their agonist functions upon mutation of all these residues to alanine 
where the activity of orthosteric agonists was either lost completely or reduced 
significantly. Functional studies with GPR84 antagonist compound-107 and 
radioligand binding studies with a chemically related radiolabelled antagonist, 
[3H]-G9543 suggested that this class of antagonists bind to a site which is 
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different from the orthosteric and allosteric binding sites, indicating three 
spatiotemporally distinct ligand binding sites within GPR84.  
Antagonists but not agonists of GPR84 displays significant variation in 
pharmacology between human and mouse orthologues as evidenced from either 
loss of activity (compound-837) or markedly reduced potencies at mouse GPR84. 
GPR84 ligands display similar pharmacology in mouse monocyte-macrophage cell 
line RAW264.7 as those observed in transfected cells expressing mouse GPR84. 
DIM, analogue 3a (5,5´-dimethoxy-3,3´-diindolylmethane) and particularly PSB-
16671 acted as highly effective positive allosteric modulators (PAM) of the 
function of orthosteric agonists through a mechanism that includes both affinity 
and efficacy modulation for embelin and C-10 or predominantly governed by 
affinity modulation with marginal effect on efficacy for full agonists including 
compound-1. These ligands display PAM activity in a ‘probe-dependent’ manner 
wherein the degree of affinity cooperativity tracks with the orthosteric agonist 
efficacy although little ‘probe-dependence’ was observed when net 
affinity/efficacy cooperativity was considered. DIM but not PSB-16671 showed 
significant variation in allosteric interactions with orthosteric agonists between 
human and mouse GPR84. Mathematical analysis of allosteric interactions 
showed that PSB-16671 binds human GPR84 with 360 and 5-fold higher affinity 
than decanoic acid and DIM, respectively while compound-1 displays 14-fold 
higher avidity than PSB-16671. The analysis also showed that the estimated 
binding affinities of these ligands for mouse GPR84 were equivalent to those 
observed for the human orthologue. In summary, the research studies presented 
herein provides new insights into ligand-GPR84 interactions and mode(s) of 
pharmacological actions of the GPR84 tool compounds which might be useful to 
accelerate structure-based drug design identifying further improved ligands or 
for translational studies assessing the therapeutic potential of this receptor.         
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1 Introduction 
1.1 G protein coupled receptors (GPCRs) and drug 
development 
1.1.1 Brief overview of drug development approaches 
Development of highly selective efficacious drugs having no side effects to treat 
unmet medical needs is the major goal of translational or therapeutic 
pharmacology. Though historically most of the drugs were discovered and 
developed to clinical use by applying phenotypic screening-based drug 
development approach, within the last three decades rational molecular target-
based approaches have gained popularity as the predominant drug development 
approach for both the pharmaceutical industry and academic translational 
research community thanks to modern developments in recombinant technology 
and molecular biology techniques along with the human genome projects 
(Croston, 2017; Eder et al., 2014; Zheng et al., 2013).Though in an analysis 
performed by Swinney and Anthony, (2011) phenotypic screening-based 
approaches were found to be more productive than the target-based approach, 
evident from the fact that 62% of 45 FDA approved small molecule first-in-class 
drugs were developed within the timeframe of 1999 to 2008 by phenotypic 
screening-based approaches, Eder et al., (2014) found that after 5 years, target-
based approach become the dominant drug development strategy contributing to 
the development of 70% of FDA approved first-in-class drugs within 1999 to 2013. 
In the phenotypic screening-based approach, also known as classical 
pharmacology or forward pharmacology, a disease model is first developed 
followed by screening of compounds for the desired outcome in cells, tissues, 
organs or animals without prior knowledge about the molecular target of the 
compounds (Schenone et al., 2013; Zheng et al., 2013). This screening process 
results in the identification of lead compounds able to ameliorate the disease 
phenotype. The molecular target is then identified for the candidate lead 
compounds which facilitates the lead optimization process. In contrast to this 
classical approach, rational target-based drug discovery process also known as 
‘reverse pharmacology’ or ‘reverse chemical genetics’, starts with the 
identification of the molecular target (proteins, gene or RNA) which is thought 
to play crucial roles in specific disease progression and modulation of this target 
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activity either through inhibition or stimulation is proposed to reverse the 
disease phenotype (Zheng et al., 2013). The proposed pathophysiological role or 
disease modifying characteristic of the drug target is then validated by several 
investigations including loss-of-function experiments through genetic elimination 
of the target gene in animals (studies with knockout animals) or gene knockdown 
studies either through RNA interference or antisense RNA technology and by 
studies using highly selective and potent tool compounds (small molecule 
chemical probes) in in vitro cellular or in vivo disease models (Hughes et al., 
2011; Bunnage et al., 2013). Several biochemical assays are then performed 
wherein large chemical libraries are tested using high throughput screening in an 
effort to identify the hits or lead compounds. These lead candidates are then 
subjected to extensive chemical optimization processes i.e. structure activity 
relationship (SAR) studies to improve the pharmacodynamics profiles including 
selectivity, affinity and efficacy as well as to ensure the favourable 
pharmacokinetic profiles (absorption, distribution, metabolism and excretion, 
ADME) (Zheng et al., 2013). Mechanism-of-action studies are then conducted 
using cell-based or animal disease models in an effort to validate the cellular 
activities of the lead compounds and to investigate the off-target effects which 
might produce side effects (Schenone et al., 2013). Only a few lead compounds 
displaying the desired efficacy with defined mechanism of action can pass to the 
next stages of a drug development program, preclinical toxicity studies and 
hopefully to the clinical trials in healthy volunteer or patients (Zheng et al., 
2013).            
Though a target-based drug discovery approach is more advantageous in terms of 
cost, speed and feasibility of SAR studies over a phenotypic screening-based 
approach, translation of pharmacology of potential drug candidates observed in 
recombinant systems to clinical results is challenging as recombinant systems are 
too simplistic to mimic the complex biology of the whole organism (Croston, 
2017). Recent analysis showed that higher rates of withdrawal of drug 
candidates from phase II or phase III clinical trials are due to lack of efficacy or 
unintended toxicity, although other factors including lack of correlation between 
disease animal models and human disease or polymorphisms in patients might be 
potential causes for failure in translatability (Bunnage et al., 2013; Zheng et al., 
2013; Morgan et al., 2012). Such reported lack of efficacy in the late stage of 
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drug development implies that improper target validation in the early stage drug 
discovery program is a major contributing factor for high attrition rates of 
clinical drug candidates in phase II or phase III clinical trials (Jones, 2016; Zheng 
et al., 2013; Bunnage et al., 2013). Therefore, in the target-based drug 
discovery approach, effective preclinical target validation is the key to success 
in translation of pharmacology of drug candidates into clinical effect. As use of 
low quality pharmacological tool compounds (nonselective and 
undercharacterized probe without having defined mechanism of action) can lead 
to incomplete or misleading results regarding the biological function and 
pathophysiological roles of the target of interest (Clegg et al., 2017), generation 
of highly selective and potent tool compounds with thorough pharmacological 
characterization is vital for uncovering the therapeutic potential of the 
molecular target (Milligan, 2018; Wacker et al., 2017).     
1.1.2 Role of GPCRs in therapeutic pharmacology 
G protein coupled receptors (GPCRs) are seven transmembrane domain (7TM) 
containing integral membrane proteins which bind and activate heterotrimeric 
G-proteins to transduce an extracellular signal to intracellular effector proteins 
leading to cellular response. As they can also interact with other cytoplasmic 
signalling proteins including kinases and β-arrestins, seven transmembrane 
receptors (7TMR) is a more appropriate terminology (Kobilka, 2007). However, 
the GPCR terminology is widely accepted and hence in this thesis this 
terminology will be used. The GPCR superfamily comprising about 800 members 
(Fredriksson and Schioth, 2005) in humans is the largest family of membrane 
spanning proteins. Among them 400 members are olfactory receptors and rest 
are nonolfactory/chemosensory receptors i.e. they are responsive to diverse 
chemicals including ions, neurotransmitters, biogenic amines, small and large 
peptides, hormones, lipids, intermediate metabolites including ATP, fatty acids 
etc. and thus regulate almost all physiological processes (Hauser et al., 2017).  
Among the various pharmacological targets including GPCRs, ion channels, 
kinases, nuclear hormone receptors, proteases and transporters, historically 
GPCRs have been considered as the most successful molecular targets for drug 
development, and several researchers (Sriram and Insel, 2018; Hauser et al., 
2017; Santos et al., 2017; Rask-Andersen et al., 2014; Rask-Andersen et al., 
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2011; Overington et al., 2006; Hopkins and Groom, 2002; Menzaghi et al., 2002) 
highlight that GPCRs are the targets for approximately 30-36% of FDA-approved 
drugs. Among the 398 nonolfactory GPCRs in human, 134 GPCRs have already 
been exploited therapeutically, contributing to the development of some 700 
FDA approved drugs (Sriram and Insel, 2018) and 66 novel GPCRs are targets for 
321 potential drug candidates which are under investigation in clinical trials 
(Hauser et al., 2017). Still there remain 198 nonolfactory GPCRs that might be 
potential untapped sources for future drug development. High success in 
therapeutic exploitation of GPCRs stems from the substantial association of 
GPCR signalling with diverse human pathophysiological processes and high 
pharmacological tractability of this superfamily due to the presence of druggable 
binding sites in the extracellular sides of the receptor which make them more 
accessible to small molecules (Sriram and Insel, 2018; Milligan, 2018; Rask-
Andersen et al., 2014). These druggable binding sites (orthosteric and allosteric 
sites) on GPCRs possess physicochemical properties required for designing small 
molecule drugs (molecular weight <900 daltons) having favourable oral 
bioavailability (Mason et al., 2012; Wacker et al., 2017). Recent developments in 
structural biology of GPCRs due to the availability of crystal structures of 44 
GPCRs and 205 ligand-receptor complexes (Hauser et al., 2017) will revolutionize 
structure-based drug design as it will facilitate virtual screening-based lead 
discovery and lead optimization processes. Along with this structural 
information, therapeutic exploitation of untapped GPCRs will be promoted by 
the utilization of new modalities of GPCR pharmacology including allosteric 
modulation and biased signalling (G protein and β-arrestin biased agonism or 
antagonism or allosteric modulation) leading to enhanced selectivity and 
specificity of the agent with concomitant improvement in drug safety profile 
(Hauser et al., 2017; Sriram and Insel, 2018). Moreover, recent discovery of new 
types of GPCR-targeted biologics including monoclonal antibodies/nanobodies, 
anti-sense oligonucleotides and gene therapy as well as novel drug delivery 
systems are likely to accelerate GPCR-based drug discovery programs (Sriram 
and Insel, 2018).     
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1.1.3  Challenges in clinical exploitation of orphan or poorly 
characterized GPCRs 
Although more than 350 genes encode for non-olfactory GPCRs (Fredriksson et 
al., 2003), only 250 of them have been characterized in terms of ligand 
recognition and there remain over 100 orphan GPCRs i.e. their endogenous 
ligands are either unexplored or there is a lack of consensus among the scientific 
community regarding the physiological relevance of proposed endogenous ligands 
(Milligan, 2018; Davenport et al., 2013; Chung et al., 2008; Geetha et al., 2007; 
Fredriksson and Schioth, 2005). Orphan GPCRs might be a potential source of 
therapeutics and several drug candidates which are currently under clinical trials 
target different orphan receptors. Based on their selective expression profile 
and association with different disease states, orphan receptors are appreciated 
to be potential therapeutics for several diseases including diabetes (GPR119), 
allergic inflammation and cardiovascular diseases such as angiotensin-II induced 
hypertension and heart failure (GPR35), multiple sclerosis (GPR55), ulcerative 
colitis (GPR84), gastrointestinal diseases (LGR4 and LGR5), Alzheimer’s disease 
(GPR3), CNS disorders including schizophrenia (GPR88) etc. (Ye et al., 2019; 
Sriram and Insel, 2018; Hauser et al., 2017; Stockert and Devi, 2015; Fang et al., 
2015; Divorty et al., 2015; Divorty et al., 2018). However, there remain a 
number of challenges to exploit these enigmatic receptors therapeutically. Due 
to the lack of structural information, designing and identifying selective and 
potent tool compounds for orphan receptors is difficult which makes 
understanding of the biological function and pharmacological properties of these 
undercharacterized receptors more challenging. Even after the receptor has 
been deorphanized i.e. paired with an endogenous ligand, orphan receptors still 
remain poorly characterized in terms of their signalling pathways, 
pharmacological properties and biological functions. As during the 
deorphanization stage, high throughput screening of a large number of chemicals 
is performed using assays (internalization assays, β-arrestin recruitment assays, 
Ca mobilization assays employing chimeric or promiscuous G proteins) in which 
final readout is independent of specific signalling pathways, one of the initial 
challenges to uncover therapeutic potential of orphan receptors is to explore 
which specific G protein(s) is coupled to the receptor and what are the 
downstream signalling pathways (Hudson et al., 2011). Such information 
regarding the signal transduction pathways are required for designing/ 
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development of assays to be employed in subsequent target validation processes 
or in defining the pharmacology of the specific receptor (Hudson et al., 2011). 
As tool compounds are vital for characterization of the receptor, development of 
potent and selective pharmacological ligands for an orphan receptor is crucial 
which can be used confidently to probe receptor functions in both physiological 
and disease states (Milligan, 2018; Wacker et al., 2017). The paucity of potent 
and selective chemical probes has been considered to be one of the major 
obstacles to the proper characterization of enigmatic receptors including GPR35, 
FFA2 etc. which has been hindering their therapeutic exploitation (Milligan, 
2018; Divorty et al., 2015; Holliday et al., 2012). In this context investigation of 
ligand binding modes i.e. defining which amino acid residues are responsible for 
the ligand recognition are essential as this information could be subsequently 
employed in structure based drug design (SBDD) to identify and generate novel  
selective and potent synthetic ligands having potential to probe receptor 
functions (Hudson et al., 2011). However in case of orphan receptors structure-
based drug design using virtual screening is challenging due to lack of any crystal 
structures and thus is dependent on constructing high quality homology models 
using the available crystal structure of other receptors which displays high 
sequence identity with the target receptor (Ngo et al., 2016). In addition, 
defining the mode of actions of pharmacological tool compounds along with 
identifying their potential orthologue selectivity and designing more improved 
disease models to be used in in vivo functions of the receptor are of paramount 
importance to uncover the therapeutic potential of such poorly characterized 
receptors (Milligan, 2018; Hauser et al., 2017).    
1.1.4  GPCRs: structural features and classification 
GPCRs are single polypeptides characterized by common structural features of 
having a seven transmembrane (TM1-7) hydrophobic α-helices connected by 
three intracellular loops (ICL1-3) and three extracellular loops (ECL1-3), a 
variable extracellular N-terminal domain and an intracellular C-terminal domain 
(Kobilka, 2007)(Figure 1.1). From the extracellular side view, the seven 
transmembrane helices are oriented in a counter-clockwise manner forming a 
helical bundle which serves as the structural core of the receptor. While the 7-
TM domain displays highest degree of sequence similarity among different 
classes of GPCRs, the N-terminus, C-terminus and ICL3 are divergent in terms of 
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structure and sequence (Kobilka, 2007). Extracellular regions contain conserved 
cysteine residues forming disulphide bonds which confer stability to the 
structure. For example, most of the GPCRs contain a disulphide bridge 
connecting ECL2 and TM3 (Venkatakrishnan et al., 2013). Broadly, extracellular 
regions of the receptor including N-terminus, extracellular loops (especially 
ECL2) and extracellular sides of the 7-TM domains serve as ligand binding 
pockets and the signal(s) is transduced to the intracellular effector proteins (G 
proteins, GRK, arrestin) by conformational rearrangements of TM domains in 
which the intracellular loops and cytoplasmic sides of TM domains constitute the 
binding pocket for cytosolic signalling effector proteins (Venkatakrishnan et al., 
2013; Katrich  et al., 2013).TM3 is considered as the structural and functional 
hub of the receptor playing crucial roles in ligand binding, signal transmission 
and G-protein interaction (Venkatakrishnan et al., 2013).  
 
 
Figure 1.1Basic characteristic topology of G-protein coupled receptors.  
All GPCRs share a common structural motif in which seven hydrophobic α helices traverse the 
phospholipid bilayer of the plasma membrane which is connected by three extracellular loops 
(ECL1-3) and three intracellular loops (ICL1-3). Besides these 7-transmembrane domains (TMD), 
GPCRs also have an extracellular N-terminus and an intracellular C-terminus domain.     
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Based on phylogenetic criteria, Fredriksson et al., (2003) divided human GPCRs 
into five main families, glutamate like, rhodopsin like, adhesion, frizzled/taste2 
and secretin (Figure 1.2).  
1.1.4.1 Rhodopsin like (Class A) family 
The rhodopsin like Class A family is the largest family comprising 719 members 
including aminergic receptors, muscarinic receptors, free fatty acid receptors 
etc. (Alexander et al., 2017). This class includes the most successfully exploited 
drug targets. Diverse ranges of small molecule ligands including 
neurotransmitters, hormones, small peptides, photons etc. bind to the binding 
pocket created by the seven transmembrane helical bundle of Class A family, 
though extracellular loops also may play important roles in ligand recognition 
(Weis and Kobilka, 2018). In contrast to the other four families, Class A family 
receptors possess a short N-terminus (Lagerstrom and Schioth, 2008) which does 
not play role in ligand binding (Fredriksson et al., 2003). Class A family receptors 
contain the highly conserved (E)/DRY motif at the interface between the 
cytoplasmic end of TM3 and ICL2, and the NPxxY motif in TM7 (Fredriksson et 
al., 2003) which act as micro-switches stabilizing the inactive conformations and 
undergo rearrangements in amino acid positions upon GPCR activation (Weis and 
Kobilka, 2018).      
1.1.4.2 Secretin family (Class B) 
The secretin family (Class B) comprises 15 GPCRs in human including calcitonin 
receptor, secretin receptor, vasoactive intestinal peptide receptor etc., and 
contains a long N-terminal tail (60-80 amino acids) having 6 conserved cysteine 
residues which form three conserved disulphide bonds imparting stability to the 
structure as well as serving to dock the C-terminal region of peptide ligands 
(Fredriksson et al., 2003; Schiöth and Fredriksson, 2005). Conserved cysteine 
residues are also present in ECL1 and ECL2. Secretin family receptors are 
responsive to diffusable ligand, large peptides which are accommodated by 
orthosteric binding sites encompassing both the N-terminus and extracellular 
loops. 
1 Introduction  9 
 
 
Figure 1.2Basic structural motifs of five families of G-protein coupled receptors.  
The GRAFS classification system divides all the GPCRs of vertebrates into five major classes. 
Rhodopsin like Class A family receptors contain a short N-terminus (A) while the other four families 
possess large N-termini with specific conserved domain(s) (B-E). A cysteine rich (cysteine residues 
are depicted as small yellow circles) hormone binding domain in N-terminus along with the 
extracellular loops constitutes the orthosteric binding site for Secretin family (B). Adhesion family 
receptors are characterized by presence of a cysteine rich GPCR proteolysis site (GPS) motif 
embedded in a conserved GPCR autoproteolysis inducing domain (GAIN) and by adhesion-like 
motifs responsible for cell-cell and cell-matrix interactions (C). The N-terminus of Class C 
Glutamate family receptors contains a unique bilobar venus fly trap domain (VFD) and a cysteine 
rich domain (CRD) (D). The cleft between two lobes of VFD represents the orthosteric binding 
pocket for orthosteric ligands, shown as blue circles. Frizzled receptors contain a conserved 
cysteine rich domain (CRD) in the N-terminus to which Wnt glycoproteins bind (E).  
     
1.1.4.3 Glutamate receptor family (Class C) 
The glutamate receptor family (Class C) contains 22 members including 
metabotropic glutamate receptors, calcium sensing receptors (CaSR), GABAB 
receptors etc. Class C glutamate like receptors are characterized by long N-
terminal tail (280-580 amino acids) containing a bilobal venus fly trap domain 
(VFD) and a cysteine rich domain in between the helical domain and VFD 
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(Lagerstrom and Schioth, 2008; Fredriksson et al., 2003). Orthosteric ligands 
bind to the cleft created by two distinct lobes of VFD while allosteric modulators 
bind within the helical bundle (Rosenbaum et al., 2009). Class C receptors form 
homodimers or heterodimers and this dimerization is required for the functional 
activation of the receptor.  
1.1.4.4  Adhesion family 
The adhesion family is the second largest family of human GPCRs containing 33 
members, most of which are orphan receptors (Largerstrom and Schioth, 2008). 
This family is also termed as Class B2 family as the 7TM domain is structurally 
similar to Class B secretin family. Similar to secretin family, these receptors 
contain a large N-terminus. In contrast to the secretin family, the N-terminus 
contains a unique conserved GPCR autoproteolysis inducing domain (GAIN 
domain) composed of some 320 amino acid residues and specific functional 
domains/cell adhesion domains (EGF, cadherin, lectin, laminin, immunoglobulin 
like domain etc.) responsible for ligand-receptor interactions (Largerstrom and 
Schioth, 2008; Hamann et al., 2015; Alexander et al., 2015). GAIN domain 
contains a cysteine rich GPCR proteolysis site (GPS) comprising approximately 40 
to 50 amino acid residues (Arc et al., 2012; Hamann et al., 2015). Adhesion 
family receptors undergo autoproteolysis in the GPS motif resulting in two parts, 
N-terminal fragment (NTF) and 7TM containing C-terminal fragment (CTF) 
connected by noncovalent interactions. Adhesion like motifs of functional 
domains are engaged in cell-cell and cell-matrix adhesion (Yona et al., 2008; 
Hamann et al., 2015; Fredriksson et al., 2003) which is the basis of the ‘adhesion 
family’ nomenclature.  
1.1.4.5 Frizzled/taste2 receptors 
Frizzled/taste2 receptors, comprising 24 members, are characterized by a large 
N-terminus (200 amino acids) containing a cysteine rich domain which, along 
with extracellular loops acts as the binding site for the orthosteric ligand such as 
secreted lipoglycoproteins/Wnt glycoproteins (Fredriksson et al., 2003; Schulte, 
2010). Similar to other GPCRs, frizzled receptors contain conserved cysteine 
residues on ECL1 and ECL2. (Schulte, 2010). Frizzled receptor-mediated 
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signalling including Wnt/β-catenin signalling is associated with developmental 
processes.      
1.2 Heterotrimeric G proteins 
Heterotrimeric G proteins are guanine nucleotide binding proteins composed of 
three subunits (α, β and γ subunits) which act as signal transducers, relaying 
information from activated cell surface receptors (GPCRs) to intracellular 
effector proteins including enzymes and ion channels (Simon et al., 1991). Gα 
subunit is composed of a Ras-like GTPase domain and an α-helical domain 
(Sprang et al., 2007). The guanine nucleotide (GDP or GTP)-binding pocket is 
located in a deep cleft between these two domains (Gurevich and Gurevich, 
2018). In resting condition, GDP is bound to Gα subunit, while GDP is displaced 
by GTP upon G protein activation. Gβ and Gγ subunits are tightly associated with 
each other forming a heterodimer which acts as a functional unit. There are 20 
isoforms of Gα subunit (Sprang et al., 2007), five isoforms of Gβ subunit (β1-5) 
and twelve isoforms of Gγ subunits (γ1-5 and γ7-13) (Wettschureck and 
Offermanns, 2005; Milligan and Kostenis, 2006). G proteins are classified based 
on the variation in Gα subunit. On the basis of sequence homology and 
functional similarities G proteins are divided into four major classes including 
Gαs, Gαi/o, Gαq/11 and Gα12/13 family G proteins (Simon et al., 1991; Syrovatkina 
et al., 2016), each class contains two or more isotypes. In the case of Gαs family 
which stimulates adenylyl cyclase enzymes, while the Gαs isotype is ubiquitously 
expressed, Gαolf is expressed largely in olfactory neurons (Syrovatkina et al., 
2016; Milligan and Kostenis, 2006). Gαi/0 family G proteins which inhibit adenylyl 
cyclase enzymes is the most diverse and largest family containing Gαi1, Gαi2, 
Gαi3, GαoA, GαoB, Gαg, Gαt1, Gαt2 and Gαz isotypes (Syrovatkina et al., 2016). 
Among them, Gαi1, Gαi2 and Gαi3 are expressed ubiquitously whilst expression of 
Gαo, Gαt and Gαz are highly restricted to neuron and neuroendocrine, retinal 
rods and cone cells and neuron and platelets, respectively (Syrovatkina et al., 
2016; Milligan and Kostenis, 2006). Gαq/11 family which activates phospholipase 
Cβ enzymes contains Gαq, Gα11, Gα14, Gα16 or Gα15 (mouse version of Gα16) 
isotypes among which Gαq and Gα11 are ubiquitous while Gα14 and Gα15/16 are 
found in only hematopoietic cells and kidney, lung or liver, respectively 
(Syrovatkina et al., 2016). Gα12/13 family G proteins comprised of Gα12 and Gα13 
isoforms are expressed in every cell/tissue and are appreciated to regulate 
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several Rho-GEFs (Syrovatkina et al., 2016; Milligan and Kostenis, 2006; 
Wettschureck and Offermanns, 2005).  
1.3 GPCR-mediated signal transduction pathways 
1.3.1  G-protein dependent pathways 
1.3.1.1  GPCR activation and G protein recruitment   
The fundamental function of a GPCR is to link extracellular signals to 
intracellular effector proteins which then regulate signalling cascades leading to 
the generation of a biological response. GPCR activation following agonist 
binding is the first stage of this complex signalling process. At resting state 
GPCRs maintain an equilibrium between active and inactive conformational 
states. Agonist binding to a specific GPCR favours and stabilizes active 
conformational states which are characterized by structural rearrangements of 
the cytoplasmic end of TM domains and side chain micro-switches. Comparison 
of inactive and active state crystal structures of several Class A GPCRs, including 
rhodopsin, β2-adreneric receptor, M2 muscarinic receptor, µ opioid receptor and 
adenosine A2A receptor revealed that agonist-stimulated conformational changes 
reflect a conserved rotation and outward movement of TM6 by 3.5-14 Aº away 
from the helical bundle with concomitant outward movement of TM5 and inward 
movement/rearrangements of TM7 (Scheerer et al., 2008; Rasmussen et al., 
2011; Lebon et al., 2011; Xu et al., 2011; Kruse et al., 2013; Ring et al., 2013; 
Huang et al., 2015). Micro-switches including the conserved (E)/DRY motif in 
TM3 and NPxxY motif in TM7 undergo rotamer conformational changes upon class 
A GPCR activation (Kruse et al., 2013; Katritch et al., 2013) and these 
rearrangements of conserved motifs are important for the stabilization of 
movement of cytoplasmic ends of TM domains (Katritch et al., 2013). For 
example, disruption of electrostatic interaction or the so called “ionic lock” 
between Arg3.50 of conserved (E)/DRY motif in the cytoplasmic end of TM3 and 
acidic residues including Glu6.30 in TM6 was reported to be associated with 
conversion from inactive to active state conformations of rhodopsin (Scheerer at 
al., 2008;), β2 adrenergic receptor (Kobilka, 2007) and probably for other Class 
A GPCRs. Breakdown of this ionic lock in rhodopsin and β2-adrenergic receptors 
facilitates outward movement of TM6 away from the core of the helical bundle 
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(Altenbach et al., 2008;  Yao et al., 2006) and thereby leads to stabilization of 
active conformations of the corresponding receptor. Similarly, the highly 
conserved Tyr7.53 of the NPxxY motif at the cytoplasmic end of TM7 undergoes 
rotamer conformational changes upon activation of several Class A GPCRs 
including rhodopsin, adrenergic receptors, adenosine receptors etc. (Labon et 
al., 2011; Xu et al., 2011; Audet and Bouvier, 2012; Katritch et al., 2013). These 
conformational rearrangements of TM5, TM6 and TM7 open a crevice lined by 
amino acid residues from TM3, TM5 and TM6 on the intracellular cytoplasmic 
sides of the transmembrane domains which serves as the binding pocket for the 
C-terminal α5 helix of the Gα subunit of a heterotrimeric G protein (Weis and 
Kobilka, 2018; Venkatakrishnan et al., 2013; Hofmann et al., 2009). Similar to 
Class A GPCRs, activated Class B family receptors including GLP-1R and the 
calcitonin receptor also display large outward movements (15 and 18Aº, 
respectively) of TM6 and a small inward movement of TM7 forming a cavity on 
the cytoplasmic sides of the helical domains to which α helix of Ras-like domain 
of the Gs subunit binds (Zhang et al., 2017; Liang et al., 2017). These studies 
implied that despite having differences in terms of amino acid sequences, the 
mechanism of GPCR activation is conserved among different classes of GPCRs. 
Not only does agonist binding promote G protein binding to the receptor, in a 
reciprocal way G protein recruitment also enhances agonist affinity for the 
receptor, which implies that GPCRs act as classic allosteric proteins (Weis and 
Kobilka, 2018).  
Binding of G protein to the agonist-bound activated GPCR triggers a 
conformational change in the G protein which promotes exchange of GTP for 
GDP in the cleft between the Ras-like domain and the α-helical domain of Gα 
subunit (Syrovatkina et al., 2016). GTP binding to Gα subunit leads to 
dissociation of the G protein from agonist-bound GPCR as well as dissociation of 
Gα subunit from the Gβγ heterodimer. Both Gα subunit and Gβγ dimer can then 
act as signal transducers stimulating downstream signalling pathways 
(Syrovatkina et al., 2016), which are described briefly in the following 
subsection. G protein-dependent signalling is terminated by the inherent GTPase 
activity of the Gα subunit which hydrolyses bound GTP into GDP and inorganic 
phosphate (Syrovatkina et al., 2016). This inherent GTPase activity is further 
accelerated by GTPase activating proteins (GAPs) such as regulators of G protein 
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signalling (RGS) proteins (Ross and Wilkie, 2000). The hydrolysis product GDP-
bound Gα subunit can then re-associate with Gβγ dimer forming the 
heterotrimeric G protein which can further bind to agonist-bound activated 
GPCR to initiate another cycle. This activation-deactivation cycle for G protein is 
depicted in Figure 1.3 (A, D).    
1.3.1.2  Gα-mediated signalling  
Activated GTP bound Gα subunits transduce extracellular signal from activated 
GPCRs to the intracellular signal effectors generating several second 
messengers. Activated Gαs (s stands for stimulatory) G protein activates 
transmembrane adenylyl cyclase (AC) enzymes which catalyse conversion of ATP 
to cyclic adenosine monophosphate (cAMP) (Gilman, 1987). Elevated 
intracellular cAMP levels lead to activation of cAMP-dependent protein kinase A 
(PKA) followed by a phosphorylation-induced cascades of downstream substrates 
ultimately leading to cellular responses including gene expression, 
glycogenolysis, lipolysis, hormone secretion etc. (Wettschureck and Offermanns, 
2005). In contrast to Gs G protein, activated Gαi/o family G proteins inhibit 
adenylyl cyclase activity resulting in decreased intracellular cAMP levels. Active 
Gαq/11 G proteins activate phospholipase Cβ which catalyses hydrolysis of 
phosphatidylinositol 4,5-bisphosphate (PIP2) into 1,4,5-triphosphate (IP3) and 
diacylglycerol (DAG) (Rhee, 2001). IP3 triggers intracellular calcium mobilization 
by interacting with the IP3 receptor on the ligand-gated calcium channel of the 
endoplasmic reticulum whilst DAG activates protein kinase C (PKC) which 
triggers downstream phosphorylation cascades (Wettschureck and Offermanns, 
2005). Depending on the cell types, these second messengers (IP3, Ca
2+, DAG) 
mediate different cellular processes including smooth muscle contraction, 
neuronal excitation, platelet activation etc. (Wettschureck and Offermanns, 
2005). Gα12/13 family G proteins were reported to mediate cellular signalling 
pathways which are associated with cytoskeleton rearrangements/cell 
contraction, cell migration, invasion, platelet activation, cell growth and 
differentiation (Juneja and Casey, 2009; Suzuki et al., 2009). Both activated 
Gα12 and Gα13 subunits were reported to activate Rho-specific guanine 
nucleotide exchange factors such as PDZ-RhoGEF and leukemia-associated 
RhoGEF (LARG) whilst activity of p115 Rho GEF was enhanced by only Gα13 
subunit (Kozasa et al., 1998; Hart et al., 1998; Fukuhara et al., 1999; Fukuhara 
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et al., 2000; Siehler, 2007; Siehler, 2009; Suzuki et al., 2009). These stimulated 
Rho GEFs then promote GTP exchange for GDP on monomeric Rho GTPases which 
activates downstream Rho kinase (ROCK) leading to actin cytoskeleton 
rearrangements and cellular contraction (Siehler, 2009; Siehler, 2007). Activated 
Gα12 has also been shown to stimulate RasGAP-Ras-MEKs and MEK5-ERK5 
pathways leading to cellular growth and transformation (Juneja and Casey, 2009) 
while activated Gα13 was reported to interact with Hax-1 protein which activates 
downstream Rac protein leading to cellular migration (Radhika et al., 2004).         
1.3.1.3  Gβγ-mediated signalling  
Gβγ heterodimer dissociated from the GTP bound Gα subunit of activated G 
protein was shown to mediate many of the signalling pathways that are similar 
to those stimulated by Gα-dependent pathways. For example, Gβγ was reported 
to activate phospholipase Cβ2 isoforms (Rhee, 2001) resulting in generation of 
second messengers IP3 and DAG from PIP2, triggering intracellular calcium 
mobilization and PKC-mediated signalling, respectively. Gβγ also stimulates 
phosphatidylinositol 3 kinases (β and γ isoforms) leading to activation of the AKT 
signalling pathway which is associated with cell survival and proliferation (Naor 
et al., 2000; Khan et al., 2013). While Gβγ was shown to stimulate adenylyl 
cyclase type II, IV and VII leading to enhanced production of intracellular cAMP 
level, adenylyl cyclase type I was reported to be inhibited by this transducer 
(Khan et al., 2013; Milligan and Kostenis, 2006). It is also appreciated that Gβγ 
dimer activates mitogen activated protein kinase (MAPK) signalling pathways 
including c-Src-mediated phosphorylation of extracellular signal-regulated 
kinase1/2 (ERK1/2) (Naor et al., 2000). Finally, Gβγ dimer was also reported to 
directly interact with ion channels including inwardly rectifying K+ channel and 
voltage-dependent Ca2+ channel (VDCC) resulting in activation and inhibition of 
the channels, respectively (Khan et al., 2013). As Gαi G proteins are expressed in 
cells more abundantly than Gαs or Gαq family G proteins, Gβγ-dependent 
signalling is usually mediated by the activation of Gαi-coupled receptors 
(Syrovatkina et al., 2016 Wettschureck and Offermanns, 2005).   
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Figure 1.3 GPCR-mediated signal transduction pathways and regulatory mechanisms of 
signal termination.  Upon agonist binding, GPCR changes its conformation by structural 
rearrangements of cytoplasmic ends opening a pocket for binding of C terminal helix of Gα subunit 
of heterotrimeric G protein (A). Activated GPCR acts as a guanine nucleotide exchange factor 
(GEF) to induce exchange of GTP for GDP on Gα subunit. GTP-bound Gα subunit then dissociates 
from Gβγ dimer and both can act as signal transducer. Gα-dependent signalling pathways are 
illustrated in (B). While active Gαs and Gαi regulate adenylyl cyclase enzyme activity resulting in 
enhanced or reduced intracellular cAMP levels, respectively, activated Gαq/11 G proteins stimulate 
PLCβ-IP3-Ca signalling pathway. Gα12/13 activates Rho guanine nucleotide exchange factors 
(RhoGEFs) which trigger RhoA/ROCK signalling pathway. G protein activation and subsequent 
signalling is terminated by inherent GTPase activity of Gα subunit which results in hydrolysis of 
GTP into GDP and phosphate group followed by re-association of Gα-GDP and Gβγ (D). 
Regulators of G protein signalling (RGS) acts as GTPase activating protein (GAP) promoting the 
hydrolysis of GTP into GDP. Gβγ dimer also can activate downstream signalling pathways 
including stimulation of adenylyl cyclase, PLCγ/PLCβ2, PI3 kinases and ERK1/2 as well as 
regulates inwardly rectifying K
+
 and Ca
2+
 channels. GPCR signalling is also regulated by 
phosphorylation of serine-threonine residues on C-terminal tails and ICL3 by G protein-coupled 
receptor kinases (GRK) and subsequent recruitment of β-arrestin to the phosphorylated active 
receptor (E) which sterically hinders further G protein coupling to the receptor. β-arrestin acts as a 
scaffolding protein to recruit clathrin and AP-2 leading to clathrin-mediated endocytosis of the 
receptor (F). β-arrestin can also stimulate downstream signalling pathways including stimulation of 
MAPKs pathways (G). Endosomal β-arrestin also can trigger G-protein independent signalling 
pathways (H). Endocytosed receptor would be then either targeted for degradation in lysosomes (I) 
leading to downregulation or subjected to dephoshorylation and recycling back to membrane to 
induce resensitization (J).    
1.3.1.4  Regulation of G protein-mediated signalling   
To counteract sustained GPCR-mediated signalling some regulatory mechanisms 
operate in every cell type. G protein-mediated signalling is terminated by a 
cascade of regulatory processes including GPCR phosphorylation and β-arrestin 
coupling, endocytosis and downregulation of GPCR by lysosomal degradation 
(Luttrell and Lefkowitz, 2002). These regulatory processes lead to the 
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desensitization of GPCR which is defined as the attenuation of response to 
agonist resulting in decreased generation of second messengers. Serine-
threonine residues on the C-terminal tail and ICL3 of agonist-bound activated 
GPCRs undergo phosphorylation by G-protein coupled receptor kinases (GRKs) 
which enhances affinity of the regulatory arrestin proteins for the receptor 
(Shukla et al., 2011). Nonvisual arrestins, β-arrestin 1 and β-arrestin 2 then bind 
to the phosphorylated agonist-activated GPCR leading to uncoupling of G-
proteins due to steric hindrance which attenuates further signalling from 
activated receptor (Luttrell and Lefkowitz, 2002; Smith and Rajagopal, 2016). β-
arrestins act as scaffolding proteins recruiting several trafficking proteins 
including clathrin, adapter protein 2 (AP-2), NSF etc which trigger endocytosis of 
the receptor (Lefkowitz and Shenoy, 2005). This internalization of receptor, 
resulting in reduced number of cell surface receptors might not be essential for 
receptor desensitization but contributes to the receptor dephoshorylation and 
re-sensitization (Shenoy and Lefkowitz, 2003). Upon internalization, Β-arrestin is 
released from the agonist-occupied endosomal receptor followed by ligand 
dissociation and dephosphorylation of the receptor by phosphatases in an 
acidified vesicle compartment (Luttrell and Lefkowitz, 2002). Endocytosed 
receptor can then either be targeted for degradation in lysosomes leading to 
downregulation of GPCR or can be recycled back to the membrane, a process 
which is known as re-sensitization (Shenoy and Lefkowitz, 2003). 
1.3.2  G-protein independent pathways 
In addition to playing a crucial role in GPCR desensitization and internalization, 
β-arrestins are appreciated to behave as signal transducers by acting as 
scaffolding proteins for recruitment of different signalling molecules to the 
activated agonist-bound GPCR (Eichel et al., 2016; Shukla et al., 2011; Ma and 
Pei, 2007; Reiter and Lefkowitz, 2006; Luttrell and Lefkowitz, 2002). Β-arrestins 
are reported to act as adapter proteins recruiting c-Src tyrosine kinase to 
activated GPCR ultimately leading to ERK1/2 activation (DeWire et al., 2007). Β-
arrestins were also shown to scaffold ERK1/2 cascades, p38 cascades and JNK3 
signalling cascades, leading to activation of the corresponding MAP kinase 
(Lefkowitz and Shenoy, 2005; Shenoy and Lefkowitz, 2003). Β-arrestin –
dependent signalling was also shown to regulate activation of PI3K-AKT pathway 
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and inhibition of NF-κB pathways (DeWire et al., 2007; Reiter and Lefkowitz, 
2006).  
1.4 Pharmacology of GPCR ligands 
1.4.1 Pharmacology of orthosteric ligands 
The pharmacology of a drug is characterized by three parameters, binding 
affinity for the receptor, target coverage and efficacy of the ligand (Kenakin, 
2013). Affinity of the drug for the receptor reflcets how strongly the drug can 
bind with the binding site on the receptor and usually is represented by the 
equilibrium dissociation constant measured in direct binding assays such as 
saturation and competition binding assays using a radiolabelled ligand or in 
florescence polarization assays using fluorescent ligands (Rossi and Taylor, 
2011). In the case of unavailability of radiolabelled or fluorescent probes, the 
potency value measured in functional assays using [35S]-GTPγS binding assays 
employing a GPCR-G protein fusion protein or BRET-based β-arrestin recruitment 
assays have been used as surrogate measures of agonist binding affinity for the 
receptor as these assay systems provide 1:1:1 stoichiometry of 
ligand:receptor:readout as G-protein activation or β-arrestin recruitment are 
immediately downstream of GPCR activation and thus are not subjected to signal 
amplification (Smith, 2012; Hudson et al., 2014b). Efficacy of a ligand is defined 
as the property of a drug to trigger measurable physiological or pharmacological 
responses following binding to the receptor (Kenakin, 2001; Smith et al., 2011a) 
and is usually defined by the parameter Emax, the maximal response obtained 
from the concentration-response curve for the ligand conducted in functional 
assays. The molecular basis of efficacy of a ligand lies in the ligand-stimulated 
change in conformation of the target receptor which exposes the active 
sequences on the cytosolic region of the receptor to trigger the binding 
and/activation of signalling effector proteins such as G-protein/arrestin or other 
proteins including GRKs leading to cellular response or change in receptor 
behaviour, respectively (Kenakin, 2002). The least complex model of GPCR 
activation is presented by the classic two state thermodynamic equilibrium 
model according to which a GPCR can exist in either an inactive or active state 
and an equilibrium is maintained between the two states (Leff, 1995; Kobilka 
and Deupi, 2007; Park et al., 2008). Upon binding to receptor, different ligands 
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can display preferential affinity for one of the two states and thereby selectively 
stabilize either of these two states, which forms the basis for the classification 
of orthosteric ligands into agonist, inverse agonist and neutral antagonist (Figure 
1.4). Agonists are further divided into full and partial agonists depending on the 
extent of receptor activation triggered by them. Full agonists can trigger the 
receptor activation to the full extent leading to generation of highest maximal 
response while partial agonists cause partial receptor activation, leading to sub-
maximal responses (Kenakin, 2001; Kobilka, 2007). Though the two state model 
can describe the different functional activities of GPCRs in response to 
treatment with various ligands having different efficacy, in reality like other 
proteins, GPCRs can exist in multiple states and always display a cluster of 
conformations described as an ensemble (Kenakin, 2002; Kenakin, 2013; Kobilka 
and Deupi, 2007). In basal condition, the unliganded receptor displays a set of 
conformations among which predominant conformations are inactive basal 
ensembles which are not related to cellular activity while very few 
conformations are associated with cellular response (G-protein activation, 
phosphorylation, arrestin recruitment etc) and are termed as the 
pharmacologically active ensemble which lead to ligand-independent signalling 
or constitutive activity (Kenakin, 2013). Ligand binding to the receptor causes a 
redistribution of such a cluster of conformations in such a way that ligand-
stabilized conformations are co-incident with the pharmacologically active 
ensemble and leads to cellular activation (Kenakin, 2002; Kenakin, 2013). As 
there are various pharmacologically active ensembles which are related to 
different responses including G-protein activation, arrestin binding, 
phosphorylation etc, it is possible that a ligand might have different efficacies in 
each i.e efficacy is pluridimensional (Kenakin, 2011). The prevalence of these 
agonist-stabilized ensembles associated with different signalling pathways is 
determined by the relative stabilization by agonist and will define the strength 
and preference of activation of a specific signalling pathway (Kenakin, 2013). 
Some ligand might preferentially activate a specific signalling pathway over 
other(s) which is termed as agonist bias or functional selectivity (Kenakin, 2011). 
This signalling bias can be exploited for the development of more selective and 
safer drug candidates.         
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Figure 1.4 Different types of orthosteric ligands based on two-state GPCR activation model. 
According to the classic ‘two-state model’ of GPCR activation, GPCRs can isomerise from the 
inactive state to active state and ligands are classified based on their ability to shift the equilibrium 
to these. If a small fraction of total receptors adopt the conformation related to active state while the 
predominant form are in inactive states, then even in the absence of any ligand, some system 
response might be found, and this activity is termed ligand-independent signalling or constitutive 
activity (Ai). Upon binding to the receptor, if a ligand shifts the equilibrium to favour active 
conformations, then it is termed as an agonist (Aii) whilst ligands that shift the equilibrium toward 
inactive conformations are classed as inverse agonists (Aiii). Neutral antagonists are thought to 
have similar binding avidity for both the active and inactive conformation of the receptor (Aiv) and 
thus although they can competitively inhibit agonist binding to the receptor, they do not possess 
any efficacy on their own right. Representative concentration-response curves for different types of 
orthosteric ligands in a constitutively active GPCR system are shown in (B). Full agonists are 
endogenous agonists displaying highest maximal response in a specific tissue/system while 
superagonists are termed as synthetic ligands which share common binding sites with endogenous 
agonist but exhibit higher maximal response than the full agonist. A partial agonist display sub-
maximal response whilst a neutral antagonist does not show any efficacy on its own right. Inverse 
agonists are ligands which counteract the ligand-independent signalling or constitutive activity in a 
concentration-dependent manner.     
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1.4.2  Complex pharmacology of allosteric ligands: new 
opportunities and challenges in drug discovery 
Though historically drug development has been based on targeting the 
orthosteric site, recently allosteric ligands which bind to sites that are distinct 
from the orthosteric site, have attracted great interest for the development of 
drug candidates with sub-type selectivity and higher safety profiles. Moreover, 
orthosteric sites of Class B, secretin family receptors are not amenable to small 
molecule drug development as the endogenous ligands are large peptides with 
diffuse pharmacophores forming several contacts with the large N-terminal 
domain as well as extracellular loops and thus are difficult to exploit 
therapeutically (Christopoulos et al., 2014). In this case, targeting allosteric 
sites might be a good option for therapeutic intervention. Allosteric modulation 
of a GPCR is a phenomenon in which a ligand, by binding to a site which is 
topographically different from the binding sites of endogenous ligands, can 
trigger a distinct change in conformation of the receptor states which results in 
either an alteration of function of the co-bound orthosteric agonist and or 
activation of the receptor on its own right in the absence of the agonist probe 
leading to cellular response (Hudson et al., 2013c). Allosteric modulators which 
potentiate the function of an orthosteric probe by enhancing the binding affinity 
for the receptor (affinity modulation which is expressed by a parameter termed 
as affinity cooperativity factor, α) and/maximal response of the orthosteric 
agonist (efficacy modulation expressed by the parameter termed as activation 
cooperativity factor, β) are called positive allosteric modulators (PAMs) while 
the modulators which decrease the function of the orthosteric agonist probe by 
either decreasing the binding affinity and/or efficacy of the co-bound probe are 
termed as negative allosteric modulators (NAMs) (Kenakin, 2017). Similar to 
orthosteric agonists, allosteric ligands can also display agonism or inverse 
agonism in its own right. Combinations of any two properties of these three 
phenotypes (positive and negative allosteric modulation and allosteric agonism) 
will lead to generation of more complex allosteric phenotypes including ago-
allosteric modulators (or PAM agonist), NAM agonist, PAM/NAM, PAM antagonist 
etc (for details see Figure 1.5 and 1.6), implying that modes of action of 
allosteric ligands are more diverse and complex than orthosteric ligands. These 
diverse modalities of action of allosteric ligands represent a set of potential 
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options of therapeutic intervention as well as making defining the pharmacology 
of the allosteric ligand more challenging (Hudson et al., 2013c). 
 
Figure 1.5 Orthosteric agonism and different phenotypes of positive allosteric modulators 
(PAMs). Binding of orthosteric agonists to a specific GPCR results in conformational change of the 
receptor which ultimately activates downstream signalling pathways producing pharmacological 
response (A). Allosteric agonists bind to the receptor on a site which is topographically distinct from 
the orthosteric binding site and in the absence of orthosteric agonist, allosteric agonist can activate 
the downstream signalling pathway leading to cellular response on its own right (B).The effect of a 
PAM of affinity on functional response of the orthosteric agonist is illustrated in (C i). PAM of affinity 
enhances the binding affinity of the orthosteric agonist for the receptor and thus enhances the 
potency of the orthosteric agonist which results in the shifting of the concentration-response curve 
for orthosteric agonist to the left (Cii) (Hudson et al., 2013c). Co-binding of a PAM of efficacy results 
in increase in efficacy of the orthosteric agonist while potency of the orthosteric agonist remains 
unaltered (Di) (Hudson et al., 2013c) and the resulting concentration-response curve for the 
orthosteric agonist in the presence of a single concentration of PAM of efficacy is shown in (D ii). 
Another allosteric phenotype is possible where the allosteric ligand can enhance both the binding 
affinity and efficacy of the orthosteric agonist (Ei) and this allosteric ligand is termed as PAM of 
affinity and efficacy; the resulting concentration-response curve for orthosteric agonist in the 
presence of a single concentration of a PAM-affinity/efficacy is displayed in (Eii). More complex 
allosteric phenotype is represented as PAM-agonist or ago-allosteric modulator whereas the 
allosteric ligand can display efficacy on its own right in the absence of the orthosteric agonist and 
also can potentiate the function of the orthosteric agonist when co-binding the receptor with the 
orthosteric agonist (Fi and Gi) (Hudson et al., 2013c; Kenakin, 2017). One variant of PAM-agonist 
increases only the binding affinity of the orthosteric agonist (Fi) resulting in left-ward shifting of the 
concentration-response curve for agonist probe (Fii) whilst another variant can enhance both the 
binding affinity and efficacy of the orthosteric agonist (Gi) resulting in left-ward and up-ward 
displacement of the concentration-response curve for orthosteric agonist (Gii); in both cases the 
allosteric agonism of the PAM-agonist is reflected as enhanced basal signal in the absent of the 
orthosteric agonist (Fii and Gii) .  
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Figure 1.6 Various phenotypes of negative allosteric modulators (NAMs) and combined 
PAM-NAM.  Negative allosteric modulators are allosteric ligands which can decrease the binding 
affinity of the orthosteric agonist for the receptor (NAM of affinity) (Ai) or the efficacy of the 
orthosteric agonist (NAM of efficacy) (Bi) resulting in right-ward (Aii) or down-ward (Bii) 
displacement of the concentration-response curve for the orthosteric agonist, respectively (Hudson 
et al., 2013c). Another variant of NAM is called NAM-agonist which can activate the receptor on its 
own right producing pharmacological response in the absence of the orthosteric agonist and also 
can decrease the efficacy of the orthosteric agonist when co-binding with the receptor (Ci), the 
resulting concentration-response curve for the orthosteric agonist in the presence of a single 
concentration of the NAM-agonist displays enhanced basal signal reflecting allosteric agonism and 
depressed maximal response reflecting NAM property (Cii) (Kenakin, 2017). More complex 
scenario is represented in (Di) where the allosteric modulator can enhance the binding affinity of 
the orthosteric agonist for the receptor with concomitant decrease in the efficacy of the agonist 
probe i.e. they can act as PAM of affinity but NAM of efficacy (αβ>1); the resulting sinistral and 
down-ward displacement of the concentration-response curve for the orthosteric agonist by co-
binding of a single concentration of the PAM-NAM is shown in (Dii) (Hudson et al., 2013c). A variant 
of PAM-NAM profile is termed as PAM-antagonist (Ei) for which the combined affinity/efficacy 
cooperativity factor (αβ) is lower than 1 (Kenakin, 2017) and the resulting concentration-response 
curve for the orthosteric agonist in the presence of a single concentration of PAM-antagonist is 
shown in (Eii). Allosteric ligand which binds to the receptor without affecting the binding affinity and 
efficacy of the orthosteric agonist is termed as negative allosteric ligand (NAL) or silent allosteric 
modulator (SAM) (F) (Wooten et al., 2013).  
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Allosteric modulators display some unique pharmacological properties including 
selectivity and saturability of the effect, probe dependence, transducer 
dependence and reciprocity of the effect (Christopoulos, 2014; Keov et al., 
2011; May et al., 2007) and each pharmacological property offers distinct 
advantages in terms of drug development. As allosteric sites are subject to less 
evolutionary pressure than orthosteric sites which need to accommodate the 
endogenous ligands, allosteric sites are usually more divergent in amino acid 
sequences among receptor subtypes compared to the orthosteric sites 
(Christopoulos, 2014). Therefore targeting the allosteric site(s) might generate 
sub-type selective drug candidates where orthosteric sites are not amenable to 
selective drug development due to the very high sequence homology across 
receptor subtypes such as muscarinic acetylcholine receptors, metabotropic 
glutamate receptors, dopamine receptors etc (Hudson et al., 2013c; May et al., 
2007). Unlike orthosteric agonism/antagonism, allosteric effects mediated by an 
allosteric ligand on orthosteric ligand affinity/efficacy reaches a saturating point 
depending on the cooperativity between two ligands which implies that after all 
the allosteric sites have been occupied by the allosteric ligand, no further 
allosteric effect will be observed irrespective of the concentration of the 
allosteric modulator (Keov et al., 2011; Kenakin and Miller, 2010). This property 
of saturability of allosteric effect would be advantageous as it will be more 
protective against overdose-mediated on-target toxicity (Wooten et al., 2013; 
Keov et al., 2011). While allosteric modulators displaying lower and limited 
cooperativity might be beneficial in terms of safety profile and fine tuning the 
physiological signalling which is advantageous in cases of a highly regulated 
physiological system (Keov et al., 2011;Christopoulos and Kenakin, 2002), this 
will concomitantly make the detection and validation of allosteric ligand 
pharmacology more challenging (Christopoulos, 2014). Pure PAMs also mimic 
physiological conditions in a sense that they will maintain the spatiotemporal 
nature of physiological signalling with concomitant potentiation of function of 
the endogenous ligand which will be beneficial in the cases of therapies against 
disorders associated with tightly regulated neurological or endocrine function 
including Alzheimer’s disease, schizophrenia, acute and chronic central 
nociception etc (Burford et al., 2015; May et al., 2007). Another unique property 
of allosteric modulation is that the allosteric effect is probe dependent which 
implies that the magnitude and direction of allosteric effect will vary depending 
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on the nature of the orthosteric ligand used to probe the receptor function 
(Keov et al., 2011). Probe dependence implies that for the detection and 
validation of an allosteric modulator, it is necessary to investigate the allosteric 
effect of the defined modulator on each of the available endogenous agonists for 
the receptor. Allosteric modulation is also transducer dependent i.e an allosteric 
ligand might modulate (either potentiation or inhibition) a specific signalling 
pathway to the exclusion of others (Christopoulos, 2014). For example, the 
marketed drug cinacalcet acts as a PAM of calcium function at CaSR in 
intracellular calcium mobilization assay while it was shown to be a neutral 
allosteric ligand (NAL) in calcium-induced ERK1/2 phosphorylation (Leach et al., 
2013). Finally, reciprocity of the allosteric effect is another unique property of 
allosterism which implies that the effect of allosteric modulator on binding 
affinity of an orthosteric agonist will be exactly the same as the effect of the 
orthosteric ligand on binding affinity of the modulator (May et al., 2007). Though 
targeting allosteric sites seems to present multiple therapeutic advantages, 
translation of allosteric pharmacology into therapeutics might face some 
challenges including potential difficulty in lead optimization process due to 
steep/flat structure activity relationship (SAR) as well as in preclinical studies 
due to potential species variation in allosteric effect which might stem from the 
more divergent allosteric sites across different species (Hudson et al., 2013c; 
Lindsley et al., 2016; Gentry et al., 2015).  
 
1.5 Free fatty acid receptors (FFARs) as novel targets for 
drug development against inflammatory and 
metabolic disorders 
Low-grade chronic inflammation plays a pivotal role in the pathogenesis of 
various chronic diseases (Minihane et al., 2015; Alvarez-Curto and Milligan, 2016) 
including type-2 diabetes and other metabolic disorders and various autoimmune 
diseases. The prevalence of these inflammation-associated diseases has been 
rising globally due to the modern diet containing nutritional overload, stressful 
and sedentary lifestyle, poor dietary habits etc and has been considered as a 
growing public health concern worldwide. Limited efficacy and selectivity, along 
with side effects of current anti-inflammatory agents have led researchers to 
develop more effective therapies for these disorders. In this regard, it has been 
suggested that G protein-coupled receptors (GPCRs) responsive to free fatty 
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acids (FFAs) would be an interesting area of research to develop drugs that can 
alleviate inflammatory conditions (Talukdar et al., 2011; Oh and Lagakos, 2011) 
as FFARs are considered to play critical roles in linking metabolism and immune 
functions (Alvarez-Curto and Milligan, 2016). Though previously free fatty acids 
were conidered only as an energy source or as building blocks of cell membrane 
with the only intracellular targets being peroxisome proliferator activated 
receptors (PPARs) (long chain fatty acids) or histone deacetylase (short chain 
fatty acids), findings from extensive research conducted for the last two decades 
have established that free fatty acids can also act as signalling molecules by 
activating several cell surface GPCRs (Milligan et al., 2017b). These include the 
long chain and medium chain fatty acid sensing FFA1, short chain fatty acid 
sensing FFA2 and FFA3 and long chain saturated and polyunsaturated fatty acid 
sensing FFA4 (Milligan et al., 2017a; Milligan et al., 2017b; Husted et al., 2017; 
Davenport et al., 2013; Hara et al., 2013; Stoddart et al., 2008b; Brown et al., 
2003; Hirasawa et al., 2005; Itoh et al., 2003; Le Poul et al., 2003). The 
signalling pathways, endogenous ligands and patho-physiological functions of 
these free fatty acid receptors are briefly shown in Table (1.1).  FFA1 and FFA4 
were shown to regulate insulin secretion and thus considered to be potential 
drug target for type II diabetes (Watterson et al., 2014; Kaku et al., 2015; 
Milligan et al., 2017a). Β-arrestin-mediated FFA4 signalling in adipocytes and 
macrophages leads to anti-inflammatory effects (Alvarez-Curto and Milligan, 
2016; Holliday et al., 2012) while FFA1 and FFA3 were reported to regulate 
inflammatory processes in gut and airways, respectively. Exploitation of these 
pathophysiological roles of FFA receptors might lead to potential drug 
development against different inflammatory and metabolic disorders (type II 
diabetes, obsesity, inflammatory bowel diseases, ulcerative colitis etc). 
However, several FFA receptor-targeted agents including TAK-875 (Phase III 
clinical trial, diabetes) and JTT-851 (Phase II clinical trial, diabetes), AMG-837 
and LY2881835 (Phase I, diabetes) and GLPG0974 (Phase II trial, ulcerative 
colitis) were withdrawn from clinical trials due to either toxicity or lack of 
efficacy, implying that further research to uncover the basic biology and 
pharmacology of these receptors are required to fully exploit them 
therapeutically.        
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Table 1-1 Brief overview of signalling pathways, physiological functions and clinical trial 
status of free fatty acid sensing GPCRs  
Receptor Signalling 
pathways 
Physiological functions Free fatty 
acids as 
activators 
(carbon chain 
length) 
Clinical trial status 
FFA1 
(GPR40) 
Gαq/11* 
Gαi/o  
β-arrestin-2 
i)Glucose stimulated insulin 
secretion(GSIS) from 
pancreatic β ells  
 
ii) Incretin (GLP-1) 
secretion from 
enteroendocrine cells 
 
iii) Anti-fibrotic activity 
LCFA and 
MCFAs 
(C6-C22) 
Saturated, 
unsaturated 
TAK-875 (partial agonist) 
in type II diabetes; 
discontinued 
from Phase III clinical 
trial due to liver 
toxicity;  
 
AMG-837 and 
LY2881835 removed 
from phase I trial (type 
II diabetes) due to 
toxicity 
 
PBI-4050 in idiopathic 
pulmonary fibrosis, 
pulmonary 
hypertension in heart 
failure with reduced 
ejection fraction (in 
phase II clinical trial, 
ongoing) 
FFA2 
(GPR43) 
Gαi/o* 
Gαq/11 
Β-arrestin 
i) GLP-1 release from 
enteroendocrine cells  
 
ii)Inhibition of lipolysis in 
adipocytes 
iii)regulation of GSIS  
iv) Chemotaxis of 
neutrophils 
 
SCFA (C1- C6) GLPG0974 (antagonist) 
in ulcerative colitis, 
discontinued from 
phase II clinical trial 
due to lack of efficacy  
FFA3 
(GPR41) 
Gαi/o i)Inhibition of GSIS 
ii) Regulation of 
inflammatory processes in 
airways 
SCFA (C3-C7) No clinical candidate 
yet 
FFA4 
(GPR120) 
Gαq/11 
β-arrestin-2 
i)Anti-inflammatory effects 
in gut and adipose tissue  
ii)incretin (GLP-1 and GIP) 
secretion 
iii)glucose uptake in 
adipocytes 
LCFAs and 
MCFAs 
(C14-C22) 
Saturated and 
polyunsaturat
ed FAs 
No clinical candidate 
yet 
GPR84 Gαi/o Pro-inflammatory; 
Immunostimulatory 
Pro-fibrotic 
MCFAs 
(C9-C14) 
(saturated) 
GLPG1205 in IPF 
(Phase II clinical trial, 
ongoing), withdrawn 
from phase II clinical 
trail in ulcerative 
colitis due to lack of 
efficacy. 
 
PBI-4050 in IPF, type 2 
diabetes associated 
with metabolic 
syndrome, Alstrome 
syndrome (phase II 
trial, ongoing) 
*the principal signalling pathway. This table is a modified version of the table shown in Alvarez-
Curto and Milligan, (2016) with input from Watterson et al., (2014) and Milligan et al., (2017b).  
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1.6 G protein coupled receptor 84 
1.6.1 Discovery of GPR84 and its basic characteristics 
G-protein coupled receptor 84 (GPR84) (initially known as EX33 receptor) is a 
member of the seven transmembrane GPCR superfamily and belongs to the 
rhodopsin-like “Class A” family (Wittenberger et al., 2001). Tikhonova (2017) 
reported that phylogenetically GPR84 belongs to the prostanoid receptor 
subfamily of Class A GPCRs. Two groups of researchers independently identified 
GPR84 in 2001 using either an expressed sequence tag data mining approach 
(Wittenberger et al., 2001) or degenerate primer RT-PCR cloning from human 
neutrophils (Yousefi et al., 2001). GPR84 is localized to chromosome 12q13.13 in 
human and is composed of a single exon of 1191 bp encoding a protein of 396 
amino acids (Wittenberger et al., 2001; Yousefi et al., 2001). Murine GPR84 is 
considered to be the orthologue of GPR84 as it bears 85% identity to human 
GPR84 in terms of amino acid sequence (Wittenberger et al., 2001). Both human 
and mouse GPR84 possess a short N-terminus and C-terminus with similar 
sequence identity while the ICL3 comprising 118 amino acid residues exhibits 
higher divergence between the two species (Wittenberger et al., 2001). Both 
these orthologues of GPR84 contain a conserved disulphide bridge between ECL1 
and ECL2 (Wittenberger et al., 2001). Though GPR84 displays characteristic 
structural features similar to the rhodopsin like Class A family GPCRs, it contains 
G117RY motif in place of the conserved D(E)RY motif in the interface between 
TM3 and ICL2 (Yousefi et al., 2001; Wittenberger et al., 2001). Wittenberger et 
al. (2001) and Yousefi et al. (2001) found only slight homology between GPR84 
and other well-known GPCRs and grouped it distantly with another orphan 
receptor, GPR85. GPR84 displays low sequence identity with the four 
characterized fatty acid sensing receptors (FFA1-4) and exhibits only 20% 
sequence homology with the well-studied β2-adrenergic receptor (Nikaido et al., 
2015; Tikhonova, 2017). Sequence comparisons conducted by Brueggemeier et 
al. (2005) and Gaidarov et al., (2018) identified 26% homology between GPR84 
and human D2 dopamine receptor. However, highest homology (31%) was found 
with the orexin 1 receptor (Tikhonova, 2017).  
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1.6.2 Tissue and cellular distribution of GPR84 expression 
Using northern blot and Q-RT-PCR analysis, several groups (Wittenberger et al., 
2001; Yousefi et al. 2001; Venkataraman and Kuo, 2005; Wang et al., 2006b; 
Lattin et al., 2008) have shown that in human and mouse, GPR84 expression is 
restricted primarily to immune-related tissues or cells including bone marrow, 
lymph nodes, thymus, spleen, lung and peripheral blood leucocytes such as 
monocytes/macrophage, neutrophils, eosinophils, T and B cells; implying that 
GPR84 might be associated with immunological functions. Among the immune 
cells, highest expression was observed in neutrophils followed by macrophages 
(Yousefi et al. 2001). Although resting expression was low, GPR84 expression was 
found to be induced strikingly under immunostimulation or inflammatory 
conditions (Figure 1.7). For example, treatment of monocytes/macrophages with 
a well-known inflammation inducer, lipopolysaccharide (LPS) resulted in 
significant enhancement of GPR84 expression (Wang et al., 2006b; Bouchard et 
al., 2007; Muller et al., 2017, Recio et al., 2018; Mancini et al., 2019). LPS-
promoted strong upregulation of GPR84 was shown to be observed in all mouse 
macrophages including bone-marrow derived macrophages (BMDMs), resident 
peritoneal macrophages, and also in RAW264.7 cells, mouse microglial cells and 
human monocyte derived macrophages (hMDMs) (Recio et al., 2018). Microglia of 
the CNS also express GPR84 markedly in response to TNF-α and IL-1 in different 
neuro-inflammatory conditions such as endotoxemia and experimental 
autoimmune encephalomyelitis (EAE) (Bouchard et al., 2007) and based on this 
finding, it has been postulated by Bouchard and his colleagues that strong GPR84 
up-regulation also might be found in CNS in other neuro-immunological disorders 
including brain injury, infection, cancer, and Alzheimer’s disease where TNF-α 
and IL-1 production are augmented. These findings indicate a link between 
GPR84 and neuro-inflammatory diseases (Bouchard et al., 2007). However, 
GPR84 was not found to play any role in the disease progression of endotoxemia 
or EAE as no alteration in terms of clinical outcome was observed between 
GPR84 deficient mice and wild type mice (Audoy-Remus et al., 2015). Though 
basal expression level of GPR84 in adipocytes is very low compared to immune 
cells (monocytes/macrophages or neutrophils), GPR84 was reported to be 
upregulated in mouse adipocytes in response to TNF-α or LPS (Nagasaki et al., 
2012). TNFα and IL1β-mediated strong upregulation of GPR84 in human 
adipocytes was also reported by Muredda et al., (2018). Nagasaki et al., (2012) 
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proposed that upregulation of GPR84 by TNF-α is mediated by NF-κB signaling 
pathways. This hypothesis was based on the observation that pre-treatment of 
adipocytes with the NF-κB inhibitors BAY11-7082 or MG132 resulted in effective 
blockade of TNFα-induced upregulation of GPR84.  
 
 
Figure 1.7 Marked upregulation of GPR84 in monocytes/macrophages upon 
immunostimulation or inflammatory conditions. GPR84 has been reported to be strongly 
upregulated in response to immunostimulants including the TLR4 agonist LPS, TLR2 agonists 
Zymosan and Pam3CysK and pro-inflammatory cytokines including IL-1β and TNF-α. All these 
stimulants activate their corresponding receptors which signal through NF-κB signaling pathway.   
1.6.3  Putative endogenous agonists of GPR84 
Using both [35S]-GTPγS binding and forskolin-stimulated cAMP assays, Wang et al. 
(2006b) for the first time reported that GPR84 is activated by medium chain 
fatty acids (MCFAs) with carbon chain lengths of 9 to 14, and among them 
decanoic acid (C10), undecanoic acid (C11) and lauric acid (C12) were shown to 
act most potently with EC50 values  of 5, 9, and 10 µM and 4, 8, and 9 µM, 
respectively, in the [35S]-GTPγS binding and the cAMP assays, respectively (Table 
1.2). Suzuki et al. (2013) have shown that 2- and 3-hydroxy MCFAs have better 
potency than the respective non-hydroxylated fatty acids. Southern et al. (2013) 
also confirmed the agonism of MCFAs such as decanoic acid and undecanoic acid 
using a β-arrestin recruitment assay. In contrast, GPR84 does not respond to 
short-chain or long-chain saturated and unsaturated FFAs while these fatty acids 
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are agonists for GPR40/41/43/120 (Wang et al., 2006b; Talukdar et al., 2011). 
However, a patent literature search revealed that eicosa-5,8,11,14-tetraenoic 
acid and 5S,6R-dihydroxy-eicosa-7,9,11,14-tetraenoic acid also have agonistic 
activity towards GPR84 (Hakak et al., 2007). Southern et al.,(2013) also reported 
that eicosatetraenoic acid activated GPR84 with higher potency and efficacy 
than decanoic acid in calcium mobilization assay using CHO cells co-expressing 
GPR84-HA and a chimeric protein Gαqi(5). These findings contradict the previous 
finding that GPR84 is not activated by long chain fatty acids. Further 
investigations are required to solve this discrepancy. Complete blockade of 
inhibition of forskolin-stimulated cAMP generation and [35S]-GTPγS binding by 
pre-treatment with pertussis toxin (PTX) confirmed that GPR84 activation 
mediated by MCFAs couples with Gi/o proteins resulting in adenylyl cyclase 
inhibition and decreased intracellular cAMP levels (Wang et al., 2006b).  
 
One of the major criteria of deorphanization of a receptor is that to be a true 
endogenous ligand for the receptor, the tissue or circulating concentration of 
the ligand under physiological conditions should be enough to activate the 
receptor effectively (Davenport et al., 2013). For example, though the 
tryptophan derivative, kynurenic acid was proposed to be the endogenous 
agonist of GPR35 (Wang et al., 2006a), this pairing has been questioned by 
others (Jenkins et al., 2011; Milligan, 2011; Divorty et al., 2015) as due to the 
low potency of this ligand at human GPR35, the circulating concentration of 
kynurenic acid would not be able to activate hGPR35 effectively. Similarly, 
MCFAs and hydroxylated-MCFAs should be considered as putative endogenous 
ligands of GPR84 as it remains uncertain whether these MCFAs are produced at 
concentrations required for GPR84 activation under physiological or pathological 
conditions (Suzuki et al., 2013; Mahmud et al., 2017; Recio et al., 2018; 
Gaidarov et al., 2018); although Wang et al. (2006b) maintained that after fatty 
meal intake, concentrations of the MCFAs would be increased to a level that 
could activate GPR84. The putative endogenous agonists MCFAs of carbon chain 
length 9-14 lack specificity towards GPR84 as they have also been shown to act 
as ligands for both FFA1(GPR40) and FFA4(GPR120) (Christiansen et al., 2015; 
Hirasawa et al., 2005; Itoh et al., 2003). Moreover, modes of binding of MCFAs 
are poorly defined and they possess low potency at GPR84 which suggests that 
they might act as surrogate agonists at GPR84 rather than the true endogenous 
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agonists. Due to the unavailability of radioligands developed against the binding 
sites shared by MCFAs, binding affinities for GPR84 are also lacking and the 
measured potency values reported by several groups cannot be used as surrogate 
measures of affinity due to the existence of receptor reserve in recombinant 
heterologous expression systems. Rapid metabolism of free fatty acids (Holliday 
et al., 2012) also remains a great challenge for using these compounds as tool 
compounds due to insufficient availability of the desired concentrations in 
biological compartments. These limitations (lack of selectivity, lower potency, 
and rapid metabolism) have made these MCFAs challenging to use as tool 
compounds for the in vivo characterization and elucidation of pharmacological 
properties of GPR84. Indeed Recio et al., (2018) and Sundqvist et al., (2018) 
reported that MCFAs generated poor biological responses in macrophages and 
neutrophils in terms of triggering electrical impedance and oxidative burst, 
respectively whereas the synthetic agonists 6-OAU and compound-1 were found 
to be highly effective, respectively.    
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Table 1-2 Potential endogenous agonists of GPR84 
Agonist 
 
Source       Potency (EC50) Comment 
 
C-9 
 
 
Tropical oils 
 
52 µM (cAMP accumulation assay) 
70 µM ([35S]-GTPγS binding assay; 
Wang et al., 2006b) 
Nonselective, 
also activates 
GPR40 and 
GPR120; 
 
Lower potency 
and undefined 
affinity 
 
Rapid 
metabolism 
 
Unsuitable to be 
used as tool 
compounds 
 
C-10 
 
Tropical oils 
 
4.5 µM (cAMP assay; Wang et al., 
2006b) 
4.6 µM ([35S]-GTPγS binding assay; 
Wang et al., 2006b) 
15 µM (biosensor-based BRET assay; 
Gagnon et al., 2018) 
6.1 µM (β-arrestin recruitment assay; 
Pillaiyar et al., 2017) 
C-11 
 
 
 
 
 
Tropical oils 
 
7.7 µM (cAMP assay) 
 
8.6µM ([35S]-GTPγS binding assay; 
Wang et al., (2006b) 
C-12 
 
Tropical oils 
 
8.8 µM (cAMP assay) 
 
10.5 µM ([35S]-GTPγS binding assay; 
Wang et al., (2006b) 
 
2-OH-C10 
 
 
formed by fatty 
acid 2-
hydroxylase 
especially in 
brain 
31 µM ([35S]-GTPγS binding assay; 
Suzuki et al., 2013) 
 
41 µM (cAMP assay; Zhang et al.,2016) 
 
3-OH-C10 
 
 
 
In vivo 
production by β-
oxidation in 
peroxisomes 
230 µM([35S]-GTPγS binding assay; 
Suzuki et al., 2013) 
2-OH-C12 
 
 
 
formed by fatty 
acid 2-
hydroxylase 
mainly in the 
brain 
9.9 µM ([35S]-GTPγS binding assay) 
 
40 µM (chemotaxis of macrophages) 
Suzuki et al., 2013) 
3-OH-C12 
 
 
In vivo 
production by β-
oxidation in 
peroxisomes 
13 µM ([35S]-GTPγS binding assay; 
Suzuki et al., (2013) 
24.2 µM (chemotaxis of PMN) 
40 µM (chemotaxis of macrophages) 
1.3 µM (cAMP assay; Pillaiyar et 
al.,2018) 
4.4 µM (β-arrestin assay; Pillaiyar et 
al.,2018) 
C-13 
 
 
Tropical oils 
 
24.8 µM (cAMP) 
21.4 µM (GTPγS binding assay) Wang et 
al., (2006b) 
C-14 
 
 
Tropical oils 
 
93 µM (cAMP) 
14.4 µM (GTPγS binding assay) Wang et 
al., (2006b) 
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1.6.4 Natural product-derived agonists of GPR84: DIM and 
embelin 
1.6.4.1  3, 3´-diindolylmethane (DIM) 
Using [35S]-GTPγS binding assay employing a GPR84-Gαi1 fusion protein, Takeda 
et al., (2003) for the first time identified that 3,3´-diindolylmethane (DIM), a 
metabolite of indole-3-carbinol, found in cruciferous vegetables acts as a 
moderately potent (EC50: 11 µM) agonist of GPR84. DIM also was reported to be 
an allosteric agonist at GPR84 (Nikaido et al., 2015) and subsequently Pillaiyar et 
al., (2017) reported that DIM acts as a PAM agonist of C-10 potency and efficacy 
in cAMP assays in recombinant cells. Though the potency of DIM is greater than 
MCFAs, it is not highly selective as DIM possesses some off-target effects, 
displaying partial agonism at the CB2 receptor (Yin et al., 2009) and has been 
shown to be an activator of aryl hydrocarbon receptor (Yin et al., 2012) and 
estrogen receptor α (ERα) (Marques et al., 2014). Due to lower potency and off-
target effects, DIM could not be used as pharmacological tool compounds to 
elucidate biological functions of GPR84.  
1.6.4.2  Embelin 
2,5-dihydroxy-3-undecyl-1,4-benzoquinone (embelin), a natural product 
obtained from fruits of Embelia ribes Burm (Lu et al., 2016) was identified as a 
GPR84 agonist by Hakak et al., (2007). Embelin has been reported to display 
moderate potency in a [35S]-GTPγS binding assay (EC50: 0.54 µM; Hakak et al., 
2007), cAMP inhibition assay (EC50: 0.8 µM; Pillaiyar et al., 2017), β-arrestin 
recruitment assay (EC50: 0.4 µM; Pillaiyar et al., 2017) and in a biosensor-based 
BRET assay (EC50: 10µM). By contrast, Gaidarov et al., (2018) reported that 
embelin exhibited higher potency in forskolin-induced cAMP accumulation assays 
(EC50: 89 nM) which was further supported by the observation that embelin 
triggered phosphorylation of ERK1/2 and Akt in IFNγ-primed human macrophages 
with potency of 3 and 78 nM, respectively. Gagnon et al., (2018) reported that 
embelin acted as a partial agonist in a Gαi2 activation biosensor-based BRET 
assay and ERK1/2 phosphorylation assay compared to C-10. However, similar to 
DIM and MCFAs, embelin lacks selectivity towards GPR84 as it was reported to be 
an inhibitor of X-linked inhibitor of apoptosis protein (XIAP) (Nikolovska-Coleska 
et al., 2004; Mori et al., 2007; Hu et al., 2011; Ahn et al., 2007).  
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1.6.5  Synthetic surrogate agonists of GPR84 
1.6.5.1 PSB-16671 
Pillaiyar et al., (2017) developed some DIM analogues showing higher potency at 
human GPR84, which could be used as pharmacological tool compounds. Among 
them, di(5,7-difluoro-1H-indole-3-yl)methane or PSB-16671 was reported to be 
6-fold more potent than its parent compound, DIM (Pillaiyar et al.,2017). PSB-
16671 exhibited 132-fold lower potency in β-arrestin recruitment assays than 
that displayed in cAMP accumulation assays, suggesting it to be Gαi-pathway 
biased (Pillaiyar et al., 2017). Similar to DIM, PSB-16671 acts as an ago-allosteric 
modulator of decanoic acid functions at human GPR84 in forskolin-induced cAMP 
accumulation assays in recombinant cells. Unlike DIM, PSB-16671 was shown to 
be inactive at the aryl hydrocarbon receptor (AhR). Unlike MCFAs, PSB-16671 did 
not display any agonism at FFA1 and FFA4 (Pillaiyar et al., 2017). PSB-16671 was 
also found to be inactive at the phylogenetically related orphan receptor GPR35 
at 10 µM concentration (Pillaiyar et al., 2017). Due to this selectivity and higher 
potency than MCFAs and DIM, PSB-16671 could be used as a pharmacological tool 
compound to explore biological activities of GPR84. 
 
1.6.5.2 6-n-octylaminouracil (6-OAU) 
6-OAU was first identified by Suzuki et al., (2013) as a specific surrogate agonist 
of GPR84 by a high-throughput screening program using a [35S]-GTPγS binding 
assay employing a GPR84-Gαi1 fusion protein. 6-OAU was reported to display 
significantly higher potency than the purported endogenous agonist, C-10 and 
allosteric agonist, DIM in both cAMP assays and [35S]-GTPγS binding assays 
(Suzuki et al., 2013; Zhang et al., 2016; Pillaiyar et al., 2018). 6-OAU has been 
shown to induce internalization of GPR84-EGFP at 6.25 to 200 µM (Suzuki et al., 
2013) and reported to trigger GPR84 desensitization and β-arrestin recruitment 
(Zhang et al., 2016). 6-OAU was also reported to inhibit forskolin-induced cAMP 
production in cultured mouse microglia in a concentration-dependent fashion 
which was effectively blocked by PTX treatment suggesting, Gαi/o-dependency of 
6-OAU-mediated GPR84 signaling (Wei et al., 2017). 6-OAU produced robust 
microglial ruffling and motility in a GPR84-dependent manner which was 
evidenced from the complete abrogation of 6-OAU-mediated microglial ruffling 
and motility when microglia isolated from mice lacking functional GPR84 were 
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used. 6-OAU also displayed higher efficacy in promoting microglial ruffling and 
motility than C-10 and embelin (Wei et al., 2017). Specificity of 6-OAU was 
confirmed by Recio et al., (2018) based on the lack of any electrical impedance 
response representing cytoskeletal rearrangements in LPS-stimulated GPR84 KO 
macrophages while 6-OAU at 1-10 µM concentrations produced robust impedance 
response in LPS-treated mouse BMDMs which was even higher than that produced 
by C5a. Compared to 6-OAU, the presumed endogenous agonists C-10, C-11 and 
C-12 were found to either inactive (C-10) or produced very weak impedance 
responses in mouse macrophages, implying that 6-OAU could be used as tool 
compound instead of weakly active MCFAs to explore biological functions of 
GPR84 (Recio et al., 2018).    
 
1.6.5.3 Compound-1, compound-51 and TUG-1765 
Using a high-throughput screening (HTS) program employing calcium mobilization 
assays in HEK293 cells stably expressing GPR84-HA and Gα16 G-protein, Zhang et 
al., (2016) identified that 2-(hexylthio)pyrimidine-4,6-diol (ZQ-16 or compound-
1) acts as a highly potent and selective agonist at GPR84. Compound-1 displayed 
similar efficacy but higher potency than 6-OAU in calcium mobilization and cAMP 
accumulation assays (Liu et al., 2016; Zhang et al., 2016). In an attempt to 
optimize the potency of compound-1, Liu et al., (2016) synthesized a set of 
derivatives among them 6-octylpyridine-2,4-diol (compound-50/TUG-1765) and 
6-nonylpyridine-2,4-diol (compound-51). These acted as highly potent activators 
of GPR84 displaying EC50 of 1.34 and 0.189 nM, respectively in calcium 
mobilization assays (Liu et al., 2016). Compound-51 is by far the most potent 
agonist of GPR84 reported to date. Both compound-1 and compound-51 were 
reported to be highly selective agonist of GPR84 as both did not display any 
agonistic activity at other fatty acid sensing receptors, FFA1,FFA3, FFA4 and 
GPR119 (Zhang et al., 2016; Liu et al., 2016). Due to their high potency and 
selectivity, these compounds could be used as surrogate agonists for 
pharmacological and physiological characterization of GPR84.    
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Table 1-3 Natural product-derived and synthetic surrogate agonists of GPR84 
            Agonist      Potency (EC50)    Efficacy Comments 
                 
                   DIM 
 
 
 
0.5 µM (([35S]-GTPγS binding 
assay; Wang et al., 2006b) 
1.1 µM (cAMP assay; Zhang et 
al., 2016) 
1.64 µM (β-arrestin 
recruitment assay; Pillaiyar et 
al.,2017) 
 
 
Partial agonist in 
β-arrestin 
recruitment assay 
Non-selective;  
Off target effect: 
activator of aryl 
hydrocarbon 
receptor and ERα; 
Partial agonist at 
CB2 receptor; 
Ago-allosteric 
modulator 
            
              PSB-16671 
 
 
41.3 nM (cAMP assay; Pillaiyar 
et al., 2017) 
5.47 µM (β-arrestin 
recruitment assay; Pillaiyar et 
al., 2017) 
 
Higher efficacy 
than C-10 
 
Selective 
ago-allosteric 
modulator; 
Biased towards 
Gαi pathway 
               
               Embelin 
 
 
 
0.63 µM ([35S]-GTPγS binding 
assay; Mahmud et al.,2017) 
0.8 µM (cAMP assay; Pillaiyar 
et al.,2017) 
0.4 µM (β-arrestin 
assay;Pillaiyar et al.,2017) 
10 µM (biosensor-based BRET 
assay; Gagnon et al., 2018) 
 
 
Partial agonist in 
BRET assay using 
Gαi2 biosensor and 
in ERK1/2 
phosphorylation 
assay 
 
Non-selective 
Off-target effect: 
inhibitor of X-
linked inhibitor of 
apoptosis protein 
(XIAP) 
                 
                6-OAU 
 
 
 
512 nM (GTPγS binding assays; 
Suzuki et al.,2013) 
341 nM (cAMP assay;Zhang et 
al., 2016) 
17 nM (cAMP assay; Pillaiyar 
et al.,2018) 
110 nM (β-arrestin 
recruitment assay; Pillaiyar et 
al.,2018) 
 
 
superagonist 
 
Selective  
 
       
         Compound-1/ZQ-16 
 
 
 
134 nM (cAMP assay;Zhang et 
al.,2016) 
 
139 nM (Ca mobilization 
assay; Liu et al., 2016) 
 
78 nM (β-arrestin recruitment 
assay; Pillaiyar et al., 2018) 
 
 
 
 
 
superagonist 
 
Selective  
Orthosteric to 
MCFAs  
          
        Compound-50 
          (TUG-1765) 
 
 
 
 
1.34 nM (Ca mobilization 
assay; Liu et al.,2016) 
 
superagonist 
 
Selective 
         
         Compound-51 
 
 
0.189 nM (Ca mobilization 
assay; Liu et al.,2016) 
 
0.35 nM (cAMP assay; Liu et 
al.,2016) 
 
superagonist 
 
Selective, most 
potent agonist 
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1.6.6  Synthetic GPR84 antagonists 
Labeguere et al., (2014) synthesized a series of selective GPR84 antagonists 
(Table 1.4) which contain dihydropyrimidinoisoquinolinones as the core moiety 
of their chemical structure. Exemplars of these antagonists, compound-9, 104, 
107 and 122 (GLPG1205) (2-([1,4]dioxin-2-ylmethoxy)-9-(pyridine-2-ylmethoxy)-
6,7-dihydro-pyrimido[6,1-a]isoquinolin-4-one; 9-(5-cyclopropyl-[1,2,4]oxadiazol-
3-ylmethoxy)-2-((R)-1-[1,4]dioxan-2-ylmethoxy)-6,7-dihydro-pyrimido[6,1-
a]isoquinolin-4-one; 2-([1,4]dioxan-2-ylmethoxy)-9-(3-phenylamino-prop-1-ynyl)-
6,7-dihydro-pyrimido[6,1-a]isoquinolin-4-one; 9-(2-cyclopropylethynyl)-2-[[(2S)-
1,4-dioxan-2-yl]methoxy]-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one, 
respectively) were reported to display high potency (EC50: 0.01-100 nM) in 
inhibiting DIM-induced [35S]-GTPγS incorporation into membranes of GPR84 
expressing cells whilst compound-161 (2-((S)-1-[1,4]dioxan-2-ylmethoxy)-9-
(tetrahydro-pyran-4-yl-methoxymethyl)-6,7-dihydro-pyrimido[6,1-a]isoquinolin-
4-one) showed moderate potency (EC50: 101-500 nM). All these ligands were 
shown to effectively antagonize embelin-induced human neutrophil chemotaxis 
displaying EC50 in the range of 0.01 to 100 nM (Labeguere et al., 2014). 
Compound-104, 107 and 161 were found to antagonize the effect of GPR84 
agonist embelin and DIM with nanomolar potency and in a non-competitive 
manner (Mahmud et al., 2017). Recio et al., (2018) reported that compound-9 
effectively blocked 6-OAU mediated GPR84 signaling including cAMP inhibition, 
cytokine expression, p65 nuclear translocation, phosphorylation of ERK1/2 and 
Akt etc. Sundqvist et al., (2018) also reported that GLPG1205 acted as highly 
potent antagonist of GPR84 activity displaying IC50 of 15 nM in inhibiting 
compound-1-mediated superoxide generation in human neutrophils. 3-
pentylbenzeneacetic acid sodium (PBI-4050), a synthetic derivative of C-10 was 
reported to be a GPR84 antagonist/inverse agonist with pIC50 of 3.4±0.06 (versus 
C-10) and 3.68±0.28 (versus embelin) measured in BRET assay using HEK-293 
cells transiently transfected with GPR84 and Gαi2 activation biosensor (Gagnon 
et al., 2018). PBI-4050 also effectively blocked ERK1/2 phosphorylation induced 
by C-10 or embelin-mediated GPR84 activation in HEK293 cells expressing GPR84 
(Gagnon et al., 2018). PBI-4050 was also found to decrease basal ERK1/2 
phosphorylation level in these cells suggesting that it might act as an inverse 
agonist.      
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Table 1-4 Synthetic ligands acting as GPR84 antagonists 
GPR84 
Antagonist 
Structure Potency 
(IC50) 
Comment 
 
Compound-9 
 
 
 
 
 
0.01-100 nM([35S]-GTPγS 
binding assay, vs DIM; 
Labeguere et al., 2014) 
 
 
Selective 
(Recio et al., 
2018) 
 
Compound-104 
 
 
 
 
 
0.01-100 nM([35S]-GTPγS 
binding assay, vs DIM; 
Labeguere et al., 2014) 
 
 
Noncompetitive 
with embelin 
and DIM 
(Mahmud et al., 
2017) 
 
Compound-107 
 
 
 
 
 
0.01-100 nM([35S]-GTPγS 
binding assay, vs DIM) 
Labeguere et al., (2014) 
 
 
Noncompetitive 
with embelin 
and DIM 
(Mahmud et al., 
2017) 
 
Compound-161 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
101-500 nM([35S]-GTPγS 
binding assay, vs DIM; 
Labeguere et al., 2014) 
 
 
Noncompetitive 
with embelin 
and DIM 
(Mahmud et al., 
2017) 
 
GLPG1205 
(compound-
122) 
 
 
 
 
 
 
0.01-100 nM([35S]-GTPγS 
binding assay, vs DIM; 
Labeguere et al., 2014) 
 
 
15 nM (ROS generation in 
neutrophils, versus 
compound-1; Sundqvist 
et al., 2018) 
 
Selective 
(>1000-fold vs 
other FFARs) 
 
PBI-4050 
 
 
 
 
 
 
200-400 µM (BRET assay; 
Gagnon et al., (2018) 
 
Very low 
potency; Might 
act as an 
inverse agonist; 
Nonselective, 
also agonist for 
FFA1(GPR40) 
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1.7 GPR84-mediated signal transduction pathways 
1.7.1 G-protein dependent signaling 
Based on aequorin reporter-based calcium mobilization assay using chimeric G 
proteins in recombinant CHO cells, Wang et al., (2006b) demonstrated that 
agonist-activated GPR84 couples to PTX sensitive Gαi/o proteins but not to Gq, Gs 
or G16 G proteins. Using Gα activation biosensors in BRET-based assays in 
transiently transfected HEK293 cells, Gagnon et al., (2018) also showed that C-
10 and embelin-mediated GPR84 activation coupled effectively to Gαi proteins 
but not to Gαq, Gαs or Gα13. In contrast to the findings revealed by Gagnon et 
al., (2018), Gaidarov et al., (2018) reported that along with Gαi/o G protein, 
embelin-mediated GPR84 activation also resulted in Gα12/13 coupling leading to 
Rho/Rac signaling pathways evidenced from the embelin-induced modest 
enhancement of intracellular cAMP levels in HEK cells co-transfected with GPR84 
and chimeric G protein, Gαs-G12(5) or Gαs-G13(5) which was further amplified by pre-
treatment of cells with Gαi/o protein inhibitor, PTX. The Gαi/o coupling mediated 
by agonist-bound GPR84 results in inhibition of adenylyl cyclase leading to 
reduction in intracellular cAMP levels in recombinant cells which was reported to 
be blocked completely by PTX treatment (Wang et al., 2006b; Zhang et al., 
2016; Mahmud et al., 2017; Gaidarov et al., 2018; Gagnon et al., 2018; Recio et 
al., 2018). Gαi-mediated inhibition of adenylyl cyclase by GPR84 activation was 
further supported by the finding that compared to wild type macrophages, 
mouse GPR84 KO macrophages displayed markedly higher intracellular cAMP 
levels in response to forskolin induction (Nicol et al., 2015). In contrast to this, 
Gaidarov et al., (2018) reported that in human macrophages agonist-mediated 
GPR84 signaling did not lead to Gαi-mediated inhibition of adenylyl cyclase 
resulting in decreased production of intracellular cAMP, rather GPR84 activation 
resulted in elevated intracellular cAMP levels in human macrophages which was 
due to the Gβγ-mediated activation of adenylyl cyclase 4 and/7 along with 
COX2-dependent PGE2 release which acted in an autocrine/paracrine fashion to 
stimulate the Gs-coupled receptor prostaglandin E receptor 2 (EP2) ultimately 
enhancing cAMP level by stimulating adenylyl cyclase (Figure 1.8). This 
prediction was based on the observations that embelin and its derivatives 
amplified the Gs-coupled receptor agonist-mediated intracellular cAMP 
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accumulations in IFNγ-primed human macrophages, elevated intracellular cAMP 
levels on their own in macrophages which was effectively inhibited by 
pretreatment with COX2 inhibitor indomethacin and Gαi inhibitor PTX and 
triggered PGE2 release from IFNγ-induced human macrophages in a Gαi and 
COX2-dependent manner (Gaidarov et al., 2018). This Gβγ-mediated cAMP 
elevation was shown to be associated with induction of expression of ABCA1 and 
ABCG1 cholesterol transporters which enhance apo-A1 mediated reverse 
cholesterol transport in human macrophages (Gaidarov et al., 2018). In 
macrophages (Figure 1.8), monocytes and neutrophils (Figure 1.9), GPR84 
activation also triggers non-canonical Gβγ-mediated PLCβ-IP3-Ca signaling 
pathway which was evidenced from the concentration-dependent robust 
increase in intracellular calcium mobilization in IFNγ-primed human 
macrophages (Gaidarov et al.,2018)  and in human neutrophils and monocytes 
(Sundqvist et al.,2018) following treatment with embelin and compound-1, 
respectively. Agonist-activated GPR84 was found to induce ERK1/2 
phosphorylation in recombinant cells (Gagnon et al., 2018; Zhang et al., 2016). 
Gαi-mediated ERK1/2 phosphorylation and Gβγ-mediated and PI3-kinase 
dependent Akt phosphorylation were also induced in human and mouse 
macrophages following embelin and 6-OAU-mediated GPR84 activation (Gaidarov 
et al., 2018; Recio et al., 2018). Absence of GPR84-agonist-induced Ca flux, 
ERK1/2 and Akt phosphorylation in macrophages or neutrophils derived from 
GPR84 deficient mice (Gaidarov et al., 2018; Recio et al., 2018) and PTX-induced 
abrogation of ERK1/2 and Akt phosphorylation confirmed the GPR84 dependency 
of stimulation of these pathways. These patterns of GPR84-mediated signaling 
are very similar to that displayed by chemotactic receptors. Recio et al., (2018) 
have shown that 6-OAU-stimulated GPR84 activation resulted in NF-κB activation 
in LPS-induced mouse macrophages which was evidenced from the significant 
increase in nuclear translocation of p65 subunit of NF-κB heterodimer in wild 
type BMDM but not in GPR84 deficient macrophages. Recio and colleagues (2018) 
proposed that activation of NF-κB pathway by GPR84 signaling resulted in 
enhanced expression of pro-inflammatory mediators from LPS-induced 
macrophages. PTX pretreatment blocked the 6-OAU-mediated upregulation of 
pro-inflammatory cytokines (TNFα, IL-6, IL-12) and chemokines (CCL2, CCL5, 
CXCL1) in LPS-treated mouse BMDMs which suggests Gi/o-dependency of pro-
inflammatory effects. Contrary to the finding reported by Recio et al., (2018), 
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Park et al., (2018) observed down-regulation of RANKL-induced NF-κB signaling 
pathway in osteoclast precursor cells, BMDMs.      
 
Figure 1.8 Proposed GPR84-mediated signaling pathways and associated patho-
physiological outcomes in macrophages.  In macrophages, agonist-activated GPR84 couples to 
Gαi/o G proteins resulting in either Gαi-mediated adenylyl cyclase inhibition leading to decreased 
intracellular cAMP production (Nicol et al., 2015) or Gβγ-mediated activation of adenylyl cyclase 
4/7 resulting in increased intracellular accumulation of cAMP (Gaidarov et al., 2018). Gβγ also 
leads to COX2 dependent prostaglandin E2 release which acts in an autocrine manner to activate 
Gs-coupled EP2 receptor resulting in activation of AC4/7 enzyme ultimately promoting 
accumulation of cAMP. These elevated cAMP levels result in enhanced expression of ATP binding 
cassette transporter, ABCA1 and ABCG1 which enhances cholesterol efflux in macrophages. 
GPR84 activation also triggers Gβγ-mediated phosphorylation of extracellular signal-regulated 
kinases ERK1/2 and activation of phosphoinositide 3-kinases (PI3K) leading to Akt 
phosphorylation. Gβγ signaling also includes stimulation of phospholipase Cβ (PLCβ) which 
catalyzes hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) into diacylglycerol and inositol 
1,4,5-trisphosphate (IP3). IP3 triggers calcium mobilization by acting on IP3-sensitive calcium 
channel on endoplasmic reticulum. Gαi coupling was also shown to be engaged in enhanced 
nuclear translocation of NF-κB which is associated with enhanced expression of pro-inflammatory 
mediators in macrophages.    
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Figure 1.9 GPR84 signaling and its patho-physiological outcomes in neutrophils. In 
neutrophils agonist-stimulated GPR84 couples to PTX sensitive Gαi/o G proteins and induces Gβγ-
mediated activation of PLCβ-IP3-Ca
2+
 signal transduction pathway resulting in triggering a robust 
calcium flux which is associated with an increased assembly of NADPH-oxidase on plasma 
membrane of the phagosome, enhanced granule mobilization and secretion and chemotaxis of 
neutrophils. Complete abrogation of compound-1-mediated superoxide release from TNF-α or 
latrunculin treated-human neutrophils following treatment with PTX but not with Gq inhibitor, YM-
254890 was indicative of Gαi dependency of GPR84-induced ROS generation in neutrophils 
(Sundqvist et al., 2018). Pro-inflammatory cytokine TNF-α amplifies the superoxide release 
mediated by GPR84 activation.  
1.7.2 G-protein-independent signaling 
Apart from G-protein-dependent signaling, GPR84 activation was also shown to 
induce G-protein independent signaling pathways such as β-arrestin recruitment, 
although details are lacking. Southern et al., (2013) for the first time reported 
that MCFAs including decanoic acid and undecanoic acid and the natural 
product-derived embelin induced robust β-arrestin recruitment towards GPR84 
in CHO cells. Agonist-mediated β-arrestin recruitment towards GPR84 was then 
further observed in recombinant cells by other groups (Zhang et al., 2016; 
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Pillaiyar et al., 2017; Pillaiyar et al., 2018). Recently, Pillaiyar et al., (2017) 
reported that some DIM analogues including di(7-azaindolyl)methane,10-ethyl-
diindolylmethane, 10-propyl-diindolylmethane and 10-isobutyl-diindolylmethane 
are absolutely biased toward β-arrestin recruitment over Gαi-mediated adenylyl 
cyclase inhibition whereas Pillaiyar et al.,(2018) identified a Gαi-pathway 
selective biased GPR84 agonist, PSB-16434, a 6-OAU derivative which displayed a 
bias factor of 1.9.  
6-OAU and compound-1 were shown to produce robust GPR84 internalization and 
desensitization (Zhang et al., 2016) and authors argued that agonist-mediated 
internalization and desensitization might be due to β-arrestin2 recruitment to 
the activated receptor. Until now, detailed mode and regulation of GPR84 
internalization and desensitization are not available. However, Sundqvist et al., 
(2018) reported that desensitization of compound-1-mediated GPR84 signaling is 
independent of the actin cytoskeleton.  
1.8 Physiological functions and pathophysiological roles 
of GPR84 
1.8.1 Immunostimulatory and pro-inflammatory activities 
mediated by GPR84  
Some groups of researchers have demonstrated an association between GPR84 
and inflammation indicating a role of GPR84 in the crosstalk between the 
metabolism of fatty acids and immunological regulation (Figure 1.10). In a study 
conducted by Wang et al. (2006b), it was found that GPR84 activation by MCFAs 
and the allosteric modulator DIM significantly and concentration-dependently 
elevated the secretion of the pro-inflammatory cytokine, IL-12-p40 subunit from 
RAW264.7 macrophages following immunostimulation such as LPS treatment. The 
up-regulation of this cytokine is responsible for the promotion of Th1 reactions 
and inhibition of Th2 reactions and thereby mediates the immune functions of 
the receptor by eradicating pathogenic microorganisms (Wang et al., 2006b). 
GPR84 activation mediated by 6-OAU and hydroxylated MCFAs has also been 
shown to mediate amplification of secretion of other pro-inflammatory 
mediators such as TNF-α and IL-8 from human macrophages and neutrophils, 
respectively upon stimulation with LPS (Suzuki et al., 2013). Role of GPR84 in 
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regulating expression of pro-inflammatory mediators was also supported by the 
observation that 6-OAU-stimulated GPR84 activation resulted in enhanced 
upregulation of TNF-α, IL-6, IL-12p40, CCL2, CCL5, CXCL1, FCγR1 and ICAM-1 in 
LPS-primed mouse peripheral macrophages but not in GPR84 deficient 
macrophages and these effects of 6-OAU were completely counteracted by the 
selective GPR84 antagonist, compound-9 (Recio et al., 2018). GPR84-mediated 
upregulation of chemokines including CXCL1 was also confirmed by an in vivo 
study which showed marked increase in blood level of CXCL1 following 
intravenous injection of 6-OAU into rats (Suzuki et al., 2013). Absence of any 
upregulation of pro-inflammatory mediators in macrophages which were not pre-
stimulated with LPS, suggested that 6-OAU or MCFAs-promoted enhanced 
expression of pro-inflammatory cytokines and chemokines in macrophages are 
mediated by GPR84 signaling and LPS acts to upregulate GPR84 expression in 
these cells (Wang et al., 2006b; Suzuki et al., 2013; Recio et al., 2018).     
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Figure 1.10 Agonist-activated GPR84 signaling generates a pro-inflammatory macrophage 
phenotype. 6-OAU-mediated GPR84 activation results in enhanced upregulation of pro-
inflammatory cytokines TNF-α, IL-6, IL-12b, chemokine CCL2, CCL5 and CXCL1 and adhesion 
molecule ICAM-1 and scavenger receptor FCγR1 in LPS-treated mouse macrophages (A) (Recio 
et al., 2018). MCFAs including C-10, C-11 and C-12 and allosteric agonist DIM were reported to 
amplify upregulation (both mRNA and protein levels) of pro-inflammatory cytokine IL-12p40 in LPS-
stimulated RAW264.7 mouse macrophages (B) (Wang et al., 2006b). GPR84 activation mediated 
by 6-OAU and hydroxylated MCFAs including 3-OH-C12 also results in enhanced secretion of pro-
inflammatory cytokine, TNF-α from LPS-treated differentiated U937 cells (C) and IL-8 from LPS-
induced human neutrophils (D) (Suzuki et al., 2013).  
Gene knockout studies in mice revealed that GPR84 deficiency leads to up-
regulation of anti-inflammatory Th2 cytokines and down-regulation of pro-
inflammatory cytokines (Figure 1.11). Under neuropathic conditions, compared 
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to wild type macrophages, LPS-induced GPR84 KO peripheral macrophages 
displayed lower induction of pro-inflammatory mediators, TNF-α, IL-6, IL-1β, IL-
12 p40, Nos2, Ptges2, CCL2, CCL3 and higher expression of anti-inflammatory 
cytokine IL-10 (Nicol et al., 2015). In response to nerve injury, compared to wild 
type macrophages, forskolin-stimulated GPR84 KO macrophages (both BMDM and 
peritoneal macrophages) also produced significantly higher level of intracellular 
cAMP levels which is consistent with the fact that GPR84 is coupled to Gαi/o 
proteins (Nicol et al., 2015). Moreover, significantly higher induction of anti-
inflammatory arginase-1 and IL-10 were observed in injured sciatic nerve of 
GPR84 KO mice than that of wild type littermates (Nicol et al., 2015). As the 
enzyme, arginase-1 (Arg-1) is downstream of cAMP, inhibition of cAMP 
production by activation of GPR84 leads to decreased activation of Arg-1, 
resulting in amplification of pro-inflammatory M1 macrophage polarization (Nicol 
et al., 2015). Based on these findings Nicol et al., (2015) proposed that GPR84 
deficiency leads to generation of anti-inflammatory macrophages phenotype (M2 
macrophages/alternatively activated) whilst GPR84 activation produces pro-
inflammatory macrophage phenotype (M1 macrophages/classically activated). 
Gaidarov et al., (2018) also reported that GPR84 deletion led to markedly 
reduced secretion of pro-inflammatory mediators including IL-6, KC-GROα, 
VEGF, macrophage-inflammatory protein2 (MIP-2) and neutrophil gelatinase 
associated lipocalin (NGAL) from LPS-treated peritoneal exudates containing 
macrophages, neutrophils and B/T cells compared to wild type exudates. 
Consistent with these findings, anti-CD3-induced secretion of IL-4 from CD4+ T 
cells was strikingly up-regulated in GPR84 KO mice, which is suggestive of a role 
of GPR84 in the regulation of IL-4 gene expression (Venkataraman and Kuo, 
2005). Venkataraman and Kuo (2005) also reported elevated expression of anti-
inflammatory Th2 cytokines such as IL-4, IL-5 and IL-13 in Th2 effector cells of 
GPR84 deficient mice compared to those from WT mice. All these findings 
suggest that GPR84 may cause disruption in Th1/Th2 balance by promoting Th1 
cytokine production and down-regulating Th2 cytokine secretion and thus might 
be involved in the pathogenesis of Th1 type diseases (Yonezawa et al., 2013). 
Although Th1 responses are essential for pathogen eradication, excessive Th1 
responses may have serious consequences that lead to aggravation of 
autoimmune diseases and inflammatory disorders such as multiple sclerosis, IBD, 
rheumatoid arthritis etc (Wang et al., 2006b). 
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Figure 1.11 GPR84 deficiency in mice leads to Th2 shift and generates an anti-inflammatory 
macrophage phenotype. Gene knockout studies in mice performed by Venkataraman and Kuo, 
(2005) revealed that GPR84 deficiency led to amplification of secretion of anti-inflammatory 
cytokine IL-4 from anti-CD3 and anti-CD28-induced CD4
+
 T lymphocytes (A) and of IL-4, IL-5 and 
IL-13 from Th2 effector cells (B) compared to those of WT mice. Attenuated expression of pro-
inflammatory mediators including TNF-α, IL-1β, IL-6, IL-12b, Nos2, Ptges2, CCL2 and CCL3 and 
higher expression of anti-inflammatory cytokine, IL-10 in GPR84 deficient macrophages (C) and 
marked reduction in secretion of pro-inflammatory mediators including IL-6, KC-GROα, VEGF, 
MIP-2 and NGAL from peritoneal exudates of GPR84 KO mice (D) were reported by Nicol et al., 
(2015) and Gaidarov et al., (2018), respectively.  
The pro-inflammatory activities of GPR84 have also been confirmed by the fact 
that the surrogate agonist, 6-OAU strongly induces chemotaxis of human 
neutrophils and macrophages in a GPR84-dependent manner in both the in vitro 
“Transwell assay” and in vivo rat air pouch model (Suzuki et al., 2013). The 
patent literature also demonstrates the role of GPR84 in chemotaxis of immune 
cells including neutrophils, macrophages and dendritic cells and shows that 
GPR84 antagonists including GLPG1205 prevent this chemotaxis effectively (Brys 
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and Dupont, 2013). Though Suzuki et al.,(2013) reported that 6-OAU and 
hydroxylated MCFAs including 2-OH-C12 and 3-OH-C12 induced robust 
chemotaxis of PMA-treated U937 cells (human model macrophages) in a PTX-
sensitive Gαi/o pathway dependent manner, Recio et al., (2018) did not find any 
chemotaxis of mouse bone marrow derived macrophages (BMDMs) in response to 
6-OAU-mediated GPR84 activation, although 6-OAU was found to significantly 
amplify C5a-mediated chemotaxis of macrophages. Gaidarov et al., (2018) also 
reported that embelin-mediated GPR84 activation induced human neutrophil 
chemotaxis. However, embelin displayed low potency in neutrophil chemotaxis 
(micromolar range) which is consistent with its low potency in calcium signaling 
assay.  
Consistent with the fact that agonist-mediated GPR84 signaling exacerbates 
inflammatory responses in macrophages as evidenced from augmented 
expression of pro-inflammatory cytokine and chemokines, Recio et al., (2018) 
found that 6-OAU-mediated GPR84 activation resulted in enhanced bacterial 
adhesion and phagocytosis by macrophages, which confirmed the role of GPR84 
in inflammatory and immunostimulatory activities. 6-OAU-mediated promotion 
of bacterial adhesion to mouse macrophages was absent in GPR84 KO mice and 
completely blocked by the GPR84 antagonist, compound-9 and Recio and 
colleagues (2018) argued that this enhanced bacterial adhesion was due to the 
marked upregulation of FcγR1 in macrophages. Similarly, 6-OAU-promoted 
marked enhancement of phagocytosis of E. coli and opsonized polystyrene beads 
by macrophages was effectively hindered by pre-treatment of cells with GPR84 
antagonist compound-9 and GPR84 KO macrophages were unable to display 
phagocytosis of E. coli and opsonized beads, confirming the GPR84 dependency 
of these pro-inflammatory activities (Recio et al., 2018). Wang et al., (2019) also 
reported that zebrafish GPR84 overexpression led to marked enhancement in 
phagocytosis of E. coli and S. aureus by RAW264.7 mouse macrophages, 
confirming the role of GPR84 in immune reactions.    
Similar to macrophages, GPR84 also modulates neutrophil biology by promoting 
immune reactions or exacerbating inflammatory responses in neutrophils which 
was evidenced from the observations that compound-1-activated GPR84 signaling 
in neutrophils resulted in enhanced chemotaxis of neutrophils along with 
enhanced granule mobilization and secretion and ROS generation from 
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neutrophils, activities associated with immunological processes such as 
phagocytosis of microorganisms (Sundqvist et al., 2018). Agonist-mediated 
GPR84 activation was also found to potentiate the fMLP and C5a-mediated ROS 
generation from neutrophils (Gaidarov et al., 2018).  While compound-1-
mediated GPR84 activation triggers robust intracellular calcium flux in human 
neutrophils and monocytes to an extent equivalent to that generated by the 
formyl peptide receptor1 (FPR1) agonist, fMLP, compared to fMLP, compound-1 
displayed significantly lower efficacy in inducing NADPH-oxidase-promoted 
superoxide production, granule mobilization and secretion and in chemotaxis 
assay (Sundqvist et al., 2018).These findings imply that though GPR84 mediates 
degranulation and chemotaxis of human neutrophils and thus acts as a 
chemoattractant receptor, compared to fMLP-FPR1 system, the GPR84-
compound-1 axis acts as a weak secretagogue and chemoattractant for human 
neutrophils. However, Mancini et al., (2019) reported that the extent of mouse 
neutrophil chemotaxis triggered by compound-1-mediated GPR84 activation was 
very similar to that generated by fMLP. Overall, these studies provide strong 
evidence for the immune functions and pro-inflammatory activities of GPR84 and 
suggest that GPR84 is an important player in mediating crosstalk between 
metabolism and immunological processes (immunometabolism).    
1.8.2  GPR84 is a potential novel target for drug development 
against chronic inflammation-associated diseases 
Based on the discussions presented in section 1.8.1, it is evident that GPR84 
mediates inflammatory responses in macrophages and neutrophils or can 
exacerbate established inflammation. Therefore, inhibition of GPR84-mediated 
pro-inflammatory activities might be an effective treatment strategy for chronic 
inflammation-associated diseases including ulcerative colitis, IBD, rheumatoid 
arthritis, chronic inflammatory arthritis, atherosclerosis, reflux esophagitis etc        
(Labeguere et al., 2014; Suzuki et al., 2013; Gaidarov et al., 2018). It is 
predicted that the highly restricted expression pattern in immune cells and 
strong up-regulation of GPR84 under inflammatory conditions may lead to the 
development of more selective and less toxic GPR84 modulators compared to 
established anti-inflammatory agents (Bouchard et al., 2007).  
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In a study investigating the pathophysiology of reflux esophagitis, Abdel-Aziz et 
al. (2016) reported strong upregulation of GPR84 in rat and human esophageal 
epithelial cells during esophagitis suggesting a causal relationship between 
GPR84 and esophagitis. Marked upregulation of GPR84 in the areas of 
macrophage infiltration in synovial tissue in rheumatoid arthritis was reported by 
Hakak et al., (2007) suggesting the potential role of GPR84 in the pathogenesis 
of rheumatoid arthritis. These reports of strong upregulation of GPR84 during 
diseased conditions imply that therapies targeting GPR84 will be advantageous in 
terms of displaying favorable safety profile.   
1.8.2.1 GPR84, a novel target for drug development against ulcerative colitis 
Due to the strong upregulation of GPR84 in ulcerative colitis (Dupont et al., 
2015) and potential role of GPR84-mediated inflammatory activities including 
neutrophil chemotaxis in the pathogenesis of ulcerative colitis, recently GPR84 
inhibition has attracted considerable interest as a novel therapeutic strategy to 
develop drugs to treat ulcerative colitis and Galapagos NV, a Belgian 
pharmaceutical company, performed some preclinical and clinical studies using 
the GPR84 antagonist, GLPG1205. GLPG1205 was found to effectively prevent 
disease progression in a chronic DSS (dextran sodium sulfate)-induced mouse 
colitis model with effective blockade of macrophage and neutrophil chemotaxis 
(Dupont et al., 2015) and displayed a satisfactory safety profile and target 
engagement in healthy human volunteers in a Phase I clinical trial (Vanhoutte et 
al., 2015). However no clinical efficacy was found in a phase II clinical trial in 
ulcerative colitis patients (Vermiere et al., 2017) suggesting that either GPR84 is 
not associated with the pathogenesis of ulcerative colitis or further studies are 
required in terms of physiological and pharmacological characterization of this 
enigmatic receptor. 
1.8.2.2 GPR84 is a potential target for development of drugs against 
atherosclerosis 
Gaidarov et al., (2018) reported that embelin-mediated GPR84 activation 
resulted in significant upregulation of the cholesterol transporters ABCA1 and 
ABCG1 in human macrophages which are involved in apolipoproteinA1-mediated 
cholesterol efflux. Due to this higher expression of cholesterol transporters, the 
GPR84 agonist embelin was found to promote 4-fold enhancement in reverse 
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cholesterol transport in human macrophages (Gaidarov et al., 2018). Patent 
literature also revealed that embelin decreased the atherosclerotic 
lesions/plaque size in apolipoprotein E KO (ApoE-/-) mice, an animal model of 
atherosclerosis (Hakak et al., 2007). Hakak et al., (2007) argued that embelin-
promoted inhibition of atherogenesis in the animal model was due to the 
upregulation of ABCA1 and downregulation of MCP-1 in macrophages in response 
to embelin-stimulated GPR84 activation because decreased expression of ABCA1 
and increased expression of MCP-1 were reported to be associated with 
pathogenesis of atherosclerosis (Dawson et al., 2003; Aiello et al., 1999; Van Eck 
et al., 2006).These findings suggest that GPR84 stimulation can be exploited 
therapeutically for the development of anti-atherosclerotic drugs. Recio et al., 
(2018) observed that under hypercholesterolemia, apolipoprotein E deficient 
mice (ApoE-/-) displayed significantly higher expression of GPR84 mRNA in aortic 
tissue and oxidized LDL-treated human monocyte-derived macrophages showed 
strong upregulation of GPR84. Based on these findings, Recio et al., (2018) 
predicted that infiltrating macrophages upregulates GPR84 in atherosclerotic 
lesions which might be associated with the pathogenesis of atherosclerosis.This 
is contrary to the anti-atherosclerotic properties of GPR84 activation mediated 
by embelin reported by Gaidarov et al., (2018), and this dichotomoy is clearly 
worthy of further investigation.   
1.8.3 Potential role of GPR84 in neuro-immune and neuro-
inflammatory processes 
1.8.3.1 Role of GPR84 in chronic neuropathic pain 
Nicol et al. (2015) explored for the first time whether GPR84 plays an important 
role in mediating chronic neuropathic nociception and if this could be exploited 
to develop an effective treatment for chronic neuropathic pain. Significant 
upregulation of GPR84 in sciatic nerve and spinal cord of wild type mice at 7 and 
21 days after peripheral nerve injury indicates the potential role of GPR84 in 
mediating neuropathic chronic pain, which was further supported by the loss of 
mechanical and thermal hypersensitivity towards chronic neuropathic pain in 
GPR84 deficient mice whereas wild type mice displayed elevated 
hypersensitivity in response to nerve injury (Nicol et al., 2015). Nicol and 
colleagues (2015) argued that this lack of neuropathic chronic pain in GPR84 KO 
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mice was due to the marked reduction in peripheral macrophages-mediated 
inflammatory responses which was evidenced from the observation that GPR84 
deletion led to significant attenuation of LPS-induced upregulation of pro-
inflammatory mediators including TNF-α, IL-1β, IL-6, IL-12b, nitric oxide 
synthase 2 (NOS2), prostaglandin E synthase 2 (PTGES2), CCL2,CCL3  in 
macrophages compared to wild type mice.        
1.8.3.2 Role of GPR84 in regulating microglia biology 
Strong upregulation of GPR84 in microglia in response to inflammatory 
stimulation (TNF-α, IL-1β) (Bouchard et al., 2007; Bedard et al., 2007) or under 
pathological conditions including neuronal injury (Wei et al., 2017; Nicol et al., 
2015), endotoxemia and experimental autoimmune encephalomyelitis (Bouchard 
et al., 2007) or Alzheimer’s disease (Audoy-Remus et al., 2015) suggests that 
GPR84 might be a potential mediator of neuroinflammation. In contrast to this 
prediction, GPR84 was not found to regulate pro-inflammatory responses in 
microglia (Wei et al., 2017; Nicol et al., 2015). Nicol et al., (2015) observed no 
alteration between GPR84 KO and wild type mice in terms of microgliosis and 
microglial activation following peripheral nerve injury. Consistent with this 
finding, Wei and colleagues (2017) observed that treatment of LPS-induced 
mouse microglia with GPR84 surrogate agonist 6-OAU did not result in any 
upregulation of pro-inflammatory mediators such as IL-1β, IL-6, IL-12p40, TNF-
α,iNOS, CXCL1 whereas strong upregulation of these mediators in LPS-stimulated 
mouse bone marrow-derived macrophages were reported by Recio et al., (2018), 
suggesting that GPR84 activation did not generate any pro-inflammatory 
response in microglia. This was further supported by the absence of nuclear 
translocation of NF-κB subunit p65 in response to agonist-mediated GPR84 
activation in LPS-induced mouse microglia (Wei et al., 2017) whilst Recio et al., 
(2018) reported 6-OAU-induced strong nuclear translocation of this NF-κB 
subunit in LPS-stimulated BMDMs. As NF-κB transcription factor is thought to be 
responsible for induction of pro-inflammatory cytokines (Sun and Ye, 2012), lack 
of activation of this pathway in microglia following treatment with GPR84 
agonists (6-OAU, embelin and C-10) is in agreement with the observation that 
GPR84 is not associated with inflammatory responses mediated by microglia.    
However, GPR84 activation was found to mediate microglial motility and ruffling 
in a Gαi/o pathway dependent manner as 6-OAU, embelin and C-10, each induced 
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robust membrane ruffling and motility of mouse microglia and 6-OAU-promoted 
motility was completely blocked by PTX pre-treatment (Wei et al., 2017). 
Recently, based on gene knock out studies in a mouse model of Alzheimer’s 
disease, Audoy-Remus et al., (2015) reported a beneficial role of microglial 
GPR84 in preventing cognitive decline during neurodegenerative disorders. 
Compared to wild type littermates, GPR84 KO APP/PS1 (mouse model for 
Alzheimer’s disease) mice displayed reduced cognitive performance and 
microgliosis along with enhanced β-amyloid-stimulated dendritic degeneration 
(Audoy-Remus et al., 2015). Based on the observations that APP/PS1 mice 
expressing microglial GPR84 exhibited significantly higher (16-32%) microglial 
recruitment around amyloid plaques along with 2.5-fold lower dendritic 
degeneration compared to the mice deficient in GPR84, the authors proposed 
that GPR84-mediated microglial recruitment prevents cognitive decline and 
plays a moderate role in dendritic homeostasis.    
1.8.4 Potential role of GPR84 in promoting insulin resistance 
under inflammatory conditions 
Chronic inflammation plays a crucial role in the pathogenesis of obesity-related 
disorders including insulin resistance, type 2 diabetes and metablic syndrome 
(Muredda et al., 2018; McArdle et al., 2013; Alvarez-Curto and Milligan, 2016; 
Nawrocki and Scherer, 2004). Strong upregulation of GPR84 in mouse bone 
marrow, kidney and brain and in mouse BMDMs in hyperglycemic conditions 
suggested that GPR84 might be associated with the pathogenesis of diabetes 
(Recio et al., 2018). Recently, the role of GPR84 in initiating insulin resistance 
during inflammatory conditions has been proposed by Nagasaki et al. (2012) who 
showed that GPR84 mRNA expression was significantly augmented in 3T3-L1 
adipocytes and in adipose tissue of obese mice, in response to inflammatory 
cytokine TNF-α secreted from macrophages which migrated to the adipose tissue 
(Figure 1.12). Although Takeuchi et al. (2006) reported  that serum adiponectin 
level is increased in response to dietary medium-chain triglycerides (MCT), in 
3T3-L1 adipocytes, GPR84 activation by MCFAs resulted in amplification of TNF-
α-induced down-regulation of adiponectin (Nagasaki et al., 2012). As adiponectin 
is appreciated to enhance insulin sensitivity (Diez and Iglesias, 2003; McArdle et 
al., 2013), MCFAs-stimulated suppression of adiponectin expression in TNF-α-
induced adipocytes implies that MCFAs-GPR84 axis may initiate insulin resistance 
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and thus mediate the cross-talk between adiposity and type 2 diabetes. 
Consistent with the finding reported by Nagasaki et al., (2012), Trayhurn and 
Denyer, (2012) observed that macrophage-conditioned medium led to significant 
increase in GPR84 mRNA expression in human adipocytes. Muredda et al., (2018) 
also reported strong upregulation of GPR84 in human adipocytes upon 
stimulation with pro-inflammatory cytokines TNF-α or IL1-β. As GPR84 mediates 
inflammatory responses (see section 1.8.1), significant upregulation of GPR84 in 
adipocytes upon inflammatory conditions implies that GPR84 can exacerbate the 
obesity-promoted inflammatory response in adipose tissue and thereby mediates 
the vicious cycle between obesity and inflammation.      
 
 
Figure 1.12 Proposed role of GPR84 in mediating cross-talk between adiposity and diabetes. 
GPR84 is strongly upregulated in adipocytes in response to inflammatory stimuli such as TNF-α 
secreted from macrophages infiltrated into inflamed adipose tissue. MCFAs-mediated GPR84 
signaling amplifies TNF-α-promoted reduction in adiponectin expression in adipocytes which can 
lead to initiation of insulin resistance exacerbating a vicious cycle between obesity and diabetes.  
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1.8.5 GPR84 displays pro-fibrotic activity and represents a 
potential target for drug development against fibrosis-
associated diseases 
Currently available antifibrotic therapeutics (pirfenidone or nintedanib) for the 
treatment of idiopathic pulmonary fibrosis (IPF) lead to gastro-intestinal and 
cardiovascular side effects which markedly decrease patient compliance 
resulting in significant discontinuation of therapy (Marium et al., 2018). 
Moreover, both antifibrotics have limited efficacy in preventing underlying 
disease progression (Khalil et al., 2019) which necessitates novel development of 
therapeutics for this life-threatening disease. Recently, based on the results 
obtained from the studies with gene knock out mice and animal models of 
fibrosis, Gagnon et al., (2018) reported that two fatty acid sensing receptors 
GPR40 and GPR84 are involved in the pathogenesis of fibrosis in different organs 
including lung, kidney, heart, pancreas etc and suggested that agonism of GPR40 
and antagonism of GPR84 could be novel therapeutic strategies to treat fibrosis-
associated diseases such as IPF. Marked upregulation of GPR84 expression in 
human dermal fibroblasts and podocytes in response to the fibrosis promoting 
TGFβ-1 and inflammatory stimuli including LPS and IFNγ along with the strong 
upregulation of GPR84 mRNA in different kidney fibrosis models despite very low 
basal expression in healthy renal tissue suggested a potential role of GPR84 in 
fibrosis pathophysiology (Gagnon et al., 2018). Consistent with these findings, 
Saniere et al., (2019) found marked upregulation of GPR84 in bronchial epithelial 
cells and infiltrated immune cells in both fibrosis mouse models and IPF patients 
whilst no expression of GPR84 in lung tissues of healthy human volunteers was 
observed. Genetic elimination of GPR84 in mice resulted in 50% reduction in 
kidney fibrosis in an adenine-promoted nephropathy model, further supporting 
role of GPR84 in fibrogenesis (Gagnon et al., 2018). Gagnon et al., (2018) also 
found that the antifibrotic agent PBI-4050 effectively blocked the TGβ-1-induced 
upregulation of the myofibroblast marker α-SMA and pro-fibrotic markers CTGF 
and COL1A1 in human dermal fibroblasts which demonstrated a link between 
GPR84 activation and fibroblast differentiation and activation in skin fibrosis as 
no GPR40 expression was found in dermal fibroblasts. Besides this, PBI-4050 
treatment also resulted in effective blockade of LPS/IFNγ-promoted 
upregulation of inflammatory mediators (MCP-1, IL-6, IL-12p40, CCL2) in mouse 
peritoneal macrophages and inhibition of LPS-stimulated upregulation of IL-6 and 
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IL-8 in human podocytes (Gagnon et al., 2018). Based on these outcomes the 
authors maintained that inhibition of GPR84-mediated pro-inflammatory 
activities might be associated with PBI-4050-mediated prevention of fibrosis in 
different rodent models. Saniere et al., (2019) also reported that 
pharmacological inhibition of GPR84-mediated inflammatory responses and 
oxidative burst was partly responsible for the observed anti-fibrotic action of 
GLPG1205 in a mouse model of lung fibrosis. As chronic inflammation is 
associated with initial stages of the pathology of fibrosis-related disorders, 
combination therapy of an anti-inflammatory GPR84 antagonist with other anti-
fibrotics might enhance the efficacy of the clinical therapy.  
Li et al., (2018) demonstrated that PBI-4050, an agonist for GPR40 and 
antagonist/inverse agonist for GPR84 effectively inhibited kidney and pancreatic 
islet fibrosis and isletitis in a mouse model of diabetic nephropathy associated 
with type 2 diabetes. They argued that along with the GPR40 agonism which is 
beneficial in counteracting fibrosis, antagonism of GPR84-mediated macrophage 
infiltration and oxidative burst in kidney and pancreatic islets were the possible 
underpinning mechanisms of actions of PBI-4050 in inhibiting disease progression 
in diabetic nephropathy. Puengel et al., (2018) also reported that inhibition of 
GPR84-mediated immune cell (neutrophil and macrophages) infiltration into 
hepatic tissue could be a possible therapeutic strategy to treat non-alcoholic 
steatohepatitis and in mouse models of acute and chronic liver injury two GPR84 
antagonists were found to effectively decrease disease progression as evident 
from significant reduction in steatohepatitis and fibrosis.       
Nguyen et al., (2019) explored that GPR84 antagonism is the potential mode of 
action of PBI-4050 in inhibiting disease progression of pulmonary hypertension 
associated with heart failure with reduced ejection fraction (HFrEF). The 
pathophysiology of this secondary pulmonary hypertension includes macrophage 
infiltration into lung tissues and lung fibroblast activation and differentiation 
into pro-fibrotic myofibroblasts resulting in excessive extracellular matrix 
deposition in the alveolar wall. The authors suggested that agonist-activated 
GPR84 is associated with ERK1/2 signaling pathway-mediated pro-fibrotic 
activities and antagonism of GPR84 is partly responsible for PBI-4050-induced 
inhibition of lung fibrosis in the animal model of heart failure. GPR84 was 
upregulated significantly in lung tissue of rats with heart failure suggesting a 
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pathophysiological role of GPR84 in the disease progression. Studies with human 
lung fibroblasts identified that GPR84 is upregulated in these cells in response to 
stimulations with TGF-β1 and endothelin-1, known mediators of pulmonary 
hypertension and heart failure and this upregulation was blocked by PBI-4050 
(Nguyen et al., 2019). The GPR84 agonists compound-1/ZQ-16 and embelin were 
found to significantly upregulate expression of myofibroblasts markers including 
α-smooth muscle actin (α-SMA), connective tissue growth factor (CTGF) and 
COL1A1 and fibroblast activator endothelin-1 (ET-1), suggesting that GPR84 
signaling is associated with lung fibrosis by activating and differentiating lung 
fibroblasts into myofibroblasts (Nguyen et al., 2019). As compound-1 and 
embelin were reported to induce GPR84-mediated ERK1/2 phosphorylation 
(Gaidarov et al., 2018; Zhang et al., 2016) and GPR84 antagonist PBI-4050 
completely blocked the TGF-β-mediated ERK1/2 phosphorylation in human lung 
fibroblasts, Nguyen and colleagues (2019) proposed that GPR84-mediated 
ERK1/2 signaling at least partly contributes to the fibrogenesis and antagonism 
of this signaling is one of the major mechanisms by which PBI-4050 acts in 
preventing lung fibrosis in heart failure with pulmonary hypertension.                   
These promising outcomes obtained in pre-clinical studies suggest that GPR84 
antagonism can be exploited therapeutically for drug development against 
fibrosis-associated diseases and currently the GPR84 antagonist GLPG1205 
(https://www.glpg.com/IPF; Saniere et al., 2019)  and PBI-4050 are in phase II 
and Phase III clinical trials, respectively in patients with idiopathic pulmonary 
fibrosis (Li et al., 2018). GLPG1205 was found to be effective in preventing 
disease progression in pre-clinical animal models of IPF (Saniere et al., 2019) 
and displayed promising safety and tolerability in healthy human volunteers in a 
Phase I clinical study. Similarly, in a phase II clinical trial, PBI-4050 was found to 
display promising clinical efficacy and safety profile in patients with either IPF 
or type 2 diabetes associated with metabolic syndrome (Gagnon et al., 2018; 
Khalil et al., 2019).   
1.8.6 GPR84 regulates osteoclastogenesis and could be a 
potential drug target for bone-destruction related diseases 
Targeting the receptor activator of nuclear factor-κB ligand (RANKL)-induced 
signaling pathways which regulate osteoclast differentiation is considered to be 
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a potential novel strategy for drug development against many diseases related to 
bone loss including osteoporosis, arthritis and rheumatoid arthritis, cancer 
metastases etc (Wada et al., 2006). Though fatty acid sensing receptors have 
mainly attracted interest as potential therapeutics for inflammatory and 
metablic disorders, recent findings show that these receptors are also associated 
with regulation of bone physiology. FFA1 (GPR40) and FFA4 (GPR120) were 
reported to block RANKL-induced osteoclast differentiation by downregulating 
the NF-κB signaling pathway (Kim et al., 2016; Wauquier et al., 2013). Similar to 
FFA1 and FFA4, GPR84 was also found to downregulate RANKL-stimulated 
osteoclastogenesis by suppressing NF-κB and MAPK signaling pathways (Park et 
al., 2018) (Figure 1.13). Overexpression of GPR84 in osteoclast precursor cells, 
bone marrow-derived macrophages (BMDM) resulted in significant inhibition of 
RANKL-induced osteoclast formation whilst GPR84 knock down by small hairpin 
RNA transfection enhanced RANKL-promoted osteoclast differentiation (Park et 
al., 2018). GPR84 overexpression in BMDM led to downregulation of c-Fos and 
NFATc1 (both mRNA and protein levels) and TRAP and cathepsin K, two 
osteoclast specific genes. In contrast, knock down of GPR84 was found to 
significantly upregulate expression of c-Fos and NFATc1 as well as TRAP and 
cathepsin K in BMDM. GPR84 also concentration-dependently suppressed RANKL-
induced NF-κB transcriptional activity as measured by a luciferase reporter assay 
in RAW264.7 cells (Park et al., 2018). Moreover ectopic expression of GPR84 led 
to significant reduction in RANKL-promoted phosphorylation of inhibitory κBα 
protein (IκBα) and JNK, p38 and ERK while GPR84 gene silencing enhanced 
phosphorylation of these signaling mediators. As c-Fos, NF-κB and NFATc1 were 
reported to play crucial roles in the gene expression essential for osteoclast 
differentiation (Kim and Kim, 2014; Asagiri  and Takayanagi, 2007; Wada et al., 
2006; Takayanagi et al., 2002;), Park et al., (2018) maintained that 
downregulation of these transcription factors by GPR84 signaling is the 
underpinning mechanism of GPR84-mediated  downregulation of RANKL-induced 
osteoclast differentiation. These findings showed that GPR84 can be a potential 
target for drug development against diseases associated with bone disorders 
including osteoporosis and rheumatoid arthritis.  
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Figure 1.13 GPR84 signaling inhibits RANKL-induced osteoclast differentiation by inhibiting 
NF-κB and MAPK signaling pathways. Binding of receptor activator of nuclear factor-κB ligand 
(RANKL) to RANK receptor on bone marrow derived macrophages (BMDM) induces recruitment of 
adaptor protein TRAF6 to the receptor which activates downstream signaling effectors associated 
with MAPKs and NF-κB pathways. Phosphorylation of NF-κB inhibitory protein IκBα leads to 
activation of NF-κB heterodimer (p50/p65) and subsequent nuclear translocation of NF-κB to act as 
a transcription factor inducing gene expressions related to osteoclast differentiation. Activated NF-
κB heterodimer also can activate another transcriptional factor, nuclear factor of activated T cells, 
cytoplasmic 1 (NFATc1). Recruitment of TRAF6 also activates AP-1 component c-Fos which acts 
as a transcription factor and an activator for NFATc1. Nuclear translocation of NFATc1 leads to 
induction of gene expression associated with osteoclast differentiation. GPR84 signaling inhibits c-
Fos expression and downregulates RANL-induced activation of NF-κB pathway by inhibiting 
phosphorylation of IκBα which ultimately lead to downregulation of NFATc1 activities (Park et al., 
2018). GPR84 also prevents RANKL-promoted phosphorylation of three mitogen activated protein 
kinases (MAPK) including c-Jun N-terminal protein kinase (JNK), p38 and extracellular signal-
regulated kinase (ERK) which might be associated with osteoclast specific gene expression (Park 
et al., 2018).  
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1.8.7  GPR84-β-catenin axis is associated with development and 
maintenance of acute myeloid leukemia  
Wnt-β-catenin signaling has been implicated in tumorigenesis and thus 
considered as a novel target for anti-cancer drug development (Krishnamurthy 
and Kurzrock, 2018; Dorsam and Gutkind, 2007). Recently, Dietrich et al. (2014) 
proposed that GPR84 acts as a positive regulator of wnt-β-catenin signaling 
pathway in leukemic stem cells (LSCs) and thereby plays an important role in the 
development and maintenance of acute myeloid leukemia (AML) (Figure 1.14). 
GPR84 expression has been shown to be significantly elevated in human and 
mouse AML LSCs compared to hematopoietic stem cells (HSCs) (Saito et al., 
2010; Dietrich et al. 2014) which suggests a potential role of GPR84 in the 
development of AML leukemia. Strong upregulation of active β-catenin in mouse 
MLL LSC along with higher expression of GPR84 is indicative of GPR84-induced 
potentiation of β-catenin expression. Small hairpin mRNA-induced GPR84 knock 
down in mouse MLL pre-LSCs resulted in significant downregulation of active β-
catenin expression with concomitant reduction in growth and proliferation of 
leukemic cells (Dietrich et al., 2014). These effects of GPR84 gene silencing 
were fully reversed by transduction of constitutively active form of β-catenin in 
leukemic cells. Moreover, overexpression of GPR84 in mouse KLS-derived pre-LSC 
transduced with the oncogenic gene Hoxa9/Meis1a (KLSA9M pre-LSC) led to 
strong upregulation of β-catenin and transcription factors, TCF7L2 and c-Fos 
(both mRNA and protein level) with concomitant upregulation of a set of wnt-β-
catenin target genes associated with leukemogenesis (Dietrich et al., 2014). 
These findings suggest that GPR84 is a positive regulator of Wnt-β-catenin 
singaling pathway and inhibition of the GPR84- β-catenin system might be a 
novel strategy for drug development for acute myeloid leukemia (AML).  
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Figure 1.14 GPR84 regulates Wnt-β catenin signaling in pre-leukemic stem cells to develop 
and maintain MLL leukemia. In the absence of wnt glycoprotein, β-catenin is phosphorylated by 
glycogen synthetase kinase 3β (GSK3β) of the destruction complex Axin-APC-GSK3 followed by 
ubiquitination and proteosomal degradation. Wnt glycoprotein ligand binds to the cysteine rich 
domain (CRD) of 7-TM frizzled receptor and to the low density lipoprotein receptor-related protein 
(LRP) which activates Disheveled (Dvl) protein followed by recruitment of Axin-APC-GSK3 complex 
to the receptor (Krishnamurthy and Kurzrock, 2018). This sequestration of cytosolic protein GSK3 
inhibits phosphorylation of β-catenin leading to subsequent accumulation of β-catenin in cytoplasm 
(Dorsam and Gutkind, 2007). β-catenin then translocates to the nucleus to act as a co-activator for 
transcription factor, T-cell factors (TCFs) which induce expression of Wnt responsive genes. 
GPR84 is supposed to act as a potentiator of Wnt-β-catenin signaling pathway by upregulating 
expression of β-catenin and its co-effectors including TCF7L2 and c-Fos which results in enhanced 
expression of MLL target genes responsible for leukemogenesis (Dietrich et al., 2014).  
1.9 Aims and objectives of the project  
GPR84 is still officially considered as ‘orphan’ receptor as the putative 
endogenous agonists MCFAs are weakly potent activators of GPR84 and their 
mode of binding to GPR84 is poorly defined. Only one study has been done on 
the mode of decanoic acid binding to GPR84. However Nikaido et al., (2015) 
failed to identify the charge partner for the carboxylate function of the fatty 
acids. Although a few articles have been published regarding the signal 
transduction pathways, physiological functions and pathophysiological roles of 
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the GPR84, it still remains poorly characterized and details of the mode of 
action of pharmacological tools are limited. As such its regulation, physiological 
functions and pathophysiological roles have not yet been clarified; hindering 
drug development programmes and therefore warrant further research. In this 
regard, investigation of modes of ligand binding to GPR84 and defining the mode 
of action of pharmacological tools are required which will aid generation of 
further improved tool compounds that can be utilized for physiological 
characterization of the receptor. The aims and objectives of my PhD thesis are 
as follows:   
1) Exploring the G protein selectivity of the receptor using novel BRET-based 
GPR84 biosensors developed using a SPASM (systematic protein affinity strength 
modulation) based approach (Sivaramakrishnan and Spudich, 2011). (Chapter 3) 
2) Defining the ligand binding pockets of GPR84 by a combination of site 
directed mutagenesis and molecular modelling. The studies will also define 
whether reported synthetic ligands act at the same site as the fatty acids or act 
as allosteric activators. (Chapter 4) 
3) Defining the ortholog selectivity of GPR84 ligands and characterizing the 
pharmacology of GPR84 ligands in more physiological settings using 
RAW264.7 cells: Though several potent and selective tool compounds have been 
developed recently, the mechanism of actions of these tool compounds including 
orthosteric and allosteric ligands are very limited. Moreover detailed orthologue 
selectivity of these pharmacological tools is unexplored. Exploring the complex 
pharmacology of these tool compounds is crucial for the characterization of this 
enigmatic receptor and is thus essential to uncover the therapeutic potential of 
this receptor. Pharmacological profiles of currently available GPR84 agonists and 
antagonists along with their potential orthologue selectivity were investigated 
using transfected cells expressing human and mouse GPR84 as well as the mouse 
monocyte macrophage cell line RAW264.7 (Chapter 5). 
4) Exploring the allosteric modulation of GPR84: Detailed allosteric 
interactions between DIM and DIM analogues and orthosteric GPR84 agonists 
were characterized using transfected cells expressing human and mouse GPR84 
and RAW264.7 cells (Chapter 6). The potential orthologue selectivity of DIM and 
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PSB-16671-mediated allosteric modulation was also investigated using human 
and mouse GPR84 expressing cell lines.    
Overall the studies performed in this project aims at investigating ligand binding 
modes and characterizing allosteric modulation of GPR84 which will aid drug 
discovery programmes either through accelerating structure-based drug design, 
identifying more improved ligands, or exploiting the novel modality of allosteric 
interaction for development of allosteric therapeutic agent(s).    
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2 Materials and methods 
2.1 Pharmacological tool compounds 
Medium chain fatty acids including decanoic acid (C-10), undecanoic acid (C-11), 
lauric acid (C-12); 3,3´-diindolylmethane (DIM) and 2,5-dihydroxy-3-undecyl-1,4-
benzoquinone (embelin) were purchased from Sigma-Aldrich.   
DIM analogues 5,5´-diiodo-3,3´- diindolyl-(4-methylphenyl)methane (2b); 5,5´-
dimethoxy-3,3´-diindolylmethane (3a); 5,5´-dimethoxy-3,3´- diindolyl-(4-
methylphenyl)methane (3b); 5,5´-dimethoxy-3,3´- diindolyl-(3,5-
difluorophenyl)methane (3c) and 5,5´-dinitro-3,3´-diindolylmethane (6a) (see 
Figure 2.1 for structures) were a gift from Dorota Maciejewska, Department of 
Organic Chemistry, Medical University of Warsaw, Poland. 
6-n-octylaminouracil (6-OAU) was purchased from Cayman Chemical (USA) while 
2-(hexylthio)pyrimidine-4,6-diol (ZQ-16 or compound-1) was provided by Trond 
Ulven, University of Copenhagen and Galapagos NV.  
A series of compound-1 derivatives including 6-phenylethylpyridine-2,4-diol 
(TUG-1758) ; 6-phenylbutylpyridine-2,4-diol (TUG-1759); 2-nonylpyridine (TUG-
1760);  2-nonyl-4-pyridone (TUG-1761); 6-undecylpyridine-2,4-diol (TUG-1762); 
6-decylpyridine-2,4-diol (TUG-1763); 6-heptylpyridine-2,4-diol (TUG-1764); 6-
octylpyridine-2,4-diol (compound-50/TUG-1765) (see Figure 2.2 for structures) 
were provided by Trond Ulven, University of Copenhagen.  
GPR84 agonist 6-nonylpyridine-2,4-diol (compound-51), GPR84 allosteric agonist 
di(5,7-difluoro-1H-indole-3-yl)methane (PSB-16671) and  GPR84 antagonists 
including compound-9 (2-([1,4]dioxin-2-ylmethoxy)-9-(pyridine-2-ylmethoxy)-6,7-
dihydro-pyrimido[6,1-a]isoquinolin-4-one); compound-104 (9-(5-cyclopropyl-
[1,2,4]oxadiazol-3-ylmethoxy)-2-((R)-1-[1,4]dioxan-2-ylmethoxy)-6,7-dihydro-
pyrimido[6,1-a]isoquinolin-4-one); compound-107 (2-([1,4]dioxan-2-ylmethoxy)-
9-(3-phenylamino-prop-1-ynyl)-6,7-dihydro-pyrimido[6,1-a]isoquinolin-4-one); 
compound-122/GLPG1205 (9-(2-cyclopropylethynyl)-2-[[(2S)-1,4-dioxan-2-
yl]methoxy]-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one); compound-161 (2-
((S)-1-[1,4]dioxan-2-ylmethoxy)-9-(tetrahydro-pyran-4-yl-methoxymethyl)-6,7-
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dihydro-pyrimido[6,1-a]isoquinolin-4-one); compound-837 and radioligand [3H]-
G9543  were synthesized and provided by Belgian pharmaceutical company 
Galapagos NV.  
 
Figure 2.1 Structure of GPR84 allosteric agonist DIM and DIM analogues used in the studies. 
Chemical structure of DIM and certain DIM analogues including 3a, 6a, 2b, 3b and 3c are shown.  
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Figure 2.2 Chemical structures of a series of compound-1 derivatives. Chemical structures of 
a set of compound-1 derivatives used in the screening assay for GPR84 agonism are shown.   
2.2 Molecular biology and cloning 
2.2.1 Preparation of LB (Luria-Bertani) medium and LB agar 
plates 
10 g tryptone, 5 g yeast extracts and 10 g NaCl were combined and 800 ml 
deionized, distilled water was added to the dry reagents followed by adjustment 
of the pH of the solution to 7.0 with NaOH. The volume of the solution was then 
brought up to 1 liter. The solution was then autoclaved on liquid cycle for 20 
minutes at 15 psi. To prepare LB agar plates, LB medium was prepared as above 
and 15 g of bacto-agar was added per 1L of LB followed by autoclaving at 126ºC. 
After autoclaving, the bottles were allowed to cool to 55°C and an appropriate 
amount of filter-sterilized antibiotic ampicillin was added at a final 
concentration of 50–100 μg/ml. The bottle was then swirled to ensure proper 
mixing of ampicillin with LB agar and approximately 20 ml of agar was poured 
into a 10 cm petri-dish. The plates were then kept at room temperature for 20 
minutes to allow the agar to solidify. After solidified and dried, the plates were 
inverted and stored at 4ºC in the dark.      
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2.2.2 Preparation of competent bacteria 
A stock of XL1-blue cells (Agilent Technologies) stored in -80ºC was taken out, 
thawed on ice and streaked out on an LB agar plate with no antibiotics and 
grown overnight at 37ºC. On the following day, a single colony was picked and 
grown in 5 ml of LB media (without antibiotic) overnight at 37ºC in a shaking 
incubator at 220 rpm. This 5 ml culture was then sub-cultured into 100 ml of LB 
media and grown at 37ºC in a shaking incubator until the optical density at 600 
nm was reached to 0.48. The growth of bacteria was halted by chilling on ice for 
5 minutes followed by centrifugation at 1811xg for 10 minutes at 4ºC in 50 ml 
sterile falcon tubes. The resulting bacterial cell pellets from each 50 ml falcon 
tubes were re-suspended in 20 ml of  solution 1 (30 mM CH3COOK, 10 mM RbCl, 
10 mM CaCl2, 50 mM MnCl2 and 15% (v/v) glycerol; pH 5.8; filter sterilized and 
stored at 4ºC) by gentle pipetting followed by chilling on ice for 5 minutes. The 
chilled pellets were further subjected to centrifugation at 1811xg for 10 minutes 
at 4ºC. The pellets from this 2nd centrifugation was then re-suspended in 2 ml of 
solution 2 (10 mM 3-morpholinopropane-1-sulfonic acid (MOPS), 10 mM RbCl, 75 
mM CaCl2, 15% (v/v) glycerol, pH 6.5 with HCl; filter sterilized and stored at 4ºC) 
by gentle pipetting and chilled on ice for a further 15 minutes. Bacterial cells 
were then aliquoted in 220µl volumes in sterile pre-chilled 1.5 ml 
microcentrifuge tubes and stored at -80ºC.   
2.2.3 Transformation of competent cells with plasmid cDNA 
Chemically competent XL1-blue cells (section 2.2.2) were taken out of -80ºC and 
thawed on ice for 20 minutes. 50 µl of thawed competent cells were aliquoted 
for each transformation into pre-chilled 1.5 ml microcentrifuge tube followed by 
addition of 1-5 µl of DNA (10-100 ng) or 5 µl of the ligation reaction mixture to 
the cells and mixing gently by flicking the bottom of the tube. The competent 
cell/DNA mixture was then incubated on ice for 15 minutes and subjected to 
heat shock at 42ºC for 90 seconds by placing the tubes on a rack which was 
placed in a water bath. The tubes were then immediately placed on ice for 2 
minutes. 500 µl of LB media without any antibiotics was added to each tube and 
bacteria were grown in 37ºC in a shaking incubator (220 rpm) for 45 seconds to 1 
hour allowing bacteria to express antibiotic resistance genes. 50 to 200 µl of 
transformation was then plated using a sterile spreader onto a pre-warmed 10 
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cm LB agar plate containing 50 µg/ml ampicillin. The plates were incubated 
upside down at 37ºC overnight. Only the cells containing the transformed 
plasmid will be able to form colonies in the LB agar ampicillin plate. On the 
following day, a single colony was picked and grown overnight in 5 ml of LB 
media containing 50 µg/ml ampicillin at 37ºC in a shaking incubator. The 
resulting cultures were either DNA mini-prep’d or sub-cultured further to make 
larger volumes of closed circular DNA (cDNA) (mid-prep and maxi-prep).        
2.2.4 Purification of plasmid DNA from bacterial culture 
Microgram quantities of plasmid DNA were purified from bacterial culture using 
Wizard® Plus SV Minipreps DNA Purification System (Promega) following the 
manufacturer’s instructions. Briefly, 5 ml of overnight bacterial culture was 
centrifuged at 3220 x g for 5 minutes and the resulting pellets were thoroughly 
re-suspended in 250 µl of cell resuspension solution (50 mM Tris-HCl (pH 7.5), 10 
mM EDTA, 100 μg/ml RNase A). The bacterial cells were then lysed by adding 250 
µl of cell lysis solution (0.2M NaOH, 1% SDS) to each sample and inverting the 
tube 4 times to ensure proper mixing. To inactivate endonucleases or other 
proteins, 10 µl of alkaline protease solution was added to each sample with 
mixing by inverting the tube 4 times followed by incubation at room 
temperature for 5 minutes. 350 µl of ice-cold neutralization solution (1.32M 
potassium acetate; pH 4.8) was then added and the tube was inverted 4 times to 
mix. In this stage, proteins and genomic DNA are precipitated while smaller 
plasmids are able to renature at lower pH and remain in solution. The mixture 
was then centrifuged at 17,900 x g for 10 minutes at room temperature and the 
resulting supernatant (cleared lysate) was carefully decanted into the spin 
column inserted into a collection tube. The supernatant was centrifuged at 
17,900 x g for 1 minute at RT allowing the plasmid DNA to bind the column. The 
flow-through was discarded and the spin column was re-inserted into the 
collection tube. The column was washed with 750 µl of column wash solution (80 
mM potassium acetate, 8.3 mM Tris-HCl (pH 7.5), 40 µM EDTA, 95% ethanol 
added [final concentration of ethanol was 55%]) by centrifugation at 17,900 x g 
for 1 minute at RT. The flow-through was discarded and the column was re-
inserted into the collection tube. Column washing was carried out once again 
with 250 µl of wash solution but this time centrifugation was performed for 2 
minutes. The spin column was then transferred to a sterile 1.5 ml 
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microcentrifuge tube prior to the addition of 100 µl nuclease-free water to the 
spin column. Plasmid DNA was then eluted by centrifugation at 17,900 x g for 1 
minute and stored in -20ºC.  
Milligram quantities of plasmid DNA was purified from 100 to 200 ml of bacterial 
culture using QIAGEN® Plasmid Maxi Kit according to the manufacturer’s 
instructions which are very similar to that described above for miniprep 
preparation with slight modification.  
After miniprep or maxiprep, the concentration and purity of the DNA were 
estimated by reading the absorbance of diluted samples (1:200) at 260 nm and 
280 nm using a UV spectrophotometer. The absorbance at 260 nm (A260) reveals 
the quantity of the DNA while the ratio of absorbance at 260 to that at 280 nm 
(A260/A280) reflects the purity of the sample with the ratio between 1.8 to 2.0 
being considered as highly pure DNA.  
2.2.5 PCR based cloning    
In polymerase chain reaction (PCR) based cloning, firstly a PCR reaction was 
performed to amplify the specific DNA fragments along with incorporating 
restriction sites on the two ends of the open reading frame (ORF) so that the 
gene of interest could easily be inserted into the recipient plasmid. The PCR 
amplified product was then purified from other PCR reaction components. This 
purified PCR product and the recipient plasmid vector were then subjected to 
double restriction digestion with two restriction endonucleases followed by 
running gel electrophoresis of restriction digests (both insert and plasmid 
vector). Gel purification was then performed to isolate and purify the digested 
insert and vector DNA which were then fused by conducting a DNA ligation 
reaction with DNA ligase enzyme ultimately leading to the generation of a 
plasmid construct containing the gene of interest.         
2.2.5.1 Polymerase chain reaction (PCR) 
In an attempt to incorporate restriction sites or epitope tag ( FLAG epitope tag 
or fluorescent protein tag) on both terminus or single terminus of the gene of 
interest and to amplify the DNA fragment, a PCR reaction was set up on ice in a 
total volume of 50 µl in a 500 µl sterile PCR tube with the following components:  
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 5 µl of 10x Pfu DNA Polymerase reaction buffer (Promega) 
 1 µl of 10 mM dNTP mix (final concentration: 200 µM of each dATP, dCTP, 
dGTP and dTTP; Promega) 
 0.5 µM of each sense and antisense oligonucleotide primers 
 50 to 100 ng of DNA template 
 1 µl of (2.5 units/µl) Pfu DNA Polymerase (Promega)  
 Nuclease-free water quantity sufficient to 50 µl  
The PCR reaction tubes were then transferred to a thermal cycler and subjected 
to thermal cycling using the following PCR programme:  
                 Step Temperature  Time 
1. Initial denaturation 95ºC  5 minutes 
2. Denaturation 95ºC 1 minute 
3. Annealing  55 to 65ºC depending 
on the Tm of the 
primers 
1 minute 
4. Extension  72ºC 1 minute 30 seconds 
(2 minutes/kb of  
DNA fragment 
length) 
5. Repeat steps 2-4 for 30 cycles 
6. Final extension 72ºC  5-10 minutes 
7. Hold 4ºC indefinite 
   
After finishing the PCR, 5 µl of the PCR product was run on an agarose gel to 
check the success of the PCR. 
2.2.5.2 PCR purification  
The amplified PCR product was purified from other PCR reagents including 
primers, nucleotides, polymerases and salts using QIAquick PCR Purification Kit 
(Qiagen) according to the manufacturer’s instructions. Briefly, 5 volumes of 
binding buffer, Buffer PB was added to 1 volume of the PCR sample and mixed 
well. To bind DNA, the sample was then transferred to the QIAquick spin column 
inserted into a collection tube followed by centrifugation at 17900 x g for 1 
minute. After discarding the flow-through, the spin column was re-inserted back 
into the collection tube. The column was then washed by adding 750 µl of Buffer 
PE (absolute ethanol was added previously to buffer PE) to the column and 
spinning down at 17900 x g for 1 minute. The flow-through was discarded again 
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and the column was placed back to the collection tube followed by an additional 
centrifugation for 1 minute to ensure the complete removal of residual ethanol.  
The spin column was then placed in a sterile 1.5 ml microcentrifuge tube prior 
to the addition of 30 µl of sterile nuclease-free water to the centre of the 
column. The column was incubated at RT for 1 minute and then spun down for 1 
minute at 17900 x g to elute the DNA into the microcentrifuge tube.  
2.2.5.3 Restriction endonuclease reaction 
The purified PCR amplified product and the recipient plasmid DNA (vector) were 
digested using two restriction endonucleases to generate sticky-end DNA 
fragments which can subsequently be ligated. The restriction endonuclease 
digest was set up on ice in a total reaction volume of 50 µl in a sterile 
microcentrifuge tube with the following components:    
 5 µl 10x CutSmart® Buffer (New England Biolabs, NEB) 
 500 ng to 1 µg PCR amplified purified DNA or 2-5 µg of recipient plasmid 
DNA 
 1-2 µl  of High-Fidelity (HF®) Restriction Endonuclease 1(NEB) 
 1-2 µl of High-Fidelity (HF®) Restriction Endonuclease 2(NEB) 
 x µl dH2O (to bring the total volume to 50 µl) 
 
These components were mixed by either flicking the bottom of the tube or 
pipetting gently up and down followed by centrifugation for a few seconds in a 
microcentrifuge. The restriction digest reaction was then incubated at 37ºC for 
at least 4 hours or overnight.  
2.2.5.4 DNA gel electrophoresis and gel purification using gel extraction 
kit 
The digested DNA fragments (insert and recipient plasmid) were subjected to gel 
electrophoresis to separate them based on their length in base pairs. Briefly, 0.3 
g of agarose was dissolved in 30 ml of TAE buffer (40 mM Tris, 1 mM EDTA (at pH 
8) and 20 mM acetic acid) followed by heating in a microwave for 2 minutes with 
intermittent swirling. The dissolved agarose was allowed to cool to 50ºC prior to 
the addition of SYBR® Safe DNA gel stain (Life Technologies) in a final dilution of 
1:1000. The melted agarose was then poured into a gel tray with the well comb 
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in place and allowed to cool for 20 minutes to solidify the gel followed by 
flooding the gel tank with TAE buffer with approximately 2 mm TAE above the 
gel. The well comb was removed carefully and 6x DNA gel loading buffer (0.4 
mg/mL sucrose, 0.25% (w/v) bromophenol blue) was added to the samples at a 
ratio of 1:5. 5 µl of 1 kb HyperLadder™ (Bioline Reagents) was then loaded to the 
first lane of the gel to quantify and determine the size of the DNA samples 
followed by addition of 5 to 50 µl of samples to other wells. The gel was then 
run at 125 V for 25-30 minutes.  
Following gel electrophoresis, the desired DNA fragments (recipient plasmid and 
insert) were cut out of the agarose gel and purified using QIAquick Gel 
Extraction Kit (Qiagen). The gel bands containing the desired DNA fragments 
were visualized under UV light and excised with a clean sharp razor blade. The 
excised gel slices were weighed in sterile microcentrifuge tubes and 3 volumes 
of Buffer QG were added to 1 volume of gel (100 mg gel~100 µl) followed by 
incubation at 50ºC in a heating block for 10 minutes with intermittent vortexing 
in every 2-3 minutes to ensure the solubilisation of the gel slice. After that, 1 gel 
volume of isopropanol was added to the sample and mixed well. The sample was 
then transferred to a QIAquick spin column placed in a 2 ml collection tube and 
centrifuged for 1 minute at 17,900 x g. After discarding the flow-through, the 
column was placed back to the collection tube and washed with 750 µl of Buffer 
PE (suggested amount of 96 to 100% ethanol was added to the buffer) by 
spinning down at 17,900 x g for 1 minute. Further centrifugation was performed 
to ensure complete removal of residual ethanol from the column and the column 
was then placed into a sterile 1.5 ml microcentrifuge tube. 30 µl of nuclease-
free water was added to the centre of the column and incubated for 1 minute. 
DNA was then eluted by centrifuging at 17,900 x g for 1 minute.       
The purified DNA (5 µl of the cut insert and recipient plasmid vector) fragments 
were again subjected to 1% agarose gel electrophoresis to determine the 
concentration of each DNA fragments in order to set up the ligation reaction. 
This approximate quantification of DNA was performed by running 5 µ of 1 kb 
HyperLadder™ in parallel and comparing the intensity of DNA intercalating dyes 
(imaged using a UV transilluminator) within the gel band of the marker with 
those of the samples. After estimating the DNA concentrations, the required 
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amounts of cut vector DNA and insert DNA to reach a molar ratio of 1:3 and 1:5 
were determined using the following formula: 
(𝑛𝑔 𝑜𝑓 𝑖𝑛𝑠𝑒𝑟𝑡) = (molar ratio of 
insert
vector
) × (
ng of vector ×kb size of insert
kb size of vector
)           
2.2.5.5 DNA ligation 
In the final stage of generation of a recombinant plasmid, the restriction 
digested DNA fragment containing the gene of interest was fused to the digested 
plasmid vector containing compatible sticky ends by performing a ligation 
reaction using T4 DNA Ligase (Promega). The ligation reaction was set up on ice 
in a total volume of 20 µl in a sterile tube with the following components: 
 2 µl of 10x T4 DNA ligase reaction buffer(Promega) 
 100 ng of vector plasmid DNA 
 x µl of insert DNA (as calculated to reach a molar ratio of 1:3 (vector: 
insert) 
 1 µl/400 units of T4 DNA ligase (Promega) 
 Nuclease-free water to a final volume of 20 µl 
 
Another reaction (vector only control) was set up in which all the above reagents 
were assembled in another sterile tube except the insert DNA. The ligation 
reaction tubes were then incubated for 4 hours at room temperature or 
overnight at 16ºC. After that, 5 µl of the ligation reaction was transformed into 
chemically competent XL1-blue cells (section 2.2.3) and the recombinant 
plasmid DNA was isolated and purified from bacterial cultures by performing 
miniprep preparation (section 2.2.4).   
2.2.6 Site-directed mutagenesis 
Point mutation of interest on DNA sequence was performed by following a 
QuickChange II Site-Directed Mutagenesis protocol (Stratagene, Cheshire, UK). In 
this method, a double-stranded mutant plasmid containing the desired mutation 
is amplified via PCR reaction with two synthetic oligonucleotide primers, each 
containing the desired mutation utilizing a double-stranded plasmid vector as 
the template. The two mutagenic oligonucleotide primers, complementary to 
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each other which contain the desired mutation in the middle of the primer, were 
designed using the software program, such as Agilent QuikChangeII 
(https://www.genomics.agilent.com/primerDesignProgram.jsp). In the case of 
primer designing, it was ensured that length of the primers was between 25 and 
45 bases with higher GC content (40 to 60%) and the melting temperature (Tm) 
was ≥78ºC.  For the amplification of mutant plasmid, a PCR amplification 
reaction (sample reaction) was set up on ice in a final volume of 50 µl in a 
sterile PCR tube containing the following components: 
 5 µl of 10x Pfu DNA Polymerase buffer with MgSO4 (Promega) 
 1 µl of 10 mM dNTP mix (200 µM each dNTP) 
 1.25 µl (125 ng) of forward oligonucleotide primer 
 1.25 µl (125 ng) of reverse oligonucleotide primer 
 50 to 100 ng of dsDNA template 
 1 µl of (2.5 units/µl) Pfu DNA Polymerase (Promega)  
 Nuclease-free water quantity sufficient to 50 µl  
Another PCR reaction (control reaction) was set up on ice in another PCR tube 
containing all the components as mentioned above except the two primers. 
Employing the following cycling programme both the PCR reaction mixtures 
(sample reaction and control reaction) were subjected to thermal cycling using 
an Eppendorf Mastercycler:  
                 Step Temperature  Time 
1. Initial denaturation 95ºC  5 minutes 
2. Denaturation 95ºC 30 seconds 
3. Annealing  55 to 65ºC depending 
on the Tm of the 
primers 
1 minute 
4. Extension  72ºC ~16 minutes for 
8kb plasmid 
(2 minutes/kb of 
plasmid length) 
5. Repeat steps 2-4 for 16 cycles 
6. Hold 4ºC  Indefinite 
   
Immediately after completion of thermal cycling, 1 µl of (10 units/µl) of DpnI 
restriction endonuclease (Promega) was added to both sample and control 
reaction mixture followed by gentle mixing and spinning down in a 
microcentrifuge for 1 minute. The reaction mixtures were then incubated at 
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37ºC for 2 hours to digest the parental methylated dsDNA leaving the synthesized 
mutant plasmid intact. 1 µl of the DpnI-treated DNA from each control and 
sample reaction was then transformed into separate 50 µl of XL1-blue competent 
bacteria following the protocol described in section (2.2.3).       
2.2.7 Plasmids and DNA constructs 
2.2.7.1 Generation of FLAG-hGPR84-Gαi2 fusion construct  
The FLAG-hGPR84-Gαi2 fusion protein was constructed by replacing enhanced 
yellow fluorescent protein (eYFP) within the FLAG-hGPR84-eYFP-
pcDNA5/FRT/TO construct (previously generated in the Milligan Lab; Mahmud et 
al., 2019) with a sequence corresponding to rat Gαi2 using NotI and XhoI 
restriction enzymes. Rat Not1-Gαi2-Xho1 was amplified by polymerase chain 
reaction (PCR) using β2AR-HindIII-Gαi2-Xho1-pcDNA5/FRT/TO as the template and 
the following forward and reverse primers designed to incorporate a NotI 
restriction site upstream and XhoI restriction site downstream of the Gαi2 
sequence.  
Forward primer: 5´-GATCGCGGCCGCGGCTGCACCGTCAGCGCCGAGGAC- 3´   
Reverse primer: 5´-GATCCTCGAGTCAGAAGAGGCCACAGTCCTTCAG-3´   
Restriction digestion of FLAG-hGPR84-eYFP-pcDNA5/FRT/TO plasmid vector and 
NotI-Gαi2-XhoI PCR amplified product with NotI and XhoI restriction enzymes 
followed by ligation with T4 DNA ligase led to the generation of FLAG-hGPR84-
Gαi2 fusion construct. The reading frame and orientation of the construct were 
then confirmed by DNA sequencing performed by the MRC PPU DNA Sequencing 
and Services (School of Life Sciences, University of Dundee, Scotland) using an 
Applied Biosystems 3730 DNA sequencer. 
2.2.7.2 Generation of PTX-insensitive mutants of the hGPR84-Gαi2 fusion 
protein  
A pertussis toxin (PTX) resistant FLAG-hGPR84-Gαi2 C352G mutant construct was 
prepared via PCR using QuickChange II Site-Directed Mutagenesis protocol 
(section 2.2.6) using the following primers 
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C352G Forward primer: 5´-CAACCTGAAGGACGGTGGCCTCTTCTG-3´ 
C352G Reverse primer: 5´-CAGAAGAGGCCACCGTCCTTCAGGTTG-3´ 
Similarly, another PTX-insensitive FLAG-GPR84-Gαi2 C352I mutant construct was 
generated through site-directed mutagenesis protocol (section 2.2.6) using the 
following primers- 
C352I Forward primer: 5´-CAA CCTGAAGGACATTGGCCTCTTCTG-3´ 
C352I Reverse primer: 5´-CAGAAGAGGCCAATGTCCTTCAGGTTG-3´ 
In both cases, FLAG-hGPR84-Gαi2-pcDNA5/FRT/TO construct was used as the 
template for the PCR reactions of site-directed mutagenesis protocol. 
2.2.2.3 Generation of point mutants of human GPR84 
A series of FLAG-hGPR84-Gαi2 C352I constructs containing point mutation of 
interest were generated by employing QuickChange II site-directed mutagenesis 
method (section 2.2.6). The oligonucleotide primers designed for the PCR 
amplification of mutant plasmid containing specific point mutation are 
mentioned below:    
F101A  
Forward primer: 5´GTATTTGGGCTCCTCCTTGCTGCCTCCAATTCTGTCTC 3´ 
Reverse primer: 5´ GAGACAGAATTGGAGGCAGCAAGGAGGAGCCCAAATAC 3´ 
 
F170A 
Forward  primer: 5´GTCTGCACCTGCAGCGCTGACCGCATCCGAGG 3´ 
Reverse primer:   5´CCTCGGATGCGGTCAGCGCTGCAGGTGCAGAC 3´ 
 
R172A 
Forward primer:  5´ CCTGCAGCTTTGACGCCATCCGAGGCCGGCC  3´ 
Reverse primer:   5´ GGCCGGCCTCGGATGGCGTCAAAGCTGCAGG 3´ 
 
R172K  
Forward primer: 5´ CCTGCAGCTTTGACAAGATCCGAGGCCGGCC  3´ 
Reverse primer: 5´ GGCCGGCCTCGGATCTTGTCAAAGCTGCAGG  3´ 
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F335A 
Forward primer: 5´CCTGAGCTACATCCCCGCCTTGCTGCTCAACATTC 3´ 
Reverse primer: 5´GAATGTTGAGCAGCAAGGCGGGGATGTAGCTCAGG 3´ 
 
W360A 
Forward primer: 5´ CTTGCTGCCAACCTCACCGCGCTCAATGGTTGCATCAAC 3´ 
Reverse primer: 5´ GTTGATGCAACCATTGAGCGCGGTGAGGTTGGCAGCAAG 3´ 
 
2.2.2.4 Generation of the FLAG-hGPR84-Gαi3 C351I fusion protein  
Using CRF-Gαi3 C351I plasmid vector as the template, PCR reaction was 
performed to amplify the sequence corresponding to rat Gαi3 C351I containing 
NotI and XhoI restriction sites on the two terminuses. The primers used in the 
PCR were as follows:   
Not1-Gαi3 Forward primer:  
5´-TAAGCAGCGGCCGCGGCTGCACGTTGAGCGCCGAGGACAAG-3´ 
Xho1-Gαi3 Reverse primer: 5´-
TAAGCACTCGAGTCAGTAAAGCCCACATTCCTTTAAGTTG-3´ 
 
FLAG-hGPR84-Gαi2-pcDNA5/FRT/TO plasmid vector and Not1-Gαi3 C351I-Xho1 
PCR amplified product were then restriction digested using both Not1 and Xho1 
restriction enzymes and Gαi3 C351I was inserted between Not1 and Xho1 
restriction sites of the plasmid vector by a ligation reaction. The construct was 
then confirmed by DNA sequencing.  
2.2.2.5 Generation of FLAG-hGPR84-SPASM sensor constructs  
The fusion fragment of systematic protein affinity strength modulation (SPASM) 
sensor and G protein peptide, SPASM-Gαi1/2 composed of mCitrine (BRET 
acceptor), ER/K α-helix, Nano Luciferase (BRET donor), and Gαi1/2 C terminus 
peptide encoding the last 27 amino acids of Gαi1/2, each element being 
separated by a flexible linker (Gly-Ser-Gly)4 residues was PCR amplified using 
FLAG-HindIII-hCXCR4-KpnI-SPASM-Gαi1/2-XhoI-pcDNA5/FRT/TO as the template 
and the primers used in this PCR reaction were as follows:  
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Forward primer, Not1-mCitrine:  
5´-TAAGCAGCGGCCGCGTGAGCAAGGGCGAGGAGCTGTTC-3´ 
Rev primer, BGH Rev Primer: 5´-TAGAAGGCACAGTCGAGGCTGATCAGC-3´ 
 
The PCR amplified product, SPASM-Gαi1/2 containing NotI and XhoI sites on its 
termini was then subcloned in frame between NotI and XhoI restriction sites of 
FLAG-hGPR84-Gαi2-pcDNA5/FRT/TO plasmid. Here, previously constructed FLAG-
hGPR84-Gαi2-pcDNA5/FRT/TO plasmid and the amplified product SPASM-Gαi1/2 
were restriction digested with Not1 and Xho1 followed by ligation reaction with 
T4 DNA ligase. The generated FLAG-hGPR84-SPASM-Gαi1/2 sensor construct was 
then confirmed by DNA sequencing.  
The FLAG-hGPR84-SPASM-NP sensor which contains a repeating (Gly-Ser-
Gly)4 residues in place of the G protein peptide (last 27 amino acids of C 
terminus of G protein) was also generated following similar sub-cloning scheme. 
Here, the SPASM-NP sensor part was PCR amplified using FLAG-HindIII-hCXCR4-
KpnI-SPASM-NP-XhoI-pcDNA5/FRT/TO plasmid as the template and the two 
primers as mentioned above. The resulting amplified product SPASM-NP was then 
sub-cloned into FLAG-hGPR84-Gαi2-pcDNA5/FRT/TO plasmid vector between 
Not1 and Xho1 restriction sites.  
2.2.2.6 Generation of FLAG-hGPR84-SPASM mNeonGreen sensors 
A series of BRET based biosensors, FLAG-hGPR84-SpNG-Gα(x) sensors were 
generated whereas the last 27 amino acids of C-terminus of different G proteins 
(Gαi1/2, Gαi3, Go/A, Gz, Gq, Gs, G12, G13, G14 and G16) were coupled to the SPASM 
sensor part of the construct which was incorporated at the C-terminus of the 
FLAG-tagged human GPR84. Here, the SPASM sensor part is composed of 
mNeonGreen (BRET acceptor), ER/K α helix and Nano luciferase (NLUC, BRET 
donor) with each element being separated by a flexible linker, a repeating (Gly-
Ser-Gly)4 residues (Mackenzie et al., 2019). 
FLAG-hGPR84-SpNG-Gα(x) sensor (where X= i1/2, i3, o, z, s, q,12,13,14 and 16) 
was generated by replacing eYFP within the FLAG-hGPR84-eYFP-pcDNA5/FRT/TO 
construct with a sequence corresponding to SpNG (stands for SPASM 
mNeonGreen) fused to Gα(x) G protein peptide using NotI and XhoI restriction 
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enzymes. The recipient plasmid FLAG-hGPR84-eYFP-pcDNA5/FRT/TO and the 
insert containing plasmid hFFA2-SpNG-Gα(x)-pcDNA5/FRT/TO (a gift from Dr 
Brian Hudson) were restriction digested with NotI and XhoI enzymes. Subsequent 
ligation of restriction fragments SpNG-Gα(x) and FLAG-hGPR84-pcDNA5/FRT/TO 
led to the generation of FLAG-hGPR84-SpNG-Gα(x) sensor construct.   
The FLAG-hGPR84-SpNG-NP sensor was generated using the same sub-cloning 
scheme as that of FLAG-hGPR84-SpNG-Gα(x) sensor only difference between 
these two sensors is that NP sensor contains a repeating (Gly-Ser-Gly)4 residues 
in the place of G protein peptide. Simply, FLAG-hGPR84-eYFP-pcDNA5/FRT/TO 
and hFFA2-SpNG-NP-pcDNA5/FRT/TO (a gift from Dr Brian Hudson) were 
restriction digested with Not1 and XhoI enzymes followed by ligation of SpNG-NP 
and FLAG-hGPR84-pcDNA5/FRT/TO restriction fragments ultimately generating 
FLAG-hGPR84-SpNG-NP-pcDNA5/FRT/TO construct. The generated SPASM sensor 
constructs were then confirmed by DNA sequencing.  
2.2.2.7 Cloning of mouse GPR84  
Mouse GPR84 was cloned from the mouse leukaemic macrophage cell line RAW 
264.7. At first, RNA was extracted from RAW 264.7 cells using RNeasy Mini Kit 
(Qiagen) followed by cDNA synthesis by reverse transcription reaction using 
QuantiTect Reverse Transcription Kit (Qiagen) according to the manufacturer’s 
instructions.  
RNA extraction from RAW264.7 cells 
 
1x106 RAW264.7 cells were harvested by scraping with a cell scraper followed by 
centrifugation at 8000 x g for 1 minute. The cells pellets were then washed with 
1XPBS and subjected to centrifugation again for 15 seconds at 17,900 x g. The 
supernatant was discarded and cell pellets were disrupted in 350 µl of buffer 
RLT and homogenized by passing through a 20 gauge needle fitted to a syringe. 
350 µl of 70% ethanol was added to the homogenized lysate and mixed well by 
pipetting followed by transferring 700 µl of the sample to an RNeasy Mini spin 
column placed in a 2 ml collection tube which was then subjected to 
centrifugation at 17,900 x g for 15 seconds. The flow-through was discarded and 
700 µl of Buffer RW1 was added to the spin column followed by centrifugation 
again at 17,900 x g for 15 seconds to wash out the contaminating carbohydrates, 
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proteins and fatty acids. After discarding flow-through, 500 µl of buffer RPE was 
added to the column and spun down for 15 seconds at 17900 x g to remove the 
traces of salts remained in the column. Flow-through was discarded and the 
column was washed again with 500 µl of RPE buffer by centrifugation at 17,900 x 
g for 2 minutes. The spin column was then placed on a new 1.5 ml Eppendorf 
microcentrifuge tube and 30 µl of RNase-free water was added directly to the 
column followed by incubation at room temperature for 1 minute. The sample 
was then centrifuged for 1 minute at 17,900 x g to elute RNA. Eluted RNA was 
immediately placed on ice. After estimating the concentration, RNA was either 
used for reverse transcription or stored in -80ºC.  
Mouse cDNA synthesis by reverse transcription reaction  
 
Firstly, genomic DNA was eliminated from the extracted RNA sample. The 
genomic DNA elimination reaction was set up on the ice. Less than 1 µg of 
template RNA, 2 µl of 7X gDNA Wipeout buffer and required volume of RNase-
free water to make a final volume of 14 µl were added to a nuclease-free 
microcentrifuge tube, mixed and stored on ice. Genomic DNA was then wiped 
out by incubating the reaction tube at 42ºC for 2 minutes. The reaction mixture 
was immediately placed on ice. 1 µl of Quantiscript Reverse transcriptase (also 
contains RNase inhibitor), 4 µl of 5x Quantiscript RT buffer (also contains Mg2+ 
and dNTPs) and 1 µl of RT random primer mix were added to the tube containing 
the entire genomic DNA elimination reaction volume (14 µl). After mixing, the 
reaction mix was incubated at 42ºC for 3 minutes followed by incubation at 95ºC 
for 3 minutes to inactivate the reverse transcriptase.   
Using this cDNA as template, FLAG epitope tag (amino acid sequence 
DYKDDDDK) was incorporated at the N-terminus of mouse GPR84 by PCR reaction 
using the following primers: 
Mouse GPR84 Forward primer: 
5´CATGTTGGATCCGCCACCATGGACTACAAGGACGACGATGATAAGTGGAACAGCTCA
GATGCCAAC 3´ 
Mouse GPR84 Reverse primer: 5´ CAT GTTGCG GCC GCGATGGAACCGGCGGAA 
ACTCTG 3´ 
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The sequences corresponding to BamHI and NotI sites required for cloning are 
underlined. The resulting PCR amplified product, FLAG-mouse GPR84 was then 
subcloned in-frame between the BamHI and NotI sites of an eYFP-
pcDNA5/FRT/TO plasmid ultimately generating FLAG-mouse GPR84-eYFP- 
pcDNA5/FRT/TO construct. The identity of the construct was then confirmed by 
DNA sequencing.  
2.2.2.8 Generation of FLAG-mGPR84-Gαi2 and FLAG-mGPR84-Gαi2 C352I 
fusion constructs  
Firstly, the internal BamHI site of Gαi2 of FLAG-hGPR84-Gαi2 and FLAG-hGPR84-
Gαi2 C352I was silently mutated by site-directed mutagenesis according to the 
QuikChange method (section 2.2.6) using the following primers:  
C636T Gαi2 Forward: 5´ GAGCGGAAGAAGTGGATTCACTGCTTTGAGGGTG 3´ 
C636T Gαi2 Reverse: 5´ CACCCTCAAAGCAGTGAATCCACTTCTTCCGCTC  3´ 
 
The FLAG-mGPR84-Gαi2 and pertussis toxin resistant construct FLAG-mGPR84-
Gαi2 C352I fusion proteins were then generated by replacing human GPR84 of 
FLAG-hGPR84-C636T Gαi2-pcDNA5/FRT/TO or FLAG-hGPR84-C636TGαi2 C352I-
pcDNA5/FRT/TO plasmid, respectively with the sequence corresponding to 
mouse GPR84 using BamHI and Not1 restriction enzymes.  
2.3. Mammalian cell culture and maintenance 
Mammalian cell culture and maintenance and transfection processes were 
performed in a Class II laminar flow biosafety cabinet following proper sterile 
techniques and guidelines. The cells were incubated in an inCu saFe SANYO 
humidified incubator supplied with 5% CO2. All solutions, reagents and 
equipment which came in contact with the cells were ensured to be sterile. All 
solutions or reagents used for the cell culture were pre-warmed for 15-30 
minutes to 37ºC using a water bath.     
2.3.1 HEK293T cells 
Human embryonic kidney 293 cells expressing SV40 T-antigen (HEK293T), which 
were employed for the transient heterologous expression of receptor of interest, 
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were maintained in Dulbecco’s modified Eagle’s Medium (DMEM) with high 
glucose (Sigma-Aldrich) supplemented with 10% heat-inactivated fetal bovine 
serum (FBS, ThermoFisher Scientific), 2 mM L-glutamine (Sigma-Aldrich), 100 
units/ml penicillin (ThermoFisher Scientific), 100 µg/ml streptomycin 
(ThermoFisher Scientific) at 37ºC and 5% CO2 under humidified atmosphere. 
After the cells have grown to 80% confluency, HEK293T cells were passaged at 
1:10 dilution into T75 cm2 cell culture flask (Corning).   
2.3.2 Flp-In™ T-REx™-293 cells 
Parental Flp-In™ T-REx™-293 cells (Invitrogen Life Technologies) employed for 
the stable transfection of receptor of interest were cultured and maintained in 
Dulbecco’s modified Eagle’s medium without sodium pyruvate (GibcoTM, 
ThermoFisher Scientific) supplemented with 10% (v/v) heat-inactivated FBS, 100 
units/ml penicillin, 100 µg/ml streptomycin and 10 µg/ml blasticidin (InvivoGen) 
at 37 °C in a 5% CO2 humidified atmosphere.  
2.3.3 Flp-In™ T-REx™-293 stable cell lines expressing GPR84 
receptor 
Flp-InTM T-RExTM-293 stable cell lines able to inducibly express human or mouse 
GPR84 were maintained in DMEM without sodium pyruvate (high glucose) 
supplemented with 10% heat-inactivated FBS, 100 units/ml penicillin, 100 µg/ml 
streptomycin,10 µg/ml blasticidin and 200 µg/ml hygromycin B (InvivoGen) at 
37ºC and 5% CO2 in humidified atmosphere. These cells were passaged routinely 
after 80% confluency by splitting cells into 1:10 or 1:20 dilution. The expression 
of the receptor construct of interest was induced on demand by treating the 
cells with 100 ng/ml of doxycycline (Sigma-Aldrich) for 24 hours. 
2.3.4 RAW 264.7 cells 
RAW 264.7 mouse monocyte-macrophages were cultured and maintained in 
DMEM (with 4.5g/L D-glucose, 0.11 g/L sodium pyruvate) (GibcoTM,ThermoFisher 
Scientific) supplemented with 10% heat-inactivated FBS, 100 units/ml penicillin, 
100 µg/ml streptomycin and 2 mM L-glutamine at 37°C and 5% CO2. These cells 
were subcultured at 1:10 dilution into 75 cm2 or 150 cm2 flask. Briefly, the 
medium was removed followed by addition of 10 ml of media to the flask. Cells 
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were then dislodged by scraping gently with a sterile cell scraper followed by 
addition of appropriate aliquots of cell suspension into new cell culture flask. To 
upregulate GPR84 expression, RAW 264.7 cells were treated with 100 ng/ml of 
lipopolysaccharide (LPS) (Sigma-Aldrich, Dorset, UK) for 5, 8, 11 or 24 hours 
prior to membrane preparation.  
2.3.5 Thawing of cells 
1 vial of cells (HEK293T or Flp-In™ T-REx™-293 stable cell lines) stored in liquid 
nitrogen were taken out, thawed at 37ºC in a water bath and decontaminated 
with 70% ethanol. After complete thawing, the cells were transferred to a 15 ml 
sterile falcon tube filled with 10 ml of pre-warmed culture media in the laminar 
flow hood followed by centrifugation at 201 x g for 4 minutes at room 
temperature. The cell pellets were then re-suspended with 10 ml of culture 
media in the hood and transferred to a 75 cm2 cell culture flask followed by 
incubation overnight in 37ºC and 5% CO2. In the next day, the media was 
aspirated and replaced with fresh media. The cells were checked daily for 
confluency. In the case of RAW264.7 cells, after thawing the cells at 37ºC in a 
water bath and decontaminating with 70% ethanol, cells were transferred to a 75 
cm2 flask pre-filled with 12 ml of warmed growth media followed by incubating 
at 37ºC and 5% CO2 for 4 hours. The media were then aspirated off and replaced 
with 10 ml of fresh pre-warmed media and incubated overnight.           
2.3.6 Passaging of cells 
When cells were grown to 80 to 90% confluency (for HEK293T or Flp-In™ T-REx™-
293 stable cell lines), all media was aspirated off and washed once with pre-
warmed 10 ml of sterile phosphate-buffered saline (PBS) (137 mM NaCl, 2.7 mM 
KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4; pH:7.4) to remove excess media and 
serum. 2 ml of pre-warmed 0.25% trypsin-EDTA solution (Sigma-Aldrich) was then 
added to the monolayer of cells to detach them from the bottom of the flask 
and kept at room temperature in the hood for 1 to 3 minutes depending on the 
adherence of the cells. To ensure cell dissociation completely, the flask was 
tapped gently. To stop trypsinization and make cell suspension, 8 ml of pre-
warmed growth media with serum was added to the flask followed by pipetting 
up and down to break down the clumps of cells. 1 ml (1:10 dilution) or 0.5 (1:20 
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dilution) ml of 10 ml cell suspension was then transferred to a new 75 cm2 cell 
culture flask with 9 ml or 9.5 ml of pre-warmed fresh media added, respectively.           
2.3.7 Cryopreservation of cells for long-term storage 
For long-term storage, cells were preserved in cryovials in liquid nitrogen. After 
reaching 80% confluency, the media was aspirated off and washed with 1XPBS 
followed by the addition of 2 ml of 0.25% trypsin-EDTA solution to detach the 
cells. Cells were then re-suspended with 8 ml media and cells were counted by 
trypan blue exclusion method using a haemocytometer. The cell suspension was 
then subjected to centrifugation at 201 x g for 4 minutes at room temperature. 
Media were carefully aspirated off and cell pellets were re-suspended at a 
density of 3x106 cells/ml in sterile freezing media (Fetal bovine serum with 10% 
DMSO for HEK293T or Flp-In™ T-REx™-293 stable cell lines; FBS with 5% DMSO for 
RAW264.7 cells). 1 ml of cell suspension was then aliquoted into each cryovial 
followed by storage in -80ºC for 24 hours prior to storage in liquid nitrogen.       
2.4. Transient transfection  
2.4.1 Transient transfection using PEI   
For transient expression of receptor of interest, receptor construct was 
transfected into HEK293T cells using cationic DNA complexing agent, 
polyethyleneimine (PEI, linear, MW: 25000, Polysciences, Inc.). PEI was dissolved 
in 150 mM NaCl by gentle shaking and sonicating to make a 1mg/ml stock 
solution followed by adjusting pH to 7.0 with HCl. PEI solution was then filter 
sterilized and aliquoted in 1 ml volume and stored in -20ºC. The day before 
transfection, 2X106 HEK293T cells were plated on 10 cm cell culture dishes by 
splitting (1:4 dilution) 80% confluent cells from T75 flask. On the day of 
transfection, 5 µg DNA was diluted in 250 µl of 150 mM sterile NaCl (pH 7.4) and 
30 µl of 1 µg/µl PEI (1:6 DNA:PEI) was diluted in 250 µl of 150 mM sterile NaCl in 
two separate sterile 1.5 ml Eppendorf microcentrifuge tubes. This volume of 250 
µl for each mixture of DNA and PEI is for one 10 cm dish and volumes can be 
scaled proportionally for additional dishes. Diluted DNA complexes were then 
added to diluted PEI tube and the mixture was vortexed for few seconds 
followed by incubation for 10 to 15 minutes at room temperature. In the 
meantime media from the 10 cm dish was removed and fresh media was added. 
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After incubation, DNA/PEI complexes were added to the cells in a dropwise 
manner (500 ul/dish). In parallel, as a negative control, pcDNA3.1 or 
pcDNA5/FRT/TO vector was also transfected to HEK293 cells in another 10 cm 
dish using the above-mentioned process. Where necessary, this protocol can be 
scaled down according to the number of cells per preparation for transfection of 
cells in 6-well plates or 12-well plates. The transfected dishes were then 
returned to the cell culture incubator. The cells were harvested after 36 to 48 
hours of transient transfection for the preparation of the membrane. 
2.4.2 Transient transfection using lipofectamine 
Cationic lipid-based transfection reagent (Lipofectamine 2000 or lipofectamine 
3000 reagents) forms liposomes by complexing with plasmid DNA or siRNA. 
Positive charges of cationic lipids neutralize negative charges of the phosphate 
backbone of DNA and impart an overall positive charge to the surface of the 
liposome in water. These surface positive charges of DNA-liposome complex lead 
to the fusion of DNA-lipid complex to the negatively charged cell membrane 
followed by delivery of the DNA to the cytosol of cells by endocytosis. The day 
before the transfection, HEK293 cells were seeded on 6-well plates/12-well 
plates/10 cm cell culture dishes so that 70 to 80% confluency would be obtained 
prior to the transfection. For the 6-well plate, transfection protocol is as follows 
which can be scaled up or down accordingly for 10 cm dishes or 12-well plates, 
respectively. One day before transfection, 0.5X106 cells were plated in 2 ml of 
growth medium in each well of the 6-well plates. On the day of transfection, 8 
µl of P3000TM reagent was diluted in 100 µl of serum-free DMEM medium or Opti-
MEM medium in a sterile microcentrifuge tube. 2.0 µg of plasmid DNA was then 
added to the diluted P3000 reagent and mixed by vortexing for a few seconds. 4 
µl of LipofectamineTM 3000 reagent (Invitrogen Life Technologies) was diluted in 
100 µl of either serum-free DMEM medium or Opti-MEM medium in another 
sterile tube. Diluted DNA in P3000 reagent was then mixed well with the diluted 
Lipofectamine 3000 reagent (1:1 ratio) and vortexed for few seconds followed by 
incubating the mixture at room temperature for 10 to 15 minutes. After 
incubation, the DNA-lipid complex was added to cells in a dropwise manner (200 
µl/well).The cells were then incubated in 37ºC and 5% CO2 in an incubator for 
24-48 hours until to be used in assays.      
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Transient transfection using Lipofectamine 2000 reagent (Invitrogen Life 
Technologies) protocol is identical to that of lipofectamine 3000 reagent 
protocol. On the day before transfection, 0.5x106 HEK293 cells were seeded in 2 
ml growth media in each well of the 6 well plates. 2.5 µg of plasmid DNA was 
diluted in 100 µl of serum-free media and 5 µl of Lipofectamine 2000 reagent 
(1:2 DNA: Lipofectamine) was diluted in 100 µl of serum-free media. Diluted 
plasmid DNA was mixed with diluted lipofectamine 2000 (1:1 ratio) and 
incubated for 15 minutes at room temperature followed by dropwise addition of 
the DNA-lipid complex to cells (200 µl/well). Transfected cells were then 
incubated in 37ºC and 5% CO2 for 24-48 hours until to be used in assays.     
2.5 Generation of Flp-In T-REx-293 cell lines inducibly 
expressing GPR84 receptor   
Doxycycline-inducible Flp-InTM T-RExTM-293 stable cell lines expressing FLAG-
hGPR84-Gαi2, FLAG-hGPR84-Gαi2 C352G, FLAG-hGPR84-Gαi2 C352I, FLAG-hGPR84-
Gαi3, FLAG-hGPR84-SPASM Gαi1/2, FLAG-hGPR84-SPASM NP, FLAG-mGPR84-eYFP, 
FLAG-mGPR84-Gαi2 or FLAG-mGPR84-Gαi2 C352I were generated. Another six 
doxycycline-inducible Flp-In T-REx-293 stable cell lines expressing FLAG-hGPR84 
R172A-Gαi2 C352I, FLAG-hGPR84 R172K-Gαi2 C352I,  FLAG-hGPR84 F170A-Gαi2 
C352I, FLAG-hGPR84 F335A-Gαi2 C352I, FLAG-hGPR84 F101A-Gαi2 C352I or FLAG-
hGPR84 W360A-Gαi2 C352I receptor construct were also developed. These stable 
cell lines were generated by co-transfection of receptor construct of interest 
subcloned into the pcDNA5/FRT/TO vector and integration plasmid vector pOG44 
(1:9 ratio, w/w) into Flp-InTM T-RExTM-293 cells using 1mg/ml of cationic DNA 
complexing agent, polyethyleneimine (PEI, MW-25000). After successful co-
transfection, Flp recombinase expressed from pOG44 plasmid catalyses the 
homologous recombination of Flp recombination target (FRT) sites on 
pcDNA5/FRT/TO vector containing gene of interest and host genome and thus 
receptor of interest is inserted into the genome of the host cells at integrated 
FRT site (Ward et al., 2011). Flp-InTM T-RExTM-293 cells were cultured in DMEM 
without sodium pyruvate (Invitrogen) supplemented with 10% FBS, 1% 
penicillin/streptomycin and 10 µg/ml blasticidin and were split into 10 cm dishes 
so that 60 to 80% confluency was attained prior to the transfection. 8 µg of DNA 
(0.8 µg receptor of interest in pcDNA5/FRT/TO vector and 7.2 µg of pOG44 
plasmid vector) was diluted in 250 µl of 150 mM sterile NaCl (pH 7.4) in a sterile 
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microcentrifuge tube. Similarly, 48 µl of PEI (ratio 1:6 DNA/PEI) was diluted in a 
similar volume of 150 mM sterile NaCl in another sterile tube. Diluted total DNA 
complexes were then added to diluted PEI and mixed well with slight vortexing 
for a few seconds. A negative control for transfection was also prepared by 
mixing empty pcDNA5/FRT/TO vector with pOG44 plasmid vector and PEI, each 
diluted in 150 mM NaCl. The DNA-PEI complexes were then incubated at room 
temperature for 10 to 15 minutes followed by addition to the cells in a dropwise 
manner. 24 hours following transfection, growth media was removed and 
replaced with fresh growth media. 48 hours after transfection, the transfected 
cells were split in 1:10 and 1:30 dilution into 10 cm dishes and incubated 
overnight. On the following day, the medium was removed and replaced with 
the medium supplemented with 200 µg/ml of hygromycin B antibiotic to initiate 
the selection of stably transfected cells. The media was changed every 3-4 days 
to remove the dead non-transfected cells. After 14 days, several hygromycin-
resistant colonies were formed which were collected by trypsinization of cells 
with 0.25% trypsin-EDTA solution and transferred to a 75 cm2 flask to grow. After 
expanding and passaging the cells for one more time, these stable transfectants 
were then tested either through western blotting or confocal microscopy to 
ensure that the receptor of interest was inducible with doxycycline. In resting 
condition, the tet repressor protein (homodimer) expressed from the host cell 
binds to the tet operator 2 (TetO2) sequence of the hybrid promoter, CMV/TetO2 
of the integrated pcDNA5/FRT/TO containing the receptor of interest and thus 
represses the transcription of gene (Ward et al., 2011). The addition of 
tetracycline such as doxycycline to culture medium leads to expression of the 
gene of interest (GOI) by binding with the tet repressor protein followed by 
dissociation of tet repressor-doxycycline complex allowing induction of 
transcription of GOI. For long term storage, some cells from early passages were 
frozen down using FBS with 10% DMSO as freezing medium and subsequently 
stored in liquid nitrogen.   
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2.6 Biochemical and functional pharmacological assays 
2.6.1 Membrane preparations 
Membranes were prepared from Flp-InTM T-RExTM-293 stable cells either 
untreated or treated with 100 ng/ml doxycycline for 24 hours to express 
receptor of interest, transiently transfected HEK-293 cells or from RAW264.7 
cells either untreated or treated for 5 hours, 8 hours, 11 hours and 24 hours with 
pure LPS (Enzo Life Sciences; acts as an specific activator of TLR4 and does not 
activate other form of TLRs including TLR2). After the specific time period of 
cellular treatment either with doxycycline or LPS/PTX or after 36 to 48 hours 
following transient transfection, cells were harvested by removing the growth 
medium, rinsing once with 10 ml of ice-cold phosphate-buffered saline (PBS; pH 
7.4) for each dish followed by either pipetting up and down to detach the cells 
or scraping the cells from the bottom of the dish with cell scraper. The cell 
suspensions in ice-cold PBS were transferred to a 50 ml falcon tube and were 
then centrifuged at 1811 x g for 5 min at 4ºC. The supernatant was discarded 
and then rinsed with 20 ml ice-cold PBS followed by re-centrifugation at 1811 x g 
at 4ºC for 5 min. The cell pellets were then stored at -80ºC until used. The 
frozen cell pellets were thawed on ice for 30 minutes and suspended in 5 
volumes (1-2 ml) of ice-cold TE membrane buffer (10 mM Tris-HCl, 0.1 mM EDTA, 
pH 7.5) containing 1xComplete EDTA free protease inhibitor cocktail tablet 
(Roche Applied Science, West Sussex, UK) (1 tablet per 50 ml of TE buffer). 
Pellet suspensions were then homogenized with 50 strokes of a ground glass on 
Teflon homogenizer (5 ml hand-held homogenizer) to rupture the cells. The 
homogenates were then transferred to a pre-chilled 7 mL bijou container 
(Greiner Bio-one) and passed 5 times through a 25 gauge needle fitted to a 2 ml 
syringe to rupture the cells again. The suspensions were then transferred to a 15 
ml falcon tube and centrifuged at 314 x g at 4ºC for 5 min to remove the 
unbroken cells, nuclei or other cellular debris. The supernatant was then 
transferred to ultracentrifuge glass tubes and centrifuged at 50,000 rpm for 45 
minutes at 4ºC using OptimaTM TLX Ultracentrifuge (Beckman Coulter) with a 
TLA100.2 rotor. After the ultra-centrifugation, the supernatant was discarded 
and each pellet of membrane fractions was re-suspended in 1 ml of ice-cold TE 
membrane buffer supplemented with protease inhibitor cocktail and passed 10 
times through a 2 ml syringe attached to a 25 gauge needle to make the mixture 
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homogenous. The generated each membrane preparation was then transferred 
to a pre-chilled 1.5 ml sterile microcentrifuge tube. The total protein 
concentration of each membrane preparation was measured by bicinchoninic 
acid (BCA) assay and membranes were aliquoted into 500 µl sample which were 
then stored at -80ºC until to be used. These stored membrane preparations are 
usable until 6 months.   
2.6.2 Determination of membrane protein concentration 
Amount of total proteins in each generated membrane preparation was 
determined by bicinchoninic acid (BCA) assay using BCA protein assay kit (Pierce, 
Fisher Scientific, Loughborough, UK). This BCA assay is a colorimetric detection 
method based on the reduction of Cu2+ (from BCA reagent B, 4% cupric sulfate) 
to Cu+ ion by peptide bond in alkaline condition followed by chelation of cuprous 
ion by the bicinchoninic acid forming a purple-coloured water-soluble complex 
which displays strong absorbance at 562 nm. Previously a series of standard 
bovine serum albumin (fatty acid-free) concentrations (0.2, 0.4, 0.6, 0.8, 1.0, 
1.2, 1.4, 1.6, 1.8, 2.0 and 2.2 mg/ml) were prepared from 5 mg/ml stock 
solution by serial dilutions using TE buffer (10 mM Tris-HCl, 0.1 mM EDTA, pH 
7.5) and were stored in -20ºC. These standard BSA solutions were thawed prior 
to the BCA assay and 10 µl of each concentration of the standard was added in 
triplicate to a 96 well clear flat bottom assay plate (Corning, USA). As a negative 
control/blank standard, 10 µl of TE buffer was also added in triplicate to the 
plate followed by addition of 10 µl of each membrane preparation in triplicate 
to the same plate. 1 part of BCA Reagent B (4% cupric sulfate) was added to 49 
parts of BCA Reagent A (sodium carbonate, sodium bicarbonate, bicinchoninic 
acid and sodium tartrate in 0.1M sodium hydroxide) to make the working 
reagent. 200 µl of this working reagent was then added to each well of the 
microplate using an Eppendorf repeater with handheld dispenser. The plate was 
then covered with a disposable seal (Topseal TM, PerkinElmer) and incubated for 
20 minutes in 37ºC followed by measuring the absorbance at 562 nm on a 
microplate reader, PHERAstar FS plate reader (BMG Labtech, Aylesbury, UK). The 
average absorbance value for the blank standard was then subtracted from the 
values for BSA standards and unknown samples followed by generation of a 
standard curve for BSA plotting blank corrected average values against the 
corresponding concentration of BSA. Using linear regression analysis, the protein 
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concentration of each unknown membrane preparation was interpolated from 
the standard curve.    
2.6.3 Sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE) 
To investigate the expression of receptor of interest in transfected cells, 
membranes generated from the cells were subjected to sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE) followed by immunoblotting with 
a specific antibody. SDS-PAGE resolves the proteins based on their 
electrophoretic mobility. SDS denatures the protein by breaking the secondary, 
tertiary and quaternary structure upon binding to the protein as well as imparts 
an overall negative charge to the protein ultimately converts the proteins into 
negatively charged linear polypeptide chains which under electric field can 
mobilize through the acrylamide mesh to the anode according to their molecular 
weight.  
Membrane preparations stored in -80ºC were thawed and diluted with TE 
membrane buffer so that all the samples have identical concentration. To 
deglycosylate the glycoprotein, membrane preparation was treated with peptide 
N-glycosidase enzyme (PNGase F; Roche Diagnostics). Briefly, the calculated 
volume of membrane sample was mixed gently with the required volume of 10X 
incubation buffer (20 mM potassium phosphate buffer, pH 7.2) and PNGase F at a 
final concentration of 0.05 unit/µl followed by heating at 37ºC for 2 hours. As a 
negative control, a similar volume of membrane sample mixed with an equal 
volume of incubation buffer without adding PNGase F was also heated at 37ºC 
for 2 hours. Each of PNGase F treated and untreated membrane samples was 
then mixed with equal volume of 2X Laemmli buffer (60 mM Tris, 80 mM sodium 
dodecyl sulphate (SDS), 50 mM dithiothreitol (DTT), 10% (v/v) glycerol, 0.01% 
(w/v) bromophenol blue, pH 6.8) followed by heating at 37ºC for 15 minutes. 
DTT disrupts disulphide bonds of proteins and thereby denatures the protein. 
SDS also acts as a denaturant as discussed above and heating also contribute to 
the denaturation of the protein. Laemmli buffer also serves as the loading buffer 
for the samples.  
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50 ml of 20X Novex  BoltTM MOPS SDS Running Buffer (Life Technologies) was 
mixed with 950 ml of deionized water. Precast gels, BoltTM 4-12% Bis-Tris 1.00 
mmX10 well (Invitrogen, Thermo Fisher Scientific) stored at 4ºC were removed 
from the fridge and kept at room temperature before running. After removal of 
the comb and peeling away the tape at the bottom of the gel cassette, the wells 
of the gel were rinsed with deionized water. Two gel cassettes were then 
inserted into two chambers of the BoltTM Mini Gel Tank (Life Technologies) which 
already have been filled with 1X MOPS SDS running buffer to just above the 
electrode. It was also ensured that wells were completely filled with buffer. 5 to 
8 µl of ECLTM RainbowTM marker, RPN800E (GE Healthcare, UK) which allow the 
estimation of protein size of the samples, was then added to the first well of the 
gel followed by addition of samples containing 10 to 20 µg of proteins to the 
following wells and any empty well was filled with 1X Laemmli buffer. Gels were 
then run in MOPS SDS buffer at 165V for 45 minutes until the bromophenol dye 
front reached just above the edge of the gel.   
2.6.3. Immunoblotting or western blot 
Following separation of proteins by SDS-PAGE, proteins were electrophoretically 
transferred from the Bis-Tris gels to Nitrocellulose blotting membrane (GE 
Healthcare Life Science) in transfer buffer (200 mM glycine, 25 mM Tris, 20% 
(v/v) methanol) at 30 V for 1 hour using an XCell IITM Blot Module (Life 
Technologies). Prior to the transfer, filter paper, sponges and nitrocellulose 
membrane were soaked in 1X transfer buffer. A sandwich of sponge pad, filter 
paper, electrophoresed Bis-Tris gel, nitrocellulose membrane, filter paper and 
sponge pad was assembled placing the cathode core on the bottom and any 
bubbles between layers of the sandwich were removed using a blotting roller. 
The anode core was then placed on the top of the sandwich and the blot module 
assembly was closed. This blot module was then inserted into the chamber of 
the XCell SureLock™ Mini-Cell Electrophoresis System (Life Technologies) 
followed by addition of 1X transfer buffer to the module core and to the 
chamber to the level of the electrode. A constant voltage of 30 V was then 
applied for 1 hour to allow the transfer of proteins from the gel to nitrocellulose 
membrane. After membrane transfer, the nitrocellulose membrane was placed 
in a tray and wet for 2 minutes in PBS-T (1X phosphate buffered saline with 0.2% 
(v/v) Tween 20). To block the nonspecific sites on the membrane, the 
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nitrocellulose membrane was blocked with 5% (w/v) Marvel powdered skimmed 
milk in PBS-T for 2 hours at room temperature with gentle shaking, ensuring that 
sufficient blocking buffer was applied to cover the membrane. Membranes were 
then incubated overnight with primary antibody at the appropriate dilution 
(made up in PBS-T with 3% milk) at 4ºC with gentle shaking. Mouse monoclonal 
anti-FLAG M2 antibody (Sigma-Aldrich) was diluted at 1:1,000 while both sheep 
polyclonal anti-GFP antiserum (produced in-house) and rabbit anti-ICL3-mouse 
GPR84 antiserum (produced in-house) were diluted at 1: 10,000 in PBS-T with 3% 
milk. On the following day, the primary antibody solution was poured off and the 
blot was washed 4 times for 5 minutes in PBS-T with shaking on a platform 
shaker. Blot was then incubated in diluted horseradish peroxidase (HRP) 
conjugated secondary antibody (made up in PBS-T with 3% milk) for 2 hours at 
room temperature with gentle shaking ensuring that blot was protected from 
light by covering the incubation box with aluminium foil. HRP-labelled anti-
mouse IgG secondary antibody (GE Healthcare Life Sciences, Buckinghamshire, 
UK) (1: 10,000 dilution), anti-goat IgG secondary antibody (1:20,000 dilution) 
and anti-rabbit IgG secondary antibody (GE Healthcare) (1:20,000 dilution) were  
used to detect anti-FLAG M2 antibody, anti-GFP antiserum and anti-ICL3-mouse 
GPR84 antiserum, respectively. The secondary antibody solution was poured off 
and the blot was then washed 4 times with PBS-T for 5 minutes with shaking on a 
platform shaker at room temperature. The blot was protected from light during 
washing.  
Proteins on the blot were detected by enhanced chemiluminescent (ECL) 
detection method which is based on the emission of light from the oxidation of 
luminol by HRP-conjugated secondary antibody in the presence of peroxide. This 
luminescence is proportional to the amount of the target protein present on the 
nitrocellulose membrane and can be detected by CCD cameras capturing a 
digital image of the western blot or photographic film. Equal parts of the 
peroxide solution and the luminol/enhancer solution of SuperSignalTM West Pico 
PLUS chemiluminescent substrate kit (Thermo Scientific, USA) were mixed to 
prepare the working solution and sufficient volume of this working solution was 
added to the membrane. The blot being protected from light was then incubated 
for 5 minutes with gentle shaking on a benchtop shaker. The working solution 
was then removed and excess reagent was drained. The blot was placed in a 
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clear plastic coating inside a developing cassette. Air bubbles were removed by 
smoothing out the plastic coating gently and the blot was then exposed to a 
Carestream KODAK BioMax Light film (Sigma-Aldrich) in a dark room for a specific 
period of time which was subsequently processed using a KODAK® X-OMAT® Film 
developer. 
2.6.5 [35S]-GTPγS binding assay   
To assess the G protein activation level of the receptor [35S]-GTPγS binding assay 
was employed. Upon receptor activation following agonist stimulation, GTP is 
exchanged for GDP on activated Gα subunit which can be terminated by GTPase 
activity of the Gα subunit resulting in hydrolysis of GTP into GDP and inorganic 
phosphate. Similar to intracellular GTP, exogenous [35S]-GTPγS which is a 
radiolabelled analogue of GTP containing a 35S on the gamma phosphate, can 
also be exchanged for GDP on Gα subunit of the activated G protein. In contrast 
to intracellular GTP, this radioligand is resistant to hydrolysis by inherent 
GTPase activity leading to accumulation of agonist-receptor- [35S]-GTPγS-bound 
G protein ternary complex (Harrison and Traynor, 2003; Strange, 2010). This 
bound radioligand can be separated from the unbound form by filtration with 
washing and the radioactivity can be counted by liquid scintillation 
spectroscopy. The resultant radioactivity is proportional to the amount of G 
protein activation level.    
[35S]-GTPγS binding assay was performed according to the method described by 
Milligan (2003). 5 µg of membrane proteins generated from transfected cells 
expressing receptor of interest or from LPS-induced RAW264.7 cells were pre-
incubated with indicated concentrations of ligands for 15 minutes at 25ºC in 
assay buffer (20 mM HEPES, 5 mM MgCl2, 160 mM NaCl, 1 µM GDP, 0.05% fatty 
acid-free bovine serum albumin, pH 7.5) in a total assay volume of 500 µl either 
in glass tubes or in 1.0 ml 96 deep-well plate (Starlab, USA). In case of 
experiments designed for assessing potential allosteric interactions between DIM 
or DIM analogues and orthosteric agonists (C-10, embelin, 6-OAU, compound-1) 
both the potential modulator and orthosteric agonist probe were added to the 
membranes at the same time. In case of experiments designed to assess the 
ability of various concentrations of antagonist (compound 9,104,107,161,837 or 
GLPG1205) to inhibit the effect of an EC80 concentration of an agonist (C-10, 
2 Materials and methods  95 
 
embelin, DIM or compound-1) or to change the position of concentration-
response curves for an agonist (Schild analysis), antagonist was pre-incubated 
with the membrane protein for 15 minutes at room temperature prior to the 
addition of agonist concentration(s). [35S]-GTPγS (50 nCi per reaction) 
(PerkinElmer Life Sciences) was then added to each tube to initiate the reaction 
followed by 45 minutes incubation at 30ºC in a temperature-controlled water 
bath. Reactions were then terminated by rapid vacuum filtration through GF/C 
filters (pre-soaked in cold PBS) using a 24-well Brandel cell harvester (Alpha 
Biotech, Glasgow, UK). In cases of assays performed in 96 deep-well plates, 
vacuum filtration was performed through GF/C glass fibre filter fitted in 96-well 
white microplate (also known as UniFilter plate, PerkinElmer Life Sciences, 
Beaconsfield, UK) using a UniFilter FilterMate Harvester (PerkinElmer Life 
Sciences, Beaconsfield, UK). To separate the bound radioligands from unbound 
forms, GF/C filters were washed three times with ice-cold phosphate buffered 
saline (pH 7.4). [35S]-GTPγS bound to the activated GPCR-G protein complex of 
the membrane was unable to pass through the filter paper while the unbound 
form of the radioligand was washed away through the filter. Filter papers were 
kept at room temperature for air drying for a minimum of 2 hours or overnight 
and then transferred to 6 ml PE Pony Vials (PerkinElmer). 3 ml liquid scintillation 
fluid (Ultima Gold TM XR scintillation cocktail, PerkinElmer Life Sciences, 
Beaconsfield, UK) was added to each cut filters. The retained radioactivity was 
measured using a liquid scintillation counter, Tri-Carb® 2910 TR (PerkinElmer). In 
the case of UniFilter, after air-drying for minimum 2 hours, adhesive BackSeal 
was applied to each UniFilter plate and 50 µl of scintillation cocktail, MicroScint-
20 (PerkinElmer Life Sciences, Beaconsfield, UK) was added to each well of the 
plate using an Eppendorf Repeater with manual handheld dispenser. Each 
UniFilter plate was then sealed with TopSealTM (PerkinElmer) and retained 
radioactivity of the bound radioligand was measured using a microplate 
scintillation counter, TopCount NXTTM (Packard). The obtained radioactivity of 
[35S]-GTPγS in the form of counts per minute (CPM) was then plotted against the 
ligand concentrations in logarithmic scale.    
2.6.6 HTRF-based cAMP accumulation assay 
Forskolin-induced cAMP accumulation assay based on the homogeneous time-
resolved fluorescence resonance energy transfer (HTRF) was performed using 
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cAMP dynamic kit (CisBio Bioassays, CisBio, Codolet, France) following the 
manufacturer’s instructions. It is a competitive immunoassay wherein cAMP 
labelled with d2 dye (FRET acceptor) competes with the unlabelled cAMP 
produced in the cells or exogenous standard cAMP for the site on the monoclonal 
antibody, anti-cAMP labelled with Eu3+-Cryptate (FRET donor). FRET occurs when 
cAMP-d2 conjugate binds with the anti-cAMP-cryptate conjugate. Therefore, 
intracellular cAMP produced by activation of adenylyl cyclase will displace the 
cAMP-d2 from the binding site on anti-cAMP-cryptate conjugate leading to no 
FRET signal, implying that the measured FRET is inversely proportional to the 
accumulated cAMP in the cells. As GPR84 is a Gαi-coupled receptor, the ability 
of agonist-promoted activated GPR84 to inhibit the forskolin-induced cAMP 
accumulation was assessed by this HTRF-based assay. Flp-InTM T-RExTM-293 stable 
cells harbouring FLAG-hGPR84-Gαi2, FLAG-hGPR84-Gαi2 C352I or FLAG-hGPR84-
Gαi2 C352G treated with 100 ng/ml doxycycline for 24 hours to express the 
receptor of interest were utilized for this experiment. The cells were dissociated 
by versene-EDTA solution followed by resuspension with Hank’s Balanced Salt 
Solution (HBSS) (137 mM NaCl, 5.3 mM KCl, 0.34 mM Na2HPO4, 0.44 mM KH2PO4, 
4 mM NaHCO3, 1.26 mM CaCl2, 0.5 mM MgCl2 and 0.4 mM MgSO4 at pH 7.3). The 
cells were then counted by trypan blue exclusion method and 5 µl of cell 
suspensions in HBSS containing 2000 cells/µl was plated in 384-well low volume 
plate and incubated for 30 minutes at room temperature with 5 µl indicated 
concentrations of agonist/vehicle (nonstimulated cells control) containing 1 µM 
forskolin. The agonist was prepared using the cell stimulation buffer which 
contains 0.5 mM 3-isobutyl-1-methylxanthine (IBMX), 1 µM forskolin and HBSS. 
Forskolin acts as an activator of the enzyme adenylyl cyclase raising the 
intracellular cAMP level while IBMX was added to the buffer to act as a 
phosphodiesterase inhibitor and thereby inhibits degradation of cAMP. In 
parallel, to generate a standard curve, 5 µl of various concentrations ranging 
from 0.17 to 712 nM of standard cAMP were added to the cells and incubated for 
30 minutes with the 5 µl of cell stimulation buffer. After cells has been 
stimulated, 5 µl of  diluted (1:20) cAMP-d2 conjugate in lysis buffer (except in 
cell negative control and standard negative control) and 5 µl of diluted (1:20) 
anti-cAMP cryptate conjugate in lysis buffer were added to each well followed 
by incubation at room temperature for 1 hour in dark. Fluorescence was 
measured at 620 nm (for Eu3+-Cryptate, FRET donor) and at 665 nm (for d2-dye, 
2 Materials and methods  97 
 
FRET acceptor) using PHERAstar FS plate reader (BMGLabtech, Aylesbury, UK). 
The 665 nm/ 620 nm fluorescence emission ratio was then calculated and the 
ability of the agonist to inhibit forskolin-induced production of cAMP was 
determined. Briefly, the emission ratio (ratio at 665 nm/620 nm) was multiplied 
by 10,000 and using this ratio for samples or negative control, the Delta F values 
were calculated using the following formula: 
𝐷𝑒𝑙𝑡𝑎 𝐹 =
Ratio for standard or sample−Ratio for negative control
Ratio for negative control
𝑥100 
Where 𝑅𝑎𝑡𝑖𝑜 =
𝐹𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒 𝑎𝑡 665 𝑛𝑚
Fluorescence at 620 nm
x104 
A cAMP standard curve was then drawn by plotting delta F (%) in the y-axis and 
respective concentrations of standard cAMP in the x-axis. Using this sigmoidal 
standard curve, the cAMP concentration of the samples was deduced from their 
respective delta F (%) value.  
2.6.7 Radioligand saturation binding assays 
[3H]-G9543, an analogue of compounds 104, 107 and 161 with the same 
characteristic 2-(substituted-alkoxy)-9-substituted-6,7-dihydro-pyrimido[6,1-
a]isoquinolin-4-one chemotype (Mahmud et al., 2017) was used for saturation 
binding assays to measure the expression of the receptor construct in 
transfected cells. Various concentrations of [3H]-G9543 were incubated with 5 µg 
of membrane protein expressing the receptor of interest with (non-specific 
binding) or without (total binding) 1 µM of GPR84 antagonist, 104 for 1 hour at 
25ºC in assay buffer (phosphate-buffered saline, 0.5% fatty acid free bovine 
serum albumin, pH 7.4) in a total volume of 500 µl in glass tubes. The reaction 
was terminated and [3H]-G9543 bound to the receptor construct was isolated 
from the unbound form by vacuum filtration through GF/C filter papers (Alpha 
Biotech) using a 24-well Brandel Cell harvester (Alpha Biotech, Glasgow, UK) 
followed by washing each reaction tube three times with ice-cold PBS (pH 7.4). 
After drying the filters for at least 2 hours at room temperature, cut filters were 
transferred to 6 ml PE Pony Vials (PerkinElmer) followed by addition of 3 ml of 
liquid scintillation fluid, Ultima Gold™ XR (PerkinElmer Life Sciences, 
Beaconsfield, UK) to each cut filter and then the retained radioactivity was 
measured by liquid scintillation analyser, Tri-Carb® 2910 TR (PerkinElmer). To 
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determine the actual concentration of [3H]-G9543 added to tubes, two aliquots 
of a similar volume of each concentration of [3H]-G9543 used in the assay were 
added to 6 ml PE vial and radioactivity was quantified after adding 3 ml Ultima 
Gold™ XR. The concentration of [3H]-G9543 added per tube was calculated using 
the following formula: 
 
Standard (DPM)
Specific activity(
DPM
fmol
)
𝑥
1
500(Assay volume)
=
fmol
µL
=
nmol
L
= 𝑛𝑀 
 
Total binding of [3H]-G9543 to the receptor was calculated using the following 
formula: 𝑇𝑜𝑡𝑎𝑙 𝑏𝑖𝑛𝑑𝑖𝑛𝑔(
𝑓𝑚𝑜𝑙
𝑚𝑔
) =
Total DPM
Specific activity(
DPM
fmol
)
𝑥
1000
Protein(
µg
tube
)
 
Nonspecific binding of the radioligand was calculated using the following 
formula: 𝑁𝑜𝑛𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐 𝑏𝑖𝑛𝑑𝑖𝑛𝑔(
𝑓𝑚𝑜𝑙
𝑚𝑔
) =
Nonspecific DPM
Specific activity(
DPM
fmol
)
𝑥
1000
Protein(
µg
tube
)
 
Specific binding was then determined by subtracting nonspecific binding from 
total binding and plotted against concentrations of [3H]-G9543 to construct 
saturation binding isotherms.   
2.6.8 Bioluminescence resonance energy transfer (BRET) assay 
using SPASM sensor  
G protein specificity of GPR84 was investigated by novel SPASM biosensor-based 
BRET assays. GPR84 SPASM biosensor is a single polypeptide in which FLAG-
tagged human GPR84 is fused at C-terminus with a G protein peptide comprising 
last 27 amino acids of the α5 helix of G protein flanked by a SPASM sensor part 
consisting of a BRET acceptor m-Citrine or mNeonGreen and a BRET donor 
NanoLuc linked by a flexible linker ERK helix. If the α5 helix peptide is of 
cognate G protein for the receptor, following agonist treatment, this G protein 
peptide will interact with GPR84 in such a way that the distance between BRET 
acceptor and donor will be decreased allowing the bioluminescence resonance 
energy transfer between them. Here NanoLuc luciferase enzyme catalyses the 
oxidation of a coelenterazine analogue, furimazine into furimamide with 
concomitant emission of light which can be transferred to mCitrine/mNeonGreen 
acceptor.      
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2.6.8.1 BRET assay using mCitrine-based SPASM sensors 
Flp-InTM T-RExTM-293 stable cell lines stably harbouring FLAG-hGPR84-SPASM 
Gαi1/2 and FLAG-hGPR84-SPASM No-pep sensor construct were used for the BRET 
assay. Cells were split in 1:4 from 80% confluent T75 flask. On the same day, 96 
well white plates with a flat bottom (Greiner Bio-one) were coated with 40 
µl/well (concentration: 50 µg/ml) of poly D lysine hydrobromide (Sigma-Aldrich) 
in serum-free DMEM media and incubated overnight at 4ºC temperature. Poly D 
lysine will enhance the cell attachment to the bottom of the plate. On the 
following day, cells were harvested along with counting by trypan blue exclusion 
method and 100 µl of cells were seeded at 50,000 cells per well on poly-D-lysine 
coated 96 well plates and after 6 hours of incubation in 5% CO2 and at 37ºC, 100 
ng/ml of doxycycline was added to induce the expression of the receptor of 
interest. The plates were incubated for overnight at 37º and 5% CO2. 24 hours 
later, media was aspirated from the plate and cells were washed for two times 
with 100 µl of pre-warmed (37ºC) HBSS (pH 7.4) buffer followed by addition of 80 
µl of HBSS per well. At this point, plates were read to measure the fluorescence 
intensity of BRET acceptor, mCitrine using a CLARIOstar (BMG Labtech) plate 
reader to determine the receptor expression. Nano Glo substrate (Promega 
Corporation, Madison, USA) was diluted from 800x stock to 10x concentration 
using pre-warmed HBSS buffer and 10 µl of the diluted substrate was added to 
each well at the final concentration of 5 µM. The plates were immediately 
wrapped with aluminium foil to protect the cells from light and were then 
incubated for 10 minutes in 37ºC followed by addition of 10 µl indicated 10X 
concentrations of ligands/vehicle. The plates being protected from light were 
incubated again for five minutes in 37ºC and luminescence at 530 nm (mCitrine 
emission) and 455 nm (emission from the oxidation of furimazine to furimamide 
by NanoLuc) was measured by CLARIOstar plate reader using a bandwidth of 50 
nm. The BRET ratio was calculated as emission at 530 nm/emission at 455 nm. 
Net BRET was determined by subtracting the value of the BRET ratio of FLAG-
hGPR84-SPASM-No peptide sensor from that of FLAG-hGPR84-SPASM-Gi1/2 sensor. 
Multiplication of this value by 1000 gives the mBRET units. Change in BRET, 
ΔBRET was calculated as follows: 
ΔBRET=BRETligand- BRETbuffer 
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2.6.8.2 BRET assay using mNeonGreen-based SPASM sensors 
FLAG-hGPR84-SpNG-Gα(x) sensors (where x= i1/2, i3, o, z, s, q,12,13,14 and 16) 
or a FLAG-hGPR84-SpNG-NP sensor construct were transfected to HEK-293T cells 
using Lipofectamine 3000 reagents (see section 2.4.2 ) and after 24 hours of 
transfection, cells were seeded at 40,000 cells per well on poly-D-lysine coated 
96 well plates. 48 hours following transfection, cells were washed for two times 
with 100 µl of HBSS-20 mM HEPES (pH 7.4) buffer and 80 µl of buffer was added 
to each well. Fluorescence intensity of mNeonGreen was then measured using 
ClARIOstar plate reader to determine the relative expression of the sensor 
constructs. Nano Glo substrate was then added to each well at the final 
concentration of 5 µM. The plates wrapped with aluminium foil were then 
incubated for 10 minutes in 37ºC followed by addition of indicated 
concentrations of ligands or of vehicle buffer. The plates were incubated again 
for five minutes in 37ºC. Using a bandwidth of 50 nm, NLUC and mNeongreen 
emission signals were then collected at 450 and 525 nm respectively by 
Clariostar plate reader. The BRET ratio was calculated as the ratio of 
luminescence at 525 nm to luminescence at 450 nm. Multiplication of this value 
by 1000 provided the mBRET units. 
2.7. Structural studies 
2.7.1 Homology modelling  
The homology modelling and ligand docking were conducted by Dr. Irina G. 
Tikhonova, School of Pharmacy, Medical Biology Centre, Queen’s University 
Belfast, Belfast, BT9 7BL, United Kingdom as part of the collaborative work. A 
hybrid template was generated by assembling the helical bundle of seven 
transmembrane domains from the OX1 receptor crystal structure (Protein Data 
Bank code: 4ZJ8) with the 2nd extracellular loop (EL2) from the crystal structure 
of rhodopsin (PDB code: 2Z73) and based on this combined template a homology 
model of GPR84 was generated with the Prime 3.8 module of the Schrodinger 
software (Schrodinger, LLC, New York, 2014) using the default energy-based 
method (Jacobson et al., 2004). The resulting homology model was then 
optimized using molecular mechanics and dynamics tools of MacroModel 10.6 
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module of the Schrodinger software package (Schrodinger, LLC, 2014) 
(Tikhonova, 2017; Mahmud et al., 2017). 
2.7.2 Ligand docking 
Using the InducedFit module (Friesner et al., 2006; Sherman et al., 2006) of the 
Schrodinger software, ligand docking to the constructed GPR84 homology model 
was performed. Herein, the induced fit docking (IFD) methodology based on 
glide (ligand sampling) and prime (receptor sampling) program (Friesner et al., 
2006) was employed to generate multiple ensembles of docking poses. The 
receptor grid was defined around Arg172 while the side chain trimming was 
performed for residues Tyr69 and Phe335 that largely occluded the binding 
cavity. From the resulting multiple ligand docking poses, the best docking pose 
was selected based on the docking energy and interactions with Arg172 (Mahmud 
et al., 2017). Maestro 9.9 of the Schrodinger software package was employed for 
the generation of figures of the molecular models.  
2.8. Data analysis and curve fitting 
Data analysis and curve fitting were carried out using the GraphPad Prism 
software package version 5.0b (GraphPad, San Diego). 
2.8.1 Analysis of functional agonist and antagonist assays 
The functional concentration-response curve (CRC) for agonist ligand displays a 
sigmoidal curve with a standard slope factor (Hill slope) of 1. Usually, seven or 
eleven concentrations of an agonist ligand were plotted in logarithmic scale on 
X-axis with the vehicle control plotted at 1 log unit lower than the lowest 
concentration of the ligand. The agonist functional response data were then 
analysed by non-linear regression analysis with fitting data to a three-parameter 
sigmoidal curve where Hill slope was constrained to unity and the model for this 
curve fitting is depicted below:     
𝑅𝑒𝑠𝑝𝑜𝑛𝑠𝑒(𝑌) = Bottom +
(Top − Bottom)
[1 + 10(logEC50−X)]
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Here, Top is the maximal asymptote of the curve reflecting the maximal 
response (Emax) displayed by the agonist ligand while bottom is the response of 
the vehicle control and logEC50 is the logarithm of the EC50 value. EC50 is the 
concentration of the agonist required for the generation of half-maximal 
response while X is the concentration of agonist ligand. The best fit values for 
the negative logarithm of EC50 (pEC50) were determined from at least three 
independent experiments and these values were then represented as 
means±SEM.      
In case of inhibition experiments with antagonists wherein the ability of several 
concentrations (seven) of antagonist to inhibit the response produced by an EC80 
concentration of an agonist was assessed, the data were analysed by non-linear 
regression analysis with data fitted to a three-parameter log (inhibitor) vs 
response inverse sigmoidal curve where Hill slope was constrained to -1 using the 
following model:     
𝑅𝑒𝑠𝑝𝑜𝑛𝑠𝑒(𝑌) = Bottom +
(Top − Bottom)
[1 + 10(X−logIC50)]
 
Here, IC50 is the concentration of the antagonist required for the 50% inhibition 
of the agonist response. The negative logarithm of IC50 i.e pIC50 was determined 
from the best-fit value of curve-fitting from at least three individual 
experiments and was presented as mean±SEM.  
2.8.2 Analysis of radioligand binding data 
Radioligand saturation binding curve follows the shape of a rectangular 
hyperbola. In this binding experiment, specific binding of the radioligand to the 
receptor was first calculated by subtracting the non-specific binding from the 
total binding and these specific binding data were analysed by non-linear 
regression by fitting data to a one site specific binding model allowing 
estimation of radioligand binding affinity (Kd,) and total number of receptor 
binding sites (Bmax) in the sample.  
𝑆𝑝𝑒𝑐𝑖𝑓𝑖𝑐 𝑏𝑖𝑛𝑑𝑖𝑛𝑔 (𝑌) =
Bmax × (𝑋)
Kd + (𝑋)
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Here, Kd is the equilibrium binding constant or the concentration of the 
radioligand required for binding half of the receptor sites in equilibrium, Bmax is 
the maximum specific binding and X is the concentration of the radioligand.  
2.8.3 Analysis of ligand co-operativity and other allosteric 
parameters 
To estimate the magnitude and direction of the allosteric effect, data obtained 
from allosterism experiments were analysed using an operational model of 
allosteric modulation described previously (Ehlert, 2005; Keov et al., 2011). The 
general version of this model can be depicted by the following equation:  
 
Where, E is the pharmacological effect, [A] and [B] are the orthosteric and 
allosteric compound concentration at equilibrium, respectively; KA and KB are 
the equilibrium dissociation constants of the orthosteric and allosteric ligands 
respectively, denoting the binding affinities of the two ligands to the receptor; α 
is the binding cooperativity factor denoting the magnitude and direction of the 
allosteric effect on binding affinity of the orthosteric agonist to the receptor, β 
is the activation cooperativity factor representing the measure of the allosteric 
effect on orthosteric efficacy. τA and τB represent the intrinsic activity (ability to 
activate the receptor directly) of the orthosteric and allosteric ligand, 
respectively. Em is the maximal possible system response and n denotes the slope 
factor of the transducer function. In case of global fitting of the allosterism data 
through this equation, Em and n values were always constrained to Emax of the 
experiment and 1, respectively and other parameters (KA, KB, α, β, τA and τB) 
were estimated. 
2.8.4 Global Gaddum/Schild EC50 shift analysis 
To investigate whether an antagonist interacts with an agonist in a competitive 
or non-competitive manner, a set of agonist concentration-response assays were 
performed in the absence or presence of a various fixed concentrations of the 
antagonist and data were globally fit to the Gaddum/Schild EC50 shift analysis 
which provides estimation of the pA2 value (the negative logarithm of the 
E=
𝐸𝑚(𝜏𝐴[𝐴](𝐾𝐵+𝛼𝛽[𝐵]+𝜏𝐵[𝐵]𝐾𝐴)
𝑛
([𝐴]𝐾𝐵+𝐾𝐴𝐾𝐵+[𝐵]𝐾𝐴+𝛼[𝐴][𝐵]
𝑛+(𝜏𝐴[𝐴](𝐾𝐵+𝛼𝛽[𝐵])+𝜏𝐵[𝐵]𝐾𝐴)
𝑛 
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concentration of antagonist needed to shift the agonist concertation-response 
curve by a factor of 2) and the Schild slope factor. While pA2 reflects the 
antagonist affinity for the receptor, the Schild slope factor, S reveals how well 
the antagonist-promoted shifting of the concentration-response curve 
corresponds to the competitive interaction between two ligands with the value 
of 1 reflecting perfect competitive nature of the interaction.      
2.8.5 Statistical analysis 
All data were presented as mean±SEM of three independent experiments. All 
statistical analysis of data was conducted using the GraphPad Prism software 
package version 5.0b. Assuming that data were normally distributed, data were 
analysed either through two-tailed unpaired student’s t-test (for two groups) or 
one-way analysis of variance (ANOVA) (for three or more groups) followed by 
Tukey’s or Dunnett’s multiple comparison test to determine the level of 
significance between treatment vs control groups with the p-value less than 0.05 
being considered as statistically significant.    
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3 Investigation of G-protein Selectivity of GPR84 
3.1. Introduction 
Elucidation of GPCR-G protein coupling selectivity is crucial for defining the 
functions and pharmacology of the G-protein coupled receptor (GPCR) of 
interest. Activation of a GPCR by endogenous and synthetic ligands is generally 
transduced by heterotrimeric G-proteins which transfer the extracellular signal 
to intracellular second messengers. So, investigation of G-protein selectivity of 
any GPCR is of paramount importance as it will link activation of the GPCR to 
physiological responses. Moreover, exploring the G-protein specificity of any 
GPCR is crucial as it will help define the downstream intracellular signalling 
pathway related to specific GPCRs ultimately defining the cellular and biological 
effects associated with it. This can be exploited for the development of drug 
screening assays for orphan receptors. Wang et al., (2006b) initially investigated 
G protein specificity of GPR84 and reported that the chimeric proteins Gqi(9) and 
Gq0(5) but not Gqs(5) significantly promoted decanoic acid stimulated activation of 
GPR84 using an aequorin-based calcium assay in Chinese Hamster Ovary (CHO) 
cells. This suggested that activated GPR84 preferentially adopts Gαi/o-coupled 
conformations. Recently Gaidarov et al., (2018) reported that along with Gαi/o, 
embelin-occupied GPR84 also couples to G12/G13 mediated signalling pathways in 
HEK-293 cells. They found that embelin and its analogues promoted intracellular 
cAMP production in a concentration-dependent fashion in HEK-293 cells co-
transfected with GPR84 and Gs13(5) or Gs12(5) chimeric proteins, an effect which 
was significantly potentiated by pre-treatment of the cells with the Gαi 
inhibitor, pertussis toxin (PTX). To explore the G-protein selectivity of GPR84 
more extensively, I have used novel BRET-based GPR84 sensors developed using 
a SPASM (systematic protein affinity strength modulation) based approach 
(Sivaramakrishnan and Spudich, 2011). Firstly, FLAG-hGPR84-SPASM mCitrine-
Gαi1/2 and FLAG-hGPR84-SPASM mCitrine-NP BRET sensor constructs were 
generated to assess whether this approach could be suitable to explore GPCR-G 
protein interaction for GPR84. In this construct, FLAG-tagged human GPR84 was 
fused at the C-terminus to a peptide encoding the last 27 amino acids of the α5-
helix of Gαi1/2 which was separated by a SPASM sensor (Figure 3.1). The SPASM 
sensor is composed of a yellow fluorescent protein, mCitrine, acting as BRET 
acceptor and a Nano Luciferase (NanoLuc) acting as a BRET donor linked by a 
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flexible sequence. This  ER/K α-helix represents a peptide motif encoding a 
repeated sequence of four glutamic acid (E) residues followed by four residues 
of either arginine (R) or lysine (K) (Sivaramakrishnan and Spudich, 2011). Each 
component of the sensor was separated by a linker composed of the (Gly-Ser-
Gly)4 sequence ensuring the flexibility of the fusion protein. The FLAG-hGPR84-
SPASM mCitrine-NP sensor was generated using the same molecular cloning 
scheme with the only difference being that NP sensor did not contain the C-
terminus G protein peptide after Nano Luc, rather it contained the (Gly-Ser-Gly)4 
linker. Both the GPR84 SPASM sensors were then subcloned into the multiple 
cloning sites of pcDNA5/FRT/TO plasmid and doxycycline-inducible Flp-In T-REx-
293 cell lines expressing FLAG-hGPR84-SPASM-Gαi1/2 or FLAG-hGPR84-SPASM-NP 
constructs were generated.  
 
Figure 3.1 Schematic diagram of a BRET-based SPASM sensor for GPR84  
 
3.2. Results 
3.2.1. Characterization of cell lines expressing GPR84 SPASM 
sensors 
The expression of the GPR84 SPASM sensor constructs was investigated by 
western blot analysis using an anti-GFP antiserum which is able to identify the 
mCitrine component of the expressed sensor. A distinct band of some 104 kDa in 
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the immunoblot of membranes generated from doxycycline (100 ng/ml for 24 
hours) induced Flp-In T-REx-293 cells confirmed the expression of either FLAG-
hGPR84-SPASM-Gαi1/2 or FLAG-hGPR84-SPASM-NP sensor constructs as intact 
polypeptides in the corresponding stable cell lines (Figure 3.2). No expression of 
SPASM sensor constructs was detected in membranes generated from untreated 
cells. Two bands of greater than 225 kDa size detected in both the membrane 
preparations obtained from doxycycline-treated cells might reflect oligomers or 
aggregates of the receptor constructs in the membrane. The pre-treatment of 
the membrane preparations with the N-glycosidase enzyme, PNGase F (0.05 
unit/µl sample) slightly enhanced the migration of the receptor construct in SDS-
PAGE, indicating that GPR84 contains some N-linked oligosaccharides. 
 
 
Figure 3.2 Doxycycline-induced expression of FLAG-hGPR84-SPASM-Gαi1/2 and FLAG-
hGPR84-SPASM-NP biosensors in Flp-In T-REx-293 stable cells. Membranes were prepared 
from treated (100 ng/ml of doxycycline; +dox; duration: 24 hours) or untreated (-dox) Flp-In T-REx-
293 cell lines harbouring FLAG-hGPR84-SPASM-Gαi1/2 or FLAG-hGPR84-SPASM-NP sensor 
constructs. These membranes were then either untreated (-PNGase F) or treated with the N-
glycosidase enzyme, PNGase F (+). Samples containing 5 µg membrane protein were then 
resolved by SDS-PAGE and immunoblotted with a goat polyclonal anti-GFP antiserum.  
3.2.2. Validation of GPR84 SPASM sensors 
To validate SPASM sensor responses, bioluminescence resonance energy transfer 
(BRET) assays were performed using established GPR84 agonists. In the absence 
of agonist, it might be expected that there would be no interaction between 
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GPR84 and G peptide, leading to very low/no BRET signal because the BRET 
donor and BRET acceptor are separated by the ER/K linker. Agonist treatment of 
the cells expressing the SPASM sensor is expected to result in enhanced BRET 
due to the interaction between GPR84 and the C terminus G peptide which 
brings the BRET donor and acceptor into closer proximity (Figure 3.1). 
Compound-1 treatment concentration-dependently induced BRET gain for the 
hGPR84-SPASM-Gαi1/2 sensor with pEC50 of 6.84± 0.03 (Figure 3.3) and ΔBRET of 
0.16±0.003 was obtained with 3 µM compound-1 treatment, which was 
significantly higher (P value <0.001) than that obtained at the NP sensor (ΔBRET: 
0.005±0.001). Similarly, compound-51 stimulation also resulted in increased 
BRET in a concentration-dependent manner for the hGPR84-SPASM-Gαi1/2 sensor 
but not for the hGPR84-SPASM-NP sensor. 100 nM of compound-51 generated a 
ΔBRET ratio of 0.21±0.004 for the hGPR84-SPASM-Gi1/2 sensor which was 
significantly higher than that obtained at the NP sensor (ΔBRET: 0.009±0.002). 
These results confirmed the functional integrity of the hGPR84-SPASM-Gαi1/2 
sensor.  
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Figure 3.3 A FLAG-hGPR84-SPASM-Gαi1/2 sensor is functional when expressed in a Flp-In T-
REx-293 stable cell line. Flp-In T-REx-293 cells were induced with doxycycline (100 ng/ml) for 24 
hours to express either FLAG-hGPR84-SPASM-Gαi1/2 or FLAG-hGPR84-SPASM-NP sensor and 
BRET was measured after addition of various concentrations of compound-1 (a) or compound-51 
(b). No significant difference in the expression level of the hGPR84-SPASM-Gi1/2 sensor and 
hGPR84-SPASM-NP sensor constructs was observed by measuring the fluorescence intensity of 
mCitrine following doxycycline treatment (c).  
3.2.3. DIM and embelin act as partial agonists and compound-1 
and compound-51 act as super-agonists at the hGPR84-
SPASM-Gαi1/2 sensor 
Decanoic acid(C-10), DIM, embelin, compound-1 and compound-51 each 
enhanced BRET  in a concentration-dependent fashion with pEC50 of 4.78±0.03, 
6.00±0.01, 6.28±0.06, 6.90±0.07 and 8.40±0.04, respectively which implies that 
agonist stimulation promoted the interaction between activated GPR84 and the 
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C-terminal Gαi1/2 peptide (Figure 3.4 and Table 3.1 ). Although potencies of DIM 
and embelin were significantly (P<0.001) higher compared to that of decanoic 
acid, both agonists showed significantly reduced efficacy (44% and 37%, 
compared to C-10) compared to decanoic acid, indicating that DIM and embelin 
acted as partial agonists in this assay. Compound-1, a synthetic agonist of GPR84 
exhibited 132-fold higher potency and 6.6-fold higher efficacy compared to the 
presumed endogenous agonist decanoic acid. Compound-51 was the most potent 
synthetic agonist and showed 8.5-fold higher efficacy than decanoic acid (Figure 
3.4). If the endogenous agonist decanoic acid is considered as a full agonist, 
then compound-1 and its analogue compound-51 behaved as super-agonists of 
GPR84 in this SPASM sensor-based assay. The rank order of intrinsic activity of 
the agonists at the hGPR84-SPASM-Gαi1/2 sensor was as follows: Embelin<DIM<C-
10<Compound-1<Compound-51.  
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Figure 3.4 DIM and embelin act as partial agonists and compound-1 and compound-51 act 
as super-agonists at the FLAG-hGPR84-SPASM-Gαi1/2 sensor.Flp-In T-REx-293 stable cell lines 
harbouring FLAG-hGPR84-SPASM-Gαi1/2 were treated with doxycycline (100 ng/ml) for 24 hours to 
induce the expression of the construct. BRET signals were then measured following treatment of 
the cells for five minutes with various concentrations of C-10 (a), DIM (b), embelin (c), compound-1 
(d) or compound-51 (e).    
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Table 3-1 Potency and relative efficacy of different GPR84 agonists at the FLAG-hGPR84-
SPASM-Gαi1/2 sensor 
Ligand pEC50, Mean±SEM 
(Efficacy, Emax)a 
C-10 4.78±0.03 
(100) 
DIM 6.0±0.01*** 
(44) 
Embelin 6.28±0.06*** 
(37) 
Compound-1 6.9±0.07*** 
(664) 
Compound-51 8.4±0.04*** 
(857) 
Potency and efficacy of different GPR84 agonists were measured in BRET assays using FLAG-
hGPR84-SPASM-Gαi1/2 biosensor as described in Figure 3.4.  
 
a
Emax values were normalized to C-10 response; Statistical analysis was performed by one-way 
analysis of variance (ANOVA) followed by Dunnett’s multiple comparison tests using potency value 
of C-10 as the reference. Statistical significance is denoted by *P<0.05, **P<0.01, ***P<0.001. 
 
3.2.4. GPR84 signals through Gαi/o pathway  
To explore the G protein selectivity of GPR84, a series of BRET-based SPASM 
sensor constructs, FLAG-hGPR84-SpNG-Gαx (where x= i1/2, i3, o, z, s, q, 12, 13, 
14, 16 and SpNG stands for SPASM NeonGreen) was generated wherein a peptide 
composed of the last 27 amino acids of the C-terminus of different G proteins 
was fused to the C-terminal tail of FLAG-tagged human GPR84 which is linked by 
a SPASM sensor composed of mNeonGreen (BRET acceptor) and Nano Luciferase 
enzyme (BRET donor) separated by ER/K α-helix. Though previously mCitrine was 
used as the BRET acceptor, for this generation of SPASM sensors, mNeonGreen 
was chosen as it was reported to be the brightest monomeric green or yellow 
fluorescent protein available (Shaner et al., 2013). Using these GPR84 SPASM 
sensor constructs, BRET assays were performed to explore the molecular 
coupling of the receptor. As measured by the fluorescence intensity of 
mNeonGreen, all the SPASM sensor constructs displayed similar expression levels 
in transiently transfected HEK-293 cells (Figure 3.5 b). Compound-1 
concentration-dependently enhanced BRET with pEC50 of 6.40±0.04, 6.64±0.08, 
6.10±0.20 and 5.65±0.05 for hGPR84-SpNG-Gαi1/2, hGPR84-SpNG-Gαi3, hGPR84-
SpNG-Go and hGPR84-SpNG-Gz sensors, respectively (Figure 3.5 a) demonstrating 
that agonist-stimulated GPR84 can interact with the C-terminus peptide of many 
Gαi/o family G-proteins. No BRET signal was obtained for SPASM sensors 
containing the C-terminal peptide of Gq, Gs, G12, G13, G14 and G16. These results 
indicated that GPR84 activation is coupled selectively to Gαi/o pathways which is 
in agreement with results previously reported by Wang et al., (2006b). 
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Importantly, no BRET signal was detected following the addition of compound-1 
to cells expressing a hGPR84-SpNG-NP sensor which lacked the C-terminal 
peptide sequence, indicating the crucial role of the C-terminus peptide in 
GPR84-G protein interaction. Similarly, TUG-1765 also promoted a 
concentration-dependent increase in BRET signal for hGPR84-SpNG-Gαi1/2, 
hGPR84-SpNG-Gαi3, hGPR84-SpNG-Go and hGPR84-SpNG-Gz sensors affording 
pEC50 of 8.13±0.1, 8.5±0.09, 8.2±0.4 and 8.1±0.2, respectively, whilst addition of 
varying concentrations of TUG-1765 to cells expressing sensors containing Gq, 
Gs, G12, G13, G14 or G16 C-terminal peptides did not produce any BRET signal 
(Figure 3.6). These data demonstrated that TUG-1765-occupied GPR84 can signal 
through Gαi/o pathways and did not couple to Gq, Gs, G12, G13, G14 and G16 G-
proteins.   
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Figure 3.5 Compound-1-occupied GPR84 adopts Gαi/o-coupled active conformations in HEK-
293 cells. HEK-293 cells were transiently transfected with either FLAG-hGPR84-SpNG-Gα (x) 
sensors (where X= i1/2, i3, o, z, s, q,12,13,14 and 16) or a FLAG-hGPR84-SpNG-NP sensor 
construct and BRET signals were monitored following treatment of the cells for 5 minutes with 
varying concentrations of compound-1 (a). The relative expression levels of the SPASM sensor 
constructs was measured by the fluorescence intensity of mNeonGreen following transient 
transfection of the sensor constructs into HEK-293 cells (b).  
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Figure 3.6 TUG-1765 stabilizes Gαi/0-coupled active conformations of GPR84 in HEK 293 
cells. BRET assays were performed using HEK-293 cells transiently transfected with either FLAG-
hGPR84-SpNG-Gα(x) sensors (where X= i1/2, i3, o, z, s, q, 12, 13, 14 and 16) or a FLAG-
hGPR84-SpNG-NP sensor construct. Changes in BRET following treatment of different GPR84-
SPASM sensors with varying concentrations of TUG-1765 are shown in (a) and the relative 
expression levels of the sensors measured by the fluorescence intensity of mNeonGreen following 
transient transfection of the SPASM sensors into HEK-293 cells are shown in (b). All the GPR84-G 
peptide SPASM sensor constructs were effectively expressed in HEK-293 cells, with only the G14 
sensor being markedly higher than others.   
3.2.5. The coupling efficiency of interaction between human 
GPR84 and individual Gαi/o G proteins 
In the case of compound-1 mediated GPR84-G protein interactions assessed by 
BRET using FLAG-hGPR84-SpNG-G peptide sensors, although similar potency 
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values were obtained for hGPR84-SpNG-Gαi1/2, hGPR84-SpNG-Gαi3 and hGPR84-
SpNG-Go sensors (Figure 3.7a and Table 3.2), the potency of compound-1 was 
decreased significantly (P<0.01) by 5.6-fold at the hGPR84-SpNG-Gz sensor 
(pEC50: 5.65±0.05) compared to that displayed at the hGPR84-SpNG-Gαi1/2 sensor 
(pEC50: 6.40±0.04). The highest maximal BRET increase was obtained for the 
hGPR84-SpNG-Gαi3 sensor (50% higher response than the hGPR84-SpNG-Gαi1/2 
sensor, P<0.001) while hGPR84-SpNG-Go and hGPR84-SpNG-Gz sensors displayed 
significantly (P<0.001) lowered maximal response  with 40% and 56% reduction in 
Emax values, respectively compared to that for Gαi1/2 sensor (Figure 3.7a and 
Table 3.2). These results suggested that compound-1 stimulation preferentially 
stabilized GPR84 active conformations that interacted with Gαi3 and Gαi1/2. The 
rank order of coupling efficiency of compound-1-stimulated interaction between 
GPR84 and individual Gαi/o protein was as follows: Gαi3> Gαi1/2> Go>Gz.    
 
Contrary to the results obtained with compound-1, TUG-1765-occupied GPR84 
coupled equally well to Gαi1/2 and Gαi3 which was evident from the fact that the 
FLAG-hGPR84-SpNG-Gαi3 sensor displayed similar potency and efficacy to that 
exhibited by the FLAG-hGPR84-SpNG-Gαi1/2 sensor (Figure 3.7b and Table 3.2). 
The efficacy of TUG-1765 was decreased drastically at both FLAG-hGPR84-SpNG-
Go and FLAG-hGPR84-SpNG-Gz sensors with 85% and 63% reduction in Emax 
values, respectively compared to that of Gαi1/2 sensor suggesting reduced 
coupling efficiency of interaction between GPR84 and Go/Gz G-peptides. The 
rank order of the relative efficiency of interaction between TUG-1765 stimulated 
GPR84 and different G protein subunits are as follows: Gαi1/2=Gαi3> Gz>Go.  
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Figure 3.7 The relative coupling efficiency of interaction between human GPR84 and 
individual Gαi/o G proteins. HEK-293 cells were transiently transfected with either FLAG-hGPR84-
SpNG-Gαi1/2, FLAG-hGPR84-SpNG-Gαi3, FLAG-hGPR84-SpNG-Go, FLAG-hGPR84-SpNG-Gz or 
FLAG-hGPR84-SpNG-NP sensors and BRET was measured following treatment of these cells for 
five minutes with various concentrations of either compound-1 (a) or TUG-1765(b). Concentration-
response curves are shown for C-10 (c) or 6-OAU (d) in the BRET assay performed using HEK-
293 cells transiently transfected with either FLAG-hGPR84-SpNG-Gαi1/2 or FLAG-hGPR84-SpNG-
NP sensors. 
Table 3-2 Potency and relative efficacy of compound-1 and TUG-1765 at different FLAG-
hGPR84-SpNG-Gα sensors 
Ligand SpNG-Gαi1/2 SpNG-Gαi3 SpNG-G0 SpNG-Gz 
Compound-1 6.4±0.04 
(100) 
6.64±0.08 
(149%)*** 
6.1±0.2 
(60%)* 
5.65±0.05** 
(44%)*** 
TUG-1765 8.13±0.1 
(100) 
8.5±0.09 
(95.4) 
8.2±0.4 
(15)** 
8.1±0.2 
(37)** 
Potency values of compound-1 and TUG-1765 measured in BRET assays (as described in Figure 
3.7) employing different Gαi/o SPASM sensors  are represented as mean±S.E.M. Emax values 
were normalized to percent of response displayed at the Gαi1/2 sensor and are shown in 
parentheses. One-way analysis of variance (ANOVA) followed by Dunnett's multiple comparison 
tests was performed to evaluate significance between potency and efficacy of compound-1 or 
TUG-1765 displayed at the Gαi1/2 sensor and other Gαi/o biosensors with *P<0.05, **P<0.01, 
***P<0.001.   
3.2.6. 6-OAU, compound-1 and TUG-1765 displayed greater 
maximal response than decanoic acid at the hGPR84-
SpNG-Gαi1/2 sensor 
Concentration-response studies for decanoic acid and 6-OAU were performed in 
the BRET assay using the FLAG-hGPR84-SpNG-Gαi1/2 sensor to compare their 
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relative efficacy. Both decanoic acid and 6-OAU generated concentration-
dependent elevation of BRET signals with pEC50 of 4.37±0.14 and 6.30±0.13, 
respectively (Figure 3.7 c-d). The estimated potency (EC50: 500 nM) of 6-OAU in 
this assay is fully consistent with those obtained in either [35S]-GTPγS binding 
assay (EC50: 512 nM) or the cAMP accumulation assay (EC50: 438 nM) as reported 
by Suzuki et al., (2013) and Liu et al., (2016), respectively. 6-OAU displayed 
greater maximal response than decanoic acid (Figure 3.7) which is in agreement 
with the finding observed in the β-arrestin recruitment assay (Pillaiyar et al., 
2018) but not with that obtained in the cAMP assay where C-10 and 6-OAU 
showed similar efficacy (Pillaiyar et al., 2018). Similarly, compound-1 and its 
analogue TUG-1765 showed significantly higher maximal effects than decanoic 
acid in this SPASM sensor-based BRET assay (Figure 3.7).  
3.3.  Discussion 
3.3.1. BRET based SPASM biosensors can be employed 
effectively for the study of GPR84-G protein interactions  
The GPCR-G protein fusion protein approach has been employed for the study of 
GPCR-G protein interactions for the last 25 years (Bertin et al., 1994; Seifert et 
al., 1999; Milligan, 2000). Compared to co-expression of GPCR and G protein as 
separate signalling moieties, GPCR-G protein fusion proteins offer some benefits. 
The rate and extent of coupling between GPCR and G protein depend on the 
relative concentration of these two proteins and on the physical closeness of the 
G protein to the plasma membrane (Seifert et al., 1999; Milligan, 2002). As 
expression levels of different endogenous G proteins in particular cells/tissues 
are different, it is difficult to define G-protein selectivity of a receptor of 
interest by co-expressing GPCR and G protein as separate polypeptides because 
the relative density of GPCR and individual G proteins may not be the same. So, 
the co-expressed system is limited for comparing the relative efficiency of 
interaction between a GPCR of interest and individual G proteins. To overcome 
this limitation, the fusion protein approach wherein the N terminus of a G 
protein α-subunit is fused to the C terminus of the receptor, was developed and 
employed successfully in the investigation of GPCR-G protein coupling. Fusion 
proteins ensure 1:1 stoichiometry between GPCR and G protein which makes it a 
suitable approach for comparing G-protein selectivity of a particular receptor 
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(Seifert et al., 1999; Wise et al., 1999; Milligan, 2002; Malik et al., 2017). 
Besides this, the 1:1 stoichiometry and close physical proximity of both proteins 
will result in enhanced coupling efficiency between them (Seifert et al., 1999). 
However, in such fusion proteins, GPCR and fused G protein are constrained 
which may decrease their rotational freedom. Recently GPCR-G protein SPASM 
sensors have been developed by Malik et al., (2013). These incorporate aspects 
of the fusion protein approach. Here GPCR and G protein/G peptide are 
separated by an ER/K α-helical linker ensuring the flexibility of each peptide 
moiety in the biosensors (Sivaramakrishnan and Spudich, 2011; Malik et al., 
2017). Based on this, FRET-based SPASM biosensors for a series of Class A GPCRs 
have been generated to study ligand-mediated GPCR-G protein coupling (Malik 
et al., 2013; Semack et al., 2016; Malik et al., 2017). For example, a FRET-based 
β2-AR-SPASM-Gα peptide fusion protein was reported by Malik et al., (2013) to 
be a suitable strategy to detect ligand-activated G-protein selective active 
conformations of the β2-adrenergic receptor in live cells. Applying these SPASM 
sensors, they found that classical agonist isoproterenol stabilized a Gs-coupled 
active conformation of the β2 adrenergic receptor in HEK-293 cells whilst the 
inverse agonist metoprolol stabilized a Gi-coupled conformation of this receptor. 
Similarly, by employing the GPCR-G peptide SPASM sensor technique, Semack et 
al., (2016) found that the Gα C terminus peptide is sufficient to detect G protein 
selectivity of six class A GPCRs, the β3-adrenergic receptor, dopamine receptor 
D1, α2-adrenergic receptor, cannabinoid receptor type 1 (CB1), α1-adrenergic 
receptor and vasopressin 1A receptor (V1A R). Using this SPASM-based approach, 
together with molecular dynamics (MD) simulations, they also explored the 
molecular determinants of the C-terminal peptide of Gs and Gq subunits which 
defined the structural basis of G-protein selection bias for the β2-adrenergic 
receptor and V1AR. Mackenzie et al., (2019) recently reported that BRET-based 
GPR35-G peptide SPASM sensors could be an appropriate system for defining the 
pharmacology of GPR35 ligands. Using these novel biosensors they explored the 
molecular basis for the G-protein selectivity of GPR35 and identified that a 
single amino acid residue (Leucine G.H5.23) located within the α-5 helix of Gα13 
defined the marked Gα13 selectivity over Gα12.  
Compared to currently available FRET or BRET assays wherein fluorescent 
protein-tagged GPCR and G protein are co-expressed into cells, FRET/BRET-
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based SPASM biosensors also offer similar benefits as that of GPCR-G protein 
fusion proteins as discussed above which makes it a novel and suitable strategy 
for the study of GPCR-G protein interactions. In order to investigate the G 
protein specificity of GPR84, I have employed BRET-based GPR84-G peptide 
SPASM biosensors where a peptide comprising the last 27 amino acids of the C 
terminus of the G protein is fused to GPR84 and both the peptides are separated 
by ER/K linker and BRET probes. The rationale for choosing this length of the C-
terminus peptide was to maintain the helical structure of the α5 helix of the Gα 
protein (Malik et al., 2013). It was reported previously that the C-terminus of 
the Gα protein is mainly responsible for binding to the agonist-stimulated active 
G-protein-coupled receptor (Conklin et al., 1996; Oldham and Hamm, 2008, 
Semack et al., 2016; Mackenzie et al., 2019).  Indeed, here also the Gα peptide 
comprising the last 27 amino acids was found to be sufficient to interact with 
GPR84, which was evident from the fact that the addition of various 
concentrations of GPR84 agonists to the cells expressing GPR84-SPASM sensors 
that contain either Gαi1/2, Gαi3, Gαo or Gz G-peptides resulted in enhanced BRET 
signals, whereas no significant BRET signal was generated by a sensor lacking the 
C-terminal peptide sequence. Although it was reported that GPR84 couples to 
Gαi/o family G-proteins, (Wang et al., 2006b; Gaidarov et al., 2018) details of G 
protein specificity within the family were lacking. For example, agonist-
mediated preferential coupling to individual Gαi/o proteins was not studied 
extensively. Moreover, both Wang et al., (2006b) and Gaidarov et al., (2018) 
investigated GPR84-G protein coupling properties by co-expression of chimeric G 
proteins and GPR84 into recombinant cells which, as discussed earlier is not 
suitable for defining preferential G protein coupling due to the differential 
expression profile of individual G proteins in cells/tissues. Consistent with 
previous findings, here I have found that compound-1 and TUG-1765 stimulated 
GPR84 coupling to Gαi/o family G proteins. Compound-1-occupied GPR84 was 
found to adopt an active conformation in HEK293 cells which preferentially 
recruited Gαi3 and Gαi1/2 over Gαo and Gαz G proteins. Though the potency of 
compound-1 was similar for the activation of Gαi1/2 and Gαi3 G-peptides, the 
maximal response for the recruitment of Gαi3 was found to be increased by 1.5-
fold compared to Gαi1/2. On the other hand, TUG-1765-occupied GPR84 coupled 
equally well to Gαi1/2 and Gαi3 as both the measured potency and efficacy of 
TUG-1765 was very similar for the activation of Gαi1/2 and Gαi3. Moreover, 
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maximal responses for the activation of both Gαo and Gαz protein were much 
lower following treatment with both compound-1 and TUG-1765. These 
variations in efficacy of agonists for activation of different Gα subunits were not 
a reflection of differential expression levels of the GPR84-SPASM sensors as all 
the sensors showed very similar expression levels in HEK-293 cells. Moreover, the 
assay employed herein relied on the measurement of ratiometric BRET signals 
which is independent of the expression level of the receptor construct 
(Mackenzie et al., 2019). 
Though Gaidarov et al., (2018) reported that embelin-mediated GPR84 
activation was transduced via Gαi/o and Gα13/Gα12  G proteins in HEK-293 cells, 
no interaction between GPR84 and Gα12/Gα13 G proteins was observed following 
activation by compound-1 or TUG-1765 in the SPASM sensor-based BRET assays. 
This might be due to the agonist-specific biased signalling. To confirm whether 
GPR84 also couples to the Gα12/Gα13-signalling pathway, further investigation 
using other agonists of GPR84 is required. Though Zhang et al., (2016) reported 
that agonist-occupied GPR84 interacted with Gα16 G-protein, no interaction 
between GPR84 and Gα16 G-peptide was found in BRET assays using hGPR84-
SPASM-Gα16 biosensor. This might be due to the full length of the G protein 
rather than the last 27 aa of the C-terminus peptide is essential for Gα16 
coupling.  
BRET-based GPR84-G-peptide SPASM sensors could be employed effectively for 
exploring the pharmacology of GPR84 ligands as the potency values of different 
GPR84 agonists estimated by this system are consistent with the values reported 
by other groups. For example, measured potencies of decanoic acid, DIM, 
embelin and 6-OAU were very similar to those reported in the published 
literature (Suzuki et al., 2013; Zhang et al., 2016; Liu et al., 2016; Mahmud et 
al., 2017). The potency (EC50:125 nM at the hGPR84-SPASM-Gαi1/2) of compound-
1 estimated in this assay was similar to that observed in calcium mobilization 
assays (EC50: 213 nM or 139 nM) and cAMP assays (EC50:134 nM or 144 nM) 
reported by Zhang et al., (2016) and Liu et al., (2016) but was about 125 times 
lower than that (EC50: 1 nM both in cAMP assays and [
35S]-GTPγS binding assays) 
reported by Mahmud et al., (2017). Similarly, the potency of compound-51 (EC50: 
4.0 nM) provided by the hGPR84-SPASM-Gαi1/2 sensor was some 11-fold and 21-
fold lower than that observed in cAMP assays (EC50: 0.35 nM) and calcium 
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mobilization assays (EC50: 0.19 nM), respectively (Liu et al., 2016). The 
substantially lower potency of compound-51 observed in the SPASM sensor-based 
BRET assay might be due to the fact that less receptor reserve is obtained for G-
protein activation compared to that generated in downstream signalling events 
like adenylyl cyclase inhibition or IP3-sensitive Ca
2+ channel opening.  
3.3.2. BRET based GPR84 SPASM sensor is an effective 
strategy to investigate the relative intrinsic activity of 
GPR84 agonists    
Investigation of the relative intrinsic activity of ligands of a particular GPCR is 
limited by the fact that the relative efficacy depends on the expression profile 
of that GPCR in a specific cellular system which may lead to differential relative 
densities of GPCR, G protein and effector protein (Milligan, 2000). As the GPCR-
G protein fusion approach ensures the 1:1 stoichiometry between GPCR and 
tethered G protein (Seifert et al., 1999; Milligan, 2002), use of this fusion 
protein could be an effective strategy for the study of relative efficacies of 
agonists of the GPCR of interest. Moreover, the BRET-based SPASM biosensor is 
employed to measure GPCR-G protein interaction which is not/less subject to 
signalling amplifications and other modulatory effects such as signal 
convergence/divergence and feedback from other signalling pathways. So, 
compared to the assays that measure efficacy at downstream signalling events, 
BRET-based SPASM sensor approaches may be more appropriate for comparing 
relative efficacies of ligands of a GPCR. In the case of GPR84, though 6-OAU and 
decanoic acid exhibited similar efficacy in the cAMP assay (Pillaiyar et al., 
2018), 6-OAU was found to display higher maximal response than decanoic acid 
in the SPASM sensor-based BRET assay. In the BRET assay employing the hGPR84-
SPASM-Gαi1/2 sensor, DIM and embelin were found to generate sub-maximal 
responses i.e they behaved as partial agonists compared to decanoic acid while 
Pillaiyar et al., (2018) reported that embelin and decanoic acid displayed similar 
efficacy in cAMP assays as well as in β-arrestin recruitment assays. Another 
important outcome was that compound-1 and its analogue TUG-1765 were found 
to activate GPR84 with markedly higher efficacy compared to the putative 
endogenous agonist, decanoic acid demonstrating that they functioned as super-
agonists in this system. Super-agonists could be potential candidates for the 
development of therapeutics. For example, MK-667, a growth hormone 
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secretagogue was reported to be a super-agonist at the ghrelin receptor and is 
considered to be a potential drug for growth hormone deficiency disorders 
(Smith et al., 2011a). Recently Gaidarov et al., (2018) have explored the anti-
atherosclerotic property of GPR84 in macrophages which might be exploited for 
the development of agonist drugs to treat atherosclerosis. In this regard, super-
agonists, compound-1 and its derivatives could be considered as potential 
therapeutic candidates. 
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4 Investigation of modes of binding of ligands to 
human GPR84 
4.1. Introduction 
Investigation of GPCR-ligand interaction is important for structure-based drug 
design (SBDD) programmes as well as for the development of pharmacological 
tool compounds which can be utilized for the physiological characterization of 
the receptor. In the case of GPR84, although some potent and selective agonists 
such as 6-n-octylaminouracil (6-OAU), 2-hexylthiopyrimidine-4, 6-diol 
(compound-1), 6-nonylpyridine-2, 4-diol (compound-51) have been developed, 
their modes of binding to GPR84 are still unknown. Even very little is known 
regarding the binding mode of the putative endogenous agonists, medium chain 
fatty acids (MCFAs). Only one study has been performed (Nikaido et al., 2015) in 
an effort to identify the molecular determinants of GPR84-decanoic acid 
interactions. As GPR84 still remains a very poorly characterized receptor, 
pharmacological tool compounds need to be generated for the elucidation of 
biological functions of this receptor. Besides this, though GPR84 has been 
considered to be a potential drug target, drug development programmes are 
hindered by the paucity of structural information on this receptor. In this 
regard, investigation of ligand binding modes to GPR84 is essential as it will aid 
the lead optimization process and thereby will accelerate drug development. 
Although the crystal structure of a GPCR complexed with the specific ligand is 
required for the elucidation of molecular determinants of ligand binding, 
computational techniques such as homology modelling can predict the 
theoretical structure of the GPCR of interest in the absence of high-resolution 
atomic level structure (Costanzi, 2013; Tikhonova, 2017). This predicted model 
structure could be then assessed by mutagenesis studies in which effects of 
mutation of specific amino acid residues on the potency and efficacy of the 
ligands are investigated. Based on input from mutagenesis studies, the docking 
of the ligands into the constructed homology model can be performed to predict 
the binding poses of the ligands which might be useful for defining the druggable 
pharmacophore sites within the receptor. As no atomic level high-resolution 
structure of GPR84 is available, we have tried to define the ligand binding 
pocket(s) of GPR84 by a combination of site-directed mutagenesis and molecular 
modelling. For the mutational analysis, I have employed the GPR84-Gα fusion 
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protein approach. At the beginning of this chapter the characterization of Flp-
InTM T-RExTM- 293 cell lines expressing human GPR84-Gαi2 fusion proteins will be 
discussed followed by the detailed description of molecular homology modelling 
and mutagenesis studies.  
4.2. Characterization of Flp-InTM T-RExTM- 293 cell lines 
expressing hGPR84-Gαi2 fusion proteins 
The GPCR-G protein fusion protein approach is appreciated to be a suitable 
strategy for the characterization of pharmacological tool compounds of specific 
GPCRs as it was found to significantly enhance the coupling efficiency between 
the receptor and Gα protein subunit compared to co-expressing both 
polypeptides as separate entities (Milligan, 2000; Milligan, 2003; Suga and Haga, 
2007). As agonist-stimulated human GPR84 was found to preferentially couple to 
Gαi1/2 and Gαi3 over Gαo and Gαz G-proteins in BRET assays employing GPR84-
SPASM sensors ( see section 3.2.5) and as Gαi2 and Gαi3 are widely expressed 
while Gαi1 shows a restricted expression pattern (Milligan and Kostenis, 2006), I 
generated FLAG-hGPR84-Gαi2 and FLAG-hGPR84-Gαi3 fusion protein constructs 
wherein the N-terminus of the wild type Gα protein subunit is coupled in frame 
to the C-terminal tail of human GPR84 and a FLAG epitope was added to the N-
terminus of GPR84. Two PTX-resistant mutant versions of Gαi2, C352G Gαi2 and 
C352I Gαi2 were also fused to the FLAG-tagged human GPR84, generating FLAG-
hGPR84-Gαi2 C352G and FLAG-hGPR84-Gαi2 C352I receptor constructs. PTX-
resistant fusion constructs were generated because the coupling to endogenous 
Gαi proteins could be blocked by the PTX treatment of cells expressing these 
constructs so that the signalling response obtained would be exclusively due to 
intra-molecular interactions between the exogenous GPR84 and fused G protein. 
All these fusion protein constructs were then stably expressed in Flp-InTM T-
RExTM-293 cells at the Flp InTM locus.   
4.2.1. Characterization of expression of hGPR84-G protein 
fusion constructs by Western blot analysis  
The expression of FLAG-hGPR84-Gαi2, FLAG-hGPR84-Gαi2 C352G and FLAG-
hGPR84-Gαi2 C352I receptor constructs was characterized by immunoblotting 
membranes prepared from Flp-InTM T-RExTM-293 cells induced with doxycycline 
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(100 ng/ml, 24 hours) to express the receptor of interest (Figure 4.1). 
Monoclonal anti-FLAG M2 antibody was used for immunoblotting the membranes 
to detect the FLAG sequence which was added to the N-terminus of the 
receptor. A distinct band of about 84 kDa was detected in the immunoblot of 
membranes purified from doxycycline-treated cells which confirmed the 
expression of either FLAG-hGPR84-Gαi2, FLAG-hGPR84-Gαi2 C352G or FLAG-
hGPR84-Gαi2 C352I receptor construct as intact polypeptides in the 
corresponding stable cell lines (Figure 4.1). No expression of fusion protein 
constructs was detected in membranes prepared from untreated cells. Another 
band of about 100 kDa detected in the immunoblot of membranes purified from 
stable cell lines expressing FLAG-hGPR84-Gαi2 C352G and FLAG-hGPR84-Gαi2 
C352I fusion proteins might reflect N-glycosylated versions of the receptor 
construct. 
 
Figure 4.1 Immunoblot of FLAG-hGPR84-Gαi2WT, FLAG-hGPR84-Gαi2 C352I and FLAG-
hGPR84-Gαi2 C352G fusion protein constructs probed with anti-FLAG antibody. Membranes 
were generated from Flp-In
TM
 T-REx
TM
-293 stable cell lines either untreated (-dox) or treated 
(+dox) with 100 ng/ml doxycycline for 24 hours to express either FLAG-hGPR84-Gαi2, FLAG-
hGPR84-Gαi2 C352G or FLAG-hGPR84-Gαi2 C352I. Samples containing 10 µg of membrane 
protein were resolved by SDS-PAGE followed by immunoblotting with monoclonal M2 anti-FLAG 
antibody.  
4.2.2. Saturation binding study  
The expression level of FLAG-hGPR84-Gαi2 and FLAG-hGPR84-Gαi2 C352I in the 
corresponding  Flp-InTM T-RExTM-293 stable cell lines was measured using 
saturation binding assays using a radiolabelled antagonist of GPR84, [3H]-G9543 
which is an analogue of GPR84 antagonist compound-104, 107 and 161. [3H]-
G9543 was found to bind to membranes expressing FLAG-hGPR84-Gαi2 fusion 
construct with high avidity (Kd: 0.3±0.01 nM; n=3) (Figure 4.2aii and Table 4.1). 
Mutation at the Cysteine 352 position of the Gαi2 to isoleucine did not alter the 
binding affinity of the radiolabelled antagonist to the receptor as similar Kd 
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value (0.25±0.02 nM; n=7) was obtained when membranes expressing FLAG-
hGPR84-Gαi2 C352I fusion protein was used in the binding study (Figure 4.2bii and 
Table 4.1). The analysis of saturation binding data also revealed that both FLAG-
hGPR84-Gαi2 and FLAG-hGPR84-Gαi2C352I receptor constructs were expressed 
effectively in the stable cell lines and their expression levels were comparable, 
which is evident from the similar Bmax values ( 6251±954 and 6538±267 fmol.mg 
protein-1, respectively). 
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Figure 4.2 The radioligand [
3
H]-G9543 displayed similar binding properties at FLAG-
hGPR84-Gαi2 and FLAG-hGPR84-Gαi2 C352I receptor constructs. Membranes were prepared 
from Flp-InTM T-RExTM-293 cells induced with 100 ng/ml doxycycline for 24 hours to express 
either FLAG-hGPR84-Gαi2 or FLAG-hGPR84-Gαi2 C352I. The capacity of various concentrations of 
[
3
H]-G9543 to bind to membrane preparations expressing either FLAG-hGPR84-Gαi2 (ai, aii) or 
FLAG-hGPR84-Gαi2 C352I (bi, bii) was assessed with (nonspecific binding) or without (total 
binding) 1 µM antagonist compound-104. Specific binding of the radioligand to the receptor was 
estimated by subtracting nonspecific binding from total binding. Data represented in (ai and aii) and 
(bi and bii) are from a representative experiment of three or seven independent experiments, 
respectively performed on separate membrane preparations.   
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4.2.3. Functional characterization of Flp-InTM T-RExTM- HEK 293 
cell lines expressing FLAG-hGPR84-Gαi2 fusion proteins 
To check the functional integrity of GPR84-G protein fusion proteins, agonist-
promoted [35S]-GTPγS binding assays were performed using membranes 
generated from Flp-InTM T-RExTM-293 cells either uninduced or induced with 
doxycycline (100 ng/ml, 24 hours) expressing either FLAG-hGPR84-Gαi2, FLAG- 
hGPR84-Gαi2 C352I or hGPR84-Gαi2 C352G constructs. Decanoic acid (C-10), 3,3′-
Diindolylmethane (DIM), DIM analogue PSB-16671 and compound-1 each 
enhanced [35S]-GTPγS binding to membranes expressing the FLAG-hGPR84-Gαi2 
fusion construct in a concentration-dependent fashion with pEC50 of 4.26±0.02, 
5.27±0.06, 6.28±0.05 and 7.54±0.06, respectively (Figure 4.3 ai-aiii). The 
potencies of decanoic acid (EC50: 54±0.02 µM) and DIM (EC50: 5±0.90 µM) 
displayed at the FLAG-hGPR84-Gαi2 fusion protein were about 10-fold lower than 
that (EC50: 4.6±0.1 µM and 0.5 µM, respectively for C-10 and DIM) observed at 
FLAG-tagged hGPR84 estimated by Wang et al., (2006b). Similarly, the potency 
of PSB-16671 (EC50: 524 nM) determined by this fusion protein-based [
35S]-GTPγS 
binding assay was 12.6-fold lower than that (EC50: 41.3 nM) estimated in the 
cAMP assay using a hGPR84 expressing CHO cell line (Pillaiyar et al., 2017). The 
potency of compound-1 (EC50: 29 nM) provided by this fusion protein was 4.4-fold 
lower than that (EC50: 6.6 nM in cAMP assays) reported by Pillaiyar et al., (2018) 
but 5-fold higher than that (EC50: 144 nM in cAMP assays) observed by Liu et al., 
(2016). Although the potency of DIM was significantly higher than decanoic acid 
(C-10), it acted as a weak partial agonist at FLAG-hGPR84-Gαi2 compared to C-
10. DIM analogue PSB-16671 is more potent (10-fold) and has a greater maximal 
effect (about 2-fold higher response) than DIM. Compound-1 displayed the 
highest maximal response at the hGPR84-Gαi2 fusion protein, acting as a super-
agonist in this assay. Noticeably, the addition of various concentrations of all 
these ligands to membranes generated from cells grown in the absence of 
doxycycline, did not result in any significant [35S]-GTPγS binding, demonstrating 
that the enhanced binding of this guanine nucleotide analogue to membranes 
purified from doxycycline-treated cells was mediated by hGPR84.   
The capacity of various concentrations of embelin and DIM to stimulate [35S]-
GTPγS incorporations into membranes purified from doxycycline-treated cells 
expressing either FLAG-hGPR84-Gαi2 C352I or FLAG-hGPR84-Gαi2 C352G fusion 
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construct was also assessed to characterize the functionality of these two PTX- 
resistant GPR84-G protein fusion proteins. Both of the agonists were found to 
promote [35S]-GTPγS binding to both constructs in a concentration-dependent 
manner (Figure 4.3b,c) while no significant incorporation of the radiolabelled 
nucleotide to membranes was observed when membranes were generated from 
cells grown in the absence of doxycycline. These results confirmed that both the 
PTX-resistant versions of fusion proteins were functionally active. Though DIM 
displayed similar potency and efficacy at hGPR84-Gαi2 C352I and hGPR84-Gαi2 
C352G fusion constructs, potency and efficacy of embelin were decreased at the 
hGPR84-Gαi2 C352G construct compared to the other constructs.  
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Figure 4.3 Functional characterization of Flp-In
TM
 T-REx
TM
-293 stable cell lines expressing 
either FLAG-hGPR84-Gαi2, FLAG-hGPR84-Gαi2 C352I or FLAG-hGPR84-Gαi2 C352G fusion 
constructs. Membranes were prepared from Flp-In
TM
 T-REx
TM
-293 stable cell lines either 
uninduced (-Dox) or induced (+Dox) with 100 ng/ml doxycycline for 24 hours to express either 
FLAG-hGPR84-Gαi2, FLAG- hGPR84-Gαi2 C352I or FLAG-hGPR84-Gαi2 C352G. The ability of 
various concentrations of C-10 (ai), either DIM or DIM analogue PSB-16671 (aii) and compound-
1(aiii) to stimulate binding of [
35
S]-GTPγS to membrane preparations generated from cells 
harbouring the FLAG-hGPR84-Gαi2 fusion protein was then assessed. Equivalent studies were 
performed to measure the [
35
S]-GTPγS binding to membranes purified from cells harbouring either 
FLAG-hGPR84-Gαi2 C352I (bi, bii) or FLAG-hGPR84-Gαi2 C352G (ci, cii) in response to varying 
concentrations of either embelin or DIM.   
4.2.4. Human GPR84 couples to PTX sensitive Gαi protein 
The pre-treatment of cells expressing the FLAG-hGPR84-Gαi2 fusion protein with 
the Gαi protein inhibitor, pertussis toxin (50 ng/ml, 24 hours) completely 
abolished DIM stimulated [35S]-GTPγS binding to membranes (Figure 4.4a) 
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indicating that hGPR84 couples to PTX-sensitive Gαi protein. As opposed to this, 
DIM-induced [35S]-GTPγS incorporation was unaffected following PTX treatment 
of cells expressing the PTX insensitive mutant construct FLAG-hGPR84-Gαi2 C352I 
(Figure 4.4b), suggesting that after PTX treatment, agonist-stimulated GPR84 
exclusively interacted with the Gαi2 G-protein that had been fused to the 
receptor rather than with any endogenous Gαi protein. In the case of another 
PTX resistant mutant construct FLAG-hGPR84-Gαi2 C352G, the PTX pre-treatment 
of cells resulted in slightly increased binding of the [35S]-GTPγS to membranes 
compared to that prepared from untreated cells (Figure 4.4c).  
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Figure 4.4 Effects of pertussis toxin (PTX) pre-treatment on DIM-induced [
35
S]-GTPγS 
binding to membranes purified from Flp-In
TM 
T-REx
TM
-293 stable cell lines expressing either 
FLAG-hGPR84-Gαi2, FLAG- hGPR84-Gαi2 C352I or FLAG-hGPR84-Gαi2 C352G. Doxycycline 
(100 ng/ml, 24 hours) induced Flp-In
TM 
T-REx
TM
-293 cells expressing either FLAG-hGPR84-Gαi2, 
FLAG- hGPR84-Gαi2 C352I or FLAG-hGPR84-Gαi2 C352G were either untreated (-PTX) or treated 
(+PTX) with 50 ng/ml of PTX for 24 hours followed by membrane generation. Using these 
membranes, [
35
S]-GTPγS binding assays were then performed to evaluate the function of DIM at 
either FLAG-hGPR84-Gαi2 (a), FLAG- hGPR84-Gαi2 C352I (b) or FLAG-hGPR84-Gαi2 C352G (c).  
4.2.5.  The GPR84-Gαi2 fusion protein approach enhances 
coupling efficiency between GPR84 and Gαi protein 
The rationale for generating GPR84-Gα fusion proteins was to enhance the 
signalling window which might be useful for the study of pharmacological 
properties of GPR84 ligands. In the [35S]-GTPγS binding assay, the magnitude of 
compound-1- stimulated [35S]-GTPγS binding obtained from the activation of 
FLAG-hGPR84-Gαi2 C352I was 10-fold higher than that generated from the FLAG-
hGPR84-eYFP (Figure 4.5a). In contrast, the potency of compound-1 was 
decreased by 30-fold at the fusion protein (pEC50: 7.53±0.07) compared to that 
shown at the eYFP tagged receptor (pEC50: 9.0±0.1). Similarly, in the case of 
embelin-mediated [35S]-GTPγS incorporation, the GPR84-G protein fusion protein 
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produced 5-fold higher signalling magnitude than FLAG-hGPR84-eYFP while 
potency was decreased by 2-fold at the FLAG-hGPR84-Gαi2 C352I compared to 
that displayed by FLAG-hGPR84-eYFP (Figure 4.5b). To confirm that the higher 
signalling magnitude displayed by the fusion protein was not merely a reflection 
of higher expression level of this construct, a saturation binding study was 
performed using the radiolabelled antagonist [3H-G9543] which revealed that 
both hGPR84-eYFP and hGPR84-Gi2 C352I constructs showed similar expression 
levels in Flp-In T-REx-293 cells as evident from their similar Bmax values 
(9075±440 and 8073±619 fmol/mg protein, respectively) (Figure 4.5 c).  
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Figure 4.5 The GPR84-Gαi2 fusion protein approach enhances coupling efficiency between 
GPR84 and Gαi protein compared to the eYFP tagged GPR84 construct. Flp-In
TM
 T-REx
TM
-293 
stable cell lines harbouring either FLAG-hGPR84-Gαi2 C352I or FLAG-hGPR84-eYFP were 
incubated with 100 ng/ml doxycycline for 24 hours to induce the expression of the receptor of 
interest. Membranes generated from these cells were subsequently used to perform [
35
S]-GTPγS 
incorporation assays to assess the function of either compound-1 (ai, aii) or embelin (bi, bii). Varying 
concentrations of [
3
H]-G9543 in the absence (total binding) or presence (nonspecific binding) of 
1µM compound-104 were evaluated for their capacity to bind to membranes expressing either 
FLAG-hGPR84-eYFP (ci) or FLAG-hGPR84-Gαi2 C352I (cii) allowing estimation of Bmax values. 
Specific binding to membranes was estimated by subtracting nonspecific binding from total binding.  
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4.2.6. GPR84 agonists displayed similar activity at the FLAG-
hGPR84-Gαi2 and FLAG-hGPR84-Gαi2C352I fusion protein 
GPR84 agonists displayed similar pharmacological properties at FLAG-hGPR84-
Gαi2 and FLAG-hGPR84-Gαi2 C352I fusion constructs. In the [
35S]-GTPγS binding 
assay, the potency and efficacy of embelin, compound-1, compound-51 and DIM 
were very similar between these two GPR84-Gα fusion constructs (Figure 4.6 a) 
which implies that the PTX-insensitive mutant version FLAG-hGPR84-Gαi2 C352I 
could be effectively employed for the pharmacological study of GPR84 ligands in 
place of the wild type G protein containing fusion protein. I also generated a 
FLAG-hGPR84-Gαi3 C351I fusion protein in an effort to check whether this 
construct generates a higher signalling window compared to the FLAG-hGPR84-
Gαi2 C352I fusion construct. In the [
35S]-GTPγS incorporation assays, potency and 
maximal response displayed by embelin were equivalent between FLAG-hGPR84-
Gαi2 C352I and FLAG-hGPR84-Gαi3 C351I (Figure 4.6b). 
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Figure 4.6 Agonists of hGPR84 display similar activity at FLAG-hGPR84-Gαi2 and FLAG-
hGPR84-Gαi2 C352I fusion proteins. Membranes were prepared from Flp-InTM T-RExTM-293 
stable cells treated with doxycycline (100 ng/ml for 24 hours) to induce the expression of either 
FLAG-hGPR84-Gαi2, FLAG-hGPR84-Gαi2 C352I or FLAG-hGPR84-Gαi3 C351I. The capacity of 
various concentrations of embelin (ai), compound-1(aii), compound-51 (aiii) or DIM (aiv) to promote 
[
35
S]-GTPγS binding to membranes expressing either FLAG-hGPR84-Gαi2 or FLAG- hGPR84-Gαi2 
C352I was assessed. A similar study was performed to evaluate the ability of various 
concentrations of embelin (b) to stimulate [
35
S]-GTPγS incorporation into membranes expressing 
either FLAG-hGPR84-Gαi2 C352I or FLAG-hGPR84-Gαi3 C351I.  
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4.2.7. Functional characterization using the cAMP inhibition 
assay 
The functional integrity of the GPR84-Gαi2 fusion proteins was also assessed in 
cAMP inhibition assays. In these assays, DIM concentration-dependently inhibited 
forskolin amplified production of cAMP in cells expressing either FLAG-hGPR84-
Gαi2, FLAG-hGPR84-Gαi2 C352I or FLAG-hGPR84-Gαi2 C352G yielding pEC50 of 
5.21±0.1, 5.47±0.14 and 5.56±0.14, respectively (Figure 4.7A). This observed 
inhibition of cAMP production in cells by agonist-activated GPR84 is in agreement 
with the receptor being coupled to Gαi/o family G-proteins. Although all three 
fusion proteins displayed similar potency of DIM, the efficacy of DIM was 
decreased by two-fold at the FLAG-hGPR84-Gαi2 C352G mutant construct 
compared to the other two fusion proteins. The reduced efficacy of DIM 
displayed at FLAG-hGPR84-Gαi2 C352G might be due to the lower expression 
level of this fusion protein construct in the cell or due to the effect of cysteine 
to glycine mutation at 352 position of the Gαi2 protein which might interrupt G 
protein coupling to the receptor because 352 position is located in the C 
terminus of the Gαi protein which is known to be involved in GPCR-G protein 
interactions. The analysis of concentration-response data obtained from the 
cAMP assay using the FLAG-hGPR84-Gαi2 receptor construct, also revealed that 
potencies of DIM (5.3±0.14) and embelin (6.3±0.12) were higher than that of the 
endogenous agonist, C-10 (4.7±0.1). Consistent with the results obtained from 
[35S]-GTPγS binding assays, in the cAMP assay DIM also acted as a partial agonist 
compared to decanoic acid (Figure 4.7B). In contrast to the BRET assay using the 
GPR84-SPASM-Gαi1/2 biosensor wherein embelin acted as a partial agonist 
compared to decanoic acid (section 3.2.3), in the cAMP assay embelin showed 
similar efficacy, suggesting that measuring pharmacological parameters at G-
protein activation level might be more useful for comparing the efficacy of 
ligands as less receptor reserve is associated with G-protein activation which is 
not/less subject to amplification of signalling or other modulatory effects  that 
may happen in the case of downstream signalling events.  
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Figure 4.7 Effects of agonist-mediated GPR84 activation on intracellular cAMP 
accumulation. The capacity of various concentrations of DIM to inhibit forskolin-induced cAMP 
production in doxycycline-treated (100 ng/ml for 24 hours) Flp-In
TM
 T-REx
TM
-293 cells expressing 
either FLAG-hGPR84-Gαi2, FLAG-hGPR84-Gαi2 C352G or FLAG-hGPR84-Gαi2 C352I fusion 
constructs was assessed (A). A similar study was done to assess the ability of varying 
concentrations of either C-10, DIM or embelin to inhibit the forskolin-promoted cAMP accumulation 
in cells expressing the FLAG-hGPR84-Gαi2 fusion protein.  
 
4.3. Investigation of the mode of binding of ligands to 
hGPR84 
Until now, very little was known regarding the mode of binding of ligands to 
GPR84. A single modelling and mutagenesis study was performed by Nikaido et 
al., (2015) to define the molecular determinants responsible for ligand binding 
to GPR84. In an effort to delineate how the putative endogenous agonist 
decanoic acid and the synthetic agonist DIM bind to GPR84, they developed a 
homology model of hGPR84 using the crystal structure of human active-state β2-
adrenergic receptor as a template. This homology model predicted that the 
carboxylate of the medium chain fatty acid decanoic acid was pointing towards 
the bottom of the binding cavity created by the transmembrane helices of 
GPR84. They reported that amino acid residues leucine 1003.32 and asparagine 
1043.36 of transmembrane domain III (Ballesteros and Weinstein residue location 
number in superscript) and asparagine 3577.39 of transmembrane domain VII were 
critical for decanoic acid recognition and function since the mutations of L100D, 
N104Q or N357D in the context of a hGPR84-Gαi1 fusion protein resulted in either 
complete loss of function or reduced activity of decanoic acid as assessed in 
[35S]-GTPγS incorporation assays. Importantly, response to DIM was unaffected 
by these mutations, demonstrating that DIM binds to another site on GPR84 that 
is distinct from the binding site of decanoic acid. Previously it was reported that 
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at least one or two arginine residues located in or near the extracellular face of 
fatty acid sensing receptors (FFA1-3 and FFA4) acted as charge partner to 
coordinate the carboxyl group of fatty acids or other synthetic ligands (Milligan 
et al., 2017b; Mahmud et al., 2017). For example, several groups confirmed that 
two arginine residues, arginine 1835.39 and arginine 2587.35 present in FFA1 
coordinate the carboxyl group of long chain fatty acids or synthetic ligands (Sum 
et al., 2007; Tikhonova et al., 2007; Srivastava et al., 2014). Similarly, arginine 
1805.39 and arginine 2557.35 located in TMD V and TMD VII, respectively of FFA2 
and arginine 1855.39 and arginine 2587.35 within FFA3 were shown to anchor the 
negatively charged carboxylate of short-chain fatty acids (Stoddart et al., 
2008a). FFA4, previously known as GPR120, which is structurally different from 
the three other fatty acid receptors, has only a single arginine residue R992.64 
which was reported to make ionic interactions with the carboxylate of long chain 
fatty acids (Hudson et al., 2014b; Watson et al., 2012;  Sun et al., 2010). In 
accordance with these findings, it is expected that similar arginine or other 
positively charged amino acid residues within GPR84 might act as anchor(s) for 
the carboxylate function of medium chain fatty acid ligands. Surprisingly, 
Nikaido et al., (2015) failed to identify any arginine residue or other positively 
charged amino acid(s) of GPR84 that can coordinate the carboxylate function of 
the medium chain fatty acid, decanoic acid. Rather their model predicted that 
asparagine 104, located in the 3.36 position within GPR84 might coordinate the 
carboxylate moiety of the fatty acid. Recently, Yin et al., (2016) reported the 
crystal structure of human OX1 receptor which shares 31% of sequence identity 
with the transmembrane domains of human GPR84 (Tikhonova, 2017). Sequence 
alignment between the extracellular loop 2 (EL2) of the crystal structure of 
rhodopsin and EL2 of human GPR84 revealed that there was 43% sequence 
conservation between them, which is quite surprising because EL2 of GPCRs 
generally differs substantially from each other in terms of primary amino acid 
sequence as well as secondary structure (Tikhonova, 2017; MacKenzie et al., 
2014; Wheatley et al., 2012; Costanzi, 2012). Combining the transmembrane 
domains of the crystal structure of OX1 receptor and EL2 from the crystal 
structure of rhodopsin, Tikhonova (2017) developed a hybrid template and based 
on this template, a novel homology model of human GPR84 was constructed in 
which the Arginine 172 of EL2 was directed towards the putative binding pocket 
created by the helical bundle (Figure 4.8A ). This homology model of GPR84 
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predicted that Arginine 172 within the extracellular loop 2 (EL2) of the receptor 
might coordinate the negatively charged carboxyl group of the medium chain 
fatty acids or other bioisosteres of natural/synthetic agonists such as embelin, 6-
OAU or compound-1. The homology model developed by Nikaido et al., (2015) 
failed to predict this arginine group within the EL2 of human GPR84 as it shares 
no sequence identity with the EL2 of the β2-adrenergic receptor used as the 
template for homology modelling. Another important thing is that the putative 
orientation of the decanoic acid into the binding pocket of GPR84 based on this 
homology model (Figure 4.8B) is opposite to that displayed by the homology 
model constructed by Nikaido and co-workers (2015). In the case of docking 
poses of decanoic acid studied by Nikaido et al., (2015) the carboxylate moiety 
of C-10 is directed towards the bottom of the binding cavity and the hydrophobic 
aliphatic chain is pointing upwards to the extracelluar side whilst herein the 
hydrophobic chain appears to be pointed deep into the core of the helical 
bundle.   
The homology model predicted that residues Y69, L73, Y81, L100, F101, N104, 
F170, R172, L182, Y186, F187, Y332, F335, N339, H352, and W360 form the 
putative ligand-binding pocket of GPR84 (Figure 4.8 B,C ). To investigate the 
role of residues R172, F170, F1013.33, F3356.51 and W3607.43  in the ligand 
recognition and/or function, aromatic residues F1013.33, F170EL2, F3356.51 and 
W3607.43 were mutated to alanine and the basic residue R172 was mutated to 
alanine or lysine (Figure 4.9) within the setting of the FLAG-hGPR84-Gαi2 C352I 
fusion construct. All these mutant constructs of GPR84 were developed by site-
directed mutagenesis and then Flp-In T-REx-293 cells stably harbouring the 
mutant receptor of interest at the Flp InTM  locus were generated.   
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Figure 4.8 Homology model of human GPR84 and the putative ligand-binding cavity.  (A) A 
GPR84 homology model was generated based on a hybrid template comprising the 
transmembrane domains of the crystal structure of the human orexin receptor (hOX1R) and the 
2nd  extracellular loop (EL2) of the crystal structure of rhodopsin (Mahmud et al., 2017). Two 
arginines, Arginine 172 and Arginine 174 located within EL2 are visualized. (B–C) The putative 
binding pocket(s) for decanoic acid (B) and embelin (C) are shown. Both agonists appear to be 
anchored at Arginine 172 of the EL2 by forming hydrogen bond/salt bridges shown as dotted black 
lines. Other potentially important amino acid residues were also visualized. These figures were 
generated by Dr Irina G. Tikhonova as part of the collaboration. 
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Figure 4.9 Primary amino acid sequence of human GPR84 highlighting the residues I have 
mutated. Red indicates that the residue (F101
3.33
, F170
EL2
, F335
6.51 
and W360
7.43
) was mutated to 
alanine and blue indicates that the residue (R172 of the EL2) was mutated to alanine as well as to 
lysine. This figure was collected from the website https://www.uniprot.org/uniprot/Q9NQS5. 
 
4.3.1. Assessment of expression levels of different mutants of 
hGPR84  
Saturation binding studies were performed using a radiolabelled form of the 
antagonist of GPR84, [3H]-G9543, to measure the expression level of different 
mutant versions of GPR84 and wild type GPR84. [3H]-G9543 bound to membranes 
expressing FLAG-hGPR84-Gαi2 C352I with high affinity yielding a Kd value of 
0.25±0.02 nM (n=7) (Figure 4.10a and Table 4.1). The binding affinity of the 
radioligand to the receptor was unaffected by mutation of arginine 172EL2 to 
either alanine or lysine as similar Kd values (0.27±0.02 nM and 0.22±0.03 nM, 
respectively for GPR84 R172A-Gαi2 C352I and GPR84 R172K-Gαi2 C352I fusion 
constructs, n=7) were obtained when membranes expressing either FLAG-hGPR84 
R172A-Gαi2 C352I or FLAG-hGPR84 R172K-Gαi2 C352I were used in the binding 
studies (Figure 4.10 b,c). On the other hand, mutation of phenylalanine 3356.51 or 
phenylalanine 170EL2 to alanine decreased the binding affinity (Kd values 
2.18±0.2 and 0.93±0.2 nM, respectively for GPR84 F335A-Gαi2 C352I and GPR84 
F170A-Gαi2 C352I) of the radioligand to the receptor by 8.7 and 3.7-fold, 
respectively. Saturation binding data also revealed that hGPR84-Gαi2 C352I, 
hGPR84 R172A-Gαi2 C352I, hGPR84 R172K-Gαi2 C352I and hGPR84 F335A-Gαi2 
C352I fusion constructs were expressed effectively in the corresponding Flp-In T-
REx cell line and there was no significant variation in their expression levels 
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since similar Bmax values were observed (Table 4.1). By contrast, the expression 
of hGPR84 F170A-Gαi2 C352I (Bmax: 1419±180 fmol/mg protein) was much lower 
than the wild type receptor (Bmax: 6538±267 fmol/mg protein). No specific 
binding of [3H]-G9543 to either GPR84 F101A or GPR84 W360A constructs was 
detected (Figure 4.11).   
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Figure 4.10 Binding properties of [
3
H]-G9543 at wild type and mutant versions of human 
GPR84. Membranes were prepared from doxycycline-induced (100 ng/ml, 24 hours) Flp-In T-Rex-
293 cells expressing the receptor of interest. Various concentrations of [
3
H]-G259543 with 
(nonspecific binding) or without (total binding) 1µM antagonist compound-104 were assessed for 
their capacity to bind to membranes expressing either FLAG-hGPR84-Gαi2 C352I (ai,aii), FLAG-
hGPR84 R172A-Gαi2 C352I (bi,bii), FLAG-hGPR84 R172K-Gαi2 C352I(ci,cii), FLAG-hGPR84 
F335A-Gαi2 C352I (di,dii) or FLAG-hGPR84 F170A-Gαi2 C352I (ei,eii) constructs. Specific binding of 
radioligand was measured by subtracting nonspecific binding from total binding. Representative 
results of five (d,e) or seven(a-c) independent experiments were shown.  
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Figure 4.11 Mutation of phenylalanine 101
3.33 
or tryptophan 360
7.43 
to alanine completely 
eliminated the ability of the radiolabelled antagonist [
3
H]-G9543 to bind to human GPR84. 
The capacity of increasing concentrations of [
3
H]-G9543 to bind to membranes expressing either 
FLAG-hGPR84 F3.33A-Gαi2 C352I or FLAG-hGPR84 W7.43A-Gαi2C352I was assessed in the 
presence (nonspecific binding) or absence (total binding) of 1µM compound-104.   
Table 4-1 Binding affinity of [
3
H]-G9543 to the wild type and mutant versions of hGPR84 and 
corresponding receptor density 
Receptor construct  Bmax (fmol/mg protein) Kd (nM) 
FLAG-hGPR84-Gαi2 6251±954 0.3±0.01 
FLAG-hGPR84-Gαi2 C352I 6538±267 0.25±0.02 
FLAG-hGPR84 R172A-Gαi2 C352I 7481±527 0.27±0.02 
FLAG-hGPR84 R172K-Gαi2 C352I 5825±203 0.22±0.03 
FLAG-hGPR84 F335A-Gαi2 C352I 5352±606 2.18±0.2*** 
FLAG-hGPR84 F170A-Gαi2 C352I 1419±180*** 0.93±0.2*** 
A series of radioligand [
3
H]-G9543 binding assays were performed to determine the Kd of the 
radiolablled antagonist and receptor density (Bmax) of the membrane preparations and data are 
expressed as mean±S.E.M. (n=5/7). Bmax and Kd values were analysed by one-way ANOVA 
followed by Dunnett’s multiple comparison tests using the values displayed at the hGPR84-Gαi2 
C352I construct as the reference. The statistical significance is presented as *P<0.05, **P<0.01, 
***P<0.001 
4.3.2. Arginine 172 of EL2 is a key molecular determinant of 
orthosteric ligand binding to hGPR84 
Decylamine (Nikaido et al., 2015) and methyl decanoate (Mahmud et al., 2017) 
have been reported to be inactive at human GPR84, demonstrating the 
importance of the carboxylic acid moiety in the agonistic function of decanoic 
acid at hGPR84. Moreover, the homology model (shown in Figure 4.8) predicted 
that the carboxylate of MCFAs is anchored by arginine 172 located within EL2 of 
GPR84. In an effort to confirm this anchoring role of arginine 172, the effect of 
mutation of this amino acid residue to alanine on the agonistic function of 
GPR84 ligands was assessed using [35S]-GTPγS binding assays. The alteration of 
the arginine 172 to alanine resulted in complete elimination of the activity of 
decanoic acid (C-10), embelin, compound-1 and 6-OAU (Figure 4.12, Table 4.2), 
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indicating that this residue is important for ligand recognition and function. This 
was not the case for DIM or the DIM analogue PSB-16671 as they were found to 
remain active at this mutant receptor. DIM displayed similar potency and 
efficacy at the R172A GPR84 mutant compared to wild type. Though the potency 
of PSB-16671 was decreased slightly (less than 2-fold), it displayed higher 
maximum response at the R172A mutant compared to the wild type receptor. 
The mutation of arginine 172 to lysine in the context of the FLAG-hGPR84-Gαi2 
C352I fusion protein also completely abolished responses to C-10, embelin and 
compound-1 (Figure 4.12). Compared to the wild type receptor this mutation 
also resulted in 64% reduction (P<0.001) of maximum response to 6-OAU while 
the potency of 6-OAU was decreased by 20-fold (P<0.001). These results 
demonstrated that along with maintenance, position of the positive charge is 
also crucial for orthosteric ligand recognition and function. Though DIM and PSB-
16671 displayed similar potency at the R172K mutant, their efficacies were 
reduced significantly by 22 and 25%, respectively compared to that of wild type 
receptor. The retention of agonist function of DIM and PSB-16671 at either 
R172A or R172K mutant of GPR84 suggested that DIM and PSB-16671 must bind a 
site which is topographically distinct from the binding site shared by C-10, 
embelin, 6-OAU or compound-1. 
The loss of orthosteric agonist function at R172A or R172K mutant receptors was 
not due to the loss of or reduced expression level of the mutant receptor as 
saturation binding studies with the radiolabelled antagonist [3H]-G9543 revealed 
that there was no significant variation (Bmax: 7481±527, 5825±203 and 6538±267 
fmol/mg protein, respectively for R172A, R172K and wild type receptor) (Figure 
4.10 and Table 4.1). Moreover, the affinity of the radioligand was unaltered by 
the mutation at arginine 172 to either alanine or lysine since similar Kd values 
were obtained for both mutant receptors (Table 4.1), confirming that these 
mutations did not result in generation of a non-functional misfolded receptor. 
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Figure 4.12 Mutation of arginine 172 of hGPR84 to either alanine or lysine abolishes the 
agonist function of decanoic acid, embelin, compound-1 and 6-OAU but not of DIM or PSB-
16671. Membranes generated from doxycycline-treated (100 ng/ml for 24 hours) Flp-In
TM
 T-REx
TM
-
293 cells expressing  either FLAG-hGPR84-Gαi2 C352I, FLAG-hGPR84 R172A-Gαi2 C352I or 
FLAG-hGPR84 R172K-Gαi2 C352I were used to assess the ability of various concentrations of 
either C-10 (a), embelin (b), compound-1 (c), 6-OAU (d), DIM (e) or PSB-16671 (f) to promote 
binding of [
35
S]-GTPγS to the Gαi2 G-protein associated with the fusion construct of interest. Data 
represent mean±SEM of three independent experiments performed on separate membrane 
preparations. To eliminate the effect of differential expression level on agonistic activity, before 
performing each [
35
S]-GTPγS binding assay, Bmax values were estimated for membrane 
preparations generated from Flp-In
TM
 T-REx
TM
-293 cells expressing either FLAG- hGPR84-Gαi2 
C352I, FLAG-hGPR84 R172A-Gαi2 C352I or FLAG-hGPR84 R172K-Gαi2 C352I fusion proteins and 
50 fmol per reaction was used for each receptor construct. 
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Table 4-2 Potency and efficacy of GPR84 ligands at wild type, R172A or R172K GPR84  
 GPR84 WT GPR84 R172A GPR84 R172K 
ligand pEC50 pEC50 ΔpEC50 Emax 
 
pEC50 ΔpEC50 Emax 
C-10 4.30±0.05 NA NA NR NA NA NR 
Embelin 5.64±0.09 NA NA NR NA NA NR 
Compound-1 7.50±0.04 NA NA NR NA NA NR 
6-OAU 6.40±0.05 4.8±0.04*** -1.6 12±0.8*** 5.1±0.01*** -1.3 36±4*** 
TUG-1765 9.50±0.1 NA NA 11±0.8*** 6.8±0.03*** -2.7 60.6±0.6*** 
DIM 5.20±0.1 4.85±0.16 -0.35 108.3±5 4.95±0.15 -0.25 78±7* 
PSB-16671 6.35±0.04 6.1±0.01** -0.25 139±2*** 5.91±0.01** -0.44 74.2±0.6*** 
A set of [
35
S]-GTPγS binding experiments were performed to determine the potency (pEC50) and 
efficacy(Emax) of the GPR84 agonists at wild type and mutant GPR84 and data are presented as 
mean±SEM of three independent experiments. Efficacy (Emax) is expressed as the percentage of 
wild type response. NA: not applicable; NR: no response; ΔpEC50  represents  mutant pEC50–wild 
type pEC50; pEC50 and Emax values were analysed by one-way analysis of variance (ANOVA) 
followed by Tukey’s multiple comparison tests with statistical significance denoted as *P<0.05, 
**P<0.01, ***P<0.001; The significance level of potency of TUG-1765 displayed at the R172K 
mutant compared to that of wild type receptor was determined by an unpaired two-tailed t-test.    
4.3.3. Embelin, compound-1 and 6-OAU share a common binding 
site with MCFAs 
The binding site of endogenous agonists is considered as the orthosteric site of 
the receptor (Smith et al., 2011a). Similar to the endogenous agonist (C-10), 
each of embelin, compound-1 and 6-OAU lost activity at both R172A and R172K 
mutants of GPR84 which suggests that embelin, compound-1 and 6-OAU share a 
same binding site within GPR84 which overlaps with the binding site of C-10. In 
all these orthosteric agonists, a hydrophilic head group (2, 5-dihydroxy-1, 4-
benzoquinone in embelin; 4, 6-dihydroxypyrimidine in compound-1 and 
pyrimidine-2, 4-dione in 6-OAU) is attached to a long hydrophobic tail. The 
mutational study showed that in addition to the carboxylate group of decanoic 
acid, the arginine 172 also coordinated the hydrophilic polar head group of 
embelin, compound-1 and 6-OAU i.e these groups acted as bioisosteres of the 
carboxylate of MCFAs. As additional support for the fact that both embelin and 
compound-1 share an overlapping binding site at human GPR84 with decanoic 
acid, concentration-response curves for compound-1 or embelin were generated 
in the presence of varying fixed concentrations of C-10 employing the [35S]-
GTPγS incorporation assay using membranes expressing FLAG-hGPR84-Gαi2 fusion 
protein. As a direct agonist, C-10 stimulated [35S]-GTPγS incorporation into 
membranes in the absence of either compound-1 or embelin. However, the 
addition of sub-maximal fixed concentrations of decanoic acid ranging from 1µM 
to 100 µM to the concentration-response assay for compound-1 did not change 
the potency of compound-1 (Figure 4.13a). Similarly, the potency of embelin 
was unaffected by the co-addition of varying fixed concentrations of decanoic 
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acid ranging from 1µM to 300 µM (Figure 4.13b). In both cases, co-addition of 
submaximal concentrations of C-10 to either compound-1 or embelin only 
produced ‘additive effect’ rather than any ‘co-operative effect’ which is 
consistent with the idea that embelin and compound-1 both are orthosteric with 
respect to decanoic acid. This conclusion is in agreement with the findings of 
Zhang et al., (2016) which also revealed that co-addition of increasing fixed 
concentrations of compound-1 ranging from 20 to 180 nM to the concentration-
response assay of 3-hydroxy lauric acid in a calcium mobilization assay did not 
alter the measured potency of the hydroxylated MCFA suggesting that 
compound-1 shares a common binding site with MCFAs.   
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Figure 4.13 Decanoic acid, embelin and compound-1 share a common binding site in 
hGPR84. Membranes were prepared from Flp-In T-REx-293 cells induced with 100 ng/ml of 
doxycycline for 24 hours to express FLAG-hGPR84-Gαi2. These membranes were then employed 
to perform [
35
S]-GTPγS binding assays to generate concentration-response curves for compound-1 
(a) or embelin (b) in the presence of increasing fixed concentrations of decanoic acid (C-10).     
  
4.3.4. TUG-1765 and related molecules bind to the orthosteric 
pocket of hGPR84 
In the [35S]-GTPγS binding assay, 6-octylpyridine-2, 4-diol (TUG-1765; designated 
as compound-50 by Liu et al., 2016) displayed about 92-fold higher potency 
(pEC50: 9.5±0.1) (Figure 4.14a) than compound-1(pEC50: 7.22±0.06). Liu et al., 
(2016) observed similar potency of TUG-1765 (EC50: 1.34 ±0.08 nM) in a Ca
2+ 
mobilization assay. As this compound is an analogue of compound-1, it is 
expected that this compound would also bind to the orthosteric site of GPR84. 
To assess this the effect of mutation at arginine 172 to alanine or lysine on the 
agonistic function of TUG-1765 was examined using the [35S]-GTPγS binding 
assay. R172A mutation in the context of hGPR84-Gαi2 C352I almost abolished the 
activity of TUG-1765 with only 10% of wild type response observed at 1µM 
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(Figure 4.14a). The potency of this compound was significantly reduced by some 
500-fold (P<0.001) when this arginine residue was mutated to lysine whilst the 
efficacy was decreased by 40% (P<0.001) (Table 4.2).The almost complete loss of 
activity at R172A GPR84 and the large reduction of agonistic function in terms of 
potency and efficacy at R172K GPR84 suggested that the arginine 172 of the EL2 
of GPR84 coordinated the 2,4-dihydroxypyridine moiety of TUG-1765, which 
therefore acted as a bioisostere of the carboxylate of MCFAs. These results 
suggested that TUG-1765 is also orthosteric with respect to decanoic acid.  
A series of compounds structurally related to compound-1 was then assessed to 
define their binding modes. Among them TUG-1758, 1759, 1761, 1762, 1763 and 
1764 (for structure see Figure 2.2) displayed similar efficacy to compound-1 in 
the [35S]-GTPγS binding assay. 2-nonylpyridine (TUG-1760) showed 812-fold 
lower potency and 5-fold lower efficacy compared to compound-1, indicating 
that the removal of hydroxyl groups from the heterocyclic ring is poorly 
tolerated. The potencies of 6-phenylethylpyridine-2,4-diol (TUG-1758) and 2-
nonyl-4-pyridone (TUG-1761) were lowered by some 33-fold compared to 
compound-1 whilst 6-phenylbutylpyridine-2,4-diol (TUG-1759), 6-
undecylpyridine-2,4-diol (TUG-1762), 6-decylpyridine-2,4-diol (TUG-1763) and 6-
heptylpyridine-2,4-diol (TUG-1764) showed significantly higher potency than 
compound-1 affording pEC50 of 8.25±0.1, 8.44±0.04, 8.20±0.07 and 8.92±0.02, 
respectively (Figure 4.14c). Similar to compound-1, each of TUG-1758, 1759, 
1762, 1763 and 1764 lacked activity at R172A GPR84 when the highest 
concentration of each ligand that could be practically applied was employed in 
the assay (Figure 4.14d). Similarly, very limited activity of these compounds was 
observed at R172K GPR84 when either 100 µM of TUG-1758 or 1 µM of TUG-1759, 
1762, 1763 and 1764 were used in the assay. These findings suggest that these 
compounds are orthosteric agonists of human GPR84. By contrast, TUG-1761 
displayed similar potency at R172A GPR84 compared to the wild type receptor 
and efficacy was reduced only by 33% (Figure 4.14b). However, the mutation of 
arginine to lysine resulted in a 5-fold reduction in potency and 80% decrease in 
efficacy for TUG-1761. Further studies are required to define the binding mode 
of TUG-1761.     
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Figure 4.14 A series of compound-1 analogues are orthosteric agonists of human GPR84. 
Effect of increasing concentrations of either TUG-1765 (a) or TUG-1761(b) was assessed for their 
ability to stimulate [
35
S]-GTPγS incorporation into membranes generated from Flp-In T-REx-293 
cells induced with 100 ng/ml of doxycycline for 24 hours to express either FLAG-hGPR84-Gαi2 
C352I, FLAG-hGPR84 R172A-Gαi2 C352I or FLAG-hGPR84 R172K-Gαi2 C352I. Similar assays 
were performed to generate concentration-response curves for TUG-1758, 1759, 1760, 1762, 
1763, 1764 or compound-1 using membranes expressing the FLAG-hGPR84-Gαi2 C352I (c). 
Effects of the mutation of arginine 172 to alanine (d) or lysine (e) on the agonistic activity of either 
100µM of TUG-1758 and TUG-1760, 1µM of TUG-1759, 1762, 1763 and 1764 or 10 µM of 
compound-1 were examined by using [
35
S]-GTPγS incorporation assays.  
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4.3.5. Phenylalanine 335 located in TMD VI might be associated 
with orthosteric ligand recognition 
A set of [35S]-GTPγS binding assays were performed to examine the potential role 
of phenylalanine 3356.51 in GPR84 ligand recognition and function. Mutation of 
phenylalanine 335 to alanine in the context of FLAG-hGPR84-Gαi2 C352I largely 
eliminated the activity of decanoic acid, compound-1 and 6-OAU (Figure 4.15, 
Table 4.3). This mutation resulted in 84% reduction (P<0.001) in efficacy for C-10 
response compared to the wild type receptor. 6-OAU showed a 38-fold (P<0.001) 
reduction in potency and 73% reduction (P<0.001) in efficacy at F335A GPR84. 
Similarly, the potency of compound-1 was decreased by 110-fold (P<0.001) at 
F335A GPR84. Another notable thing was that the response to embelin was 
completely abolished by the F335A mutation. This was not the case for either 
DIM or PSB-16671 as they retained their agonist functions at this mutated version 
of the receptor. This further supports that DIM and PSB-16671 bind to an 
allosteric site within GPR84 which is different from the binding site shared by C-
10 and embelin. Although DIM showed about 3.5-fold (P<0.05) reduction in 
potency at the F335A variant, the maximum response was not statistically 
different (P>0.05). PSB-16671 displayed some 2.3-fold (P<0.001) higher efficacy 
at this mutant receptor compared to wild type GPR84 whilst potency of PSB-
16671 was reduced by 2-fold (P<0.001).  
The complete loss of activity of embelin allayed to the significant reduction in 
agonist function of decanoic acid, compound-1 and 6-OAU at F335A GPR84 likely 
not due to the decreased expression level of this construct in Flp-In T-REx-293 
cells as similar expression level of the F335A mutant (Bmax: 5352±606 fmol/mg 
protein) was detected compared to the wild type receptor (Bmax: 6538±267 
fmol/mg protein) (Figure 4.10 and Table 4.1). Moreover, membranes containing 
50 fmols receptor of each construct were employed in each assay reaction. The 
full retention of agonist functions of DIM and PSB-16671 at F335A GPR84 
indicated that the mutation of phenylalanine to alanine at this position did not 
produce a variant of the receptor having poor organization and folding.  
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Figure 4.15 Phenylalanine 335 of human GPR84 might be part of the orthosteric ligand 
binding site. Increasing concentrations of DIM (a), PSB-16671 (b), C-10 (c), embelin (d), 6-OAU 
(e) or compound-1(f) were assessed for their ability to promote [
35
S]-GTPγS binding to membranes 
prepared from Flp-In
TM
 T-REx
TM
-293 cells induced with 100 ng/ml doxycycline for 24 hours to 
express either FLAG-hGPR84-Gαi2 C352I or FLAG-hGPR84 F335A-Gαi2 C352I fusion constructs. 
Data represent means± SEM of combined data collected from 3 independent experiments 
performed on 3 different membrane preparations.   
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Table 4-3 Potency and efficacy of GPR84 agonists at wild type and F335
6.51
A GPR84 in [
35
S]-
GTPγS binding assays. 
 GPR84 WT-Gαi2 C352I GPR84 F335A-Gαi2 C352I 
 
Ligand pEC50±SEM Emax±SEM 
(% of WT) 
pEC50±SEM ΔpEC50 Emax 
(% of WT) 
C-10 4.3±0.01 99.7±0.5 4.3±0.05 0 15.7±2.9*** 
Embelin 5.64±0.07 100±1 Inactive NA NR 
Compound-1 7.40±0.04 100±0.3 5.36±0.08*** -2.04 80.4±4.6*** 
6-OAU 6.52±0.08 99.4±0.6 4.94±0.02*** -1.58 27.0±3*** 
DIM 5.27±0.15 100±4.3 4.73±0.1* -0.54 112.7±10 
PSB-16671 6.27±0.05 97.9±0.8 5.93±0.04** -0.34 233±18*** 
A series of [
35
S]-GTPγS binding experiments were performed to determine the potency (pEC50) and 
efficacy (Emax) of the GPR84 agonists at wild type and F335A GPR84 mutant. Efficacy (Emax) is 
expressed as the percentage of wild type response. NA: not applicable; NR: no response; ΔpEC50  
represents  mutant pEC50 - wild type pEC50; Analysis of pEC50 and Emax values by two-tailed 
unpaired t-test was done with statistical significance denoted as *P<0.05, **P<0.01, ***P<0.001 
 
4.3.6. Role of Phenylalanine 170 of GPR84 in ligand recognition 
To assess the potential role of phenylalanine 170 in ligand recognition or 
function, effects of alteration of F170 to alanine on the agonistic functions of 
GPR84 ligands were investigated using [35S]-GTPγS binding assays. Saturation 
[3H]-G9543 binding studies showed that the expression level of the FLAG-hGPR84 
F170A-Gαi2 C352I mutant protein (Bmax: 1419±180 fmol/mg protein) was some 
4.6 times lower than that of the wild type receptor (Bmax: 6538±267 fmol/mg 
protein) (Figure 4.10 and Table 4.1). To control for the effect of the lowered 
expression level of the mutant, the receptor density of each membrane 
preparation was estimated prior to the individual [35S]-GTPγS binding assay and 
membranes containing 50 fmols of each fusion construct were added to each 
reaction. Alteration of phenylalanine 170 to alanine resulted in complete 
ablation of responses to either C-10 or embelin (Figure 4.16a-b). This mutation 
also significantly (P<0.01) reduced the measured potency (6.3-fold reduction) of 
compound-1 without affecting efficacy (Figure 4.16 d). Similarly, at F170A 
GPR84, 6-OAU showed a 10-fold (P<0.01) decrease in potency and 42.8% 
reduction in efficacy compared to the wild type receptor (Figure 4.16c; Table 
4.4). By contrast, DIM retained its function at F170A mutant displaying a 2-fold 
(P<0.01) higher maximal response compared to the wild type receptor. Though 
potency of DIM was reduced by 2.8-fold, this variation was not statistically 
significant. PSB-16671 showed similar potency at the F170A mutant but efficacy 
was enhanced by 2-fold compared to wild type GPR84.  
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In such mutational studies, it is important to ensure that lack of or reduced 
activity of ligands at the mutant receptor is not due to either generation of a 
protein having improperly folded structure or defective cell surface trafficking 
(Stoddart et al., 2008a). The maintenance of agonistic functions of DIM and PSB-
16671 at F170A GPR84 suggested that the mutant is functional. Moreover, the 
alanine replacement of the F170 did not result in a large reduction in binding 
affinity of the radiolabelled antagonist [3H]-G9543. Though this mutation 
decreased the binding affinity of the radioligand by 3.7-fold compared to the 
wild type receptor, the radioligand still bind F170A GPR84 with sub-nM affinity 
(Kd: 0.93±0.2 nM) (Figure 4.10) suggesting that alanine mutation of F170 did not 
generate a non-functional protein with improper folding. 
 
 
 
4 Investigation of modes of binding of ligands to human GPR84 153 
 
-8 -7 -6 -5 -4 -3 -2
0
50
100
150
GPR84 WT
GPR84 F170A
log[C-10]
G
T
P

S
 i
n
c
o
rp
o
ra
ti
o
n
 (
%
 o
f 
W
T
 r
e
s
p
o
n
s
e
)
-11 -10 -9 -8 -7 -6 -5 -4
0
50
100
150
GPR84 WT
GPR84 F170A
log[embelin]
G
T
P

S
 i
n
c
o
rp
o
ra
ti
o
n
 (
%
 o
f 
W
T
 r
e
s
p
o
n
s
e
)
-10 -9 -8 -7 -6 -5 -4
0
50
100
150
GPR84 WT
GPR84 F170A
log[6-OAU]
G
T
P

S
 i
n
c
o
rp
o
ra
ti
o
n
 (
%
 o
f 
W
T
 r
e
s
p
o
n
s
e
)
-11 -10 -9 -8 -7 -6 -5 -4
0
50
100
150
GPR84 WT
GPR84 F170A
log[compound-1]
G
T
P

S
 i
n
c
o
rp
o
ra
ti
o
n
 (
%
 o
f 
W
T
 r
e
s
p
o
n
s
e
)
-9 -8 -7 -6 -5 -4
0
100
200
300
GPR84 WT
GPR84 F170A
log[DIM]
G
T
P

S
 i
n
c
o
rp
o
ra
ti
o
n
 (
%
 o
f 
W
T
 r
e
s
p
o
n
s
e
)
-10 -9 -8 -7 -6 -5 -4
-50
0
50
100
150
200
250
GPR84 WT
GPR84 F170A
log[PSB-16671]
G
T
P

S
 i
n
c
o
rp
o
ra
ti
o
n
 (
%
 o
f 
W
T
 r
e
s
p
o
n
s
e
)
a b
c d
e f
 
Figure 4.16 The effect of alteration of phenylalanine 170 to alanine on GPR84 ligand 
recognition. Membranes were generated from Flp-In T-REx-293 cells induced with 100 ng/ml of 
doxycycline for 24 hours to express either FLAG-hGPR84-Gαi2 C352I or FLAG-hGPR84 F170A-
Gαi2 C352I. These membranes were then employed in [
35
S]-GTPγS incorporation assays to assess 
the ability of increasing concentrations of C-10 (a), embelin (b), 6-OAU (c), compound-1(d), DIM (e) 
or PSB-16671 (f) to promote [
35
S]-GTPγS binding to Gαi2 G-protein associated with the fusion 
construct. Data represent mean±SEM of three independent experiments (a-e) performed on three 
different membrane preparations or of a single experiment (f) performed in triplicate.  
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Table 4-4 Potency and efficacy of GPR84 ligands at wild type and F170A GPR84 
 GPR84 WT-Gαi2 C352I GPR84 F170A-Gαi2 C352I 
Ligand pEC50±SEM Emax±SEM 
 
pEC50±SEM ΔpEC50 Emax±SEM 
(% of WT) 
C-10 4.2±0.04 100±0.9 Inactive NA NR 
Embelin 5.52±0.06 100±3.9 Inactive NA NR 
Compound-1 7.3±0.1 100±6 6.5±0.07** -0.8 96.3±1.6 
6-OAU 6.41±0.15 100±5.4 5.38±0.08** -1.03 57.2±6.2* 
DIM 5.2±0.12 100±2.3 4.75±0.2 -0.45 231±25** 
PSB-16671 6.2±0.04 100±2.86 5.9 (n=1) -0.3 204.7 (n=1) 
A series of [
35
S]-GTPγS binding experiments were performed to determine the potency (pEC50) and 
efficacy (Emax) of the GPR84 agonists at wild type and F170A GPR84 mutant. Efficacy (Emax) 
was expressed as the percentage of wild type response. NA: not applicable; NR: no response; 
ΔpEC50  represents  mutant pEC50 - wild type pEC50; pEC50 and Emax values were analysed  by 
two-tailed unpaired t-test with statistical significance represented as *P<0.05, **P<0.01, ***P<0.001 
 
4.3.7. Assessment of effects of mutation of phenylalanine 101 or 
tryptophan 360 to alanine on agonist functions of different 
GPR84 ligands 
To assess the potential roles of two aromatic amino acid residues, phenylalanine 
1013.33 and tryptophan 3607.43 in the ligand detection or function, [35S]-GTPγS 
binding assays were performed using membranes generated from Flp-In T-REx-
293 cells expressing either FLAG-hGPR84-Gαi2 C352I, FLAG-hGPR84 F101A-Gαi2 
C352I or FLAG-hGPR84 W360A-Gαi2 C352I. Alteration of phenylalanine 101 to 
alanine did not affect the agonistic activity of decanoic acid and compound-1 as 
they showed similar potency and efficacy at this mutant compared to the wild 
type receptor (Figure 4.17 a,c and Table 4.5). Similarly, the potency of embelin 
was unaltered at this mutant receptor. By contrast, 6-OAU showed a 6.3-fold 
reduction in potency (P<0.01) and about 27% decrease in efficacy (P<0.05) at the 
F101A mutant. Though potencies were unaffected, F101A GPR84 exhibited some 
2 and 1.6-fold higher maximal responses for DIM and PSB-16671, respectively 
compared to the wild type receptor (Figure 4.17 e,f). Overall, this aromatic 
residue is not associated with ligand functions. On the other hand, mutation of 
tryptophan 3607.43 to alanine completely ablated the agonist function of embelin 
at GPR84 (Figure 4.17b). Though the potency of decanoic acid was enhanced by 
2.4-fold (P<0.05), the maximum response to decanoic acid was reduced by 67% 
(P<0.001) at W360A GPR84 compared to the wild type receptor. Similarly, 
maximum responses to compound-1 and 6-OAU were reduced significantly 
(P<0.05) by 65% and 72%, respectively due to the alteration of tryptophan 360 to 
alanine. The potencies of compound-1 and 6-OAU were also decreased by 3.5-
fold (P<0.001) and 5.6-fold (P<0.01), respectively. By contrast, DIM maintained 
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its function at W360A GPR84 displaying similar efficacy and 2.3-fold higher 
potency than that displayed at the wild type receptor. Though the potency of 
PSB-16671 was enhanced by 3.5-fold (P<0.01), the efficacy was reduced 
significantly by about 33.8% compared to wild type GPR84.  
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Figure 4.17 Effects of mutation of either F101 or W360 to alanine on GPR84 ligand functions. 
Flp-In T-REx-293 cells harbouring either FLAG-hGPR84-Gαi2 C352I, FLAG-hGPR84 F101A-Gαi2 
C352I or FLAG-hGPR84 W360A-Gαi2 C352I were induced with 100 ng/ml of doxycycline for 24 
hours prior to membrane preparation. These membranes were then used in [
35
S]-GTPγS 
incorporation assays to measure the activity of C-10 (a), embelin (b), compound-1 (c), 6-OAU (d), 
DIM (e) or PSB-16671 (f). Data represent mean±SEM of three independent experiments performed 
on three individual membrane preparations. 
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Table 4-5 Potency and efficacy of GPR84 agonists at wild type, F101A and W360A GPR84 in 
[
35
S]-GTPγS binding assays 
 GPR84 WT GPR84 F101A GPR84 W360A 
Ligand pEC50 pEC50 
 
ΔpEC50 Emax 
 
pEC50 
 
ΔpEC50 Emax 
 
C-10 4.22±0.02 4.14±0.15 -0.08 91.7±3.7 4.60±0.04* 0.38 33±3.7*** 
Embelina 5.72±0.07 5.44±0.05* -0.4 58±6.2*** NA NA NR 
Compound-1 7.46±0.06 7.40±0.03 -0.28 119±7.4 6.91±0.07*** -0.55 34.6±2.9*** 
6-OAU 6.60±0.05 5.80±0.03** -0.8 72.7±9.0* 5.85±0.09** -0.75 27.5±1.9*** 
DIM 5.20±0.07 5.14±0.07 -0.06 195±30** 5.56±0.06* 0.36 106±9.5 
PSB-16671 6.35±0.04 6.31±0.03 -0.04 163±14.5** 6.90±0.05** 0.55 66.2±2.2* 
A series of [
35
S]-GTPγS binding experiments were performed to determine the potency (pEC50) and 
efficacy (Emax) of various GPR84 agonists at wild type, F101A GPR84 and W360A GPR84 
mutants and data are represented as mean±SEM of three independent experiments performed on 
three separate membrane preparations; NA: not applicable; NR: no response; Efficacy (Emax) is 
expressed as the percentage of wild type response. ΔpEC50  represents  mutant pEC50– wild type 
pEC50; pEC50 and Emax values were analysed by one-way analysis of variance (ANOVA) followed 
by Tukey’s multiple comparison tests with statistical significance denoted as *P<0.05, **P<0.01, 
***P<0.001;  
a
Analysis of pEC50 and Emax values for embelin was done by unpaired two-tailed t-
test.   
The complete elimination of agonistic action of embelin or highly reduced 
activity of decanoic acid, compound-1 and 6-OAU at the W360A GPR84 might be 
either due to loss of/lower expression of the mutant or it truly reflects the role 
of the amino acid in the orthosteric ligand detection. To assess whether loss of 
function/reduced activity of tested ligands at W360A mutant is not merely a 
reflection of the loss of expression of the mutant, the relative expression levels 
of the mutant and wild type receptor need to be estimated. The saturation 
binding study revealed that the radiolabelled antagonist [3H]-G9543 lost its 
ability to bind W360A GPR84 (Figure 4.10b) indicating either loss of expression of 
the mutant or change in protein structure/conformation. However, the complete 
retention of the agonist function of DIM at this mutant suggested that the 
mutant receptor was expressed effectively. As embelin activates human GPR84 
with greater efficacy than DIM, the complete abolition of activity of embelin at 
W360A mutant whereas DIM maintained its ability to activate the receptor 
suggested that tryptophan 360 might be associated with embelin recognition by 
the receptor.   
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4.3.8. Potential docking poses of orthosteric agonists 
Based on the mutagenesis studies described in this chapter, preliminary docking 
studies of GPR84 orthosteric agonists to the constructed homology model were 
performed. These studies showed that the binding site for decanoic acid, 
embelin and embelin-like ligands (6-OAU and compound-1) is likely to be at the 
centre of the pocket created by transmembrane helices 2, 3, 6 and 7. Docking of 
embelin to the homology model suggested that one carbonyl oxygen and another 
hydroxyl oxygen atom of the 2, 5-dihydroxy-1, 4-benzoquinone core of embelin 
are involved in hydrogen bonding/salt bridges with arginine 172 (Figure 4.18). 
This is fully consistent with the finding that embelin entirely lost ability to 
activate hGPR84 upon mutation of arginine 172 to either alanine or lysine. 
Asparagine 339 and tyrosine 81 were also predicted to form hydrogen bonds with 
the carbonyl oxygen of the head group of embelin. This predicted role of these 
two residues needs to be confirmed by further mutational analysis. 
Phenylalanine 170 of EL2 stabilizes arginine 172 by forming a cation-π 
interaction which is in agreement with the finding that R172K was not responsive 
to embelin and the fact that embelin lost its function at F170A GPR84. 
Phenylalanine 335 and tryptophan 360 might be involved in hydrophobic 
interactions with either the aromatic ring or aliphatic side chain of embelin. 
These supplemental roles of phenylalanine 335 and tryptophan 360 in the 
binding of embelin were evident from the mutagenesis studies wherein embelin 
was found to be completely inactive at both F335A and W360A mutants. These 
two residues might be important for the formation of the shape of the binding 
pocket. Leucine 100 seems to be involved in hydrophobic interactions with the 
aromatic ring and/or aliphatic side chain of embelin which again needs to be 
validated by further mutational analysis.  
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Figure 4.18 The putative binding mode of embelin in GPR84. A potential docking pose of 
embelin is shown. The polar head group 2, 5-dihydroxy-1, 4-benzoquinone is coordinated by 
arginine 172, asparagine 339 and tyrosine 81. The anchoring role of arginine 172 is in full 
agreement with the findings from the mutational analysis while the role of the other two residues 
needs to be validated. Hydrogen bonds or salt bridges are shown in dotted black lines while the 
cation-π interaction between F170 and R172 is depicted as a green dotted line. This figure was 
generated by Dr. Irina G. Tikhonova as part of collaborative work.  
The docking poses of 6-OAU and compound-1 (Figure 4.19 and 4.20) are very 
similar to that of embelin. In both cases, one carbonyl oxygen atom of the 
pyrimidinedione core is coordinated by arginine 172 of EL2 which is entirely 
consistent with the complete ablation of agonistic functions of both ligands at 
R172A GPR84 and another oxygen atom is supposed to be involved in hydrogen 
bonding with asparagine 339. Similar to the case of embelin binding, 
phenylalanine 170 of EL2 is implicated in stabilizing arginine 172 by forming a 
cation-pi interaction while phenylalanine 335 and tryptophan 360 seem to be 
associated with hydrophobic interactions with the heterocyclic ring or the 
aliphatic side chain of both 6-OAU and compound-1. These putative roles of 
phenylalanine 170 and 335 in the recognition of both ligands were in agreement 
with the significant reduction in potency of 6-OAU and compound-1 due to the 
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alanine replacement of either F170 or F335.  Docking studies also predicted that 
the aliphatic amino acid leucine 100 might be important for the detection of 6-
OAU and compound-1 by forming hydrophobic interaction with the heterocyclic 
ring or the hydrophobic tail of these ligands. To fully understand the binding 
modes of these embelin-like ligands, further mutational analysis with N339, Y81, 
L100, L73, and F96 are suggested. 
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Figure 4.19 A potential docking pose of 6-OAU within GPR84. 
Arginine 172 and asparagine 339 are involved in hydrogen bonding/salt bridges with the pyrimidinedione 
polar head group while the aliphatic hydrophobic tail is likely to be located in the inter-helical gap. Salt 
bridges/hydrogen bonds are depicted as black dotted lines while the dotted green line represents the 
cation-pi interaction between R172 and F170. This figure was from Dr. Irina G. Tikhonova as part of 
collaborative work.    
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4.3.9. GPR84 antagonist compound-107 binds to a site on GPR84 
which is topographically distinct from the orthosteric and 
allosteric agonist binding sites 
Labeguere et al., (2014) reported a novel class of GPR84 antagonists containing 
dihydropyrimidinoisoquinolinones as the core chemical structure. Although this 
class of GPR84 antagonists have been considered to have potential therapeutic 
activity for the treatment of chronic inflammatory diseases including ulcerative 
colitis and inflammatory bowel diseases (Dupont et al., 2015; Vermeire et al., 
2017), their modes of binding to GPR84 is still unexplored. Among this series of 
GPR84 antagonists, compound-104, 107 and 161 (chemical structures are shown 
in Table 1.4) were reported to concentration-dependently inhibit [35S]-GTPγS 
binding induced by EC80 concentrations of either C-10, embelin or DIM in a non-
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Figure 4.20 A putative binding mode of compound-1 within GPR84. 
Compound-1 is likely located at the cavity involving transmembrane helices 2, 3, 6 and 7. The 
pyrimidinedione core structure is anchored at the centre of the binding pocket by arginine 172. Hydrogen 
bonds or salt bridges are represented by black dotted lines while the cation-π interaction between arginine 
172 and phenylalanine 170 is shown as dotted green line. This figure was generated by Dr. Irina G. 
Tikhonova as part of collaborative work. 
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competitive manner (Mahmud et al., 2017) suggesting that these compounds did 
not bind to either the orthosteric site shared by decanoic acid and embelin or 
the allosteric site occupied by DIM. Saturation binding studies using the 
radiolabelled antagonist [3H]-G9543, which is an analogue of compound 104, 107 
and 161, revealed that the radioligand retained its ability to bind R172A GPR84-
Gαi2 C352I and R172K GPR84-Gαi2 C352I with similar affinity (Figure 4.10 b, c) 
compared to the wild type receptor, indicating that this radioligand and the 
related compound 107 binds to a site within GPR84 which is distinct from the 
orthosteric binding site. Compound-107 also does not bind the allosteric site 
occupied by DIM, which is evident from the fact that the potency of compound-
107  to block DIM stimulated [35S]-GTPγS incorporation was very similar at 
hGPR84 R172A-Gαi2 C352I mutant (pEC50: 8.05±0.07) to that of WT version of the 
receptor (pEC50: 7.97±0.03) (Figure 4.21). 
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Figure 4.21 GPR84 antagonist compound-107 does not bind to the orthosteric or allosteric 
agonist sites within GPR84. Increasing concentrations of compound-107 were assessed for their 
ability to inhibit DIM-stimulated [
35
S]-GTPγS incorporation into membranes generated from Flp-In 
T-REx-293 cells induced with 100 ng/ml of doxycycline for 24 hours to express either FLAG-
hGPR84-Gαi2 C352I (a) or FLAG-hGPR84 R172A-Gαi2 C352I (b). Data represent mean±S.E.M of 
three independent experiments performed in triplicate.    
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4.4. Discussion 
The [35S]-GTPγS binding assay was employed for the characterization of 
pharmacological tool compounds of GPR84 as this assay is recognized to be a 
suitable functional assay system for measuring pharmacological parameters of 
Gαi-coupled receptors (Harrison and Traynor, 2003; Strange, 2010). The 
suitability of this assay for Gαi-coupled receptors over other G protein-coupled 
receptors (such as Gs-coupled and Gq-coupled receptors) stems from the fact 
that higher signalling window could be obtained for Gαi-coupled receptors owing 
to significantly higher expression level of Gαi protein in any cells/tissues as well 
as higher rate of exchange of guanine nucleotides at Gαi (Milligan, 2003; 
Harrison and Traynor, 2003; Strange, 2010). This assay is also appreciated to be 
more useful to measure relative efficacy of ligands as there would be less 
receptor reserve for G protein activation which is not subject to signalling 
amplification or other modulatory effects compared to other assays which target 
downstream signalling pathway such as inhibition of adenylyl cyclase (Umland et 
al., 2001; Engström et al., 2005; Strange, 2010). 
For the study of the pharmacology of GPR84 ligands and mutational analysis, I 
have employed a GPR84-Gα fusion protein approach as it is well appreciated that 
such a fusion protein strategy generates higher signalling window due to the 
enhanced coupling efficiency of GPCR and G protein interaction (see section 
3.3.1). As expected, in the case of GPR84, the signalling magnitude generated by 
the fusion protein was 5-10 fold higher compared to that produced by eYFP-
tagged GPR84 although potencies of agonists were reduced significantly 
compared to the other system. For example, the potency of both decanoic acid 
and DIM estimated at GPR84-Gαi2 fusion protein was 10-fold lower than those 
reported by Wang et al., (2006b) measured using a FLAG-tagged GPR84. 
Compound-1 also displayed 30-fold decreased potency at the fusion protein 
compared to that showed at FLAG-hGPR84-eYFP. The 1:1 stoichiometry between 
GPCR and G protein in the fusion protein, which significantly increases the rate 
and extent of G protein coupling leading to enhanced signalling magnitude, at 
the same time, is responsible for reduced potency of ligands as it correlates the 
fraction of G protein recruitment directly to the ligand binding affinity to the 
receptor. So, in the GPCR-G protein fusion protein approach, the amount of 
interacting G protein is directly proportional to the fraction of activated 
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receptor which is ultimately governed by the affinity of the ligand to the 
receptor, implying that the functional outcome of G protein activation herein 
will be related to receptor occupancy. By contrast, in other systems the 
functional response may or may not be directly proportional to the receptor 
occupancy depending on the relative abundance of endogenous G proteins 
compared to the expressed receptor and thus there might be generation of 
receptor reserve. 
4.4.1. Arginine 172 of EL2 is integral to orthosteric ligand 
recognition and functions 
Though the development of crystal structures of a GPCR complexed with specific 
ligands is required to get accurate molecular insight into GPCR-ligand 
interactions, X-ray crystallography of GPCRs, especially for non-rhodopsin Class A 
family proteins, remains challenging and time-consuming (Kobilka and Schertler, 
2008). Due to the presence of low % of polar amino acid residues compared to 
the largely dominant hydrophobic amino acids of the GPCR, it is always 
troublesome to solubilize these membrane proteins compared to the other non-
membrane proteins. More importantly, the flexible and dynamic nature of the 
GPCR protein structure leads to exceptional instability and heterogeneity in 
terms of conformation, making it very difficult to get a stable conformational 
state of the protein for accurate crystallogenesis (Peeters et al., 2011; Kobilka 
and Schertler, 2008). Due to these challenges in crystallography of GPCRs, 
generation of atomic-level structures of GPCRs is slow and until now crystal 
structures of only 43 GPCRs are available (Isberg et al., 2016), among them 25 
are of rhodopsin-like Class A family. With unavailability of experimental 
structural information, homology modelling of a GPCR along with site-directed 
mutagenesis is still widely recognized to be a suitable technique for unravelling 
the mode of binding of ligands to a GPCR of interest (Nikaido et al., 2015; 
Costanzi, 2013; Costanzi, 2010; Tikhonova et al., 2007). As no crystal structure 
of GPR84 is available, we have applied homology modelling and site-directed 
mutagenesis to investigate potential binding modes of medium chain fatty acids 
and other orthosteric agonists. To construct an accurate homology model for any 
GPCR, choosing the appropriate template is crucial and this will ultimately 
depend on the availability of the crystal structure of other GPCRs having at least 
30% sequence identity with the target GPCR (Baker and Sali, 2001; Tikhonova, 
4 Investigation of modes of binding of ligands to human GPR84 164 
 
2017). For homology modelling, Nikaido et al., (2015) used the crystal structure 
of G-protein bound human β2-adrenergic receptor as the template although this 
shares only 20% of sequence identity with GPR84. Due to this low level of 
sequence conservation between the template and GPR84, this model structure 
of GPR84 was unable to implicate any arginine or other positively charged amino 
acid residue in anchoring the carboxylate function of MCFAs (Tikhonova, 2017). 
Stitham et al., (2003) identified Arginine-279, located in the transmembrane 
domain VII of the human prostacyclin receptor, as the charge partner for the 
carboxyl group of prostacyclin and related ligands. As it was reported that 
GPR84 belongs to the prostanoid receptor subfamily (Tikhonova, 2017), a similar 
positively charged amino acid moiety within GPR84 was expected to be involved 
in the ionic interaction with the carboxylate of medium chain fatty acids. More 
importantly, as four free fatty acid sensing receptors (FFA1-4) contain at least 
one arginine residue which is involved in electrostatic interaction with the 
carboxylate of fatty acids, a similar arginine residue within GPR84 might 
coordinate the carboxylate function of MCFAs. As part of a collaborative study 
Tikhonova (2017) developed a homology model of GPR84 using a hybrid template 
comprising the transmembrane architecture of crystal structure of human orexin 
1 receptor (33% sequence homology with GPR84) and the 2nd extracellular loop 
from the crystal structure of rhodopsin (shares 43% sequence identity with EL2 of 
GPR84). This homology model predicted that arginine 172, located within the 2nd 
extracellular loop of GPR84, is the putative charge partner for the carboxylic 
acid group of decanoic acid. This prediction was then confirmed by mutagenesis 
as removal of this arginine, even with maintenance of the positive charge, 
completely eliminated the function of decanoic acid, embelin, compound-1 and 
6-OAU, but not of DIM or PSB-16671. These results indicated that arginine 172 is 
integral to detection of orthosteric agonist ligands by human GPR84, whilst DIM 
(and analogues) binds to an allosteric site on GPR84 that is topographically 
distinct from the orthosteric binding site. As for decanoic acid, arginine 172 was 
also found to coordinate the hydrophilic head group of embelin and embelin-like 
compounds such as 6-OAU, compound-1 and compound-1765 indicating that 
these polar head groups are acting as bioisosteres of the carboxylate function of 
MCFAs. The complete loss of agonistic activity of decanoic acid, embelin and 
compound-1 and greatly reduced activity of 6-OAU at the R172K mutant 
demonstrated that arginine 172 could not be replaced by lysine. The homology 
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model predicted that arginine 172 coordinates phenylalanine 170 and asparagine 
339 as well as likely forms contacts with other aromatic residues like tryptophan 
360, and thereby plays a critical role in organizing the binding pocket for 
orthosteric ligands. This tendency of arginine to form multiple contacts with 
nearby aromatic residues is due to the presence of the guanidinium moiety 
which has the potential for forming multiple hydrogen bonds/salt bridges. 
Although lysine retains the positive charge of arginine, the size, shape and 
location of the charge are different from that of guanidine group and thus is 
unable to form multiple hydrogen bonds. So it is impossible for lysine to make as 
many interactions with other amino acid residues and thus cannot organize and 
stabilize the binding cavity as arginine does.  
4.4.2. Phenylalanine 170 and 335 might be associated with ligand 
recognition 
The homology modelling followed by mutational analysis also suggested that 
another two residues phenylalanine 170 of EL2 and phenylalanine 335 of 
transmembrane helix VI might play supplemental roles in ligand recognition by 
human GPR84. Though phenylalanine 170 is not directly involved in the 
detection of orthosteric agonists, the homology modelling and docking studies 
showed that F170 is involved in cation-π interaction with nearby arginine 172 
and thus plays an important role for the stabilization of this residue. As arginine 
172 is critical for ligand interaction and function (section 4.3.2), phenylalanine 
170 might have a contribution in the ligand binding or function by stabilizing 
arginine 172. The importance of this cation-pi interaction was supported by the 
fact that alteration of arginine 172 to lysine completely ablated responses to 
orthosteric agonists. The indirect role of phenylalanine 170 in the orthosteric 
ligand binding mode is consistent with mutagenesis studies wherein decanoic 
acid and embelin completely lost their agonistic functions and 6-OAU and 
compound-1 displayed 10 and 6.3-fold reduction in potency, respectively upon 
mutation of F170 to alanine. The role of amino acid residues of EL2 in the 
stabilization of the arginine residue which coordinates the carboxylate function 
of fatty acid was also observed in the case of FFA1. Tikhonova and co-workers 
(2007) identified an electrostatic interaction between glutamate 172 of EL2 and 
arginine 2587.35  and suggested that this interaction was important for ligand 
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function as evidenced from the 100-fold reduction in potency of  synthetic 
agonist GW9508 at a R258K FFA1 mutant.  
The role of EL2 of GPR84 in ligand recognition and function is not unusual as 
similar roles of EL2 of other GPCR have been reported by several groups (for 
review see Peeters et al., 2011). For example, amino acid residues, located 
within EL2 have been implicated in ligand binding to prostanoid receptors, 
including the thromboxane A2 receptor (So et al., 2003; Ruan et al., 2004) and 
the prostacyclin receptor (Ni et al., 2008).  
The generated homology model of GPR84 also suggested that phenylalanine 335 
might play an important role in the detection of ligands by forming hydrophobic 
interactions with either aromatic/heterocyclic ring of embelin and embelin-like 
ligands or the aliphatic chain of the free fatty acids. This putative role of 
phenylalanine 335 in ligand binding was supported by the fact that embelin was 
found to be totally inactive and decanoic acid displayed markedly reduced 
activity at the F335A mutant while 6-OAU and compound-1 showed significantly 
lowered potency (38 and 110-fold reduction in potency, respectively) compared 
to the wild type receptor. Docking studies using the constructed homology model 
of GPR84 also showed that tryptophan 360 is likely to be involved in hydrophobic 
interactions with the aromatic rings or aliphatic side chains of orthosteric 
agonists and stabilizes the network of interactions within the receptor. Though 
alteration of tryptophan 360 to alanine resulted in reduction in agonistic 
functions of orthosteric agonists, it was not clear whether these reduced 
activities were due to the lowered expression level of the mutant protein or 
were just reflection of the effects of mutation on protein folding and/or 
organization. Further work is necessary to solve these issues.   
Overall, the putative binding site of orthosteric agonists within GPR84 is quite 
different from the other four fatty acid sensing receptors (FFA1-4). The 2nd 
extracellular loop of GPR84 plays the critical role in ligand binding and 
activation of GPR84 which is not the case for FFA1-4 receptors wherein 
conserved arginine residue(s) located at 5.39 and 7.35 position of TMD V and VII, 
respectively (FFA1-3) or at the 2.64 position of TMD II (For FFA4) are vital for 
ligand recognition. Though recently Srivastava and co-workers (2014) confirmed 
that glutamate 172 of EL2 of FFA1 is involved in recognition of the agonist by 
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forming a hydrogen bond with arginine 258, this role of EL2 in the ligand binding 
mode to FFA1 is supplemental to the anchoring role of arginine 258 and arginine 
183. Another important difference is that the putative orthosteric binding site in 
GPR84 contains less aliphatic amino acid residues compared to other free fatty 
acid receptors. As GPR84 is quite different from other free fatty acid receptors 
in terms of sequence identity, these differences in ligand binding mode are not 
surprising. 
4.4.3. Mutational analysis and functional studies suggested 
multiple distinct binding sites on human GPR84 
Mutational analysis and docking of the ligands against the constructed homology 
model of GPR84 suggested that embelin, 6-OAU, compound-1 and compound-1 
analogues, including TUG-1765, are orthosteric to decanoic acid while DIM and 
PSB-16671 bind to an allosteric site within human GPR84. Saturation binding 
studies using the radiotracer [3H]-G9543 also suggested that GPR84 antagonist 
compound-107 and related molecules do not bind the orthosteric binding site as 
it maintained the ability to bind R172A and R172K GPR84 mutants affording 
similar binding affinity compared to the wild type receptor. Noticeably, 
compound-107 also did not bind to the allosteric site shared by DIM as it 
displayed similar potency at R172A GPR84 mutant to inhibit the DIM-induced  
[35S]-GTPγS binding to membranes compared to that exhibited at wild type 
receptor. These studies suggested three distinct binding sites within human 
GPR84. The presence of multiple binding sites on a GPCR is not uncommon. 
Srivastava et al., (2014) reported three presumed distinct binding sites on FFA1 
which was evident from the crystal structure of FFA1 complexed with the partial 
agonist, TAK-875. The atomic-level crystal structure of FFA1 complexed with 
both partial agonist MK-8666 and ago-PAM AP8 also confirmed the presence of 
separate binding sites for the partial agonist and allosteric ligand within FFA1 
(Lu et al., 2017). Based on the findings from several functional assays in 
conjunction with the homology modelling of FFA2 developed using the crystal 
structure of β2-adrenergic receptor as the template Lee et al., (2008) also 
suggested that positive allosteric modulators and endogenous agonist short-chain 
fatty acids bind to non-overlapping distinct sites within FFA2. Similarly, 
functional studies together with mutational analysis revealed the possibility of 
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the presence of multiple binding sites for allosteric activators and short-chain 
fatty acids within FFA2 (Bolognini et al., 2016) and FFA3 (Hudson et al., 2014a).  
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5 Defining the orthologue selectivity of GPR84 
ligands 
5.1. Introduction 
Ligands of a GPCR might display variations in pharmacology and functions among 
different orthologues. Investigation of this orthologue selectivity is important for 
the elucidation of physiological functions of orphan or enigmatic G-protein 
coupled receptors (Milligan, 2018; Jenkins et al., 2012). For example, although 
antagonist GLPG0974 and CATPB showed high affinity at human FFA2 and thus 
effectively inhibited short chain fatty acid-mediated responses in transfected 
cells expressing human FFA2 or in human-derived cells, they have been reported 
to be inactive at the mouse orthologue (Milligan, 2018; Sergeev et al., 2016; 
Pizzonero et al., 2014; Hudson et al., 2013a) which hindered the investigation of 
the patho-physiological role(s) of this therapeutically important drug target. 
Similarly, antagonists of GPR35 were shown to display species-selective 
pharmacology. While the antagonists CID-2745687 and ML-145 have been shown 
to effectively block agonist functions at human GPR35 with high potency, they 
were found to be inactive to antagonize the agonist effects of zaprinast or 
cromolyn disodium in Flp-In T-REx cells expressing rat or mouse GPR35 (Jenkins 
et al., 2012). Similar to FFA2 receptors, the study of the biological functions or 
patho-physiological roles of GPR35 remains challenging due to this reported 
inactivity of certain antagonists at mouse or rat orthologues. Defining the 
orthologue selectivity of a specific GPCR having potential therapeutic activity is 
also important for drug discovery programmes (Strasser et al., 2013) as murine 
animal models are routinely used for this purpose. The variation in the 
pharmacology of the potential small-molecule drugs among human and rodent 
orthologues needs to be explored before initiating the target validation 
processes performed in rodent models of human diseases.  
There is 85% sequence conservation between human and mouse GPR84 (Wang et 
al., 2006b; Gaidarov et al., 2018) and thus mouse GPR84 is considered to be the 
true orthologue of human GPR84. Though mouse GPR84 was reported to respond 
to medium chain fatty acids (Wang et al., 2006b) and to embelin and embelin 
derivatives (Gaidarov et al., 2018) in a manner similar to that of human GPR84, 
studies with other agonists or antagonists of GPR84 to define potential species-
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selective pharmacology are lacking. To explore the orthologue selectivity of 
GPR84 ligands, FLAG-mGPR84-eYFP, FLAG-mGPR84-Gαi2 and FLAG-mGPR84-Gαi2 
C352I fusion constructs were generated. This chapter aimed at  
i) Defining the orthologue selectivity of GPR84 agonists and antagonists 
by employing both eYFP-tagged human and mouse GPR84 as well as 
the fusion protein approach of human and mouse GPR84 
ii) Exploring the pharmacology of GPR84 ligands in a RAW264.7 cell line 
which is widely used as a murine immune cell model 
5.2. Characterization of cell lines expressing FLAG-
mGPR84-Gαi2, FLAG-mGPR84-Gαi2 C352I or FLAG-
mGPR84-eYFP constructs 
5.2.1. Characterization of the expression of FLAG-mGPR84-Gαi2 
or FLAG-mGPR84-Gαi2 C352I by western blot analysis 
The expression of FLAG-mGPR84-Gαi2 or FLAG-mGPR84-Gαi2 C352I in doxycycline-
induced Flp-In T-REx-293 cells was characterized by immunoblotting membranes 
prepared from both uninduced and doxycycline-induced cells with an anti-ICL3-
mouse GPR84 antiserum which is able to detect the 3rd intracellular loop (ICL3) 
of the expressed receptor. Immunoblots of membranes purified from 
doxycycline-induced cells revealed poorly resolved multiple bands having 
molecular masses between 80 and 105 kDa (Figure 5.1 A). These bands were 
specific as they were not detected in immunoblots of membranes generated 
from cells grown in the absence of doxycycline. The pre-treatment of 
membranes of doxycycline-treated cells with peptide N-glycosidase enzyme 
(PNGase F) at a final concentration of 0.05 U/µl converted these bands into a 
predominant single band having an apparent molecular mass of 80 kDa which 
migrated more rapidly in the gel (Figure 5.1A). These outcomes confirmed the 
expression of FLAG-mGPR84-Gαi2 in Flp-In T-REx-293 cells as an intact 
polypeptide and revealed that multiple bands in the immunoblot of membranes 
of doxycycline-treated cells represented N-glycosylated forms of the receptor 
construct. Similarly, the detection of a diffuse band having an apparent 
molecular mass between 80 and 105 kDa in the immunoblot of membranes 
generated from doxycycline-induced Flp-In T-REx-293 cells harbouring FLAG-
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mGPR84-Gαi2 C352I confirmed the effective expression of the fusion protein in 
the cell line (Figure 5B).  
 
Figure 5.1 Immunoblot of FLAG-mGPR84-Gαi2 and FLAG-mGPR84-Gαi2 C352I probed with 
anti-ICL3-mouse GPR84 antiserum. Flp-In T-REx-293 cells stably harbouring FLAG-mGPR84-
Gαi2 were either uninduced (-Dox) or induced (+Dox) with 100 ng/ml of doxycycline for 24 hours 
prior to membrane preparation. These membranes were then either untreated (-PNGase F) or 
treated with N-glycosidase F (+PNGase F) at a final concentration of 0.05 units/µl followed by 
heating for 3 hours at 37ºC. These samples containing 10 µg proteins were then resolved by 
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) followed by 
immunoblotting with anti-ICL3-mouse GPR84 antiserum (A). Similarly, membranes generated from 
uninduced (-Dox) or doxycycline-induced (100 ng/ml, 24 hours, +Dox) Flp-In T-REx -293 cells 
harbouring FLAG-mGPR84-Gαi2 C352I were subjected to SDS-PAGE and subsequently 
immunoblotted with anti-ICL3-mouse GPR84 antiserum (B).  
 
5.2.2. Characterization of the expression of FLAG-mGPR84-
eYFP or FLAG-hGPR84-eYFP in HEK-293 cells 
To characterize the expression of FLAG-mGPR84-eYFP and FLAG-hGPR84-eYFP in 
HEK-293 cells, membranes generated from transiently transfected HEK-293 cells 
were subjected to immunoblotting with either an anti-GFP antiserum which is 
able to detect the eYFP moiety of the expressed receptor construct or with anti-
ICL3-mouse GPR84 antiserum which can recognize the 3rd intracellular loop of 
mouse GPR84 and potentially that of human GPR84 as well. A discrete band 
having an apparent molecular mass between 150 and 160 kDa representing a 
potential dimer of the receptor constructs and another discrete band having a 
molecular weight of 70 to 75 kDa corresponding to the monomeric form 
confirmed the expression of either FLAG-mGPR84-eYFP or FLAG-hGPR84-eYFP in 
the corresponding cells (Figure 5.2A). Pre-treatment of membranes with N-
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glycosidase enzyme (PNGase F) resulted in greatly increased intensity of the 
band having a molecular weight consistent with the monomeric form (~72 kDa), 
suggesting the cleavage of glycan(s) from glycosylated forms of the receptor. 
This enzyme treatment also slightly increased the migration speed of the 
immunoreactive species corresponding to the monomeric form of both human 
and mouse GPR84. Importantly, the band having molecular mass between 150 
and 160 kDa was also detected in the immunoblot following treatment with the 
N-glycosidase enzyme, suggesting that the deglycosylation process did not 
significantly affect the dimerization of GPR84. The presence of the other three 
specific bands having a molecular mass greater than 225 kDa in the immunoblots 
might reflect aggregates or oligomeric forms of the receptor construct.  
Similar to the immunoblot performed using anti-GFP antiserum, immunoblots 
with anti-ICL3-mouse GPR84 antiserum confirmed the expression of FLAG-
mGPR84-eYFP or FLAG-hGPR84-eYFP in transiently transfected HEK-293 cells 
which was evidenced from the detection of a specific band having a molecular 
mass of about 150 kDa, probably corresponding to a dimeric form of the receptor 
construct (Figure 5.2B). The intensity of this band having a molecular mass of 
about 150 kDa in the immunoblot of membranes generated from cells 
transfected with FLAG-hGPR84-eYFP was substantially reduced compared to that 
of FLAG-mGPR84-eYFP, indicating that the anti-ICL3-mouse GPR84 antiserum 
was less sensitive to detect the 3rd intracellular loop of human GPR84. Another 
band having a molecular mass of some 70 kDa appeared in the immunoblot of 
membranes following treatment with the N-glycosidase enzyme which was not 
detected in the blot of untreated membranes, further supporting the N-
glycosylation of mouse GPR84.   
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Figure 5.2 Immunoblot of FLAG-mGPR84-eYFP and FLAG-hGPR84-eYFP probed with anti-
GFP (A) or anti-ICL3-mouse GPR84 antiserum (B). HEK-293 cells were transiently transfected 
with FLAG-hGPR84-eYFP, FLAG-mGPR84-eYFP or empty vector pcDNA5 and membranes were 
generated after 36 hours of transfection. Membranes purified from cells transfected with FLAG-
hGPR84-eYFP or FLAG-mGPR84-eYFP were then either untreated (-PNGase F) or treated 
(+PNGase F) with N-glycosidase enzyme (PNGase F) followed by incubating for 2 hours at 37ºC 
(+heat). These samples containing 8 µg of proteins were subsequently subjected to SDS-PAGE to 
resolve the proteins. To assess the effect of the application of heat on degradation/migration of 
protein, membranes which were not (-heat) incubated at 37ºC were also run in the gel. The 
resolved proteins were then immunoblotted with either an anti-GFP antiserum (A) or with the anti-
ICL3-mouse GPR84 antiserum (B). Possible N-glycosylation sites within the N-terminus of human 
and mouse GPR84 are highlighted in red (C).  
5.2.3. Functional characterization using [35S]-GTPγS binding 
assays 
I generated doxycycline-inducible Flp-In T-REx-293 cell lines stably harbouring 
FLAG-mGPR84-Gαi2, FLAG-mGPR84-Gαi2 C352I or FLAG-mGPR84-eYFP receptor 
constructs. To check the functionality of these mouse GPR84 receptor 
constructs, agonist-induced [35S]-GTPγS incorporation assays were performed 
using membranes prepared from both uninduced (no doxycycline added) and 
doxycycline-induced (100 ng/ml, 24 hours) cells expressing FLAG-mGPR84-Gαi2, 
FLAG-mGPR84-Gαi2 C352I or FLAG-mGPR84-eYFP constructs. Compound-1, 
embelin, PSB-16671 and DIM each enhanced [35S]-GTPγS binding to membranes 
generated from cells induced with doxycycline to express FLAG-mGPR84-Gαi2 in 
a concentration-dependent fashion with pEC50 of 7.51±0.10, 5.54±0.04, 
6.50±0.10 and 5.36±0.01, respectively (Figure 5.3 ai,aii). These results confirmed 
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that FLAG-mGPR84-Gαi2 expressed in Flp-In T-REx-293 cells is functionally 
active. Each of ligands did not promote any significant [35S]-GTPγS incorporation 
into membranes generated from Flp-In T-REx-293 cells which were not induced 
with doxycycline, implying that agonist-promoted binding of [35S]-GTPγS into 
membranes purified from doxycycline-induced cells was mediated by activation 
of mouse GPR84. Consistent with the results observed at FLAG-hGPR84-Gαi2 (see 
section 4.2.3), PSB-16671 also displayed substantially higher potency (about 13-
fold) and efficacy (about 2.6-fold) than parent compound DIM at FLAG-mGPR84-
Gαi2, indicating that DIM also acted as a partial agonist at mouse orthologue. 
Contrary to the result observed at FLAG-hGPR84-Gαi2 wherein PSB-16671 
displayed lower efficacy than compound-1 (section 4.2.3), at FLAG-mGPR84-Gαi2  
both agonists showed an equivalent maximal response (Figure 5.3 ai, aii).  
Compound-1 and embelin also concentration-dependently promoted binding of 
[35S]-GTPγS into membranes generated from doxycycline-induced Flp-In T-REx-
293 cells expressing FLAG-mGPR84-Gαi2 C352I whilst no significant binding of 
radiolabelled guanine nucleotide was observed when membranes prepared from 
cells grown in the absence of doxycycline were employed (Figure 5.3 bi, bii). 
These results demonstrated the functional integrity of the FLAG-mGPR84-Gαi2 
C352I construct. Compound-1 and embelin displayed similar potency at FLAG-
mGPR84-Gαi2 and FLAG-mGPR84-Gαi2 C352I, implying that mutation of cysteine 
352 of Gαi2 to isoleucine did not alter the pharmacology of GPR84 agonists.  
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Figure 5.3 FLAG-mGPR84-Gαi2, FLAG-mGPR84-Gαi2 C352I and FLAG-mGPR84-eYFP are 
functionally active in [
35
S]-GTPγS binding assays. Flp-In T-REx-293 cells stably harbouring 
FLAG-mGPR84-Gαi2, FLAG-mGPR84-Gαi2 C352I or FLAG-mGPR84-eYFP were either uninduced 
(-Dox) or induced (+Dox) with 100 ng/ml of doxycycline for 24 hours prior to membrane 
preparation. Various concentrations of either compound-1 or embelin (ai) and PSB-16671 or DIM 
(aii) were then assessed for their ability to stimulate [
35
S]-GTPγS binding to membranes prepared 
from either untreated or doxycycline-treated cells harbouring FLAG-mGPR84-Gαi2. Equivalent 
studies were performed to evaluate the capacity of increasing concentrations of compound-1 (bi) or 
embelin (bii) to induce promotion of [
35
S]-GTPγS incorporation into membranes generated from 
cells harbouring FLAG-mGPR84-Gαi2 C352I. Similarly, the effects of mouse GPR84 activation on 
[
35
S]-GTPγS incorporation into membranes purified from cells harbouring FLAG-mGPR84-eYFP 
were evaluated following addition of increasing concentrations of compound-1(ci) or embelin (cii).  
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Compound-1 and embelin also concentration-dependently stimulated 
incorporation of [35S]-GTPγS into membranes prepared from doxycycline-induced 
cells expressing FLAG-mGPR84-eYFP (Figure 5.3 ci, cii) displaying pEC50 of 
8.3±0.08 and 6.0±0.08, respectively. Though compound-1 and embelin displayed 
higher potency (about 6.5 and 3-fold increased potencies, respectively) at FLAG-
mGPR84-eYFP compared to that displayed at FLAG-mGPR84-Gαi2, the signalling 
magnitudes generated by FLAG-mGPR84-eYFP were much lower than the fusion 
protein construct. While embelin did not promote any significant binding of 
[35S]-GTPγS to membranes generated from cells which were not treated with 
doxycycline to allow expression of FLAG-mGPR84-eYFP, compound-1 was found 
to promote some [35S]-GTPγS incorporations into same membrane preparations 
perhaps indicating some degree of leaky expression.  
5.2.4. Mouse GPR84 couples to PTX-sensitive Gαi G proteins 
The pre-treatment of cells expressing FLAG-mGPR84-Gαi2 fusion protein with the 
Gαi protein inhibitor, pertussis toxin (50 ng/ml, 24 hours) either completely or 
largely (80% reduction compared to untreated cells) inhibited [35S]-GTPγS 
binding to Gαi2 protein induced by embelin or compound-1, respectively (Figure 
5.4 ai, aii) which is in agreement with the fact that mouse GPR84 couples to PTX-
sensitive Gαi. In contrast, agonist-induced [
35S]-GTPγS incorporation was not 
altered substantially following the PTX treatment of cells expressing PTX-
insensitive fusion protein FLAG-mGPR84-Gαi2 C352I (Figure 5.4 bi, bii), implying 
that after addition of PTX to cells, most of the [35S]-GTPγS incorporation into 
membranes reflected binding of the radiolabelled guanine nucleotide into the 
fused exogenous Gαi2 G protein while contribution from the endogenous Gαi 
protein was marginal.  
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Figure 5.4 Mouse GPR84 couples to pertussis toxin-sensitive Gαi G proteins. Flp-In T-REx-
293 cells stably harbouring FLAG-mGPR84-Gαi2 or FLAG-mGPR84-Gαi2 C352I were induced with 
100 ng/ml doxycycline to express the receptor of interest. These cells were then either untreated 
(PTX-) or treated (PTX+) with 50 ng/ml of PTX for 24 h prior to membrane preparation. Various 
concentrations of compound-1 (ai) or embelin (aii) were then assessed for their capacity to 
stimulate binding of [
35
S]-GTPγS into membranes expressing FLAG-mGPR84-Gαi2. Equivalent 
experiments were performed to assess the ability of increasing concentrations of compound-1 (bi) 
or embelin (bii) to promote [
35
S]-GTPγS binding to Gαi2 associated with FLAG-mGPR84-Gαi2 C352I.  
5.3. Orthosteric and allosteric agonists display similar 
activities at human and mouse orthologues of 
GPR84  
In a preliminary study, [35S]-GTPγS binding assays were performed using 
membranes prepared from HEK-293 cells transiently transfected with FLAG-
mGPR84-eYFP, FLAG-hGPR84-eYFP or the empty vector pcDNA5. In this assay, 
decanoic acid(C-10), undecanoic acid(C-11), embelin, DIM, compound-1 and 6-
OAU displayed similar potencies at both human GPR84 and mouse GPR84 (Figure 
5.5 and Table 5.1). The variation in efficacy of these ligands found in the assay 
might reflect differential expression levels of mouse and human GPR84 in 
transiently transfected cells. Agonist functions of all these ligands were also 
evaluated by performing equivalent [35S]-GTPγS binding assays using membranes 
prepared from HEK-293 cells transiently transfected with FLAG-hGPR84-Gαi2 
C352I or FLAG-mGPR84-Gαi2 C352I fusion constructs. In these assays, orthosteric 
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agonists decanoic acid(C-10), undecanoic acid(C-11), embelin, 6-OAU and 
compound-1 as well as both the allosteric agonists DIM and PSB-16671 
concentration-dependently promoted  [35S]-GTPγS binding to membranes 
displaying similar potencies and efficacies at human and mouse orthologues of 
GPR84 (Figure 5.6 and Table 5.1). Potencies of C-10, embelin, compound-1, 6-
OAU, DIM or PSB-16671 were also indistinguishable between  human and mouse 
GPR84 when membranes prepared from doxycycline-induced (100 ng/ml, 24 
hours) Flp-In T-REx-293 cells stably harbouring FLAG-hGPR84-Gαi2 C352I or FLAG-
mGPR84-Gαi2 C352I were used in [
35S]-GTPγS binding assays (Figure 5.7 and Table 
5.2). The similar rank order of potency of tested agonists was observed between 
FLAG-hGPR84-Gαi2 C352I and FLAG-mGPR84-Gαi2 C352I which is as follows:  
Compound-1>6-OAU=PSB-16671>Embelin>DIM>C-10. 
The FLAG-mGPR84-Gαi2 C352I also maintained the similar rank order of efficacy 
of agonists compared to that displayed at FLAG-hGPR84-Gαi2 C352I (Figure 5.7 
g,h): Compound-1>6-OAU>PSB-16671>C-10> embelin=DIM 
Embelin, compound-1, DIM and PSB-16671 also showed similar functions at  
FLAG-hGPR84-Gαi2 and FLAG-mGPR84-Gαi2 when membranes prepared from Flp-
In T-REx-293 cells induced with 100 ng/ml doxycycline for 24 hours were 
employed in the assay (Figure 5.8 and Table 5.2).  
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Figure 5.5 Agonists of human GPR84 display very similar activity at mouse GPR84. 
Membranes were purified from HEK-293 cells transiently transfected with FLAG-hGPR84-eYFP, 
FLAG-mGPR84-eYFP or empty vector pcDNA5. [
35
S]-GTPγS binding assays were then performed 
using these membranes to assess the ability of increasing concentrations of C-10 (a), C-11 (b), 
embelin (c), 6-OAU (d), compound-1 (e) or DIM (f) to induce [
35
S]-GTPγS incorporation into 
membranes.  
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Figure 5.6 Human and mouse GPR84 showed similar responsiveness to orthosteric and 
allosteric ligands in HEK-293 cells. Increasing concentrations of C-10 (a), C-11 (b), embelin (c), 
6-OAU(d), compound-1 (e), DIM (f) or PSB-16671 (g) were evaluated for their ability to promote 
binding of [
35
S]-GTPγS to membranes generated from HEK-293 cells transiently transfected with 
FLAG-hGPR84-Gαi2 C352I, FLAG-mGPR84-Gαi2 C352I or empty vector pcDNA5. 
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Table 5-1 Potency of different GPR84 agonists at human and mouse GPR84 observed in 
transiently transfected HEK-293 cells 
 
A series of [
35
S]-GTPγ assays were performed using membranes generated from transiently 
transfected HEK-293 cells expressing FLAG tagged human and mouse GPR84 and human and 
mouse GPR84 fused to Gαi2 C352I as described in Figure 5.5 and 5.6 and potencies of different 
ligands were determined. Data (pEC50) are expressed as mean±S.E.M.   
 
 
 
 
 
 
 
 
 
 
                  Human GPR84 Mouse GPR84 
Ligand hGPR84-Gαi2 C352I hGPR84-eYFP mGPR84-Gαi2 C352I mGPR84-eYFP 
C-10 4.24±0.04 5.00±0.20 4.15±0.04 5.13±0.40 
C-11 
4.34±0.20 4.05±0.28 4.32±0.25 4.24±0.50 
Embelin 
5.63±0.12 6.10±0.10 5.58±0.10 6.20±0.20 
Compound-1 
7.31±0.10 8.38±0.10 7.04±0.08 8.14±0.10 
6-OAU 6.51±0.08 7.20±0.10 6.50±0.07 7.16±0.16 
DIM 5.40±0.10 6.00±0.30 5.10±0.04 6.04±0.30 
PSB-16671 6.21±0.08  6.16±0.10  
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Figure 5.7 Mouse GPR84 responds to different GPR84 agonists in a manner very similar to 
human orthologue. Flp-In T-REx-293 cells stably harbouring FLAG-hGPR84-Gαi2 C352I or FLAG-
mGPR84-Gαi2 C352I were incubated with 100 ng/ml of doxycycline for 24 hours followed by 
generation of membranes. Using these membranes, [
35
S]-GTPγS binding to Gαi2 associated with 
FLAG-hGPR84-Gαi2 C352I or FLAG-mGPR84-Gαi2 C352I were measured in response to varying 
concentrations of C-10 (a), embelin (b), compound-1 (c), 6-OAU (d), DIM (e) or PSB-16671 (f). 
Data for all the agonists from (a-f) are shown again in (g) and (h) to compare their relative efficacy 
at FLAG-hGPR84-Gαi2 C352I or FLAG-mGPR84-Gαi2 C352I, respectively.   
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Figure 5.8 Comparison of GPR84 agonist functions between human and mouse GPR84. Flp-
In T-REx-293 cells stably harbouring FLAG-hGPR84-Gαi2 or FLAG-mGPR84-Gαi2 were incubated 
with 100 ng/ml of doxycycline for 24 hours prior to membrane preparation. These membranes were 
then employed to assess the ability of increasing concentrations of DIM (a), PSB-16671 (b), 
embelin (c) or compound-1 (d) to stimulate [
35
S]-GTPγS binding to the Gαi2 associated with FLAG-
hGPR84-Gαi2 or FLAG-mGPR84-Gαi2. Data represent mean±SEM of three independent 
experiments performed on three individual membrane preparations.  
  
Table 5-2 Potency of different agonists at human and mouse GPR84 observed in 
doxycycline-inducible Flp-In T-REx-293 cells expressing human or mouse GPR84 as fusion 
protein constructs 
 Human GPR84 Mouse GPR84 
Ligand hGPR84-Gαi2 hGPR84-Gαi2 C352I mGPR84-Gαi2 mGPR84-Gαi2 C352I 
C-10  4.24±0.01  4.26±0.06 
Embelin 
5.72±0.12 5.67±0.06 5.54±0.04 5.55±0.03 
Compound-1 
7.54±0.06 7.46±0.06 7.51±0.10 7.21±0.01 
6-OAU  6.60±0.05  6.46±0.06 
DIM 5.30±0.07 5.20±0.07 5.36±0.01 5.06±0.03 
PSB-16671 6.28±0.05 6.35±0.04 6.50±0.10 6.25±0.04 
A set of [
35
S]-GTPγS incorporation assays were conducted using membranes prepared from 
doxycycline induced stable cell lines expressing human or mouse GPR84 as fusion protein 
construct with either Gαi2 or pertussis toxin resistant Gαi2 C352I as described in Figure 5.7 and 5.8.  
Data (pEC50) are expressed as mean±S.E.M of three (for h/mGPR84-Gαi2) or two (for PTX-
insensitive fusion proteins h/mGPR84-Gαi2 C352I) independent experiments performed on 
separate membranes isolated from doxycycline-treated Flp-In T-REx-293 cells.  
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5.4. Defining the pharmacology of GPR84 ligands in 
RAW 264.7 cells 
5.4.1. Orthosteric and allosteric agonists of GPR84 display 
similar pharmacology in RAW 264.7 cells to those 
observed in transfected cells expressing FLAG-mGPR84-
eYFP 
It is well established that GPR84 is expressed in the mouse monocyte-
macrophage cell line RAW 264.7 and the expression is upregulated following 
treatment with the TLR4 agonist, lipopolysaccharide (Wang et al., 2006b; Recio 
et al., 2018; Mancini et al., 2019). To investigate the pharmacological properties 
of GPR84 ligands in a more relevant physiological setting, I used RAW 264.7 cells 
as a model murine cell line. In an attempt to investigate whether LPS treatment 
leads to enhanced functional responses to GPR84 ligands, [35S]-GTPγS binding 
assays were performed using membranes generated from untreated (LPS-) or 
LPS-treated (100 ng/ml) RAW 264.7 cells. The synthetic GPR84 agonist 
compound-1 concentration-dependently enhanced [35S]-GTPγS incorporation into 
membranes generated from RAW 264.7 cells both untreated or treated with LPS 
for 5 hours and 11 hours exhibiting pEC50 of 7.3±0.15, 7.66±0.06 and 7.57±0.02, 
respectively (Figure 5.9a,b). Although the LPS pre-treatment for 5 and 11 hours 
increased the maximal response of compound-1 by 32 and 20%, respectively 
compared to untreated cells (Figure 5.9a), no statistically significant (P>0.05) 
enhancement of potency of compound-1 was observed, which implies that LPS 
treatment of RAW 264.7 cells did not produce any significant receptor reserve 
for GPR84. The allosteric agonist PSB-16671 was also found to promote [35S]-
GTPγS binding to membranes purified from RAW 264.7 cells treated with 100 
ng/ml of LPS for 5 and 11 hours displaying pEC50 of 6.78±0.13 and 6.75±0.10, 
respectively (Figure 5.9b). Decanoic acid, embelin and DIM also concentration-
dependently enhanced [35S]-GTPγS binding to membranes from LPS-treated (100 
ng/ml, 11hours) RAW 264.7 cells with pEC50 of 4.36±0.06, 6.5±0.20 and 
6.50±0.25, respectively (Figure 5.9c). Potencies of decanoic acid, embelin, 
compound-1, DIM and PSB-16671 displayed at RAW264.7 cells were very similar 
to those estimated at transfected HEK-293 cells expressing mouse GPR84-eYFP 
(Table 5.1 and Table 5.3). By contrast, although potencies of C-10, compound-1 
and PSB-16671 were indistinguishable between RAW 264.7 cells and Flp-In T-REx-
293 cells expressing FLAG-mGPR84-Gαi2, both embelin and DIM displayed about 9 
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and 13-fold higher potencies, respectively at RAW 264.7 cells compared to stably 
transfected Flp-In T-REx cells (Table 5.2 and 5.3). In contrast to transfected 
cells expressing mouse GPR84, wherein compound-1 and PSB-16671 displayed 
similar efficacy, in RAW 264.7 cells compound-1 showed about 30% higher 
maximal response than PSB-16671 (Figure 5.9 b). Whereas C-10 displayed similar 
efficacy to PSB-16671, maximal responses of DIM and embelin were substantially 
lower than those of PSB-16671, compound-1 or C-10 (Figure 5.9b,c) which 
implies that DIM and embelin acted as partial GPR84 agonists at RAW 264.7 cells 
in [35S]-GTPγS binding assays which is consistent with the results observed in 
transfected cells expressing mouse GPR84.  
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Figure 5.9 RAW 264.7 cells respond to GPR84 orthosteric and allosteric agonists in a 
manner equivalent to transfected cells expressing mouse GPR84. The effect of increasing 
concentrations of compound-1 to induce stimulation of [
35
S]-GTPγS binding to membranes 
prepared from RAW 264.7 cells either untreated (LPS-) or treated (LPS+) with 100 ng/ml of LPS for 
5 or 11 hours is shown (a). Similarly, the capacity of varying concentrations of compound-1 or PSB-
16671 to enhance binding of [
35
S]-GTPγS to membranes purified from RAW 264.7 cells induced 
with LPS for 5 hours (bi) or 11 hours (bii) was assessed. Effects of various concentrations of C-10, 
embelin or DIM in promoting binding of [
35
S]-GTPγS to membranes generated from RAW264.7 
cells treated with LPS for 11 hours are also shown (c). Data presented in (a) and (c) are from a 
representative experiment of three and two independent experiments, respectively and data shown 
in (bi) and (bii) are expressed as mean±S.E.M. of three and five independent experiments, 
respectively performed on separate membrane preparations.   
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Table 5-3 Potencies of GPR84 orthosteric and allosteric agonists in LPS-treated RAW 264.7 
cells 
 pEC50 (mean±S.E.M.) 
Ligand LPS (+) 5 h LPS(+) 11 h 
C-10  4.36±0.06 
Embelin  6.50±0.20 
Compound-1 7.66±0.06 7.57±0.02 
DIM  6.50±0.25 
PSB-16671 6.78±0.13 6.75±0.10 
A set of [
35
S]-GTPγS binding studies were performed using membranes generated from LPS-
induced RAW264.7 cells as described in Figure 5.9 and potencies of different GPR84 agonists 
were determined. Data are expressed as mean±S.E.M. of three independent experiments 
performed using separate membrane preparations isolated from RAW 264.7 cells treated with 100 
ng/ml of LPS for 5 and 11 hours.  
 
5.4.2. GPR84 antagonists showed reduced potency in RAW 
264.7 cells compared to human GPR84 expressing THP-1 
cells 
Though the maintenance of similar potency values of orthosteric and allosteric 
agonists at RAW 264.7 cells to those observed at transfected cells expressing 
cloned mouse GPR84 suggested that effects of these ligands in RAW264.7 cells 
might be mediated in a GPR84-specific manner, to confirm this in more detail, 
the capacity of the established GPR84 antagonists compound-104, 107,161 or 
GLPG1205 to block ligand-mediated [35S]-GTPγS binding to membranes of RAW 
264.7 cells was examined. GPR84 antagonist compound-104, compound-107 and 
GLPG1205 completely inhibited compound-1-induced binding of [35S]-GTPγS to 
membranes generated from LPS-treated RAW 264.7 cells in a concentration-
dependent manner with pIC50 of 6.44±0.16, 6.52±0.07 and 6.22±0.05, 
respectively (Figure 5.10a). In contrast, compound-837 was inactive at RAW 
264.7 cells in inhibiting the response to compound-1 (Figure 5.10a). Compound-
107, compound-161 and GLPG1205 also effectively and concentration-
dependently blocked PSB-16671-stimulated incorporation of [35S]-GTPγS into 
membranes from LPS-treated RAW 264.7 cells displaying pIC50 of 6.82±0.08, 
6.35±0.28 and 6.44±0.06, respectively (Figure 5.10b). Similarly, in [35S]-GTPγS 
binding assays, response to an EC80 concentration of decanoic acid (C-10) was 
also concentration-dependently antagonized by compound-104 , compound-161 
and GLPG1205 with pIC50 of 6.92±0.12, 5.70±0.15 and 6.43±0.08, respectively 
whilst compound-837 was inactive in suppressing the C-10-induced [35S]-GTPγS 
binding (Figure 5.10c). Moreover, GPR84 antagonist GLPG1205 completely and 
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concentration-dependently inhibited embelin or DIM-induced [35S]-GTPγS binding 
to membranes of RAW264.7 cells displaying pIC50 of 6.55±0.04 and 6.52±0.17, 
respectively (Figure 5.10 d,e). These studies confirmed that compound-1, 
decanoic acid, PSB-16671, embelin or DIM-induced promotion of [35S]-GTPγS 
incorporation into membranes isolated from LPS-stimulated RAW 264.7 cells 
were mediated in a GPR84-specific manner.  
GPR84 antagonist compound-107 displayed some 20 to 30-fold decreased 
potency at RAW 264.7 cells in inhibiting the agonistic function of compound-1 
and PSB-16671, respectively compared to that displayed at LPS-induced THP-1 
cells estimated by Mancini et al., (2019). Moreover, potencies of compound-104 
and 161 to block agonist function of C-10 displayed in RAW 264.7 cells were 
some 5 and 12.6-fold lower, respectively than those estimated at FLAG-hGPR84-
eYFP reported by Mahmud et al., (2017). These substantial reductions in 
potencies of compound-107, 104 and 161 at RAW 264.7 cells in comparison with 
cells expressing human GPR84 suggested substantially lower affinity of this series 
of antagonists for mouse GPR84. While the radiolabelled antagonist [3H]-G9543 
has been reported to bind membranes purified from LPS-treated THP-1 cells with 
sub-nM affinity (Mancini et al., 2019), this radioligand did not show any 
significant specific binding to membranes generated from LPS-treated RAW 
264.7 cells (Figure 5.9 f), implying that [3H]-G9543 and potentially the related 
antagonist compounds-104, 107 or 161 displayed greatly reduced affinity for 
mouse GPR84. This result is consistent with the decreased potency of compound-
107 and related molecules at mouse GPR84 compared to the human orthologue.  
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Figure 5.10 GPR84 antagonists compound-104, 107,161 and GLPG1205 but not compound-
837 effectively blocked agonist-induced responses in RAW 264.7 cells. Membranes were 
generated from RAW 264.7 cells which were treated with LPS (100 ng/ml for 5 hours) to allow 
upregulation of GPR84 expression. Membranes containing 5 µg of proteins were then employed to 
assess the ability of varying concentrations of compound-104, 107, 837 or GLPG1205 to inhibit 
[
35
S]-GTPγS binding induced by an EC80 concentration of compound-1(a). Effects of various 
concentrations of compound-107,161 or GLPG1205 in blocking PSB-16671-stimulated binding of 
[
35
S]-GTPγS were also examined (b). Similar studies were performed assessing the capacity of 
increasing concentrations of compound-104, 161, 837 or GLPG1205 to block [
35
S]-GTPγS 
incorporation into membranes mediated by an EC80 concentration of C-10 (c). Increasing 
concentrations of GLPG1205 were also assayed for their ability to block [
35
S]-GTPγS binding to 
membranes stimulated by an EC80 concentration of either embelin (d) or DIM (e). Increasing 
concentrations (ranging from 0.13 nM to 20.5 nM) of radioligand [
3
H]-G9543 with (nonspecific 
binding) or without (total binding) 1 µM compound-104 were assessed for their ability to bind to 
membranes purified from LPS-treated RAW 264.7 cells (f).  
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Table 5-4 Potencies of GPR84 antagonists to inhibit the response to an EC80 concentration 
of various agonists at LPS-induced RAW264.7 cells 
                                         Agonist 
Antagonist Compound-1 PSB-16671 C-10 Embelin DIM 
Compound-104 6.44±0.16  6.92±0.12   
Compound-107 6.52±0.07 6.82±0.08    
Compound-161  6.35±0.28 5.70±0.15   
GLPG1205 6.22±0.05 6.44±0.06 6.43±0.08 6.55±0.04 6.52±0.17 
Compound-837 Inactive  Inactive   
A series of [35S]-GTPγS incorporation assays were performed using membranes prepared from 
LPS-induced RAW264.7 cells as described in Figure 5.10 to determine the potencies of different 
GPR84 antagonist in inhibiting response to different GPR84 agonists. Data are expressed as pIC50 
(mean±S.E.M, n=3).  
5.4.3. GLPG1205 displays differential modes of action in 
antagonizing the effect of compound-1 and PSB-16671 in 
RAW264.7 cells 
In an attempt to investigate the mode of action of GPR84 antagonist GLPG1205 
(designated as compound-122 in the patent literature (Labeguere et al. 2014; 
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=101
71), effects of addition of increasing fixed concentrations of GLPG1205 on the 
position of concentration-response curves of compound-1 were analysed by 
employing [35S]-GTPγS binding assay using membranes generated from naïve 
RAW264.7 cells. Though increasing fixed concentrations of GLPG1205 
progressively decreased the potency of compound-1, the effect of antagonism 
was not fully surmounted when higher concentrations of the antagonist were 
applied (Figure 5.11a); this implies that antagonism of GLPG1205 in blocking 
compound-1-mediated effect did not follow classical simple competitive 
antagonism. However, global fitting of dataset with Gaddam/Schild EC50 shift 
analysis revealed that the Schild slope factor is close to 1.0, suggesting that 
GLPG1205 antagonized the agonist function of compound-1 in RAW264.7 cells in 
a competitive manner. The global analysis also estimated the pA2 affinity value 
for the antagonist to be 7.23. Similarly, increasing fixed concentrations of 
GLPG1205 also caused a progressive right-shift of the position of concentration-
response curves for compound-1 (Figure 5.11b) when membranes generated from 
Flp-In T-REx-293 cells expressing FLAG-mGPR84-Gαi2 were employed in [
35S]-
GTPγS incorporation assay. Once again, though antagonism mediated by higher 
concentrations (3 and 10 µM) of GLPG1205 was not surmounted fully, the global 
fitting of data with Gaddam/Schild EC50 shift analysis revealed that the slope 
factor is 1.04 which is consistent with the competitive mode of antagonism. The 
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estimated pA2 affinity value of GLPG1205 for FLAG-mGPR84-Gαi2 was 6.90 which 
is similar to that observed in RAW264.7 cells. By contrast, addition of varying 
fixed concentrations of GLPG1205 to the concentration-response assays for PSB-
16671 did not significantly affect the potency of PSB-16671 rather resulted in 
progressive decrease in maximal response (Figure 5.11c), indicating that in 
RAW264.7 cells, GLPG1205 antagonized the effect of PSB-16671 in a non-
competitive manner i.e GLPG1205 binds to a site on GPR84 that is distinct from 
the binding site shared by PSB-16671. 
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Figure 5.11 GLPG1205 antagonizes effect of compound-1 in a competitive manner while it is 
non-competitive with PSB-16671 in blocking effect of PSB-16671 in RAW264.7 cells. 
Concentration-response curves for compound-1 were generated in the presence or absence of 
varying fixed concentrations (ranging from 100 nM to 10 µM) of antagonist GLPG1205 using [
35
S]-
GTPγS binding assays employing membranes prepared from naïve RAW264.7 cells (a) or Flp-In T-
REx-293 cells (b) induced with 100 ng/ml doxycycline for 24 hours to express FLAG-mGPR84-
Gαi2. Data shown in (a) and (b) are from globally fitted data with Gaddam/Schild EC50 shift analysis. 
Similarly, [
35
S]-GTPγS incorporation assays were performed using membranes of naïve RAW264.7 
cells in which increasing fixed concentrations of antagonist GLPG1205 ranging from 300 nM to 10 
µM were added to concentration-response assays for PSB-16671(c). In all these assays, 
membranes were pre-incubated with fixed concentrations of antagonist GLPG1205 for 15 minutes 
at room temperature followed by addition of agonist.   
    
5.5. Antagonist 107 and 104 display reduced potency at 
mouse GPR84 compared to the human orthologue 
while antagonist 837 was inactive at mouse GPR84 
In the case of blockade of the agonist function of compound-1 and PSB-16671 as 
assessed by [35S]-GTPγS incorporation assays, GPR84 antagonist compound-107 
showed reduced potency at RAW 264.7 cells compared to the human monocytic 
cell line THP-1 (section 5.4.2). As further support for this variation in the 
pharmacology of GPR84 antagonists between mouse and human orthologues, 
transfected cells expressing cloned mouse and human GPR84 were employed.  
HEK-293 cells were transiently transfected with FLAG-hGPR84-Gαi2 C352I and 
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FLAG-mGPR84-Gαi2 C352I fusion constructs and membranes were generated after 
36 hours of transfection. In [35S]-GTPγS binding assays using these membranes, 
both compound-104 and 107 effectively inhibited response to EC80 
concentrations of orthosteric agonist compound-1 in a concentration-dependent 
manner at both human and mouse GPR84-Gαi2 fusion proteins, affording pIC50 of 
7.65±0.03 and 6.5±0.08 (human vs mouse GPR84) and 8.05±0.14 and 6.68±0.05 
(human vs mouse GPR84), respectively (Figure 5.12 a,b). Moreover, potencies of 
compound-104 and 107 were decreased by about 15 and 23-fold, respectively at 
FLAG-mGPR84-Gαi2 C352I compared to FLAG-hGPR84-Gαi2 C352I. Although 
compound-837 effectively and concentration-dependently blocked compound-1-
promoted binding of [35S]-GTPγS to Gαi protein associated with human GPR84 
with pIC50 of 7.96±0.04, it was totally inactive at FLAG-mGPR84-Gαi2 C352I 
(Figure 5.12c).  
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Figure 5.12 Antagonist compounds -104 and 107 are more potent at human GPR84 than the 
mouse orthologue while compound 837 is inactive at mouse GPR84. Concentration-response 
curves for compound-104 (a) or compound-107 (b) inhibiting compound-1-stimulated [
35
S]-GTPγS 
binding to membranes generated from HEK-293 cells transiently transfected with FLAG-hGPR84-
Gαi2 C352I or FLAG-mGPR84-Gαi2 C352I are shown. Similar studies were performed assessing 
the ability of varying concentrations of compound-837 to block compound-1-mediated [
35
S]-GTPγS 
binding to membranes of HEK-293 cells (c).  
More intense variations in potencies of compound-104 and 107 between human 
and mouse GPR84 were observed when membranes purified from doxycycline-
induced Flp-In T-REx-293 cells expressing FLAG-hGPR84-Gαi2 or FLAG-mGPR84-
Gαi2 were used in [
35S]-GTPγS binding assays. While compound-104 and 
compound-107 completely reversed compound-1-mediated [35S]-GTPγS binding 
to Gαi2 associated with both FLAG-hGPR84-Gαi2 and FLAG-mGPR84-Gαi2, 
potencies to do that were decreased by some 68 and 48-fold, respectively at the 
FLAG-mGPR84-Gαi2 compared to the equivalent form of human GPR84 (Figure 
5.13 a,c; Table 5.5). In comparison with FLAG-hGPR84-Gαi2, FLAG-mGPR84-Gαi2 
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also displayed some 43 and 50-fold reduction in potencies for compound-104 and 
107, respectively in inhibiting the response to an EC80 concentration of PSB-
16671 (Figure 5.13 b,d; Table 5.5). Another notable thing was that while both 
compound-104 and 107 were able to completely block the PSB-16671-induced 
[35S]-GTPγS binding to membranes expressing FLAG-hGPR84-Gαi2, both 
antagonists failed to block fully agonist function of PSB-16671 mediated by 
FLAG-mGPR84-Gαi2. Saturation binding studies with the radiolabelled antagonist 
[3H]-G9543 also revealed the marked differences in affinity of this class of 
antagonists between human and mouse GPR84. While [3H]-G9543 bound to FLAG-
hGPR84-Gαi2 with high affinity (Kd: 0.3±0.01 nM), it did not display any 
significant specific binding to FLAG-mGPR84-Gαi2 (Figure 5.14) at concentrations 
up to 30 nM. Consistent with the results obtained from HEK-293 cells transiently 
transfected with PTX-insensitive fusion proteins, compound-837 entirely blocked 
agonist effects of both compound-1 and PSB-16671 in Flp-In T-REx-293 cells 
expressing FLAG-hGPR84-Gαi2 with pIC50 of 8.00±0.02 in both cases whilst it was 
inactive in cells expressing FLAG-mGPR84-Gαi2 (Figure 5.13 e,f).    
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Figure 5.13 Compound-104 and 107 display markedly lower potency at mouse GPR84 
compared to the human orthologue while compound-837 is inactive at mouse GPR84. Flp-In 
T-REx-293 cells stably harbouring FLAG-hGPR84-Gαi2 or FLAG-mGPR84-Gαi2 were induced with 
100 ng/ml of doxycycline for 24 hours prior to membrane preparation. These membranes were then 
employed to assess the ability of varying concentrations of compound-104 (a), 107 (c) or 837 (e) to 
inhibit [
35
S]-GTPγS incorporation induced by an EC80 concentration of compound-1. Similar studies 
were performed to assess the capacity of increasing concentrations of compound-104 (b), 107 (d) 
or 837 (f) to block [
35
S]-GTPγS binding stimulated by an EC80 concentration of PSB-16671. Data 
represented are pooled from three independent experiments performed on three individual 
membrane preparations.  
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Table 5-5 Potencies of compounds-104, 107 and 837 to inhibit the response to an EC80 
concentration of compound-1 or PSB-16671 at FLAG-hGPR84-Gαi2 or FLAG mGPR84-Gαi2. 
[
35
S]-GTPγS binding assays were conducted using membranes generated from doxycycline-treated 
stable cells expressing human or mouse GPR84 as fusion protein constructs to determine the 
potency of different antagonists in inhibiting agonist functions of compound-1 or PSB-16671 as 
described in Figure 5.13.  Data (pIC50) are expressed as mean±S.E.M of three independent 
experiments performed using three separate membrane preparations generated from doxycycline 
induced Flp-In T-REx cells stably harbouring FLAG-hGPR84-Gαi2 or FLAG-mGPR84-Gαi2. pIC50 
values were analysed by two-tailed unpaired t-test. Statistical significance between human and 
mouse GPR84 are represented as *P<0.05, **P<0.01 and ***P<0.001.  
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Figure 5.14 The radiolabelled antagonist [
3
H]-G9543 did not display significant binding to 
mouse GPR84.  Various concentrations (ranging from 0.3 to 30 nM) of radioligand antagonist [
3
H]-
G9543 in the presence (nonspecific binding) or absence (total binding) of 1µM compound-104 were 
assessed for their ability to bind to membranes generated from Flp-In T-REx cells treated with 100 
ng/ml of doxycycline for 24 hours to induce expression of FLAG-mGPR84-Gαi2.   
  
 Agonist 
 Compound-1 PSB-16671 
Antagonist hGPR84 mGPR84 hGPR84 mGPR84 
Compound-104 8.04±0.02 6.20±0.04*** 8.03±0.02 6.40±0.03*** 
Compound-107 8.35±0.04 6.67±0.02*** 8.20±0.04 6.50±0.07** 
Compound-837 8.00±0.02 Inactive 8.01±0.02 Inactive 
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5.6. Discussion 
5.6.1. Human and mouse GPR84 can exist as N-glycosylated 
forms  
Glycosylation is a common post-translational phenomenon which has been 
implicated in regulation and functions of GPCRs (Li et al., 2017). Depending on 
the type of GPCR, glycosylation has been implicated in protein folding, receptor 
expression, cell surface trafficking, ligand binding, internalization, 
desensitization, dimerization and even in signalling bias. For example, Min et 
al., (2015) reported that N-linked glycosylations are involved in cell surface 
trafficking and internalization of D2 and D3 receptors and desensitization of D3 
receptors. Glycosylations on asparagine 5 and asparagine 15 of the N-terminus 
were reported to contribute to the dimerization of the β2 adrenergic receptor (Li 
et al., 2017). Recently Soto et al., (2015) reported that glycosylations on 
asparagine 250 and asparagine 259 within the EL2 of the protease-activated 
receptor-1 (PAR1) were responsible for the Gα12/13 selectivity of thrombin-
activated PAR1 over Gq G protein. Being a very poorly characterized receptor 
little is known about the regulation of GPR84 and no studies have been 
performed regarding the roles or extent of glycosylation of this receptor. Herein 
for the first time I have demonstrated that both human and mouse GPR84 are N-
glycosylated. The pre-treatment of membranes generated from cells expressing 
FLAG-mGPR84-Gαi2 with peptide N-glycosidase (PNGase F) converted poorly 
resolved multiple bands on SDS-PAGE into predominantly a single band with 
apparent molecular mass of some 80 kDa, consistent with the monomeric form of 
the fusion protein construct and confirming differentially N-glycosylated forms 
of mouse GPR84. Similarly, pre-treatment of membranes of cells expressing 
FLAG-mGPR84-eYFP or FLAG-hGPR84-eYFP with PNGase F enhanced the intensity 
of the band having a molecular mass of some 70 kDa which confirmed the 
cleavage of N-glycans from the glycosylated form of both human and mouse 
GPR84. PNGase treatment also resulted in slight enhancement of electrophoretic 
mobility of the protein band having a molecular mass consistent with the 
monomeric form. These studies confirmed that both human and mouse GPR84 
exist as N-glycosylated forms. Asparagine 3 and asparagine 8 of the N-terminus 
of GPR84 might be the possible N-glycosylation sites because both of these 
asparagine residues within human and mouse GPR84 are present in the Asn-Xaa-
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Ser/Thr motif (where Xaa is not proline) which is known to be the consensus 
sequence for N-glycosylation of Class A GPCRs (Li et al., 2017; Min et al., 2015; 
Soto et al., 2015; Landolt-Marticorena and Reithmeier, 1994). Deglycosylation by 
PNGase treatment also preserved the band having molecular mass of some 155 
kDa, corresponding potentially to the dimeric form in the immunoblot of 
membranes of cells expressing FLAG-hGPR84-eYFP or FLAG-mGPR84-eYFP, 
suggesting that removal of N-glycans might not affect the dimerization of human 
or mouse GPR84.  
5.6.2. Characterization of orthosteric and allosteric activators of 
GPR84 in RAW 264.7 cells 
The mouse monocyte/macrophage cell line RAW 264.7 is widely employed as an 
immune cell model to characterize the physiological functions of certain GPCRs 
having immuno-modulatory effects (Han et al., 2018; Han et al., 2017; Liu et al., 
2014; Hudson et al., 2013b; Oh et al., 2010;  Wang et al., 2006b). Though 
previously it was shown that GPR84 mRNA is upregulated in RAW 264.7 cells by 
pre-treatment with the toll-like receptor 4 (TLR4) agonist LPS, very little was 
known regarding the functional consequences of LPS treatment and detailed 
study of the pharmacology of GPR84 ligands in RAW 264.7 cells was also lacking. 
Only a single study performed by Wang et al., (2006b) reported that the GPR84 
agonists decanoic acid, undecanoic acid, lauric acid and DIM enhanced secretion 
of the pro-inflammatory cytokine IL-12 p40 from LPS-stimulated RAW 264.7 cells 
in a concentration-dependent manner, while addition of these ligands resulted in 
no significant release of this cytokine from untreated cells. Though these studies 
suggested the potential role of GPR84 to control inflammatory processes, it was 
not confirmed whether these responses of MCFAs or DIM in promoting release of 
cytokine from RAW 264.7 cells were mediated exclusively by GPR84 as no GPR84 
antagonist was available at that time to be used as tool compound to 
characterize the cellular functions of GPR84. Herein I have characterized the 
pharmacology of orthosteric and allosteric GPR84 agonists in RAW 264.7 cells 
and confirmed at least partly that the agonist functions of these ligands were 
mediated by GPR84 activation in RAW 264.7 cells which were evidenced from 
the complete blockade of agonist-stimulated effects by established GPR84 
antagonists. Herein I have found that in [35S]-GTPγS binding assay, LPS treatment 
of RAW 264.7 cells led to higher signalling magnitude than in untreated cells, 
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suggesting increased G protein activation due to the upregulation of GPR84 
following LPS stimulation. Despite this, no statistically significant increase in 
potency for compound-1 was observed following LPS treatment of RAW 264.7 
cells, suggesting that upregulation of GPR84 by LPS treatment failed to produce 
any significant receptor reserve for GPR84. The orthosteric agonists decanoic 
acid, compound-1, embelin and allosteric agonists DIM and PSB-16671 were 
found to produce a robust and concentration-dependent enhancement of [35S]-
GTPγS incorporation into membranes generated from LPS-induced RAW 264.7 
cells. These responses to compound-1, PSB-16671 or decanoic acid in RAW 264.7 
cells were exerted by GPR84 activation as such effects were effectively and 
concentration-dependently antagonized by the GPR84 antagonists compound-104 
and 107, which displayed similar potencies to those shown at Flp-In T-REx cells 
expressing mouse GPR84-Gαi2. The responses to embelin or DIM in RAW264.7 
cells were also mediated by GPR84 activation which was evidenced from the 
complete blockade of responses to an EC80 concentration of DIM or embelin by 
the GPR84 antagonist GLPG1205. Another important outcome was that in [35S]-
GTPγS incorporation assays employing membranes of LPS-treated RAW264.7 
cells, DIM and embelin functioned as partial agonists of GPR84 compared to 
decanoic acid and PSB-16671, while compound-1 displayed the highest maximal 
response. These results are in agreement with those observed in transfected 
cells expressing cloned mouse GPR84. Compared to decanoic acid, DIM was also 
found to act as a partial agonist in inducing secretion of IL-12 p40 from LPS-
stimulated RAW 264.7 cells (Wang et al., 2006b). Yin et al., (2009) explored that 
DIM behaved as a partial agonist at the Gi-coupled receptor cannabinoid receptor 
type 2 (CB2) and functioned as a weak inverse agonist at CB1 receptor. They also 
reported that DIM-induced inhibition of upregulation of the pro-inflammatory 
cytokine IL1-β in LPS-stimulated RAW264.7 cells was partially exerted by CB2 
receptor as evident from the partial blockade of effect of DIM by a CB2 
antagonist. These results indicated that effect of DIM-induced G protein 
activation in RAW264.7 cells as assessed by [35S]-GTPγS assay might not be 
exclusively mediated by GPR84. However, herein I found that DIM-induced 
enhanced G protein activation was mediated by GPR84 as DIM-stimulated [35S]-
GTPγS incorporation into membranes of LPS-induced RAW264.7 cells was 
completely and effectively inhibited by the GPR84 antagonist GLPG1205.      
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The potency of embelin measured in RAW 264.7 cells (EC50: 316 nM) was similar 
to that (EC50: 220 nM in cAMP assays) displayed in HEK-293 cells expressing 
mouse GPR84 estimated by Gaidarov et al., (2018). While the potency of 
compound-1 in promoting [35S]-GTPγS binding to membranes of LPS-induced RAW 
264.7 cells was very similar to that observed at mouse bone marrow-derived 
neutrophils (pEC50: 7.89±0.12) estimated by Mancini et al., (2019), the potency 
of PSB-16671 displayed at RAW 264.7 cells was some 15-fold higher than that 
showed in mouse neutrophils, suggesting that GPR84 might not be the primary 
target for PSB-16671 in mouse neutrophils. However, measured potencies of 
compound-1 and PSB-16671 at RAW 264.7 cells were similar to those estimated 
at LPS-treated THP-1 cells (pEC50: 7.79±0.08 and 6.94±0.07, respectively) which 
is in agreement with the maintenance of similar pharmacology of GPR84 agonists 
between human and mouse orthologue. Further support to this, the potency of 
compound-1 (EC50: 21 nM) estimated in LPS-induced RAW 264.7 cells was highly 
similar to that displayed in human neutrophils (EC50: 42 nM in intracellular 
calcium mobilization assay, Sundqvist et al., 2018).  
5.6.3. Antagonists but not agonists of GPR84 display significant 
variations in pharmacology between human and mouse 
orthologues 
Mouse GPR84 was found to respond to orthosteric and allosteric agonists of 
GPR84 in a manner very similar to human orthologue, implying that they can be 
used for translating the pharmacology of GPR84 observed in transfected cells to 
in-vivo mouse models designed to study the pathophysiological role of 
GPR84.This maintenance of similar pharmacology of GPR84 agonists between 
human and mouse GPR84 was observed in both cases when eYFP-tagged receptor 
or the fusion-protein approach was employed. By contrast, GPR84 antagonists 
displayed marked variations in potency or affinity between human and mouse 
orthologues. Though compound-837 was found to effectively antagonize the 
responses to compound-1 or PSB-16671 at human GPR84 with high potency (IC50: 
10 nM), it lacked activity at mouse GPR84 both in Flp-In T-REx cells expressing 
FLAG-mGPR84-Gαi2 and in LPS-treated RAW 264.7 cells, implying that this 
antagonist could not be employed in murine models for the elucidation of 
physiological functions of GPR84. Though the non-competitive GPR84 antagonist 
compound-104 displayed high potency (IC50: 10 nM) in blocking the agonist 
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functions of compound-1 or PSB-16671 at FLAG-hGPR84-Gαi2, the potency of this 
ligand was reduced by 68 and 43-fold, respectively at the equivalent fusion 
protein of mouse GPR84. Similarly, as estimated by the [35S]-GTPγS binding 
assay, compound-107 displayed very high potency (IC50: 4.5 nM vs compound-1; 
6.3 nM vs PSB-16671) in inhibiting the agonist effect of compound-1 or PSB-16671 
at FLAG-hGPR84-Gαi2 whereas mouse versions of the fusion construct showed 48 
and 50-fold lower potency, respectively. These lowered potencies of this class of 
antagonists in blocking effects of GPR84 agonists were also maintained in LPS-
treated RAW264.7 mouse monocytes. For example, compared to human 
monocytes THP-1, RAW 264.7 cells displayed some 23 and 30-fold reductions in 
potency for compound-107 in inhibiting compound-1 and PSB-16671-mediated G-
protein activation, respectively. Similarly, while the GPR84 antagonist GLPG1205 
displayed an IC50 of 15 nM in blocking compound-1-promoted increased 
production of reactive oxygen species (ROS) in TNFα-stimulated human 
neutrophils (Sundqvist et al., 2018), the measured IC50 value for blocking 
compound-1-mediated [35S]-GTPγS incorporation into membranes of LPS-induced 
RAW264.7 cells was 600 nM. Though variation in potency between two different 
assays is not unusual, a 40-fold reduction in potency for GLPG1205 in mouse 
macrophage compared to human neutrophil suggested that this large variation 
stems from the species difference. The greatly reduced potencies of this class of 
antagonists at the mouse orthologue were consistent with the finding that 
modest concentrations of radiolabelled antagonist [3H]-G9543 did not show 
significant specific binding to membranes generated from LPS-treated RAW264.7 
cells or transfected cells expressing FLAG-mGPR84-Gαi2, indicating substantially 
lowered affinity of the radioligand or related antagonists to mouse GPR84. These 
results imply that care should be taken in the case of utilization of these 
antagonists as GPR84 tool compounds either in mouse disease models or murine 
cell lines.   
Though GLPG1205 failed to generate therapeutic efficacy in phase II clinical trial 
in ulcerative colitis patients (Vermiere et al., 2017), currently it is under 
investigation in phase II clinical trial for idiopathic pulmonary fibrosis (IPF) 
(https://www.glpg.com/IPF; Saniere et al., 2019). Despite being considered as a 
promising therapeutic candidate, mode of binding or mechanism of antagonism 
of GLPG1205 had not been available in scientific literature. Herein I have found 
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that GLPG1205 displays varying modes of antagonism in blocking agonist effect 
of compound-1 and PSB-16671 at mouse GPR84. While GPLG1205 was found to 
antagonize the agonist function of PSB-16671 in naïve RAW264.7 mouse 
monocytes in a non-competitive manner, the antagonism of GLPG1205 in 
blocking the effect of compound-1 in RAW264.7 cells seems to follow a 
competitive mode of action, displaying a pA2 affinity value of 7.23. GLPG1205 
was also found to be competitive with compound-1 in Flp-In T-REx-293 cells 
expressing FLAG-mGPR84-Gαi2 showing a pA2 affinity value of 6.9. These results 
suggested that GLPG1205 is likely to bind to a site on mouse GPR84 which is 
overlapping with the compound-1 binding site but distinct from the site occupied 
by PSB-16671. Further studies are required to confirm the binding mode of this 
therapeutically important antagonist.  
Though the species-selectivity of ligands of a GPCR poses a great challenge for 
the biological characterization of the receptor, the elucidation of molecular 
insight into orthologue selectivity of ligands of specific GPCRs might be helpful 
to define ligand-binding modes and thus might be utilized for the development 
of more selective and/potent ligands (Strasser et al., 2013; Milligan, 2011). For 
example, by applying sequence alignment, homology modelling, mutagenesis 
studies and radioligand binding assays, Sergeev et al., (2017) identified a single 
amino acid residue, lysine 65 located within the transmembrane domain II of 
FFA2 receptor which defined the human-selectivity of the antagonists GLPG0974 
and CATPB over rodent orthologues. Similarly, the determination of the 
molecular basis of human-selectivity of GPR84 antagonist compound-837 over 
the mouse orthologue might help define the binding mode of this highly potent 
antagonist. Moreover, defining the molecular determinant(s) responsible for 
reduced affinity of antagonist compounds-104, 107, 161 or GLPG1205 for mouse 
GPR84 compared to human orthologue might be helpful for the elucidation of 
their binding modes and these pieces of information could be used for the 
generation of more potent antagonist(s). In this context, investigations of 
molecular basis of species differences in pharmacology of GPR84 antagonists is 
required for the development of tool compounds to be applied in the translation 
of in-vitro pharmacology to in-vivo animal disease models.  
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6 Allosteric modulation of GPR84 
6.1. Introduction 
Recently allosteric modulation of GPCRs has attracted great interest as this 
property can be exploited for the development of more selective and safer drug 
candidates compared to classical drugs which act on orthosteric sites of GPCRs 
(Hudson et al., 2013c). Drug development programmes based on targeting the 
orthosteric sites of GPCRs which display high degrees of sequence homology 
among sub-types face great challenges due to potential off-target effects 
leading to adverse drug reactions. For example, due to the high sequence 
homology across orthosteric sites of different sub-types of muscarinic 
acetylcholine receptors (M1, M2, M3, M4 and M5 mAChR), the development of sub-
type selective drugs remains challenging (Korczynska et al., 2018; Christopoulos, 
2014; Suratman et al., 2011; Chan et al., 2008). In this context, targeting 
allosteric sites of muscarinic receptors is currently considered to be an effective 
therapeutic strategy to limit Alzheimer’s disease and other neurodegenerative 
disorders (Korczynska et al., 2018; Moran et al., 2018; Bradley et al., 2017). As 
allosteric sites are often more divergent than orthosteric sites, allosteric 
modulators of GPCRs frequently have more sub-type selectivity (Christopoulos, 
2014; Wooten et al., 2013; Keov et al., 2011). The sub-type selectivity might 
also be obtained from selective cooperativity wherein despite having similar 
binding affinity for different sub-types, allosteric modulators may display 
cooperativity with the orthosteric agonist only at one sub-type of the receptor. 
For example, though thiochrome and LY2033298 bind to the allosteric sites of all 
the mAchR sub-types, they only act as PAMs of function of acetylcholine at M4 
mAchR whilst displaying neutral cooperativity at other subtypes (Suratman et 
al., 2011; Chan et al., 2008; Lazareno et al., 2004). Moreover, allosteric 
modulators have been considered to be safer in the case of overdose (Hudson et 
al., 2013c). This low risk of overdose-mediated toxicity arises from the 
saturability of the allosteric effect of modulators on orthosteric agonist affinity 
or efficacy which is limited by the extent of cooperativity between the two 
ligands (Keov et al., 2011; Wooten et al., 2013). This ceiling effect of allosteric 
interaction will lead to decreased side effects or toxicity (Christopoulos, 2014) in 
cases where the drug target (metabotropic glutamate receptors, muscarinic 
receptor, GABAA receptor etc.) is associated with highly regulated physiological 
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function wherein overstimulation can cause adverse drug reactions. One classic 
example is that benzodiazepines including diazepam, which allosterically 
enhance the binding affinity of GABA for the GABAA ionotropic receptor resulting 
in enhanced opening of the chloride ion channel. This is considered to be safe 
because the cooperativity between benzodiazepines and GABA is limited 
(Christopoulos, 2014) which means that after all the allosteric binding sites on 
the receptor have been occupied by the benzodiazepine, no further 
enhancement in GABA-mediated signalling will occur irrespective of the 
concentration of the benzodiazepine in the tissue compartment. Though 
allosteric modulation of GPCRs has been considered to be a novel therapeutic 
strategy, only four allosteric modulators (cinacalcet, evocalcet, etelcalcitide 
and maraviroc) have yet approved  for clinical applications (Trinh et al., 2018; 
Fukagawa et al., 2018; Fukagawa et al., 2017;  Dorr et al., 2005; Lindberg et al., 
2005).  
Recently 3,3´-diindolylmethane (DIM) and the DIM analogue PSB-16671 have 
been identified as allosteric modulators of human GPR84 (Nikaido et al., 2015; 
Pillaiyar et al., 2017). Though Pillaiyar and colleagues (2017) reported that both 
ligands acted as positive allosteric modulators (PAM) of potency and efficacy of 
decanoic acid at human GPR84 in cAMP accumulation assays, information on the 
allosteric interaction of DIM or PSB-16671 with other orthosteric GPR84 agonist is 
lacking. Moreover, no studies have been performed to assess the allosteric 
effects of DIM or DIM analogues on orthosteric agonist affinity or efficacy at 
other species orthologues of GPR84. Recently, Gaidarov et al., (2018) reported 
that GPR84 activation might be exploited for the development of therapeutics to 
treat atherosclerosis. Though the putative endogenous agonists MCFAs can 
activate GPR84 with moderate potency, the actions of MCFAs or other synthetic 
orthosteric agonists at GPR84 could potentially be substantially enhanced by 
PAM agonists such DIM and it is plausible to exploit such allosteric modulation of 
GPR84 to develop novel combination therapies against atherosclerosis. In this 
context, further studies on allosteric modulation of GPR84 are required. Herein I 
have performed detailed characterization of allosteric interactions between DIM 
and DIM analogues and orthosteric GPR84 agonists at both human and mouse 
GPR84.        
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6.2. DIM analogues 6a and 3a are activators of human GPR84 
In [35S]-GTPγS binding assays employing membranes purified from Flp-In T-REx-
293 cells expressing FLAG-hGPR84-Gαi2, two DIM analogues 5,5´-dinitro-3,3´-
diindolylmethane (6a) and 5,5´-dimethoxy-3,3´-diindolylmethane (3a) displayed 
GPR84 agonism whilst three further DIM analogues 5,5´-diiodo-3,3´- diindolyl-(4-
methylphenyl)methane (2b), 5,5´-dimethoxy-3,3´- diindolyl-(4-
methylphenyl)methane (3b) and 5,5´-dimethoxy-3,3´- diindolyl-(3,5-
difluorophenyl)methane (3c) were found to be inactive (Figure 6.1). Though 6a 
displayed similar potency (pEC50: 5.3±0.9) as DIM (pEC50: 5.3±0.08), the maximal 
response to 6a (143±9.0% of DIM response) was significantly higher than that of 
DIM. DIM analogue 3a showed reduced potency (pEC50: 4.7±0.10) and efficacy 
(80±6.3% of DIM response) than DIM at FLAG-hGPR84-Gαi2 (Figure 6.1). In 
mutagenesis studies it was found that DIM and the DIM analogue PSB-16671 bind 
to an allosteric site on human GPR84 that is topographically distinct from the 
orthosteric binding site (section 4.3). Small molecule agonists binding to the 
allosteric site distinct from that shared by orthosteric agonists frequently affect 
the potency or efficacy of orthosteric agonists i.e they act as ago-PAMs (Hudson 
et al., 2014a; Smith et al., 2011b). To assess whether DIM and DIM analogues 
display any allosteric effects on orthosteric agonist binding affinity or efficacy, 
interaction studies were performed  using [35S]-GTPγS binding assays.  
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Figure 6.1DIM analogues 6a and 3a retain the ability to activate human GPR84 while 2b, 3b 
and 3c lack agonist function. Membranes were purified from doxycycline-induced (100 ng/ml, 24 
hours) Flp-In T-REx-293 cells stably harbouring FLAG-hGPR84-Gαi2 and were subsequently 
employed in [
35
S]-GTPγS incorporation assays to evaluate the functions of DIM and DIM analogues 
2b, 3a, 3b, 3c and 6a.   
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6.3. DIM is a potent PAM agonist at human GPR84 
6.3.1. DIM is a potent PAM of potency and efficacy of decanoic 
acid 
The potential allosteric interaction between DIM and the presumed endogenous 
agonist decanoic acid (C-10) was evaluated using [35S]-GTPγS binding assays 
employing membranes of Flp-In T-REx-293 cells expressing FLAG-hGPR84-Gαi2. In 
this assay co-addition of increasing fixed concentrations of DIM resulted in 
progressive increase in potency and efficacy of decanoic acid (Figure 6.2a) 
indicating that DIM acted as a positive allosteric modulator (PAM) of both affinity 
and efficacy of C-10. DIM-induced enhancement in potency and efficacy of C-10 
approached a saturating level at higher concentrations of DIM (Figure 6.2a) 
which is consistent with the anticipated saturability of the allosteric effect 
(Kenakin, 2010; May et al., 2007). Global analysis of the data sets using an 
operational model of allosterism (Ehlert, 2005; Leach et al., 2007) revealed that 
DIM showed a high positive cooperativity with C-10 displaying an affinity 
cooperativity factor, (α value) of 28 (logα: 1.45±0.09) but a more limited 
activation cooperativity factor, β value of 2.32 (logβ: 0.36±0.06) (Table 6.1). In 
reciprocal interaction studies where the protocol was reversed, co-incubation of 
increasing defined concentrations of C-10 was found to progressively enhance 
the potency and maximal response of DIM (Figure 6.2b) with estimated affinity 
cooperativity factor (α value) of 20 (logα: 1.30±0.09)  and activation 
cooperativity factor, β value of 16 (logβ: 1.20±0.05). These results are broadly 
consistent with the expected reciprocity of ligand allosteric effects (May et al., 
2007) as similar affinity cooperativity values were obtained when the 
experimental protocol was reversed. The larger variation in the estimated 
activation cooperativity value (2.3 versus 16 in reciprocal assays) is due to the 
large difference in intrinsic agonist activity between C-10 and DIM. The 
estimated average τ value (0.2) for DIM was much lower than that for C-10 
(average τ value 1.58) which is consistent with DIM acting as a partial agonist of 
GPR84 compared to C-10. The extent of allosteric effect on modulation of 
maximal response i.e the activation cooperativity factor (β) is usually governed 
by the intrinsic efficacy of the modulator used (van der Westhuizen et al., 2018; 
Hudson et al., 2014a; Keov et al., 2011). Due to some 8-fold higher intrinsic 
activity of C-10 than DIM, 7-fold higher activation cooperativity was obtained 
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when C-10 was employed as the modulator in the reciprocal assay compared to 
the value observed when DIM was utilized as the modulator. The net 
affinity/efficacy cooperativity factor (αβ) combining the allosteric effects of 
allosteric modulator on both affinity and efficacy of orthosteric agonist can also 
be used for quantifying the magnitude of cooperativity between the two ligands 
(Hudson et al., 2014a; Smith et al., 2011b; Langmead, 2011). The high net 
cooperativity value (αβ: 66 and 297 in reciprocal experiment) estimated by the 
mathematical analysis of allosteric interactions between DIM and C-10 revealed 
that these ligands strongly modulate the function of each other at human 
GPR84.    
Global fitting of the experimental data obtained from the interaction study 
between DIM and C-10 using an operational model of allosterism also provided 
estimates of the binding affinities of DIM and C-10 for the FLAG-hGPR84-Gαi2 
fusion protein. The measured affinity of DIM (KA: 5.6 to 6.9 µM) for FLAG-
hGPR84-Gαi2 was about 100 fold higher than for decanoic acid (KA: 0.18 to 0.50 
mM).  
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Figure 6.2DIM and C-10 display strong positive cooperativity in modulating function of each 
other at human GPR84. Membranes purified from doxycycline-treated (100 ng/ml, 24 hours) Flp-
In T-REx-293 cells expressing FLAG-hGPR84-Gαi2 were employed in [
35
S]-GTPγS incorporation 
assays to evaluate effects of co-addition of increasing fixed concentrations (ranging from 100 nM to 
10 µM) of DIM on the concentration-response curves for C-10 (a). In reciprocal experiments, 
various defined concentrations of C-10 ranging from 1 µM to 300 µM were assessed for their ability 
to modulate concentration-response curves for DIM (b). Data shown in (a) and (b) represent 
mean±SEM of three individual experiments performed on three separate membrane preparations 
carried out in triplicate  and curves displayed are best fit curves obtained from global analysis of 
datasets with an operational model of allosterism. The best fit values of allosteric paramaters for 
the interaction between C-10 and DIM are shown in Table 6.1.   
 
 
6 Allosteric modulation of GPR84  207 
 
Table 6-1 Allosteric parameters for the interaction between DIM and C-10 at FLAG-hGPR84-
Gαi2. 
 
Agonista C-10 DIM 
Modulatorb DIM C-10 
logα 1.45±0.09 1.30±0.09 
logβ 0.36±0.06 1.20±0.05 
logτA 0.30±0.058 -0.66±0.05 
logτB -0.70±0.02 0.08±0.04 
pKA
c 3.30±0.08 5.16±0.056 
pKB
d 5.25±0.03 3.75±0.066 
α 28.34 20.0 
β 2.32 15.87 
αβ 65.74 297.2 
a
Agonist is the compound used to generate concentration-response curve 
b
Modulator is the compound used in fixed concentrations 
c 
pK
A
 are values estimated for the agonist  
d
 pK
B
 are values estimated for the modulator 
[
35
S]-GTPγS binding studies were performed using membranes generated from doxycycline-
induced Flp-In T-REx-293 cells expressing FLAG-hGPR84-Gαi2  as described in Figure 6.2 to 
estimate the cooperativity parameters. Data are means ± SEM of three individual experiments 
performed on three separate membrane preparations carried out in triplicate.  
6.3.2. DIM displays strong allosteric interactions with other 
orthosteric agonists of human GPR84  
To assess whether DIM displays any allosteric effects on binding affinity or 
efficacy of other orthosteric agonists of GPR84, a set of [35S]-GTPγS binding 
assays were performed using membranes expressing FLAG-hGPR84-Gαi2. Co-
incubation of increasing fixed concentrations of DIM ranging, from 100 nM to 30 
µM, was found to progressively increase the potency of compound-1 without 
altering the maximal response (Figure 6.3 ai), displaying an affinity cooperativity 
factor, α value of 120 (logα 2.08±0.04)  (Table 6.2) which indicates that DIM 
behaved as a very strong PAM of potency of compound-1. The effect of DIM on 
binding affinity modulation approached a limit as the potentiation of the 
potency reached a saturating point at higher concentrations of DIM. In reciprocal 
assays, increasing defined concentrations of compound-1 ranging from 0.3 nM to 
100 nM also progressively enhanced the potency and maximal response of DIM 
(Figure 6.3 aii) with an affinity cooperativity factor, α value of 63 (logα: 
1.80±0.1) and activation cooperativity factor, β value of 25 (logβ: 1.40±0.04). 
Though the magnitude of allosteric effect of compound-1 on binding affinity of 
DIM was 1.9-fold higher than that of DIM on compound-1, the difference did not 
reach statistical significance level (P value>0.05, two-tailed unpaired t test). 
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The large variation in the activation cooperativity value (0.9 vs 25 in the 
reciprocal assays) was not unexpected as it stems from the substantial 
difference in intrinsic agonist activity between compound-1 (average τ value 6.8) 
and DIM (average τ value 0.43). Global analysis of the experimental data with an 
operational model of allosterism revealed that compound-1(average KA: 100 nM) 
binds FLAG-hGPR84-Gαi2 with 50-fold higher affinity than DIM (average KA: 5.0 
µM).  
DIM also acted as a highly effective PAM of potency of 6-OAU as increasing 
defined concentrations of DIM progressively enhanced the potency of 6-OAU 
(Figure 6.3 ci) with the binding affinity cooperativity factor, α value, of 126 
(logα: 2.1±0.14) (Table 6.2) without altering the maximal response. Equivalent 
outcomes were obtained in reciprocal assays wherein various concentrations of 
6-OAU ranging from 10 nM to 3 µM gradually increased the potency as well as 
maximal response of DIM (Figure 6.3 cii) with the affinity cooperativity factor, α 
value of 68 (logα: 1.83±0.1) and activation cooperativity factor, β value of 8.0. 
As 6-OAU (average τ value: 3.41) displayed some 8.3-fold higher intrinsic agonist 
activity than DIM (average τ value 0.41), proportionally 8-fold higher activation 
cooperativity value was obtained when 6-OAU was used as the modulator in the 
allosteric interaction study than in the case when DIM was employed as the 
modulator. Mathematical analysis of allosteric interaction between 6-OAU and 
DIM estimated the binding affinity of the two ligands to be 1.3 µM and 8.9 µM, 
respectively.  
DIM acted as a PAM of potency and efficacy of embelin as increasing fixed 
concentrations of DIM was found to increase the potency as well as maximal 
response of the embelin (Figure 6.3 bi) with an affinity cooperativity factor, α 
value of 16 and activation cooperativity factor, β value of 7.6 (Table 6.2). 
Similar outcomes were obtained in the reciprocal assay, where various fixed 
concentrations of embelin also caused a large leftward and upward shifting of 
the concentration-response curves of DIM (Figure 6.3 bii) with affinity 
cooperativity factor, α value of 13.0 and activation cooperativity factor, β value 
of 11.4. Embelin (average τ value: 0.57) displayed 1.78-fold higher intrinsic 
efficacy than DIM (average τ value: 0.32) and thus a 1.5-fold higher magnitude of 
allosteric effect on efficacy was observed when embelin was employed as the 
modulator in reciprocal allosteric experiments. The net affinity/efficacy 
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cooperativity factor, αβ value of 122 and 148 (for the reciprocal assay) revealed 
that the magnitude of cooperativity between embelin and DIM was very high and 
in contrast to allosteric effects between DIM and compound-1/6-OAU, allosteric 
effects of DIM on embelin were governed by both affinity and efficacy 
modulation. Global analysis of allosteric effects of embelin on DIM and vice versa 
also estimated the binding affinities of two ligands. Embelin (average KA: 2.6 µM) 
was found to bind human GPR84 with 2.7-fold higher avidity than DIM (average 
KA: 7.1µM).   
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Figure 6.3 DIM is a potent PAM of potency of compound-1 and 6-OAU at human GPR84 
while it modulates both the potency and efficacy of embelin.  Membranes prepared from 
doxycycline-induced (100 ng/ml, 24 hours) Flp-In T-REx-293 cells stably harbouring FLAG-
hGPR84-Gαi2 were used in [
35
S]-GTPγS incorporation assays wherein increasing fixed 
concentrations of DIM ranging from 100 nM to 30 µM were co-added to concentration-response 
assays for compound-1(ai), embelin (bi) or 6-OAU (ci) to assess their capacity to modulate the 
function of the corresponding orthosteric agonist. Similar co-addition studies assessing the effect of 
various increasing concentrations of compound-1(aii), embelin (bii) or 6-OAU (cii) on concentration-
response curves for DIM were performed. Data are means±SEM of three independent experiments 
performed on three separate membrane preparations carried out in duplicate (ai, bi, ci) or triplicate 
(aii, bii, cii). Fitted curves displayed are from global analysis of datasets fitted with an operational 
model of allosterism. The best fit values of allosteric parameters of interaction between DIM and 
corresponding orthosteric agonist are shown in Table 6.2.   
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Table 6-2 Allosteric parameters for the interactions between DIM and different orthosteric 
agonists in [
35
S]-GTPγS binding assays at FLAG-hGPR84-Gαi2. 
Agonista Compound-1 DIM Embelin DIM 6-OAU DIM 
Modulatorb DIM Compound-1 DIM Embelin DIM 6-OAU 
logα 2.08±0.04 1.80±0.10 1.20±0.05 1.11±0.04 2.10±0.14 1.83±0.10 
logβ -0.06±0.01 1.4±0.04 0.88±0.03 1.06±0.03 -0.03±0.07 0.91±0.2 
logτA    0.73±0.10 -0.43±0.03 -0.2±0.02 -0.5±0.03 0.61±0.07 -0.28±0.15 
logτB -0.31±0.01 0.91±0.10 -0.5±0.02 -0.3±0.01 -0.52±0.06 0.44±0.04 
pKA
c 7.21±0.03 5.24±0.04 5.5±0.04 5.1±0.03 5.76±0.1 5.05±0.05 
pKB
d 5.31±0.03 6.72±0.10 5.2±0.04 5.7±0.02 5.1±0.01 6.00±0.10 
α 120 63 16 13 126 68 
β 0.9 25 7.6 11.4 0.93 8.0 
αβ 108 1575 122 148 117 544 
a
Agonist is the compound used to generate concentration-response curve 
b
Modulator is the compound used in defined concentrations 
c 
pK
A
 are values estimated for the agonist  
d
 pK
B
 are values estimated for the modulator 
A set of [
35
S]-GTPγS binding studies were performed using membranes generated from 
doxycycline-induced Flp-In T-REx-293 cells expressing FLAG-hGPR84-Gαi2 as described in Figure 
6.3 to estimate the allosteric parameters for the interaction between DIM and GPR84 orthosteric 
agonists. Data are means ± SEM of three independent experiments performed on three separate 
membrane preparations.  
6.3.3. DIM displays probe dependence in allosteric modulation 
of potency of orthosteric agonists 
DIM displayed probe dependence in enhancing the potency of orthosteric GPR84 
agonists (Figure 6.4 a). The greatest increment of the potency was observed for 
compound-1 and 6-OAU (affinity cooperativity values of 120 and 126, 
respectively). This enhancement in potency of compound-1 and 6-OAU was 
significantly higher (P<0.001) than DIM-promoted potentiation (α value of 28) of 
the potency of the putative endogenous agonist, C-10. Moreover, the DIM-
induced increase (16-fold) in potency of embelin was significantly (P<0.05) lower 
than that for C-10 (28-fold increase). These results indicated that the magnitude 
of positive affinity cooperativity between DIM and various potential orthosteric 
agonists depends on the nature of the orthosteric agonist and strongly correlates 
with the efficacy of the orthosteric agonist. The higher the maximal response of 
the orthosteric agonist used as the probe for GPR84 function, the higher was the 
affinity modulation exerted by DIM. This feature of probe dependence of DIM-
promoted allosteric modulation of GPR84 orthosteric agonist functions indicated 
that allosteric interaction of DIM with human GPR84 might follow the two-state 
Monod-Wyman-Changeux (MWC) model which has been implicated for the 
mechanism of probe-dependence of allosteric ligands (Canals et al., 2012). 
However, little probe dependence was observed when net affinity/efficacy 
cooperativity (αβ) displayed by the allosteric interaction of DIM with orthosteric 
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agonists was considered (Figure 6.4 b). Similar net positive cooperativity (αβ= 
122) was observed with a low efficacy agonist i.e. embelin compared to those 
displayed when full agonist compound-1 (αβ= 108) or 6-OAU (αβ=117) was used 
as the modulator. Though, the net positive cooperativity (αβ= 67) obtained from 
the allosteric interaction of DIM with C-10 was some 1.6-fold lower than that for 
compound-1, the difference was not statistically significant.     
              DIM, FLAG-hGPR84-G i2
C
-1
0
C
om
po
un
d-
1
6-
O
A
U
E
m
be
lin
0.0
0.5
1.0
1.5
2.0
2.5 *** ***
*
L
o
g
( 
)
              DIM, FLAG-hGPR84-G i2
C
-1
0
C
om
po
un
d-
1
6-
O
A
U
E
m
be
lin
0
50
100
150
n
e
t 
c
o
o
p
e
ra
ti
v
it
y
 (


)
a b
 
Figure 6.4 Probe dependence of DIM-promoted affinity modulation of different GPR84 
orthosteric agonists at FLAG-hGPR84-Gαi2. Logarithm of the binding affinity cooperativity (logα) 
or net affinity/efficacy cooperativity (αβ) were determined by fitting data obtained from allosteric 
interaction studies between DIM and orthosteric agonists to the operational model of allosterism. 
Logα or αβ values were analysed by one-way ANOVA followed by Dunnett’s multiple comparison 
tests using value for C-10 as the control. Statistical significance between values for C-10 and other 
orthosteric agonist was expressed as *P<0.05, **P<0.01, ***P<0.001       
 
6.3.4. DIM acts as a moderately potent PAM of potency of 
compound-1 and C-10 at mouse GPR84 while it behaves 
as a potent PAM of potency but weak NAM of efficacy of 
compound-1 in LPS-treated RAW264.7 cells 
To see whether DIM displays any orthologue selectivity in terms of cooperativity 
with compound-1, allosteric interaction studies were performed assessing effects 
of increasing fixed concentrations of DIM on the ability of compound-1 to 
stimulate [35S]-GTPγS binding to membranes purified from doxycycline-induced 
Flp-In T-REx-293 cells expressing FLAG-mGPR84-Gαi2 or from LPS-treated 
RAW264.7 cells. DIM was also found to act as a PAM of potency of compound-1 at 
FLAG-mGPR84-Gαi2 as increasing concentrations of DIM caused a progressive left-
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ward shift of concentration-response curve of compound-1 (Figure 6.5a). 
However a marked decrease in cooperativity between DIM and compound-1 was 
observed at FLAG-mGPR84-Gαi2 compared to FLAG-hGPR84-Gαi2. DIM displayed 
7.5-fold lower binding affinity cooperativity (α: 16 vs 120, for FLAG-mGPR84-Gαi2 
and FLAG-hGPR84-Gαi2, respectively) and approximately 4-fold lower net 
affinity/efficacy cooperativity (αβ: 26 vs 108) at mouse GPR84 than the human 
orthologue. The estimated binding affinities of compound-1 and DIM for FLAG-
mGPR84-Gαi2 (KA: 181 nM and 4.8 µM, respectively) were very similar to those for 
FLAG-hGPR84-Gαi2 (KA: 100 nM and 5.0 µM, respectively) which is in good 
agreement with the maintenance of similar potency values of compound-1 and 
DIM between human and mouse GPR84 (section 5.3).  
In LPS-treated RAW264.7 cells DIM behaved as a potent PAM of potency but weak 
NAM of efficacy of compound-1, displaying a binding affinity cooperativity 
factor, α, value of 129 and efficacy cooperativity factor, β, value of 0.22 (Figure 
6.5b, Table 6.3). Though DIM caused a 4.5-fold (β: 0.22) decrease in maximal 
response to compound-1, this effect was outcompeted by high positive binding 
cooperativity (α: 129) leading to an overall affinity/efficacy cooperativity value, 
αβ of 28 which is equivalent to that displayed at FLAG-mGPR84-Gαi2. By 
contrast, DIM acted as a moderately potent PAM of potency of C-10 (Figure 6.5c) 
displaying affinity cooperativity factor, α, value of 16.3  while the effect of DIM 
on efficacy of C-10 was marginal (β: 0.74). These results demonstrated that DIM 
also displayed probe dependence in modulating function of orthosteric agonists 
of GPR84 in RAW264.7 cells as it showed 7.9-fold lower affinity cooperativity and 
2.4-fold lower net affinity/efficacy cooperativity with C-10 than those exhibited 
with compound-1. This higher cooperativity with compound-1 than C-10 was due 
to the higher intrinsic agonist activity of compound-1(τ: 8.7) than C-10 (τ: 3.2) in 
RAW264.7 cells which is consistent with the fact that degree of cooperativity 
tracks with the intrinsic efficacy of the orthosteric probe (van der Westhuizen et 
al., 2018). 
Similar to the results observed at FLAG-hGPR84-Gαi2 and FLAG-mGPR84-Gαi2, DIM 
acted as a weak partial agonist (operational efficacy, τ: 0.32) at RAW264.7 cells 
compared to compound-1 (τ: 8.7) or C-10 (τ: 3.2). Similarly, equivalent binding 
affinities of compound-1 and DIM for mouse GPR84 were observed at RAW264.7 
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cells (KA: 190 nM and 6.0 µM, respectively) and transfected cells expressing 
FLAG-mGPR84-Gαi2.    
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Figure 6.5 DIM acts as a PAM of potency of compound-1 at FLAG-mGPR84-Gαi2 while it 
behaves as a PAM of affinity and NAM of efficacy of compound-1 at LPS-treated RAW264.7 
cells. Membranes were generated from doxycycline-induced (100 ng/ml, 24 hours) Flp-In T-REx-
293 cells stably harbouring FLAG-mGPR84-Gαi2 or from LPS-treated (100 ng/ml, 5 hours) 
RAW264.7 cells. Effects of co-incubation of increasing fixed concentrations of DIM on compound-
1-mediated [
35
S]-GTPγS incorporation into membranes expressing FLAG-mGPR84-Gαi2 were then 
evaluated (a). Similarly, interaction studies were performed using membranes of LPS-treated 
RAW264.7 cells wherein effects of various increasing fixed concentrations of DIM on potency and 
efficacy of compound-1(b) or C-10 (c) were assessed. Data are mean±SEM of two (a, c) or three 
(b) independent experiments performed on separate membrane preparations carried out in 
duplicate (a,b) or in triplicate (c). Curves displayed are from fitting datasets with an operational 
model of allosterism and allosteric parameters of interaction between DIM and compound-1/C-10 
are shown in Table 6.3.  
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Table 6-3 Allosteric parameters for the interaction between compound-1/C-10 and DIM at 
mouse GPR84. 
 FLAG-mGPR84-Gαi2 RAW264.7 
Agonista Compound-1 Compound-1 C-10 
Modulatorb DIM DIM DIM 
logα 1.20±0.10 2.11±0.23 1.21±0.38 
logβ 0.20±0.09 -0.65±0.10 -0.13±0.20 
logτA 0.51±0.18 0.94±0.10 0.50±0.17 
logτB -0.32±0.08 -0.5±0.10 -0.53±0.17 
pKA
c 6.74±0.01 6.72±0.10 3.88±0.26 
pKB
d 5.32±0.01 5.22±0.20 5.30±0.30 
α 16 129 16.3 
β 1.6 0.22 0.74 
αβ 25.44 28.4 12.0 
a
Agonist is the compound used to generate concentration-response curve 
b
Modulator is the compound used in fixed concentrations 
c 
pK
A
 are values estimated for the agonist  
d
 pK
B
 are values estimated for the modulator 
A series of [
35
S]-GTPγS binding studies were performed using membranes generated from 
doxycycline-induced Flp-In T-REx-293 cells expressing FLAG-mGPR84-Gαi2 or from LPS-treated 
RAW264.7 cells as described in Figure 6.5 and the allosteric parameters for the interaction 
between DIM and GPR84 orthosteric agonists were then measured using an operational model of 
allosterism.Data are means ± SEM of two (for FLAG-mGPR84-Gαi2) or three (for RAW264.7 cells) 
individual experiments performed on separate membrane preparations.  
6.4. DIM analogue 3a is a PAM agonist at human GPR84 
6.4.1. DIM analogue 3a is a potent PAM of potency of 
compound-1 and 6-OAU 
As for DIM, the DIM analogue 3a (5,5´-dimethoxy-3,3´-diindolylmethane) was 
also found to act as a strong positive allosteric modulator at human GPR84 as 
increasing concentrations of 3a increased the potency of compound-1 (Figure 6.6 
ai) and 6-OAU (Figure 6.6 bi) yielding affinity cooperativity factor, α, values of 
56 and 100, respectively. When the allosteric assay protocol was reversed, both 
compound-1 and 6-OAU also potentiated the function of 3a by modulating both 
potency and maximal response (Figure 6.6 aii and bii) with affinity cooperativity 
factor, α, value of 25.1 and 29.5, respectively and activation cooperativity 
factor, β, value of 19.5 and 14, respectively (Table 6.4). Though the allosteric 
effect of 6-OAU on binding affinity of 3a for hGPR84 was not statistically 
different (P>0.05) from that of 3a on 6-OAU, the magnitude of affinity 
modulation of 3a by compound-1 was statistically different (P<0.001) from that 
of compound-1 by 3a, which is not consistent with the maintenance of similar 
value in reciprocal allosteric interaction studies. The operational efficacy value, 
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τ for 3a (average τ: 0.26 and 0.35, respectively for interaction with compound-1 
and 6-OAU) was 16 and 11-fold lower than that for compound-1(average τ: 4.1) 
and 6-OAU (average τ: 3.81), respectively; indicating that 3a is a weak partial 
agonist compared to compound-1 and 6-OAU. Owing to this marked variation in 
intrinsic agonist activity between 3a and compound-1/6-OAU, 19.5 and 11-fold 
higher magnitudes of efficacy modulation were obtained when compound-1 or 6-
OAU was employed as the modulator than when 3a was used as the modulator in 
the allosterism experiments. Application of an operational model of allosterism 
to the global analysis of allosterism data revealed that 3a binds FLAG-hGPR84-
Gαi2 with modest affinity (average KA: 12.5 µM and 29 µM, respectively for 
interaction with compound-1 and 6-OAU) while the binding affinity of compound-
1 and 6-OAU was estimated to be 86 nM and 1.0 µM, respectively. These are very 
similar to measured binding affinity values obtained from the mathematical 
analysis of allosteric interaction of DIM with compound-1/6-OAU (section 6.3.2).  
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Figure 6.6DIM analogue 3a is a potent PAM of potency of compound-1 and 6-OAU at human 
GPR84. Effects of co-incubation of increasing fixed concentrations of 3a ranging from 300 nM to 30 
µM on the concentration-response assays of compound-1(ai) or 6-OAU(bi) were evaluated using 
[
35
S]-GTPγS incorporation assays employing membranes of Flp-In T-REx-293 cells expressing 
FLAG-hGPR84-Gαi2. Equivalent co-addition studies were performed assessing the effects of 
increasing fixed concentrations of compound-1(aii) or 6-OAU (bii) on the concentration-response 
curves for 3a. Data represent means±SEM of five (ai), three (aii, bi) or two (bii) independent 
experiments performed on separate membrane preparations. Curves displayed are from global 
fitting of datasets with operational model of allosterism and best fit values of allosteric parameters 
are shown in Table 6.4.   
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6.4.2. DIM analogue 3a is a moderately potent PAM of potency 
and efficacy of decanoic acid 
DIM analogue 3a and C-10 also displayed effective positive cooperativity in 
modulating function of each other at FLAG-hGPR84-Gαi2 and this cooperativity 
was governed by both affinity and efficacy modulation. Co-incubation of various 
defined concentrations of 3a ranging from 300 nM to 30 µM resulted in 
progressive enhancement of potency as well as maximal response to C-10 (Figure 
6.7a), yielding an affinity cooperativity factor, α, value of 6.84 (log α: 0.65±0.2) 
and activation cooperativity factor, β value of 4.5 (Table 6.4). Equivalent 
outcomes were obtained in reciprocal assays wherein increasing defined 
concentrations of C-10 also enhanced the potency and efficacy of 3a (Figure 
6.7b) with affinity cooperativity factor, α, value of 3.4 (log α: 0.53±0.13) and 
activation cooperativity factor, β, value of 82.7. The 18-fold increase in the 
magnitude of efficacy modulation in such reciprocal assays reflected similar 
degrees of increase in intrinsic agonist activity of C-10 (average τ: 2.0) 
compared to that of 3a (average τ: 0.1) which is consistent with the dependence 
of the efficacy modulation on the intrinsic activity of the modulator used. The 
estimated binding affinities  of C-10 and 3a for FLAG-hGPR84-Gαi2 obtained from 
fitting data with an operational model of allosterism were 0.38 mM and 7 µM, 
respectively, which are similar to the values obtained in the allosteric 
interaction studies between C-10 and DIM (section 6.3.1) and between 3a and 
compound-1 (section 6.4.1).  
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Figure 6.7 DIM analogue 3a is a moderately potent PAM of potency and efficacy of C-10 at 
human GPR84. Membranes isolated from doxycycline-treated (100 ng/ml, 24 hours) Flp-In T-REx-
293 cells expressing FLAG-hGPR84-Gαi2 were employed in [
35
S]-GTPγS binding assays in which 
increasing fixed concentrations of DIM analogue 3a, ranging from 300 nM to 30 µM, were 
assessed for their ability to affect concentration-response curves for C-10 (a). In reciprocal 
interaction studies, increasing fixed concentrations of C-10 ranging from 3 µM to 0.3 mM were co-
incubated with concentration-response assays for 3a to evaluate their effects on potency and 
efficacy of 3a. Curves shown in (a) and (b) are from global fitting of datasets with an operational 
model of allosterism and best fit values of allosteric parameters are shown in Table 6.4.     
Table 6-4 Operational model parameters of allosteric interactions between 3a and different 
orthosteric agonists at FLAG-hGPR84-Gαi2 
Agonista Compound-1 3a 6-OAU 3a C-10 3a 
Modulatorb 3a Compound-1 3a 6-OAU 3a C-10 
logα 1.75±0.05 1.4±0.09*** 2.0±0.14 1.47±0.06 0.83±0.2 0.53±0.13 
logβ -0.06±0.02 1.3±0.06 0.1±0.05 1.15±0.04 0.65±0.16 1.92±0.12 
logτA 0.70±0.13 -0.62±0.01 0.65±0.1 -0.45±0.04 0.46±0.1 -1.07±0.12 
logτB -0.54±0.13 0.51±0.1 -0.46±0.03 0.5±0.02 -1.1±0.08 0.05±0.04 
pKA
c 7.01±0.04 4.82±0.06 5.9±0.07 4.62±0.05 3.24±0.14 5.2±0.07 
pKB
d 5.0±0.05 7.12±0.05 4.46±0.14 6.1±0.03 5.1±0.06 3.71±0.07 
α 56 25.1 100 29.5 6.84 3.4 
β 0.9 19.5 1.25 14.0 4.5 82.7 
αβ 50.4 490 125 413 31 281 
a
Agonist is the compound used to generate concentration-response curve 
b
Modulator is the compound used in defined concentrations 
c 
pK
A
 are values estimated for the agonist  
d
 pK
B
 are values estimated for the modulator 
A series of [
35
S]-GTPγS binding studies were performed using membranes generated from 
doxycycline-induced Flp-In T-REx-293 cells expressing FLAG-hGPR84-Gαi2 as described in Figure 
6.6 and 6.7 and the allosteric parameters for the interaction between DIM analogue 3a and  
different GPR84 orthosteric agonists were then estimated using an operational model of 
allosterism.Data are means ± SEM. Logα values were analysed by unpaired two-tailed t test with 
statistical significance expressed as ***P<0.001.  
6.4.3. DIM analogue 3a displays probe dependence in 
modulating function of GPR84 orthosteric agonists 
DIM analogue 3a displayed probe-dependence in potentiating function of 
orthosteric agonists in human GPR84. In [35S]-GTPγS binding assays, the extent of 
3a-mediated binding affinity modulation for compound-1 or 6-OAU was 
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significantly higher than for C-10 (Figure 6.8) which correlated with the higher 
efficacy of compound-1/6-OAU (average τ: 4.1 and 3.8, respectively) than C-10 
(average τ: 2.0). Though the degree of potentiation of binding affinity of 6-OAU 
for human GPR84 was 2.4-fold higher than that for compound-1, the difference 
did not reach statistical significance level (P>0.05, two-tailed unpaired t test). 
Another important thing to be noted was that 3a significantly enhanced the 
maximal response of C-10 by a factor of 4.5 whereas no significant efficacy 
modulation was obtained from the allosteric interaction between 3a and 
compound-1 or 6-OAU (β: 0.9 and 1.25, respectively). The greatest extent of 
overall positive cooperativity (αβ: 125) was obtained for 6-OAU which was 
significantly higher than those displayed in the interaction study when C-10 (αβ: 
31) or compound-1 (αβ: 51) was used to probe the function of human GPR84.  
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Figure 6.8DIM analogue 3a exhibits probe-dependence in modulating binding affinity of 
orthosteric agonists at human GPR84 in [
35
S]-GTPγS binding assays. Logα values were 
determined by applying an operational model of allosterism to data obtained from the interaction 
study between 3a and defined orthosteric agonists and were analysed by one way-ANOVA 
followed by Tukey’s multiple comparison tests. Statistical significance is expressed as *P<0.05, 
**P<0.01 and ***P<0.001.   
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6.5. DIM analogue 6a is a weak NAM of efficacy of 
compound-1at human GPR84 
DIM analog 5,5´-dinitro-3,3´-diindolylmethane (6a) is a weak negative allosteric 
modulator (NAM) of the efficacy of compound-1 at FLAG-hGPR84-Gαi2 as co-
addition of different increasing concentrations of 6a resulted in decrease in 
maximal response to compound-1 with activation cooperativity factor, β value of 
0.12, without altering the potency of compound-1 (Figure 6.9 and Table 6.5). 
The application of an operational model of allosterism for analysis of 
experimental data estimated the binding affinity of compound-1 for FLAG-
hGPR84-Gαi2 to be 125 nM which is equivalent to values measured from the 
analysis of allosteric effects of DIM on compound-1 (section 6.3.2). The 
estimated binding affinity of 6a (KA: 9.0 µM) was very similar to that of parent 
compound DIM (KA: 5 µM) which is in agreement with their equivalent potency 
values at FLAG-hGPR84-Gαi2 (Figure 6.1)   
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Figure 6.9 DIM analogue 6a acts as a weak NAM of efficacy of compound-1 at human 
GPR84. Effects of various fixed concentrations of 6a, ranging from 300 nM to 30 µM, on the ability 
of compound-1 to induce promotion of [
35
S]-GTPγS incorporation into membranes of Flp-In T-REx 
cells expressing FLAG-hGPR84-Gαi2 were evaluated. Data are expressed as mean±SEM of three 
independent experiments performed on three separate membrane preparations carried out in 
duplicate. Curves are from data fitted to an operational model of allosterism where the logα value 
was constrained to 1 as the potency of compound-1 was unaltered by co-addition of increasing 
fixed concentrations of 6a. The allosteric parameters are shown in Table 6.5.     
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Table 6-5 Allosteric parameters for interaction between 6a and compound-1 at FLAG-
hGPR84-Gαi2 
Agonist
a
 Modulator
b
 logβ 
 
 
logτA logτB pK
A
c
 
 
pK
B
d
 
 
β 
Compound-1 6a -0.92±0.17 0.84±0.03 -0.2±0.03 6.9±0.04 5.04±0.07 0.12 
a
Agonist is the compound used to generate concentration-response curve 
b
Modulator is the compound used in defined concentrations 
c 
pK
A
 are values estimated for the agonist  
d
 pK
B
 are values estimated for the modulator 
Allosteric parameters for interaction between DIM analogue 6a and compound-1 were extracted 
from the data generated from [
35
S]-GTPγS binding study using membranes prepared from 
doxycycline-treated Flp-In T-REx cells expressing FLAG-hGPR84-Gαi2 as described in Figure 6.9. 
Data are means ± SEM (n=3).  
6.6. DIM analogues 2b and 3c lack affinity at human 
GPR84 
In [35S]-GTPγS incorporation assays, DIM analog 2b (5,5´-diiodo-3,3´-diindolyl(4-
methylphenylo)methane) and 3c (5,5´-dimethoxy-3,3´-diindolyl(3,5-
difluorophenyl)methane) were found to be inactive at hGPR84 (Figure 6.1). To 
assess whether these inactive small molecules displayed any potential allosteric 
interaction with orthosteric agonists of GPR84, a set of co-addition studies were 
performed where various fixed concentrations of 2b or 3c were added to the 
concentration-response assay of decanoic acid (Figure 6.10 ai and bi) or 
compound-1 (Figure 6.10 aii and bii). In all these experiments, both the potency 
and efficacy of C-10 and compound-1 were unaffected by co-addition of defined 
concentrations of both 2b and 3c which indicated that these DIM analogues 
lacked ability to bind to hGPR84. Both these DIM analogues contain a bulky 
substitution on the linker between two indole rings. The lack of affinity of 2b 
and 3c for human GPR84 implies that the bulky substitution on the linker is 
intolerable for receptor binding.  Pillaiyar et al. (2017) reported that any aryl or 
alkyl substitution on the linker between two indole rings diminishes the potency 
of the DIM analogue. Further SAR studies with a broader range of these DIM 
analogues might explore the potential binding pocket of such allosteric ligands.  
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Figure 6.10 DIM analogues 2b and 3c lack ability to bind human GPR84. Membranes were 
prepared from Flp-In T-REx-293 cells induced with 100 ng/ml of doxycycline for 24 hours to 
express FLAG-hGPR84-Gαi2. Using these membranes, [
35
S]-GTPγS binding assays were 
performed in which increasing fixed concentrations of 2b were co-added to the concentration-
response curve for C-10 (ai) or compound-1(aii) to assess their ability to affect the function of the 
respective orthosteric agonist. Equivalent studies were performed assessing the ability of various 
increasing fixed concentrations of 3c to affect the concentration-response curves for C-10 (bi) or 
compound-1(bii).  
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6.7. DIM analogue PSB-16671 is a potent PAM agonist at 
both human and mouse GPR84 
6.7.1. PSB-16671 is more effective than DIM in enhancing the 
potency of decanoic acid  
Though DIM displays strong cooperativity with orthosteric agonists of GPR84 
(section 6.3), the affinity of DIM for human GPR84 is modest (average KA: 6.3 µM) 
which necessitates the development of new PAM agonists having higher affinity 
for GPR84. Recently Pillaiyar et al., (2017) reported a more potent and 
efficacious DIM analogue PSB-16671 which has 10-fold higher potency and 2-fold 
higher efficacy than DIM (section 4.2.3). Compared to DIM, PSB-16671 was 
reported to be more effective in potentiating the function C-10 in cAMP 
accumulation assays (Pillaiyar et al., 2017). To investigate whether PSB-16671 
also displayed a higher magnitude of positive cooperativity than DIM in [35S]-
GTPγS binding assays which measure the signalling effect immediately 
downstream of GPCR activation, concentration-response assays for C-10 were 
conducted in the absence or presence of various increasing fixed concentrations 
of PSB-16671 (Figure 6.11a). Indeed, in this assay PSB-16671 was found to be 
more effective than DIM in the function of C-10 as a significantly higher 
magnitude of binding affinity modulation of C-10 (logα: 2.37±0.22, α= 232) was 
obtained than that produced by DIM (logα: 1.45±0.09; α= 26). When the 
experimental protocol was reversed, increasing concentrations of decanoic acid 
increased both the potency and efficacy of PSB-16671 (Figure 6.11b) with 
affinity cooperativity factor, α, value of 41 (logα:1.61±0.13) and activation 
cooperativity factor,β value of 6.7 (Table 6.5). Though theoretically it is 
expected that the magnitude of allosteric modulation of binding affinity 
obtained from the reciprocal assay should be similar to that yielded in the 
allosteric interaction study, the extent of the binding affinity modulation (logα 
:1.61±0.13, α=41) of PSB-16671 exerted by C-10 was significantly lower than that 
of C-10 by PSB-16671. This discrepancy in maintaining similar binding affinity 
modulation in reciprocal allosteric experiments is not unusual as Lee et al., 
(2008) also reported similar inconsistency in observing similar binding 
cooperativity in reciprocal allosteric interaction studies in which the PAM agonist 
phenylacetamide 1 potentiated the function of acetate at FFA2 in calcium 
mobilization assays, displaying a 89-fold increase in potency of acetate (Logα: 
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1.95; α=89) whilst acetate-induced enhancement of the potency of 
phenylacetamide 1 was significantly lower (logα: 1.38; α= 24). However, in the 
reciprocal experiments equivalent outcomes were obtained in terms of net 
affinity/efficacy cooperativity factor (αβ) (292 vs 272 in reciprocal assays). 
Operational model analysis of these datasets revealed that PSB-16671 (average 
KA: 1.5 µM) binds human GPR84 with 240-fold higher affinity than decanoic acid 
(average KA: 0.36 mM) while compared to DIM (average KA: 6.3 µM, Table 6.1), 
the affinity of PSB-16671 is 4.2 times higher. 
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Figure 6.11 PSB-16671 is a PAM of potency of C-10 at human GPR84. Effects of co-addition of 
increasing concentrations of PSB-16671, ranging from 30 nM to 0.1 µM, on the ability of C-10 to 
stimulate [
35
S]-GTPγS incorporation into membranes of Flp-In T-REx-293 cells expressing FLAG-
hGPR84-Gαi2 were assessed (a). Equivalent studies were conducted assessing the effects of co-
incubation of increasing concentrations (ranging from 3µM to 30 mM) of C-10 on PSB-16671-
mediated [
35
S]-GTPγS binding to FLAG-hGPR84-Gαi2 (b). Data are mean±SEM of three 
independent experiments performed on separate membrane preparations. The curves displayed 
are from global fitting of the experimental data with the operational model of allosterism and the 
estimated allosteric parameters are shown in Table 6.6.   
6.7.2. PSB-16671 is more effective than DIM in potentiating 
function of compound-1 and embelin at human GPR84   
To investigate whether PSB-16671 displays any probe-dependence in modulating 
functions of GPR84 orthosteric agonists, a series of interaction studies were 
conducted assessing the effects of increasing fixed concentrations of PSB-16671 
on concentration-response assays for compound-1 and embelin (Figure 6.12). 
PSB-16671 also displayed very strong allosteric interaction with compound-1 at 
human GPR84 as the potency of compound-1 was progressively enhanced by the 
co-addition of increasing concentrations of PSB-16671 (Figure 6.12ai) affording 
an affinity cooperativity factor, α, value of 257 (logα: 2.41±0.17). This allosteric 
modulation of potency of compound-1 reached a saturating limit at higher 
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concentrations of PSB-16671. Though PSB-16671 caused a small reduction in the 
maximal response to compound-1(activation cooperativity factor, β value of 
0.71), it was greatly outweighed by the high degree of binding affinity 
modulation, ultimately led to a high net affinity/efficacy cooperativity (αβ) 
value of 182.5. In reciprocal experiments, equivalent outcomes were obtained 
where compound-1 increased the potency and efficacy of PSB-16671 (Figure 
6.12aii) with an affinity cooperativity factor, α value of 105 (logα: 2.02±0.11) 
and activation cooperativity factor, β value of 2.34 (Table 6.6). Mathematical 
analysis of the allosteric interaction between PSB-16671 and compound-1 also 
estimated the binding affinity of PSB-16671 and compound-1 for FLAG-hGPR84-
Gαi2 fusion protein as being 0.9 µM and 69 nM, respectively. Again PSB-16671 was 
found to be more effective than DIM (α: 120) in enhancing the measured potency 
of compound-1 although this higher degree (2-fold) of binding affinity 
modulation exerted by PSB-16671 compared to DIM did not reach the statistical 
significance level (P>0.05, two tailed unpaired t-test).  
PSB-16671 was also found to strongly potentiate the function of embelin at 
human GPR84 (Figure 6.12b) by positively modulating both potency and efficacy 
of embelin, yielding an affinity cooperativity factor, α value of 16.4 and 
activation cooperativity factor, β value of 15.5. Though PSB-16671-induced 
enhancement of the potency of embelin was equivalent to that produced by DIM 
(logα: 1.22±0.08 vs 1.20±0.05, respectively for PSB-16671 and DIM), PSB-16671 
displayed 2-fold higher magnitude of positive modulation of efficacy of embelin 
than that generated by DIM (β: 15.5 vs 7.6) which is correlated with the higher 
intrinsic agonist activity of PSB-16671 (average τ: 0.91) than that of DIM (average 
τ: 0.32). Application of an operational model of allosterism to the global analysis 
of experimental data revealed that PSB-16671 and embelin bind FLAG-hGPR84-
Gαi2 with similar avidity (average KA: 1.4 vs 1.5 µM, respectively).  
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Figure 6.12 PSB-16671 acts as a PAM of potency of compound-1 while it behaves as a 
strong PAM of potency and efficacy of embelin at human GPR84. A [
35
S]-GTPγS binding 
assay was performed using membranes purified from Flp-In T-REx cells expressing FLAG-
hGPR84-Gαi2 in which  increasing fixed concentrations of PSB-16671 ranging from 30 nM to 30 µM 
were evaluated for their ability to modulate compound-1-induced [
35
S]-GTPγS binding (ai). 
Equivalent co-addition studies were performed assessing the effects of various fixed 
concentrations of compound-1 ranging from 0.3 nM to 100 nM on PSB-16671-mediated [
35
S]-
GTPγS incorporation into membranes (aii). Similarly, concentration-response assays for embelin 
were also performed with or without increasing fixed concentrations of PSB-16671 ranging from 30 
nM to 30 µM (b). Data are expressed as mean±SEM of four (ai, aii) or two (b) individual 
experiments performed on separate membrane preparations carried out in duplicate. Curves 
displayed are from experimental data best fit to the operational model of allosterism and estimates 
of allosteric parameters are shown in Table (6.6).  
Table 6-6 Operational model parameters of allosteric interactions between PSB-16671 and 
orthosteric agonists at FLAG-hGPR84-Gαi2 
Agonista C-10 PSB-16671 Compound-1 PSB-16671 Embelin 
Modulatorb PSB-16671 C-10 PSB-16671 Compound-1 PSB-16671 
logα 2.37±0.22 1.61±0.13 2.41±0.17 2.02±0.11 1.22±0.08 
logβ 0.1±0.20 0.82±0.04 -0.15±0.06 0.37±0.12 1.2±0.05 
logτA 0.67±0.2 -0.002±0.03 0.86±0.05 0.28±0.1 -0.59±0.05 
logτB 0.2±0.02 0.15±0.07 0.22±0.05 0.65±0.1 -0.04±0.02 
pKA
c 3.41±0.2 5.72±0.06 7.0±0.2 6.1±0.1 5.82±0.06 
pKB
d 5.95±0.06 3.47±0.1 6.02±0.13 7.42±0.07 5.85±0.04 
α 232 40.6 257 104.7 16.4 
β 1.26 6.7 0.71 2.34 15.5 
αβ 292 272 182.5 245 254.2 
a
Agonist is the compound used to generate concentration-response curve 
b
Modulator is the compound used in defined concentrations 
c 
pK
A
 are values estimated for the agonist  
d
 pK
B
 are values estimated for the modulator 
Allosteric parameters for interaction between PSB-16671 and GPR84 orthosteric agonists were 
extracted from the data generated from [
35
S]-GTPγS binding study using membranes prepared 
from doxycycline-treated Flp-In T-REx cells expressing FLAG-hGPR84-Gαi2 as described in Figure 
6.11 and 6.12. Data are means ± SEM (n=3). 
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6.7.3. PSB-16671 displays little probe-dependence in allosteric 
modulation of orthosteric agonists at human GPR84 
Though compound-1 displayed higher intrinsic activity than C-10 (average τ: 5.85 
vs 3.04, respectively), equivalent magnitude of PSB-16671-induced binding 
affinity modulation of compound-1 and C-10 (α: 257 vs 232, respectively) was 
observed at FLAG-hGPR84-Gαi2 in [
35S]-GTPγS incorporation assays, which 
indicates that PSB-16671 displayed little probe-dependence in allosteric 
modulation of human GPR84. However, the PSB-16671-promoted increase in the 
potency of embelin (16.4 fold) was significantly lower in comparison with those 
obtained from the allosteric interaction between PSB-16671 and compound-1/C-
10, which is consistent with the significantly lower intrinsic activity of embelin 
(τ: 0.26). Another notable thing is that while allosteric efficacy modulation of 
compound-1 exerted by PSB-16671 was marginal, PSB-16671 generated some 
15.5-fold increase in the efficacy of embelin. However, PSB-16671 generated 
equivalent net affinity/efficacy cooperativity factor (αβ: 292, 182.5, 254.2; 
respectively with C-10, compound-1 and embelin) in allosteric interaction 
studies with C-10, compound-1 or embelin, suggesting that in [35S]-GTPγS 
binding assays, PSB-16671 exhibited no overall probe-dependence in displaying 
positive cooperativity with orthosteric agonists of GPR84.      
6.7.4.  PSB-16671 is also a potent PAM of activity of orthosteric 
agonists at mouse GPR84 
There might be differences among species orthologues of a GPCR in terms of 
magnitude and direction or probe-dependence of cooperativity between an 
allosteric agonist and orthosteric agonist (Christopoulos, 2014; Wooten et al., 
2013). To investigate whether PSB-16671 displays any variation between human 
and mouse orthologues of GPR84 in terms of cooperativity with orthosteric 
agonists, a set of interaction studies were performed using membranes 
expressing FLAG-mGPR84-Gαi2 wherein the effects of increasing fixed 
concentrations of PSB-16671 on concentration-response assays for compound-1, 
C-10 or embelin were evaluated (Figure 6.13). Similar patterns of allosteric 
interactions between PSB-16671 and compound-1 was observed at mouse GPR84 
in which co-addition of increasing concentrations of PSB-16671 ranging from 30 
nM to 10 µM resulted in progressive increase in the potency of compound-1 
(Figure 6.13ai) with binding affinity cooperativity factor, α value of 105 (logα: 
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2.02±0.11) indicating that PSB-16671 is also a strong PAM agonist at mouse 
GPR84. Similar magnitude of positive binding affinity cooperativity between PSB-
16671 and compound-1 was observed (logα: 2.15±0.1; α: 141) in reciprocal 
experiments when increasing concentrations of compound-1 ranging from 0.3 nM 
to 100 nM were added to the concentration-response assay for PSB-16671 (Figure 
6.13 aii), which is in full agreement with the reciprocity of the allosteric effect. 
In both cases, no efficacy modulation was observed and effect of PSB-16671 on 
the binding affinity of compound-1 vice versa approached a saturable limit at 
higher concentrations of the modulator. In comparison with DIM, PSB-16671 
exhibited 6.5-fold higher binding affinity cooperativity and 4.5-fold higher net 
affinity/efficacy cooperativity with compound-1 at FLAG-mGPR84-Gαi2. Though 
compared to mouse GPR84, human GPR84 displayed some 2.4-fold higher 
magnitude of binding affinity cooperativity and 1.5-fold higher net 
affinity/efficacy cooperativity between PSB-16671 and compound-1 in [35S]-
GTPγS binding assays, these differences were not statistically significant 
(P>0.05; two-tailed unpaired t-test).   
Global analysis of these datasets using an operational model of allosterism 
showed that estimated binding affinity of PSB-16671 (average KA: 0.94 µM) and 
compound-1 (average KA: 81.5 nM) for FLAG-mGPR84-Gαi2 was equivalent to that 
observed at the fusion protein version of human GPR84, which is also consistent 
with the fact that both the ligands displayed no variation in potency between 
human and mouse orthologues (section 5.3). Compared to DIM (KA: 4.8 µM, Table 
6.3), PSB-16671 has a 5-fold higher affinity for mouse GPR84.  
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Figure 6.13 PSB-16671 displays strong positive cooperativity with different orthosteric 
agonists of GPR84 at FLAG-mGPR84-Gαi2. The ability of increasing fixed concentrations of PSB-
16671 to affect compound-1-induced [
35
S]-GTPγS binding to membranes purified from Flp-In T-
REx-293 cells expressing FLAG-mGPR84-Gαi2 was evaluated (ai). In reciprocal interaction studies, 
various concentrations of compound-1 were evaluated for their capacity to modulate PSB-16671-
promoted binding of [
35
S]-GTPγS into Gαi2 associated with FLAG-mGPR84-Gαi2 (aii). Equivalent 
co-addition studies were performed assessing the effects of increasing concentrations of PSB-
16671 on concentration-response curves for C-10 (b) or embelin (c). Data represent mean±SEM of 
four (ai, aii) or two (b,c) individual experiments performed using separate membrane preparations. 
Curves displayed are from global fitting of experimental data with operational model of allosterism; 
the allosteric parameters are shown in Table 6.7.      
Table 6-7 Operational model parameters of allosteric interactions between PSB-16671 and 
different orthosteric agonists at FLAG-mGPR84-Gαi2 
Agonista Compound-1 PSB-16671 C-10 Embelin 
Modulatorb PSB-16671 Compound-1 PSB-16671 PSB-16671 
logα 2.02±0.11 2.15±0.1 2.1±0.2 1.33±0.08 
logβ 0.05±0.09 0.12±0.04 0.16±0.1 0.9±0.03 
logτA 0.68±0.1 0.46±0.02 0.58±0.1 -0.12±0.03 
logτB 0.42±0.02 0.54±0.06 0.48±0.06 0.43±0.02 
pKA
c 6.98±0.17 5.96±0.08 3.51±0.2 5.97±0.06 
pKB
d 6.1±0.13 7.2±0.07 5.75±0.08 6.0±0.03 
α 104.7 141.2 125.4 21.3 
β 1.12 1.3 1.45 7.9 
αβ 117 183 182.4 168.3 
a
Agonist is the compound used to generate concentration-response curve 
b
Modulator is the compound used in defined concentrations 
c 
pK
A
 are values estimated for the agonist  
d
 pK
B
 are values estimated for the modulator 
Allosteric parameters for interaction between PSB-16671 and GPR84 orthosteric agonists were 
extracted from the data generated from [
35
S]-GTPγS binding study using membranes prepared 
from doxycycline-treated Flp-In T-REx cells expressing FLAG-mGPR84-Gαi2 as described in Figure 
6.13. Data are means ± SEM. 
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PSB-16671 also displayed very high positive cooperativity with C-10 (Figure 6.13 
b) or embelin (Figure 6.13c) at FLAG-mGPR84-Gαi2 in [
35S]-GTPγS binding assays, 
exhibiting affinity cooperativity factor, α, values of 125.4 and 21.3, respectively 
(Table 6.7). Though approximately 1.9-fold lower affinity cooperativity between 
PSB-16671 and C-10 was obtained at the FLAG-mGPR84-Gαi2 than displayed at 
FLAG-hGPR84-Gαi2, this variation was not statistically significant. In the case of 
allosteric interaction between PSB-16671 and embelin, similar magnitude of 
affinity modulation of embelin by PSB-16671 was observed between human and 
mouse GPR84 (α: 16.4 vs 21.3) whilst human GPR84 displayed 2-fold higher 
degrees of efficacy modulation of embelin by PSB-16671 than that exhibited at 
mouse GPR84 (β: 15.5 vs 7.9). Application of an operational model of allosterism 
for the global analysis of datasets obtained from the allosteric interaction 
between PSB-16671 and C-10 predicted the estimated binding affinities of PSB-
16671 and C-10 for FLAG-mGPR84-Gαi2 to be 1.7 µM and 0.3 mM, respectively 
which were very similar to those measured by similar studies at FLAG-hGPR84-
Gαi2 (average KA: 1.5 µM and 0.36 mM, respectively for PSB-16671 and C-10). 
Similarly, mathematical analysis of datasets from interaction studies between 
PSB-16671 and embelin revealed that both agonists bind mouse GPR84 with 
similar avidity (KA: 1.0 µM) and there was no variation in binding affinities of 
PSB-16671 and embelin between mouse and human (KA: 1.4 and 1.5 µM, 
respectively) orthologues of GPR84. This maintenance of binding affinities of 
PSB-16671, C-10 and embelin between human and mouse GPR84 are in good 
agreement with the equivalent potencies of these agonists at human and mouse 
GPR84 (section 5.3).    
Consistent with the results obtained from the interaction studies using FLAG-
hGPR84-Gαi2, PSB-16671 potentiated the binding affinity of compound-1 and C-
10 for mouse GPR84 to a similar extent (α: 105 vs 125). Though PSB-16671-
promoted enhancement (21.3 fold) of potency of embelin was significantly lower 
than that observed when compound-1 or C-10 was used to probe the function of 
mouse GPR84, PSB-16671 caused some 8-fold increase in efficacy for embelin 
whilst no significant modulation of efficacy was observed for compound-1 
(β=1.12) or C-10 (β= 1.45). However, equivalent magnitude of net 
affinity/efficacy cooperativity was obtained whether compound-1, C-10 or 
embelin (αβ: 117, 182 and 168, respectively) was used as a probe for receptor 
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function, suggesting little probe-dependence of allosteric interaction of PSB-
16671 with orthosteric GPR84 agonists in [35S]-GTPγS incorporation assays.       
6.7.5. PSB-16671 is a potent PAM agonist of the function of 
orthosteric agonists of mouse GPR84 in RAW 264.7 cells 
To study the allosteric interaction between PSB-16671 and orthosteric GPR84 
agonists in a more physiological setting, the mouse monocyte-macrophage cell 
line RAW264.7 was employed. Membranes were prepared from both LPS-treated 
(100 ng/ml, 5 hours) and untreated (LPS-) RAW 264.7 cells and subsequently 
employed in [35S]-GTPγS binding assays to investigate the effects of varying fixed 
concentrations of PSB-16671 on concentration-response curve for compound-1 
(Figure  6.14 a, bi). In both cases, progressive increases in measured potency of 
compound-1 was observed upon co-addition of increasing concentrations of PSB-
16671 with affinity cooperativity factor, α value of 219 and 251, respectively 
(Table 6.8) for LPS untreated and treated cells, which indicates that PSB-16671 
is a potent PAM of potency of compound-1 at RAW 264.7 cells. This is consistent 
with the results obtained in transfected cells expressing FLAG-mGPR84-Gαi2. 
Though co-addition of PSB-16671 resulted in a small reduction in maximal 
response to compound-1 (β: 0.63 and 0.83, for LPS-treated and untreated cells, 
respectively), this effect was completely outweighed by high affinity 
cooperativity values which led to high net affinity/efficacy cooperativity factor, 
αβ value of 159 and 182, respectively for LPS-treated and untreated RAW264.7 
cells. These results suggested that LPS-treatment of RAW264.7 cells did not alter 
the magnitude of cooperativity between compound-1 and PSB-16671. In 
reciprocal allosterism experiments, co-incubation of increasing concentrations of 
compound-1 caused both leftward and upward shifts of the concentration-
response curve for PSB-16671 (Figure 6.14 bii), yielding an affinity cooperativity 
factor, α value of 87 and activation cooperativity factor, β value of 2.14 (Table 
6.8). Though the extent of modulation of binding affinity (logα: 1.94±0.03) of 
PSB-16671 by compound-1 obtained in reciprocal assays was significantly lower 
(P<0.001) than that for compound-1 by PSB-16671 (logα: 2.4±0.04), similar net 
affinity/efficacy cooperativity value (αβ: 159 vs 186.4 in reciprocal assays) was 
maintained between both assays whether PSB-16671 or compound-1 was used as 
the modulator. The degree of potentiation of binding affinity of compound-1 by 
PSB-16671 observed in RAW264.7 cells was significantly (P<0.05, two-tailed 
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unpaired t test) higher than that displayed in Flp-In T-REx-293 cells expressing 
FLAG-mGPR84-Gαi2 (logα: 2.4±0.04 vs 2.02±0.11, respectively). However, similar 
affinity cooperativity was observed between RAW264.7 cells and transfected 
cells expressing the cloned mouse receptor (logα: 1.94±0.03 vs 2.15±0.09, 
respectively, P>0.05) when the ability of increasing concentrations of compound-
1 to modulate the potency and efficacy of PSB-16671 was investigated. 
Moreover, no significant variation (P>0.05) in net affinity/efficacy cooperativity 
(αβ: 159 vs 117) was observed between RAW264.7 cells and transfected cells 
expressing FLAG-mGPR84-Gαi2. Similar estimated binding affinities of PSB-16671 
(average KA= 0.5 µM) and compound-1 (average KA= 79 nM) for mouse GPR84 
were observed at RAW 264.7 cells compared to those displayed at Flp-In T-REx-
293 cells expressing FLAG-mGPR84-Gαi2 .  
Marked variation in allosteric interaction with compound-1 was observed 
between DIM and PSB-16671 at LPS-treated RAW-264.7 cells. Compared to DIM, 
PSB-16671 displayed 2-fold higher binding affinity cooperativity (128 vs 251) with 
compound-1 although this variation did not reach statistical significance level 
(P>0.05, two-tailed unpaired t test). Though DIM caused a 4.5-fold (β: 0.22) 
decrease in maximal response to compound-1, acting as a weak NAM of efficacy, 
PSB-16671-mediated efficacy modulation of compound-1 was marginal (β: 0.63, 
1.6-fold decrease in efficacy). However, PSB-16671 displayed some 5.7-fold 
higher net affinity/efficacy cooperativity (αβ: 159 vs 28) than DIM in modulating 
the function of compound-1 at LPS-treated RAW264.7 cells.  
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Figure 6.14 PSB-16671 displays high positive cooperativity in modulating function of 
compound-1, C-10 and embelin in [
35
S]-GTPγS binding assays in RAW 264.7 cells. Increasing 
fixed concentrations of PSB-16671 ranging from 30 nM to 10 µM were assessed for their ability to 
affect compound-1-mediated [
35
S]-GTPγS incorporation into membranes purified from naïve (-LPS) 
RAW264.7 cells (a). Similar interaction study was performed to evaluate the effect of increasing 
defined concentrations of PSB-16671 on the ability of various concentrations of compound-1 to 
stimulate [
35
S]-GTPγS binding to membranes generated from LPS-induced (100 ng/ml, 5 hours) 
RAW264.7 cells (bi). In reciprocal experiment, the capacity of increasing fixed concentrations of 
compound-1 to modulate the potency and efficacy of PSB-16671 were investigated (bii). Equivalent 
allosteric interaction studies were performed using membranes of LPS-treated (LPS+) RAW264.7 
cells in which concentration-response assays for C-10 (c) or embelin (d) were conducted with or 
without increasing fixed concentrations of PSB-16671. Data represented in (bi) and (bii) are 
mean±SEM of four and three independent experiments performed on separate membrane 
preparations while data presented in (a), (c) and (d) are representative of two individual 
experiments. Curves drawn are from fitting the datasets with operational model of allosterism and 
the allosteric parameters quantified from these analyses are shown in Table 6.8.    
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Table 6-8 Operational model parameters of allosteric interactions between PSB-16671 and 
different orthosteric agonists at RAW 264.7 cells. 
Agonista Compound-1 Compound-1 PSB-16671 C-10 Embelin 
Modulatorb PSB-16671e PSB-16671f Compound-1f PSB-16671f PSB-16671f 
logα 2.34±0.13 2.4±0.04 1.94±0.03*** 1.81±0.4 1.36±0.2 
logβ -0.1±0.14 -0.20±0.05 0.33±0.08 0.25±0.2 0.8±0.06 
logτA 0.62±0.2 0.53±0.05 0.14±0.02 0.50±0.24 -0.56±0.05 
logτB 0.11±0.02 0.15±0.03 0.3±0.03 0.24±0.07 0.21±0.1 
pKA
c 6.54±0.05 7.0±0.1 6.3±0.15 3.51±0.3 6.2±0.1 
pKB
d 6.26±0.43 6.3±0.1 7.24±0.05 6.12±0.13 5.5±0.2 
α 219 251.2 87.1 64 23 
β 0.83 0.63 2.14 1.8 6.3 
αβ 182 159 186.4 115.2 145 
a
Agonist is the compound used to generate concentration-response curve 
b
Modulator is the compound used in defined concentrations 
c 
pK
A
 are values estimated for the agonist  
d
 pK
B
 are values estimated for the modulator 
e 
experiment performed with  membranes generated from naïve  RAW264.7 cells 
f 
experiments performed with membranes generated from LPS-treated RAW264.7 cells. Allosteric 
parameters for interaction between PSB-16671 and different GPR84 orthosteric agonists were 
extracted from the data generated from [
35
S]-GTPγS binding study using membranes prepared 
from naïve or LPS-treated RAW264.7 cells as described in Figure 6.14. Data are means±SEM.  
To assess whether PSB-16671 exhibited any probe-dependence in allosteric 
interaction with orthosteric agonists of GPR84 at RAW264.7 cells, interaction 
studies were performed using [35S]-GTPγS binding assays whereby effects of 
increasing defined concentrations of PSB-16671 on the potency and efficacy of 
C-10 (Figure 6.14 c) or embelin (Figure 6.14 d) were evaluated. PSB-16671 also 
acted as a strong PAM of potency and efficacy of C-10 or embelin at LPS-treated 
RAW264.7 cells and the allosteric effects reached a limit at higher 
concentrations of the modulator. Though PSB-16671-mediated potentiation of C-
10 binding affinity for mouse GPR84 was 2-fold lower in RAW264.7 cells 
compared to that displayed at FLAG-mGPR84-Gαi2 (α: 64 vs 125), the magnitude 
of binding affinity cooperativity with embelin was equivalent between RAW264.7 
cells and transfected cells expressing FLAG-mGPR84-Gαi2 (α: 23 vs 21.3). Similar 
to the results obtained from FLAG-hGPR84-Gαi2, PSB-16671 was found to be more 
effective than DIM in potentiating the function of C-10 in RAW264.7 cells 
displaying 4-fold higher affinity cooperativity (α: 64 vs 16.3) and 9.5-fold higher 
net affinity/efficacy cooperativity (αβ: 115 vs 12) with C-10 which strongly 
correlates with some 6-fold higher intrinsic agonist activity of PSB-16671 (τ: 
1.74) than DIM (τ: 0.3) in RAW264.7 cells.     
Mathematical analysis of allosteric interaction between PSB-16671 and C-10 
revealed that PSB-16671(KA: 0.76 µM) binds mouse GPR84 with 400-fold higher 
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affinity than C-10 (KA: 0.31 mM). Similarly global fitting of datasets obtained 
from interaction studies between PSB-16671 and embelin with an operational 
model of allosterism estimated binding affinity of PSB-16671 and embelin for 
mouse GPR84 to be 3 µM and 0.63 µM, respectively, which are very similar to 
those measured at transfected cells expressing FLAG-mGPR84-Gαi2.  
6.7.6. PSB-16671 exhibits probe-dependence in modulating 
function of orthosteric agonists of GPR84 in RAW264.7 
cells 
PSB-16671 exhibited probe-dependence in modulating the binding affinity of 
orthosteric agonists for mouse GPR84 in LPS-induced RAW264.7 cells as 
evidenced from the findings that greatest magnitude of affinity modulation was 
observed for compound-1(α: 251) followed by for C-10 (α: 64) and lowest binding 
affinity modulation (α: 23) was generated when embelin was used to probe the 
receptor function. These results are in good agreement with the correlation of 
magnitude of affinity modulation with the efficacy of the orthosteric agonist 
used in the allosteric interaction study. While the cooperativity with compound-
1 was solely governed by the affinity modulation, the cooperativity with C-10 or 
embelin incorporated both the affinity and efficacy modulation. The highest 
potentiation of efficacy by PSB-16671 was observed for embelin (β: 6.3) which 
was 3.5-fold higher than that for C-10. However, no significant variation in 
overall affinity/efficacy cooperativity was observed irrespective of the nature of 
the orthosteric agonist used as a probe for the receptor function (αβ: 159, 115, 
and 145, respectively for compound-1, C-10 and embelin).    
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6.8. Discussions 
6.8.1. Orthosteric and allosteric ligand act co-operatively to 
greatly enhance the function of GPR84 which may be a 
therapeutic strategy to limit atherosclerosis  
Though DIM was reported to be a PAM agonist at GPR84 (Nikaido et al., 2015) 
based on the additive effects of DIM and MCFAs in double stimulation assay 
performed using [35S]-GTPγS binding assay, the mechanism of allosteric effect 
was unexplored at that time. Recently Pillaiyar et al., (2017) have studied 
allosteric interaction between DIM or DIM analogue PSB-16671 and the putative 
endogenous agonist C-10 using forskolin-induced cAMP accumulation assays in 
CHO cells expressing human GPR84 and reported that DIM and PSB-16671 both 
acted as PAM of potency and efficacy of C-10 at human GPR84. Though this study 
revealed that allosteric effect of DIM or PSB-16671 on C-10 is governed by both 
potency and efficacy modulation, other allosteric features including ‘reciprocity 
of the allosteric effect’ and ‘probe dependence’ of allosteric interaction were 
not studied. Moreover, allosteric interaction of DIM or DIM derivatives in mouse 
GPR84 was lacking. In this context, detailed studies of allosteric modulation of 
GPR84 are required. To assess whether combinations of orthosteric and allosteric 
ligands enhance the function of GPR84 substantially, I have performed detailed 
studies of allosteric interactions of DIM and DIM analogues with a series of 
orthosteric GPR84 agonists, C-10, compound-1, embelin or 6-OAU using [35S]-
GTPγS binding assays employing membranes of transfected cells expressing 
FLAG-hGPR84-Gαi2. Moreover, to assess whether DIM and PSB-16671 exhibit any 
species selectivity in displaying cooperativity with orthosteric agonists, 
interaction studies were also performed using transfected cells expressing FLAG-
mGPR84-Gαi2 and the mouse monocyte-macrophage cell line RAW264.7. In these 
assays, DIM, DIM analogue 3a and particularly PSB-16671 acted as highly 
effective positive allosteric modulator of function of orthosteric GPR84 agonists, 
implying that DIM and DIM analogues could be used with MCFAs or synthetic 
orthosteric agonist as a combination therapy to limit atherosclerosis as recently 
Gaidarov et al., (2018) suggested that stimulation of GPR84 could be a potential 
therapeutic strategy to treat atherosclerosis. Recently several groups reported 
that PAM or ago-PAMs including BQCA and BQZ-12 which displayed selectivity on 
M1 mAchR over other muscarinic receptor subtypes could be an effective 
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therapeutic candidate to treat cognitive decline associated with Alzheimer’s 
disease or other neurodegenerative disorders as these allosteric modulators will 
greatly potentiate function of endogenous agonist acetylcholine at M1 mAchR 
concomitantly will preserve the spatiotemporal physiological signalling of 
acetylcholine (Bradley et al., 2017; Dallagnol et al., 2018). Similarly, application 
of ago-PAM of GPR84 including DIM or PSB-16671 might be an effective 
therapeutic strategy to treat atherosclerosis as it will greatly enhance the 
function of putative endogenous agonist MCFAs at GPR84. The plasma 
concentration of decanoic acid in human healthy volunteers is below µM 
concentration (Nagasaki et al., 2012). Shrestha et al., (2015) estimated the 
plasma concentration of C-10 in healthy Japanese volunteers to be below 0.5 µM 
although this concentration might be higher in the community who routinely 
take coconuts or coconuts oil in their diet including south Indian. The very low 
potency of decanoic acid (57 µM at FLAG-hGPR84-Gαi2 C352I and FLAG-mGPR84-
Gαi2 C352I, 10 µM at FLAG-hGPR84-eYFP and 43 µM at RAW264.7 cells), as well as 
low affinity to human and mouse GPR84 (average KA: 300 µM) are not in good 
agreement with the physiological relevance of GPR84-MCFAs pairing. This lower 
affinity of decanoic acid at GPR84 indicates that concentrations in the blood are 
too low in isolation to activate the receptor significantly which suggests that 
MCFAs might not be the true endogenous activators of GPR84. However, this may 
be overcome in the presence of an allosteric agonist, DIM or DIM-like molecules. 
DIM was found to enhance the potency of decanoic acid by a factor of 28 while 
in reciprocal assay C-10 displayed a 20-fold increase in the potency of DIM. Due 
to this high cooperativity between DIM and C-10, it is expected that decanoic 
acid will be able to activate GPR84 at a concentration much lower than the 
plasma concentration in the presence of DIM. As such, in the presence of 10 µM 
allosteric agonist DIM, the plasma concentration of C-10 might be able to 
produce half-maximal effects of GPR84 which would not be possible for C-10 in 
isolation. The potentiation of action of C-10 at GPR84 in the presence of PSB-
16671 will be much more pronounced as PSB-16671 was found to enhance the 
potency of C-10 by more than 200-fold. High cooperativity between C-10 and DIM 
or DIM derivatives also predicted that similar endogenous molecules might 
enhance the function of C-10 at GPR84 resulting in lower concentrations of C-10 
required for the activation of GPR84 (Mahmud et al., 2017).  
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Recently allosteric interaction across dimer (homodimer or heterodimer) or even 
oligomer of GPCR has been proposed as a mean to generate the cooperativity 
between two interacting ligands (Burford et al., 2015; Lane et al., 2014; 
Wootten et al., 2013; Smith and Milligan, 2010; Springael et al., 2007; May et 
al., 2007) wherein binding of an allosteric or orthosteric ligand to their 
corresponding binding site(s) on one protomer (homomer or heteromer) can 
either alter the binding affinity of the same ligand or other ligand for the 
interacting protomer and/or affect the maximal signalling response generated 
from the second protomer. For example, Lane et al., (2014) reported that 
bitopic ligand SB269652, which is a NAM of affinity of dopamine at D2R, displayed 
negative cooperativity with orthosteric agonist dopamine across a D2R 
homodimer. Considering this possibility, the observed high positive cooperativity 
between DIM or PSB-16671 and orthosteric GPR84 agonists might be generated 
due to the allosteric interaction across GPR84 dimer in which binding of DIM or 
PSB-16671 on the allosteric site within one protomer of GPR84 might result in 
either enhancement in binding affinity of the orthosteric agonists for the 
orthosteric binding site on the second protomer of the receptor and/or increase 
in maximal response of this ligand generated from the opposing homomer. 
However, retention of agonist function of DIM or PSB-16671 at both R172A GPR84 
and R172K GPR84 (section 4.3.2) suggested that DIM or PSB-16671 and 
orthosteric agonists bind to the same monomer of GPR84 to modulate the 
function of each other.            
6.8.2. MCFAs may act as endogenous allosteric modulators of 
GPR84 rather than acting as orthosteric agonists 
DIM is produced in vivo from the metabolism of indole-3-carbinol which is 
present in the cruciferous vegetables including broccoli, kale, cauliflower (Reed 
et al., 2006; Maciejewska et al., 2009). Following an oral dose of 1000 mg 
indole-3-carbinol, the peak plasma level of DIM in healthy women was estimated 
to be 607 ng/ml which is equivalent to 2.5 µM (Reed et al., 2006). Considering 
the potency of DIM to be 1 to 5 µM estimated at eYFP tagged human or mouse 
GPR84 and human or mouse GPR84-Gαi2 fusion protein, respectively and the 
affinity of DIM for GPR84 to be 5 µM, this peak level of DIM will be able to 
activate GPR84 partially. However, as C-10 was found to enhance the potency of 
DIM by 20 fold when co-bound to GPR84, in the presence of high plasma levels of 
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decanoic acid or other MCFAs, significantly much lower concentration of DIM will 
be sufficient to activate GPR84 than in the absence of MCFAs. So it is possible for 
DIM to activate GPR84 even at lower concentrations produced from lower dosing 
of indole-3-carbinol. As such C-10 or other MCFAs might act as endogenous 
allosteric modulators of GPR84 rather than acting as orthosteric agonists 
(Mahmud et al., 2017). As several lipids or lipid-derived molecules including 
cholesterol, endocannabinoids, lipoxin A4, pregnenolone have been reported to 
behave as endogenous allosteric modulators of different GPCRs (see van der 
Westhuizen et al., 2015; Christopoulos and Kenakin, 2002 for review), this will 
not be unusual that MCFAs may act as endogenous allosteric regulator of GPR84.   
6.8.3. The relative contribution of affinity and efficacy 
modulation to the functional cooperativity between DIM 
or PSB-16671 and orthosteric GPR84 agonists  
In the case of allosteric interaction studies performed using [35S]-GTPγ binding 
assays, a general trend was that DIM or PSB-16671-promoted enhancement in 
efficacy was significantly higher for partial agonist embelin than for C-10 whilst 
the efficacy modulation of compound-1 or 6-OAU appeared to be marginal. This 
conclusion is based on the mathematical analysis of allosterism data with an 
operational model of allosterism and needs to be validated by direct binding 
assays. Unfortunately, to date, no radioligand is available which targets the 
binding sites of these ligands. Both DIM and PSB-16671 potentiated the maximal 
response to embelin to a greater extent displaying efficacy cooperativity factor, 
β of 7.6 and 15.5, respectively in Flp-In T-REx-293 cells expressing FLAG-
hGPR84-Gαi2. PSB-16671 also enhanced the efficacy of embelin by a factor of 8 
and 6.3 in transfected cells expressing FLAG-mGPR84-Gαi2 and LPS-treated 
RAW264.7 cells, respectively. These results demonstrated that DIM and PSB-
16671-mediated allosteric effects on embelin were governed by both affinity and 
efficacy modulation. Though DIM enhanced the maximal response of C-10 by 2.3-
fold in transfected cells expressing FLAG-hGPR84-Gαi2 which is consistent with 
the result reported by Pillaiyar et al., (2017) in cAMP accumulation assays, no 
significant modulation of efficacy (β: 0.74) was observed in LPS-treated 
RAW264.7 cells, indicating species variation in allosteric effect of DIM on C-10. 
In the case of high positive cooperativity between PSB-16671 and C-10, 
contribution from efficacy modulation was insignificant compared to potency 
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modulation as evidenced from the finding that PSB-16671 enhanced maximal 
response to C-10 displaying efficacy cooperativity factor, β value of 1.3, 1.45 
and 1.8 at FLAG-hGPR84-Gαi2, FLAG-mGPR84-Gαi2 and in LPS-treated RAW264.7 
cells, respectively whereas the net affinity/efficacy cooperativity factor, αβ 
values were 292,182 and 115, respectively.  
In the case of study of allosteric interaction between the modulator and full 
agonist in functional assays, detection of efficacy modulation is quite 
challenging as full agonist can elicit signalling response which might reach 
maximal system response with or without the modulator used (Berizzi et al., 
2016). Though DIM displayed very high net cooperativity factor, αβ of 108 and 
117 with compound-1 and 6-OAU, respectively in human GPR84, the efficacy 
cooperativity factor, β values were 0.9 and 0.93, respectively. This was also the 
case for allosteric interaction of 3a with compound-1 or 6-OAU in human GPR84. 
As 6-OAU and compound-1 both are full agonists at human GPR84, it is difficult 
to quantify relative efficacy modulation if any without performing direct binding 
assays. In the case of allosteric interaction of DIM with compound-1 in 
transfected cells expressing FLAG-mGPR84-Gαi2 wherein although some degrees 
of increase in maximal response to compound-1 was obtained (β: 1.6), the exact 
quantification of the contribution of efficacy modulation remains challenging 
due to the full agonism of compound-1 at the FLAG-mGPR84-Gαi2. By contrast, 
DIM was found to decrease the maximal response to compound-1 by some 4.5-
fold (β: 0.22) in LPS-induced RAW264.7 cells. On the other hand, the high 
positive cooperativity between PSB-16671 and compound-1 obtained from 
allosteric interaction studies in transfected cells expressing FLAG-hGPR84-Gαi2 or 
in LPS-treated RAW264.7 cells appeared to be solely governed by the binding 
affinity modulation as PSB-16671 decreased the maximal response of compound-
1 by 1.4-fold (β: 0.71) and 1.6-fold (β: 0.63), respectively.   
6.8.4. Probe-dependence of allosteric effects of DIM and DIM 
analogues 
DIM displayed probe-dependence in exhibiting positive affinity cooperativity with 
orthosteric agonists of GPR84 including C-10, embelin, compound-1 and 6-OAU in 
a manner that degree of affinity cooperativity strongly correlates with the 
efficacy of the orthosteric agonist used as a probe for receptor function which is 
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consistent with the postulate of two states MWC model (Canals et al., 2012). The 
rank order of positive affinity cooperativity with orthosteric agonists was as 
follows: compound-1=6-OAU>> C-10>embelin. A similar correlation between the 
extent of positive cooperativity and orthosteric agonist efficacy in allosteric 
interaction at M1 mAChR were reported by Canals et al., (2012) and van der 
Westhuizen et al., (2018). In contrast, little probe-dependence in allosteric 
interaction between DIM and orthosteric agonists was observed in human GPR84 
when net affinity/efficacy cooperativity was considered. In transfected cells 
expressing FLAG-hGPR84-Gαi2 or FLAG-mGPR84-Gαi2, PSB-16671 potentiated 
binding affinity of compound-1 and C-10 for human or mouse GPR84 to the 
similar extent (α: 257 vs 232 and 105 vs 125, respectively for compound-1 and C-
10 at human and mouse GPR84, respectively) despite compound-1(average τ: 
5.85 and 4.8) displayed higher operational efficacy than C-10 (average τ: 3.04 
and 3.8) at both human and mouse GPR84. This result indicates little probe-
dependence of PSB-16671 in modulating the function of compound-1 and C-10. In 
contrast, PSB-16671 showed some 15-fold (for human GPR84) and 5-fold (for 
mouse GPR84) lower affinity cooperativity with embelin than that displayed with 
compound-1 or C-10 which is strongly linked with the significantly lower intrinsic 
agonist activity of embelin (τ: 0.26 and 0.76, respectively for human and mouse 
GPR84) than either compound-1 or C-10. However, equivalent net positive 
affinity/efficacy cooperativity (αβ) values were obtained whether C-10, 
compound-1 or embelin was used as the probe for GPR84 function, suggesting 
little probe-dependence of PSB-16671 in allosteric interaction with orthosteric 
agonists. On the other hand, PSB-16671 displayed strong probe-dependence in 
modulating binding affinity of orthosteric agonists in mouse monocyte-
macrophage cell line RAW264.7 cells which was evidenced from some 11 and 
2.8-fold higher positive affinity cooperativity with compound-1 and C-10, 
respectively than with embelin. However, once again similar net 
affinity/efficacy cooperativity was maintained in allosteric interaction of PSB-
16671 with orthosteric agonist, C-10, embelin or compound-1.   
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6.8.5. Relative to DIM or 3a, PSB-16671 displays markedly 
higher positive cooperativity with orthosteric GPR84 
agonists  
Estimates of operational efficacy (τ) values for DIM and PSB-16671 obtained from 
the global analysis of datasets of allosteric interaction between DIM/PSB-16671 
with compound-1 by an operational model of allosterism showed that relative to 
DIM, PSB-16671 has 4.2, 5.8 and 4.4-fold higher intrinsic agonist activity (τ) in 
FLAG-hGPR84-Gαi2, FLAG-mGPR84-Gαi2 and RAW264.7 cells, respectively which is 
fully consistent with the finding that DIM acts as a partial agonist compared to 
PSB-16671 (section 4.2.3, 5.2.3 and 5.4). Owing to this higher intrinsic agonist 
activity of PSB-16671 than DIM, in comparison with DIM, PSB-16671 displayed 
higher degrees of positive affinity cooperativity (2.0 and 6.5-fold higher in 
RAW264.7 cells or at FLAG-hGPR84-Gαi2 and at FLAG-mGPR84-Gαi2, respectively) 
with compound-1 which is consistent with the correlation between degrees of 
affinity cooperativity and operational efficacy (τ) of the modulator used (Canals 
et al., 2012; Keov et al., 2011). A similar correlation between the magnitude of 
positive affinity cooperativity and operational efficacy of allosteric modulator 
was observed among human M1 mAchR PAMs in modulating the function of 
orthosteric agonist acetylcholine wherein higher efficacy modulator MIPS1780 (τ: 
6) and MIPS1745 (τ: 1.1) showed 7.5 and 3.2-fold higher positive binding 
cooperativity with acetylcholine than that displayed by BQCA (τ: 0.3) in IP1 
accumulation assays (van der Westhuizen et al., 2018). Relative to DIM, PSB-
16671 displayed some 1.7, 4.6 and 5.6-fold higher net affinity/efficacy 
cooperativity (αβ) with compound-1 at FLAG-hGPR84-Gαi2, FLAG-mGPR84-Gαi2 
and RAW264.7 cells, respectively. Similarly, consistent with significantly higher 
intrinsic efficacy of PSB-16671 than 3a, PSB-16671 exhibited 3.7 and 9.4-fold 
higher composite cooperativity (αβ) with compound-1 and C-10, respectively in 
human GPR84. This strong correlation between observed functional cooperativity 
and degrees of intrinsic efficacy of modulator suggests that allosteric interaction 
of DIM or DIM analogues with orthosteric agonists of GPR84 likely follow two-
state MWC model of action (Dallagnol et al., 2018). PSB-16671 also exhibited 
markedly higher positive affinity cooperativity than DIM when C-10 was used to 
probe the GPR84 function which is consistent with the finding reported by 
Pillaiyar et al., (2017). Compared to DIM, PSB-16671 showed some 8 and 4-fold 
higher affinity cooperativity with C-10 in transfected cells expressing FLAG-
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hGPR84-Gαi2 and LPS-treated RAW264.7 cells, respectively which is strongly 
correlated with the variation in intrinsic agonist activity between PSB-16671 and 
DIM in respective cells. Though DIM and PSB-16671 exhibited similar affinity 
cooperativity with embelin at human GPR84, PSB-16671 showed 2-fold higher 
efficacy modulation of embelin than DIM. These results demonstrated that PSB-
16671 is much more effective than DIM in potentiating the function of 
orthosteric GPR84 agonists in both transfected cells expressing human and 
mouse GPR84 and in RAW264.7 cells implying that PSB-16671 appears to be more 
effective to be used as a potential therapeutic candidate or lead compound to 
develop further potent allosteric drug to treat atherosclerosis.  
 
6.8.6. DIM but not PSB-16671 displays marked variation 
between human and mouse GPR84 in modulating the 
function of orthosteric agonists 
As compared to orthosteric sites, allosteric sites of GPCRs are likely to display 
more variation in amino acid sequences between species orthologues (Lindsley et 
al., 2016), it is expected that allosteric modulators might exhibit species 
selectivity in displaying cooperativity with orthosteric agonists which might pose 
a great challenge for the translation of pharmacology of allosteric modulators 
observed in transfected cells into animal disease models (Christopoulos, 2014; 
Suratman et al., 2011; Smith and Milligan, 2010). However, in interaction studies 
using [35S]-GTPγS binding assays, PSB-16671 showed no significant variation 
(P>0.05; two-tailed unpaired t-test) in displaying positive cooperativity with 
orthosteric GPR84 agonists between human and mouse GPR84. Though PSB-16671 
displayed 2.4-fold higher affinity cooperativity and 1.5-fold higher net 
affinity/efficacy cooperativity with compound-1 at FLAG-hGPR84-Gαi2 than at 
FLAG-mGPR84-Gαi2, these variations did not reach statistical significance. 
Moreover, equivalent affinity cooperativity (257 vs 251) and net affinity/efficacy 
cooperativity (182 vs 159) between PSB-16671 and compound-1 were observed 
between transfected cells expressing FLAG-hGPR84-Gαi2 and mouse monocyte-
macrophage cell line RAW264.7. Similarly, no significant variations in binding 
affinity modulation or net affinity/efficacy modulation were observed between 
human and mouse orthologues when C-10 or embelin was used to probe the 
GPR84 function. By contrast, DIM displayed marked variation in cooperativity 
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with compound-1 or C-10 between human and mouse GPR84. In comparison with 
FLAG-hGPR84-Gαi2, FLAG-mGPR84-Gαi2 showed significantly lower affinity 
cooperativity (α: 120 vs 16) and net affinity/efficacy cooperativity (αβ: 108 vs 
25.4) between DIM and compound-1. Though equivalent magnitudes of binding 
affinity modulation of compound-1 (120 vs 129) or C-10 (28 vs 16) by DIM were 
observed between transfected cells expressing cloned human GPR84 and LPS-
treated RAW264.7 cells, DIM showed some 4 and 5.5-fold lower net 
affinity/efficacy cooperativity with compound-1 and C-10, respectively at LPS-
treated RAW264.7 cells relative to Flp-In T-REx-293 cells expressing  FLAG-
hGPR84-Gαi2. Global analysis of datasets with an operational model of 
allosterism yielded similar estimates of binding affinity of DIM for human and 
mouse GPR84 (average KA: 5 µM for both human and mouse GPR84), implying 
that the observed species variation in allosteric effect of DIM on compound-1 or 
C-10 between human and mouse orthologues was due to differential 
cooperativity rather than affinity. Suratman et al., (2011) also reported an ago-
PAM, LY2033298 which has identical affinity for human and mouse M4 mAchR but 
displayed significantly lower positive cooperativity with acetylcholine at mouse 
M4 mAchR than human orthologue. As relative to DIM, PSB-16671 has 5-fold 
higher affinity for human and mouse GPR84 and was found to be more effective 
in potentiating function of orthosteric GPR84 agonists both in human and mouse 
GPR84 without displaying any significant species selectivity, PSB-16671 has more 
potential to be used as a tool compound to characterize the allosteric site(s) of 
GPR84 and biological function of the receptor.      
 
6.8.7. Complex allosterism between DIM and compound-1 in 
LPS-treated RAW264.7 cells  
While allosteric interaction between DIM and orthosteric agonists displayed in 
transfected cells expressing FLAG-hGPR84-Gαi2 could be explained by two state 
MWC model as the probe-dependence of DIM in modulating binding affinity of 
orthosteric agonists followed the postulate of this two state model that higher 
efficacy agonist will be potentiated to greater extent than the lower efficacy 
agonist, the allosteric interaction between DIM and compound-1 in RAW264.7 
cells could not be explained by this two state scheme. DIM displayed higher 
affinity cooperativity with compound-1 than with C-10 which is consistent with 
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the two state MWC model according to which, the degree of cooperativity will 
be strongly correlated with the intrinsic efficacy of orthosteric probe. By 
contrast, DIM was found to behave as a potent PAM of affinity but a weak NAM of 
efficacy (4.5-fold decrease in maximal response) of compound-1 in LPS-induced 
RAW264.7 cells. This opposing effect of DIM on compound-1 affinity and efficacy 
cannot be explained by the two states MWC model as according to this model 
allosteric ligand which enhances the binding affinity of the orthosteric ligand 
will also potentiate the maximal response to orthosteric agonist (Keov et al., 
2011) and thus a multi-state model would be required to explore the 
mechanistic insight into the complex allosterism between DIM and compound-1 
in RAW264.7 cells. This complex allosteric modulation wherein the allosteric 
modulator enhances the binding affinity of orthosteric agonist but decreases the 
efficacy was also observed in CB1 receptor and FFA3 receptor. Price et al., 
(2005) reported that Org27569 and PSNCBAM-1 both acted as a strong NAM of 
efficacy and simultaneously enhanced the binding affinity of the orthosteric CB1 
receptor agonist. Similarly, Hudson et al., (2014a) reported that compound 6, an 
analogue of hexahydroquinolone-3-carboxamide behaved as a potent NAM of 
efficacy of FFA3 agonist propionate (C3) while it displayed positive binding 
cooperativity with C3. In both cases, these allosteric modulators acted as PAM 
antagonists (αβ<1). In contrast, DIM did not act as a PAM antagonist as it showed 
high net affinity/efficacy cooperativity, αβ of 28.  
6.8.8. Orthosteric and allosteric ligands bind human and mouse 
GPR84 with similar affinity 
Though binding affinity of antagonist 104 or 107 for human GPR84 can be 
estimated using the radiolabelled antagonist [3H]-G9543 (section 4.3.1; Mancini 
et al., 2019; Mahmud et al., 2017), no other radioligand targeting other binding 
sites within GPR84 is available which makes it very challenging to estimate the 
binding affinity of different orthosteric and allosteric ligands. Moreover, the 
measured potency values of GPR84 ligands estimated in different heterologous 
expression systems cannot be used as surrogate measures of affinity due to the 
existence of receptor reserve generated from the higher expression level of the 
receptor. The application of an operational model of allosterism (Leach et al., 
2007; Ehlert, 2005) for global analysis of datasets obtained from the interaction 
studies between DIM or DIM analogues and orthosteric agonists of GPR84 
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provided estimates of binding affinity of both ligands to the receptor. As 
expected, these estimates of binding affinity of the ligand for GPR84 were found 
to be constant for different combinations of orthosteric and allosteric agonists. 
For example, the estimated binding affinity of decanoic acid (C-10) for FLAG-
hGPR84-Gαi2 remains constant (average KA: 0.34, 0.38 and 0.36 mM, 
respectively) whether DIM, 3a or PSB-16671 was used as the allosteric modulator 
in the interaction study. Similarly, the mathematical analysis of allosteric 
interaction between C-10 and DIM, 3a or PSB-16671 yielded the binding affinity 
of DIM, 3a or PSB-16671 for the human GPR84 to be 6.2, 7.0 and 1.5 µM, 
respectively. The estimated binding affinities of compound-1, 6-OAU and 
embelin for FLAG-hGPR84-Gαi2 were 69-100 nM, 1-1.3 µM and 1.5-2.6 µM, 
respectively. Equivalent estimates of binding affinities of DIM (KA: 5.0-8.9 µM), 
3a (KA: 12.5- 29 µM) and PSB-16671 (KA: 0.9-1.4 µM) for human GPR84 were 
obtained when compound-1, 6-OAU or embelin was used to probe the receptor 
function. The rank order of affinity of these ligands for FLAG-hGPR84-Gαi2 is as 
follows: 
Compound-1>> 6-OAU=PSB-16671=embelin>DIM>3a>>C-10  
Based on these estimates of binding affinities, PSB-16671 has 360 and 5-fold  
higher affinity for human GPR84 than C-10 and DIM, respectively while 
compound-1 binds human GPR84 with 14 times higher avidity than PSB-16671. 
The binding affinities of C-10, DIM, PSB-16671, embelin and compound-1 for 
FLAG-mGPR84-Gαi2 were estimated to be 0.3 mM, 4.8 µM, 1.2 µM , 1.0 µM and 
130 nM which were very similar to those obtained from the allosteric interaction 
studies performed in LPS-treated RAW264.7 cells and in transfected cells 
expressing FLAG-hGPR84-Gαi2. These results demonstrated that orthosteric and 
allosteric ligands bind human and mouse GPR84 with similar affinity which is 
consistent with the maintenance of equivalent potencies of these ligands 
between human and mouse GPR84 (section 5.3). These results imply that 
mathematical analysis of the effect of allosteric agonist on the activity of 
orthosteric agonist by an operational model of allosterism can provide estimates 
of binding affinity of each ligand to the receptor and this is particularly useful in 
the case of unavailability of direct binding assays for poorly characterized 
receptor like GPR84. Gregory et al., (2012) found that estimates of binding 
affinities of a series of allosteric modulators for mGlu5 receptor obtained from 
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the analysis of the allosteric effect of allosteric modulators on orthosteric 
agonist by an operational model of allosterism were very similar to those derived 
from radioligand binding assays. Bolognini et al., (2016) also validated the use of 
this approach for estimation of binding affinity of allosteric ligand AZ1729 and 
reported no variation in measured affinity between operational model analysis 
and radioligand binding assays. Another notable thing was that the estimated 
binding affinities of DIM and embelin for GPR84 were equivalent to their 
measured potency values in [35S]-GTPγS binding assays employing FLAG-hGPR84-
Gαi2. Moreover, no large variation between affinity for GPR84 and potency to do 
G protein activation for PSB-16671, compound-1 and 6-OAU were observed 
wherein potency values were 2.3, 3 and 3.5-times higher than the corresponding 
affinity value, respectively. This was not the case for C-10 for which affinity was 
found to be 6.7 times lower than the potency value. Despite this, these 
outcomes suggested that the measured potencies of GPR84 ligands using [35S]-
GTPγS binding assay employing GPR84-Gαi fusion protein could be used as 
surrogate measures of binding affinity of the corresponding ligand for GPR84.  
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7 Final discussion 
G protein-coupled receptor 84 (GPR84), a member of the rhodopsin-like Class A 
GPCR family, recently has received considerable interest as a novel target for 
drug development against inflammation-associated diseases (ulcerative colitis, 
IBD, rheumatoid arthritis, chronic neuropathic pain, esophagitis, atherosclerosis) 
and fibrosis-associated diseases (idiopathic pulmonary fibrosis,  pulmonary 
hypertension associated with heart failure with reduced ejection fraction 
(HFrEF), diabetic nephropathy, non-alcoholic steatohepatitis) due to the  
potential role of GPR84 signalling in promoting or exacerbating inflammation 
and/or fibrosis (Vermiere et al., 2017; Nicol et al., 2015; Gaidarov et al., 2018; 
Gagnon et al., 2018; Saniere et al., 2019; Li et al., 2018; Puengel et al., 2018; 
Nguyen et al., 2019). Based on its restricted and lower basal expression in 
immune cells with strong upregulation in the diseased conditions, therapeutics 
targeting GPR84 are predicted to be more selective and less toxic compared to 
currently available anti-inflammatory or anti-fibrotic agents. Despite these 
potentials for being a therapeutic target, GPR84 still remains poorly 
characterized in terms of signal transduction pathways, biological functions and 
mode of ligand-GPR84 interactions and is still officially considered as an 
‘orphan’ receptor as the proposed endogenous agonists, MCFAs possess poor 
potency/affinity in activating the receptor, with a lack of consensus among the 
scientific community whether the concentration of these putative endogenous 
agonists under physiological conditions will reach the level required for 
activation of the receptor. Though recent years have seen synthesis of some 
potent and selective synthetic agonists including 6-OAU, compound-1 and its 
derivatives and the allosteric agonist PSB-16671, as well as a series of potent 
and selective GPR84 antagonists including the clinically trialled GLPG1205, their 
mode of binding to GPR84 as well as mode of pharmacological actions are 
unclear, which has hindered detailed characterization of the receptor. In this 
context, in an attempt to uncover the therapeutic potential of GPR84, this thesis 
aimed at elucidating the G protein selectivity of the receptor, defining ligand-
GPCR interactions and characterizing the pharmacological profiles of currently 
available tool compounds along with their potential orthologue selectivity. The 
major experimental findings of this thesis are as follows: 
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 Using a series of BRET-based GPR84 SPASM biosensors, agonist-activated 
human GPR84 was found to couple to Gαi/o G protein family members 
(Figure 3.5 and 3.6). Within the Gαi/o G protein family, Gαi1/2 and Gαi3 
were found to be preferentially recruited to agonist-activated human 
GPR84 over Gαz and Gαo (Figure 3.7).  
 In BRET assays using SPASM-based GPR84 biosensors, DIM and embelin 
were found to behave as partial agonists compared to the presumed 
endogenous agonist decanoic acid (C-10) while compound-1 and TUG-1765 
acted as super-agonists at human GPR84 (Figure 3.4). Similar trends of the 
relative efficacy of these GPR84 agonists were also observed in [35S]-
GTPγS binding assays employing membranes generated from transfected 
cells expressing FLAG-hGPR84-Gαi2 (Figure 5.7g) or from LPS-induced 
RAW264.7 cells (Figure 5.9). 
 An integral role of arginine 172 of EL2 in orthosteric ligand detection and 
function was predicted by homology modelling (Figure 4.8) and 
subsequently confirmed in site-directed mutagenesis studies (Figure 4.12 
and 4.14) in which arginine 172 coordinates the carboxylate function of 
MCFAs and the bioisosteres of carboxylate i.e. hydrophilic head groups of 
embelin and embelin-like molecules including 6-OAU, compound-1 and 
TUG-1765.  
 Homology modelling, site-directed mutagenesis and ligand docking to 
constructed homology model also suggested that in addition to arginine 
172, phenylalanine 170 of EL2, phenylalanine 3356.51 and tryptophan 
3607.43 are likely to play important roles in orthosteric ligand recognition 
(Figure 4.15, 4.16 and 4.17).  
 Mutagenesis studies suggest that embelin, 6-OAU, compound-1 and TUG-
1765 bind human GPR84 at a site that is overlapping with the binding site 
of the presumed endogenous agonist, decanoic acid i.e they are 
orthosteric to C-10 whilst DIM and its analogue PSB-16671 bind to hGPR84 
on a site that is topographically distinct from the orthosteric binding site 
(Chapter 4). 
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 Functional studies and radioligand saturation binding studies with a 
radiolabelled antagonist [3H]-G9543, which is an analogue of GPR84 
antagonists compound-104, 107, 161, revealed that [3H]-G9543 and the 
related antagonists are likely to bind to a site which is distinct from the 
orthosteric and allosteric binding sites on human GPR84 (Figure 4.10 and 
4.21). Despite no atomic-level structure of GPR84 being available to date, 
mutational analysis and functional studies suggest at least three binding 
sites on human GPR84 which are spatiotemporally distinct from each 
other.  
 The pharmacology of orthosteric agonists including C-10, embelin, 
compound-1 and allosteric agonists including DIM and PSB-16671 as well as 
antagonists of GPR84 observed in RAW264.7 cells was similar to those 
displayed in transfected cells expressing mouse GPR84 (Figure 5.9 and 
5.10).  
 In [35S]-GTPγS binding assays, antagonists but not agonists of GPR84 
displayed significant variation in pharmacology between the human and 
mouse orthologues as evidenced from either loss of activity of 
competitive antagonist compound-837 or markedly reduced potencies of 
non-competitive GPR84 antagonists including compound-104,107 and 161 
at mouse GPR84 (Figure 5.13 and 5.10).  
 DIM and DIM analogue PSB-16671 acted as highly effective positive 
allosteric modulators (PAM) of function of GPR84 orthosteric agonists 
including C-10, embelin, 6-OAU and compound-1 at both human and 
mouse GPR84 through a mechanism which incorporates both affinity and 
efficacy modulation of embelin and C-10 or through predominantly 
modulating binding affinity of full agonist (6-OAU/compound-1) (Figure 
6.2, 6.3, 6.5, 6.11, 6.12, 6.13).  
 DIM and PSB-16671 displayed PAM activity at human and mouse GPR84 in a 
‘probe-dependent’ manner wherein the positive binding affinity 
cooperativity tracks with the intrinsic efficacy of the orthosteric agonist 
(Figure 6.4a, Table 6.6 and 6.7). However, no significant probe-
dependence was observed in allosteric interaction between DIM/DIM 
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analogues and orthosteric agonists at human/mouse GPR84 when net 
affinity/efficacy cooperativity was considered (Figure 6.4b, Table 6.6 and 
6.7).  
 Compared to DIM, PSB-16671 displayed significantly higher positive 
binding affinity cooperativity and higher net affinity/efficacy 
cooperativity with C-10/compound-1 at human and mouse GPR84, 
implying that the functional cooperativity with orthosteric GPR84 agonists 
tracks with the intrinsic efficacy of the modulator used (Chapter 6).  
 Mathematical analysis of allosteric interaction between DIM/DIM 
analogues and GPR84 orthosteric agonists showed that the estimated 
binding affinities of GPR84 ligands for mouse GPR84 were equivalent to 
those observed for the human GPR84 (Chapter 6).   
In summary, throughout this thesis, I characterized GPR84 orthosteric and 
allosteric ligands in terms of their binding modes and mechanism of 
pharmacological actions. These research efforts would have a broader 
implication in generating therapeutics targeting GPR84. GPR84 antagonists 
including GLPG1205 in isolation or in combination with other anti-inflammatory 
or anti-fibrotic agent would be potential therapeutics for the treatment of 
idiopathic pulmonary fibrosis, chronic neuropathic pain, pulmonary hypertension 
associated with heart failure with reduced ejection fraction (HFrEF), diabetic 
nephropathy etc. while GPR84 agonists such as compound-1 and its derivatives 
or a combination of orthosteric and allosteric agonist (PSB-16671) would be a 
potential therapy for atherosclerosis although further research is required to 
validate the role of GPR84 signalling in the pathogenesis of atherosclerosis.     
Although compound-1 and its derivatives, including TUG-1765/compound-51 are 
highly potent and selective agonists of the receptor, the predicted modes of 
ligan-GPR84 interaction described in this thesis will accelerate the structure- 
based drug design (SBDD) and thus will lead to the development of further 
improved ligands which can be employed as tool compounds or future 
therapeutics. 
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Despite being a potential therapeutic target, little is known regarding the 
biological roles of this receptor hindering the target validation process of the 
receptor. Although recombinant heterologous expression systems are widely 
employed for the study of pharmacology of GPCRs owing to their simplicity and 
ubiquity, the observed pharmacology might not be truly representative of 
physiological function of a receptor (Croston, 2017) and thus GPR84 research 
should now be focussed on the translation of the observed pharmacology in 
transfected cells into primary human and murine cell lines including 
lymphocytes, neutrophils, dendritic cells etc. and on the elucidation of 
pathophysiological roles of the receptor by employing animal disease models 
including mouse models of atherosclerosis, Alzheimer’s disease, Type II diabetes, 
diabetic nephropathy and different fibrosis models.  
As the availability of potent and selective tool compounds with a defined mode 
of action is required for the success in the target validation process, the 
characterization of GPR84 orthosteric and allosteric ligands described in this 
thesis might be useful for the translational research on GPR84. Based on the 
findings from the pharmacological characterization of GPR84 ligands in 
transfected cells expressing human and mouse GPR84 and murine macrophage 
cell line RAW264.7 cells, compound-1 and its derivatives TUG-1765 can be used 
as potent and selective tool compound to characterize the orthosteric site of 
GPR84 whilst DIM analogue PSB-16671 instead of DIM can be employed as a tool 
compound to characterize the allosteric site of GPR84 or as a lead compound to 
develop further improved allosteric ligand as PSB-16671 was found to be more 
effective in enhancing the function of orthosteric GPR84 agonists with higher 
affinity for GPR84 displaying no species selectivity between human and mouse 
orthologues. Potent and selective agonists compound-1, TUG-1765 and PSB-
16671 can also be fluorescently labelled which might be useful in the biological 
and pharmacological characterization of GPR84.  
In the context of ongoing debate on the physiological agonist of the receptor, 
investigation of role of GPR84 signalling in the pathogenesis of human and mouse 
atherosclerosis or neuro-inflammatory diseases might inform true endogenous 
agonist of the receptor as GPR84 was reported to be associated with progression 
of atherosclerotic plaque formation (Recio et al., 2018) and with microglial 
motility and ruffling in response to neuronal injury (Wei et al., 2017).  
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As there might be substantial variation in the pharmacology of GPCR ligands 
between different species orthologues, which can hinder the translation of in 
vitro pharmacology into in-vivo animal disease models, I investigated the 
potential orthologue selectivity of GPR84 ligands using transfected cells 
expressing either human and mouse GPR84 and the mouse monocyte-
macrophage cell line RAW264.7. The maintenance of similar pharmacology of 
GPR84 orthosteric and allosteric agonists between human and mouse GPR84 
implies that these ligands can be utilized as tool compounds in mouse-derived 
cell lines or mouse disease models.  
The observed selectivity of GPR84 antagonist compound-837 for human GPR84 
over mouse orthologue implicates that compound-837 could not be employed for 
in vivo mouse disease models and the observed significant reduction in potency 
of a series of non-competitive antagonists (compound-104, 107) at mouse GPR84 
implies that cautions should be taken in the use of these antagonists in mouse 
models/cell lines. Further studies are required to investigate the molecular basis 
of human selectivity of compound-837 over the mouse orthologue employing the 
humanized mouse GPR84 and to define the molecular determinants responsible 
for the reduced affinity of non-competitive GPR84 antagonists at mouse GPR84 
compared to the human orthologue. Such structural information might be useful 
for defining their binding modes which can then be utilized to design and 
develop further improved ligands. In terms of defining the orthologue selectivity 
of GPR84 ligands, future research should include investigation of GPR84 
signalling in a broader range of species orthologues including rat, bovine, guinea 
pig, sheep receptor.   
As elucidation of signal transduction pathways of a GPCR is necessary to find out 
the specific biological function(s) of the receptor, future study with GPR84 
should also focus on the extensive investigation of downstream signalling 
pathways as current scientific literature shows conflicting information on the 
GPR84 signalling pathways. For example, though Recio et al., (2018) reported 
that 6-OAU-activated GPR84 promotes NFκB translocation to the nucleus 
resulting in enhanced expression of pro-inflammatory mediators in LPS-induced 
macrophages, GPR84 was found to be associated with inhibition of NFκB 
signalling pathways in osteoclast precursor cells, BMDMs (Park et al., 2018). 
Similarly, Park et al., (2018) reported that GPR84 activation inhibits ERK 
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signalling pathways in BMDM which is in sharp contrast with the finding reported 
by Recio et al., (2018) and other groups that GPR84 activates ERK1/2 signalling. 
Moreover, though Gaidarov et al., (2018) reported that embelin-induced GPR84 
activation results in coupling to Gα12/13-induced Rho-Rac signalling pathways, no 
interaction between compound-1/TUG-1765-activated human GPR84 and Gα12/13 
G protein was found using the SPASM sensor-based BRET assay (Figure 3.5 and 
3.6) which is in agreement with findings reported by Gagnon et al., (2018). 
Further studies are required to investigate this discrepancy. In this context, 
employing the CRISPR/Cas9 engineered cells lacking G protein(s) or GPR84 
receptor might be an effective strategy to elucidate the signalling pathways and 
associated biological functions of this poorly characterized receptor.  
As signalling outcome of a GPCR in a specific cell is also dependent on the 
‘phosphorylation barcodes’ of the receptor, future research should be directed 
towards the investigation of phosphorylation profile(s) of GPR84. Recently biased 
agonists of GPCR have attracted considerable interests due to their potential to 
display fewer side effects compared to the conventional unbiased agonists and 
thus the biased agonism if any at GPR84 in terms of G protein versus β-arrestin-
mediated signalling needs to be investigated.           
The research efforts presented in this thesis provides new insights into 
mechanisms of allosteric interactions of GPR84 with detailed pharmacology of 
such allosteric interactions including ‘probe-dependence’ and potential 
orthologue variation of allosteric effects between human and mouse GPR84. 
These characterizations of allosteric pharmacology might accelerate drug 
development program targeting the allosteric sites of this receptor. However, to 
validate the allosteric modulation at GPR84 as a potential therapeutic strategy 
to treat diseases like atherosclerosis, further research is required to uncover the 
binding modes of these allosteric ligands to the receptor and to translate the 
allosteric pharmacology observed in in vitro cell lines into in vivo animal models.  
Similar to the allosteric ligands for FFA3 (Hudson et al., 2014a) and for 
metabotropic glutamate receptors (Wood et al., 2011), the DIM derivatives were 
also found to be characterized by the presence of the so-called ‘molecular 
switches’ i.e small chemical modifications that can alter the allosteric effects 
dramatically in a series of allosteric ligands which was evidenced from the 
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observed differential modes of allosteric interactions such as ago-PAM (DIM, 
analogue 3a and PSB-16671), weak NAM (analogue 6a), PAM/NAM (DIM in 
RAW264.7 cells) activity and loss of allosteric modulation and agonism (analogue 
2b and 3c). Although the existence of these types of molecular switches 
represents a shallow SAR for GPR84 allosteric ligands, thereby posing a challenge 
for lead optimization, this also can be exploited for the generation of diverse 
ligands with differential modes of allosteric pharmacology. The PAM/NAM 
activity of DIM on compound-1 in RAW264.7 cells suggests that there is a 
possibility to design allosteric agonists acting as PAM antagonists at GPR84 which 
might have improved target coverage and longer half-life compared to the 
currently available orthosteric antagonists (Kenakin and Strachan, 2018).    
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